The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALECENSA	NNP	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
orally	RB	O
twice	JJ	FREQ
daily	RB	FREQ
with	IN	O
food	NN	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

(	(	O
9	CD	O
)	)	O
Patient	NNP	O
alarm	NN	O
device	NN	O
:	:	O
An	DT	O
alarm	NN	O
device	NN	O
within	IN	O
the	DT	O
UVA	NNP	O
irradiator	NN	O
chamber	NN	O
should	MD	O
be	VB	O
accessible	JJ	O
to	TO	O
the	DT	O
patient	NN	O
for	IN	O
emergency	NN	O
activation	NN	O
.	.	O

100	CD	DOS
mg	NN	UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
at	IN	PER
least	JJ	PER
10	CD	PER
days	NNS	PER
.	.	O

Limit	NNP	O
the	DT	O
use	NN	O
of	IN	O
ABSTRAL	NNP	O
to	TO	O
treat	VB	O
four	CD	DOS
or	CC	O
fewer	JJR	O
episodes	NNS	O
of	IN	O
breakthrough	NN	O
pain	NN	O
per	IN	FREQ
day	NN	FREQ
.	.	O

Each	DT	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
mixed	JJ	O
under	IN	O
sterile	JJ	O
conditions	NNS	O
with	IN	O
832	CD	DOS
mL	NNS	UNIT
of	IN	O
Dextrose	NNP	O
70	CD	O
%	NN	O
will	MD	O
provide	VB	O
a	DT	O
solution	NN	O
of	IN	O
1.95	CD	O
%	NN	O
of	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
in	IN	O
44	CD	O
%	NN	O
dextrose	NN	O
.	.	O

Clinical	JJ	O
trial	NN	O
and	CC	O
postmarketing	VBG	O
experience	NN	O
suggest	VBP	O
that	IN	O
debilitated	JJ	WHO
patients	NNS	WHO
or	CC	WHO
patients	NNS	WHO
taking	VBG	WHO
additional	JJ	WHO
medications	NNS	WHO
that	WDT	WHO
decrease	VBP	WHO
gastrointestinal	JJ	WHO
motility	NN	WHO
may	MD	O
be	VB	O
at	IN	O
greater	JJR	O
risk	NN	O
of	IN	O
serious	JJ	O
complications	NNS	O
of	IN	O
constipation	NN	O
.	.	O

If	IN	O
you	PRP	O
stop	VBP	O
using	VBG	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	DOS
mg	NN	UNIT
)	)	O
,	,	O
continue	VBP	O
with	IN	O
a	DT	O
diet	JJ	O
and	CC	O
exercise	JJ	O
program	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACCOLATE	NNP	O
in	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

In	IN	O
adults	NNS	WHO
,	,	O
hypertonic	JJ	O
mixtures	NNS	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	VB	O
may	MD	O
be	VB	O
safely	RB	O
administered	VBN	O
by	IN	O
continuous	JJ	O
infusion	NN	O
through	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
with	IN	O
the	DT	O
tip	NN	O
located	VBN	O
in	IN	O
the	DT	O
vena	NN	O
cava	NN	O
.	.	O

Once	RB	O
a	DT	O
stable	JJ	O
dose	NN	O
is	VBZ	O
attained	VBN	O
,	,	O
monitor	VB	O
trough	IN	O
concentrations	NNS	O
every	DT	O
3	CD	FREQ
to	TO	O
6	CD	FREQ
months	NNS	FREQ
in	IN	O
patients	NNS	WHO
with	IN	WHO
changing	VBG	WHO
body	NN	WHO
surface	JJ	WHO
area	NN	WHO
or	CC	O
every	DT	O
6	CD	FREQ
to	TO	O
12	CD	FREQ
months	NNS	FREQ
in	IN	O
patients	NNS	WHO
with	IN	WHO
stable	JJ	WHO
body	NN	WHO
surface	JJ	WHO
area	NN	WHO
for	IN	O
the	DT	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

More	JJR	O
than	IN	O
two	CD	DOS
5	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
of	IN	O
amiloride	JJ	O
HCl	NNP	O
daily	RB	FREQ
usually	RB	O
are	VBP	O
not	RB	O
needed	VBN	O
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
little	JJ	O
controlled	JJ	O
experience	NN	O
with	IN	O
such	JJ	O
doses	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AROMASIN	NNP	O
in	IN	O
early	JJ	O
and	CC	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
is	VBZ	O
one	CD	DOS
25	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
once	IN	FREQ
daily	JJ	FREQ
after	IN	O
a	DT	O
meal	NN	O
.	.	O

See	JJ	O
Dosage	NNP	O
Guidelines	NNP	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
:	:	O
1	CD	O
)	)	O
by	IN	O
incremental	JJ	O
injection	NN	O
as	IN	O
an	DT	O
analgesic	JJ	O
adjunct	NN	O
to	TO	O
anesthesia	VB	O
with	IN	O
barbiturate	JJ	O
/	NNS	O
nitrous	JJ	O
oxide	IN	O
/	NNP	O
oxygen	NN	O
for	IN	O
short	JJ	O
surgical	JJ	O
procedures	NNS	O
(	(	O
expected	VBN	O
duration	NN	O
of	IN	O
less	JJR	O
than	IN	O
one	CD	O
hour	NN	O
)	)	O
;	:	O
2	CD	O
)	)	O
by	IN	O
continuous	JJ	O
infusion	NN	O
as	IN	O
a	DT	O
maintenance	NN	O
analgesic	JJ	O
with	IN	O
nitrous	JJ	O
oxide	JJ	O
/	NNP	O
oxygen	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
;	:	O
and	CC	O
3	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
in	IN	O
anesthetic	JJ	O
doses	NNS	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
with	IN	O
a	DT	O
minimum	NN	O
expected	VBN	O
duration	NN	O
of	IN	O
45	CD	O
minutes	NNS	O
;	:	O
and	CC	O
4	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
as	IN	O
the	DT	O
analgesic	JJ	O
component	NN	O
for	IN	O
monitored	JJ	O
anesthesia	NN	O
care	NN	O
(	(	O
MAC	NNP	O
)	)	O
.	.	O

NIASPAN	NNP	O
must	MD	O
be	VB	O
titrated	VBN	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
not	RB	O
be	VB	O
increased	VBN	O
by	IN	O
more	JJR	O
than	IN	O
500	CD	DOS
mg	JJ	UNIT
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
2000	CD	DOS
mg	NN	UNIT
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ADDYI	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
once	RB	FREQ
per	IN	FREQ
day	NN	FREQ
at	IN	O
bedtime	NN	O
.	.	O

Administer	NNP	O
intravenously	RB	O
25	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
within	IN	O
5	CD	O
minutes	NNS	O
and	CC	O
then	RB	O
0.15	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	FW	O
(	(	O
or	CC	O
0.075	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
≤60	NNP	WHO
mL	NN	WHO
/	NNP	O
min	NN	O
)	)	O
,	,	O
for	IN	O
up	IN	O
to	TO	O
18	CD	O
hours	NNS	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
<	VBP	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
weighing	VBG	WHO
≥	$	WHO
70	CD	WHO
kg	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	DOS
mCi	NN	UNIT
(	(	O
370	CD	DOS
MBq	NNP	UNIT
)	)	O
[	VBD	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

Such	JJ	O
infusates	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
dilutions	NNS	O
of	IN	O
Aminosyn	NNP	O
-	:	O
HF	$	O
8	CD	O
%	NN	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
or	CC	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
to	TO	O
prepare	VB	O
isotonic	JJ	O
or	CC	O
slightly	RB	O
hypertonic	JJ	O
solutions	NNS	O
for	IN	O
peripheral	JJ	O
infusion	NN	O
.	.	O

A	DT	O
dosage	NN	O
of	IN	O
0.5	CD	DOS
to	TO	O
1	CD	DOS
gram	NN	UNIT
of	IN	O
essential	JJ	O
amino	NN	O
acids	NNS	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	FREQ
day	NN	FREQ
will	MD	O
meet	VB	O
the	DT	O
requirements	NNS	O
of	IN	O
the	DT	WHO
majority	NN	WHO
of	IN	WHO
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

For	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
,	,	O
up	RB	O
to	TO	O
4.4	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Example	NN	O
:	:	O
UPAH	NNP	O
=	VBZ	O
8.0	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O

The	DT	O
dose	NN	O
of	IN	O
ADCETRIS	NNP	O
should	MD	O
be	VB	O
held	VBN	O
for	IN	O
Grade	NNP	O
3	CD	O
or	CC	O
4	CD	O
neutropenia	NN	O
until	IN	O
resolution	NN	O
to	TO	O
baseline	VB	O
or	CC	O
Grade	VB	O
2	CD	O
or	CC	O
lower	JJR	O
.	.	O

When	WRB	O
improvement	NN	O
is	VBZ	O
noted	VBN	O
,	,	O
dosage	NN	O
should	MD	O
be	VB	O
gradually	RB	O
reduced	VBN	O
to	TO	O
maintenance	NN	O
levels	NNS	O
ranging	VBG	O
from	IN	O
125	CD	DOS
mg	NNS	UNIT
to	TO	O
500	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

Once	RB	O
an	DT	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
established	VBN	O
,	,	O
amoxapine	NN	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
may	MD	O
conveniently	RB	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
bedtime	NN	UNIT
dose	NN	UNIT
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
300	CD	DOS
mg	NNS	UNIT
.	.	O

Patients	NNS	WHO
requiring	VBG	WHO
reductions	NNS	WHO
in	IN	WHO
LDL	NNP	WHO
cholesterol	NN	WHO
of	IN	O
20	CD	O
%	NN	O
or	CC	O
more	JJR	O
to	TO	O
achieve	VB	O
their	PRP$	O
goal	NN	O
(	(	O
see	VB	O
INDICATIONS	NNP	O
AND	NNP	O
USAGE	NNP	O
)	)	O
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
of	IN	O
lovastatin	NN	O
.	.	O

In	IN	O
studies	NNS	O
comparing	VBG	O
0.1	CD	DOS
,	,	O
0.5	CD	DOS
and	CC	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
day,8	VBD	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
PRESTALIA	NNP	O
is	VBZ	O
3.5	CD	DOS
/	JJ	O
2.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
(	(	WHO
age	NN	WHO
≥	VBZ	WHO
65	CD	WHO
years	NNS	WHO
)	)	WHO
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
CARDURA	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
either	CC	O
in	IN	O
the	DT	O
morning	NN	O
or	CC	O
evening	NN	O
.	.	O

Congestive	JJ	O
Heart	NNP	O
Failure	NN	O
:	:	O
For	IN	O
diuresis	NN	O
in	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
is	VBZ	O
usually	RB	O
250	CD	DOS
to	TO	O
375	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
(	(	O
5	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
)	)	O
.	.	O

Thereafter	RB	O
,	,	O
the	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
over	IN	O
the	DT	O
next	JJ	O
several	JJ	O
weeks	NNS	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
250	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

Using	VBG	O
the	DT	O
transfer	NN	O
device	NN	O
provided	VBD	O
,	,	O
reconstitute	NN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
accompanying	VBG	O
100	CD	DOS
mL	JJ	UNIT
vial	NN	UNIT
of	IN	O
SWFI	NNP	O
to	TO	O
the	DT	O
100	CD	DOS
mg	JJ	UNIT
vial	NN	UNIT
of	IN	O
Activase	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
(	(	O
37.5	CD	DOS
mg	NN	UNIT
)	)	O
daily	RB	FREQ
,	,	O
as	IN	O
prescribed	VBN	O
by	IN	O
the	DT	O
physician	NN	O
,	,	O
administered	VBN	O
before	IN	O
breakfast	NN	O
or	CC	O
1	CD	O
to	TO	O
2	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
.	.	O

A	DT	O
syringe	NN	O
,	,	O
filled	VBN	O
with	IN	O
fluorescein	NN	O
,	,	O
is	VBZ	O
attached	VBN	O
to	TO	O
transparent	VB	O
tubing	NN	O
and	CC	O
a	DT	O
25	CD	O
gauge	NN	O
scalp	NN	O
vein	NN	O
needle	NN	O
for	IN	O
injection	NN	O
.	.	O

Aseptically	RB	O
,	,	O
reconstitute	VB	O
each	DT	O
vial	NN	O
by	IN	O
injecting	VBG	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
to	TO	WHO
moderate	VB	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2.5	CD	DOS
mg	NNS	UNIT
over	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
and	CC	O
a	DT	O
1	CD	DOS
-	:	O
mg	NN	O
starting	VBG	O
dose	NN	O
is	VBZ	O
recommended	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Mitchell2	NNP	O
has	VBZ	O
shown	VBN	O
that	IN	O
particles	VBZ	O
less	JJR	O
than	IN	O
10	CD	DOS
microns	NNS	UNIT
should	MD	O
be	VB	O
retained	VBN	O
in	IN	O
the	DT	O
respiratory	NN	O
tract	JJ	O
satisfactorily	RB	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
parenteral	JJ	O
administration	NN	O
of	IN	O
a	DT	O
solution	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	JJ	O
requires	VBZ	O
an	DT	O
accurate	JJ	O
estimate	NN	O
of	IN	O
the	DT	O
total	JJ	O
fluid	NN	O
and	CC	O
electrolytes	VBZ	O
needed	VBN	O
to	TO	O
compensate	VB	O
for	IN	O
the	DT	O
patient	NN	O
's	POS	O
measurable	JJ	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
i.e	FW	O
,	,	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
daily	JJ	FREQ
losses	NNS	O
.	.	O

When	WRB	O
acetaZOLAMIDE	NN	O
is	VBZ	O
given	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
anticonvulsants	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
250	CD	DOS
mg	JJ	UNIT
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
existing	VBG	O
medications	NNS	O
.	.	O

Using	VBG	O
a	DT	O
new	JJ	O
needle	NN	O
and	CC	O
syringe	NN	O
,	,	O
withdraw	JJ	O
0.5	CD	DOS
mL	NN	UNIT
of	IN	O
reconstituted	JJ	O
vaccine	NN	O
and	CC	O
administer	NN	O
intramuscularly	RB	O
.	.	O

The	DT	O
dose	JJ	O
increase	NN	O
increment	NN	O
should	MD	O
not	RB	O
exceed	VB	O
0.5	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
any	DT	O
one	CD	O
week	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
troche	NN	UNIT
five	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
fourteen	JJ	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
ALDACTONE	NNP	O
25	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
if	IN	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
potassium	NN	O
is	VBZ	O
≤	JJ	O
5	CD	O
mEq	NN	O
/	NNP	O
L	NNP	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
is	VBZ	O
≤	JJ	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TRADJENTA	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Avoid	IN	O
the	DT	O
use	NN	O
of	IN	O
concomitant	NN	O
strong	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
itraconazole	NN	O
,	,	O
clarithromycin	NN	O
,	,	O
atazanavir	NN	O
,	,	O
nefazodone	NN	O
,	,	O
saquinavir	NN	O
,	,	O
telithromycin	NN	O
,	,	O
ritonavir	NN	O
,	,	O
indinavir	NN	O
,	,	O
nelfinavir	RB	O
,	,	O
voriconazole	NN	O
)	)	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
AFINITOR	NNP	WHO
Tablets	NNPS	WHO
or	CC	O
AFINITOR	NNP	O
DISPERZ	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

A	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
no	DT	O
greater	JJR	O
than	IN	O
6	CD	DOS
mg	JJ	UNIT
/	NNP	O
mL	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

To	TO	O
ensure	VB	O
the	DT	O
precise	JJ	O
delivery	NN	O
of	IN	O
the	DT	O
small	JJ	O
volumes	NNS	O
of	IN	O
fluid	NN	O
necessary	JJ	O
for	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
in	IN	O
infants	NNS	WHO
,	,	O
accurately	RB	O
calibrated	VBN	O
and	CC	O
reliable	JJ	O
infusion	NN	O
systems	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

When	WRB	O
high	JJ	O
dose	NN	O
therapy	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
A	NNP	O
-	:	O
Methapred	NNP	O
(	(	O
methylprednisolone	CD	O
sodium	NN	O
succinate	NN	O
)	)	O
sterile	NN	O
powder	NN	O
is	VBZ	O
30	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
.	.	O

ALDACTONE	NNP	O
in	IN	O
a	DT	O
dosage	NN	O
ranging	VBG	O
from	IN	O
25	CD	DOS
mg	NNS	UNIT
to	TO	O
100	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
is	VBZ	O
useful	JJ	O
in	IN	O
treating	VBG	O
a	DT	O
diuretic	JJ	O
-	:	O
induced	JJ	O
hypokalemia	NN	O
,	,	O
when	WRB	O
oral	JJ	O
potassium	NN	O
supplements	NNS	O
or	CC	O
other	JJ	O
potassium	NN	O
-	:	O
sparing	NN	O
regimens	NNS	O
are	VBP	O
considered	VBN	O
inappropriate	JJ	O
.	.	O

Narcolepsy	NNP	O
seldom	NN	O
occurs	VBZ	O
in	IN	O
children	NNS	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
;	:	O
however	RB	O
,	,	O
when	WRB	O
it	PRP	O
does	VBZ	O
,	,	O
dextroamphetamine	VB	O
sulfate	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

The	DT	O
total	JJ	O
radiation	NN	O
exposure	NN	O
from	IN	O
Amyvid	NNP	O
administration	NN	O
and	CC	O
subsequent	JJ	O
scan	NN	O
on	IN	O
a	DT	O
PET	NNP	O
/	NNP	O
CT	NNP	O
scanner	NN	O
is	VBZ	O
estimated	VBN	O
to	TO	O
be	VB	O
9	CD	O
mSv	NN	O
.	.	O

The	DT	O
maximum	JJ	O
daily	JJ	FREQ
dose	NN	O
is	VBZ	O
63	CD	DOS
mg	NN	UNIT
(	(	O
four	CD	DOS
doses	NNS	UNIT
)	)	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	FW	O
hydrochloride	NN	O
)	)	O
should	MD	O
be	VB	O
individualized	VBN	O
and	CC	O
titrated	VBN	O
to	TO	O
the	DT	O
desired	JJ	O
effect	NN	O
in	IN	O
each	DT	O
patient	NN	O
according	VBG	O
to	TO	O
body	NN	O
weight	NN	O
,	,	O
physical	JJ	O
status	NN	O
,	,	O
underlying	VBG	O
pathological	JJ	O
condition	NN	O
,	,	O
use	NN	O
of	IN	O
other	JJ	O
drugs	NNS	O
,	,	O
and	CC	O
type	NN	O
and	CC	O
duration	NN	O
of	IN	O
surgical	JJ	O
procedure	NN	O
and	CC	O
anesthesia	NN	O
.	.	O

Consider	VB	O
titrating	VBG	O
to	TO	O
dosages	VB	O
higher	JJR	O
than	IN	O
2.5	CD	DOS
mg	NNS	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
if	IN	O
tolerated	VBN	O
,	,	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
smoke	VBP	WHO
.	.	O

The	DT	O
suggested	VBN	O
intravenous	JJ	O
dosage	NN	O
level	NN	O
for	IN	O
Cysteine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
(	(	O
10	CD	DOS
mL	NN	UNIT
)	)	O
for	IN	O
every	DT	O
12.5	CD	DOS
g	NN	UNIT
(	(	O
179	CD	DOS
mL	NN	UNIT
)	)	O
of	IN	O
Aminosyn	NNP	O
-	:	O
PF	VBD	O
7	CD	O
%	NN	O
administered	VBN	O
(	(	O
see	VB	O
package	NN	O
insert	NN	O
for	IN	O
Cysteine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
)	)	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
who	WP	WHO
have	VBP	WHO
tolerated	VBN	WHO
AGRYLIN	NNP	WHO
therapy	NN	O
for	IN	O
one	CD	PER
week	NN	PER
may	MD	O
have	VB	O
their	PRP$	O
dose	NN	O
increased	VBN	O
.	.	O

After	IN	O
reconstitution	NN	O
with	IN	O
saline	JJ	O
diluent	NN	O
(	(	O
0.4	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
)	)	O
,	,	O
ActHIB	NNP	O
vaccine	NN	O
should	MD	O
be	VB	O
administered	VBN	O
promptly	RB	O
or	CC	O
stored	VBN	O
refrigerated	VBN	O
between	IN	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
35°	CD	O
to	TO	O
46°F	CD	O
)	)	O
and	CC	O
administered	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
.	.	O

For	IN	O
peripheral	JJ	O
intravenous	JJ	O
infusion	NN	O
,	,	O
1	CD	DOS
to	TO	O
1.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
of	IN	O
total	JJ	O
amino	NN	O
acids	NNS	O
will	MD	O
reduce	VB	O
protein	JJ	O
catabolism	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
AMARYL	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
or	CC	O
2	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
phosphate	NN	O
added	VBN	O
to	TO	O
a	DT	O
liter	NN	O
of	IN	O
TPN	NNP	O
solution	NN	O
(	(	O
containing	VBG	O
25	CD	O
%	NN	O
dextrose	NN	O
)	)	O
is	VBZ	O
12	CD	DOS
mM	NN	UNIT
.	.	O

Heart	NNP	O
Failure	NNP	O
Post	NNP	O
Myocardial	NNP	O
Infarction	NN	O
:	:	O
For	IN	O
patients	NNS	WHO
with	IN	WHO
heart	NN	WHO
failure	NN	WHO
and	CC	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

It	PRP	O
should	MD	O
not	RB	O
be	VB	O
less	JJR	O
than	IN	O
0.5	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

In	IN	O
both	DT	WHO
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
,	,	O
the	DT	O
daily	JJ	FREQ
dose	NN	O
can	MD	O
be	VB	O
given	VBN	O
as	IN	O
single	JJ	DOS
infusion	NN	UNIT
or	CC	O
in	IN	O
equally	RB	O
divided	JJ	O
infusions	NNS	O
at	IN	O
6	CD	O
-	:	O
,	,	O
8	CD	O
-	:	O
,	,	O
or	CC	O
12	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
at	IN	O
the	DT	O
recommended	JJ	O
final	JJ	O
concentration	NN	O
of	IN	O
not	RB	O
greater	JJR	O
than	IN	O
6	CD	DOS
mg	JJ	UNIT
/	NN	O
mL	NN	O
(	(	O
see	VB	O
Preparation	NNP	O
of	IN	O
Solution	NNP	O
)	)	O
.	.	O

Stability	NN	O
in	IN	O
IV	NNP	O
Fluids	NNP	O
:	:	O
Amikacin	NNP	O
sulfate	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
5.0	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
in	IN	O
the	DT	O
following	JJ	O
solutions	NNS	O
:	:	O

Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
score	NN	WHO
ranging	VBG	WHO
from	IN	WHO
5	CD	WHO
to	TO	WHO
8	CD	WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
of	IN	O
450	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
and	CC	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
score	NN	WHO
ranging	VBG	WHO
from	IN	WHO
9	CD	WHO
to	TO	WHO
12	CD	WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
of	IN	O
300	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
:	:	O
Hepatic	JJ	O
Insufficiency	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
,	,	WHO
children	NNS	WHO
and	CC	WHO
older	JJR	WHO
infants	NNS	WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
box	NN	O
)	)	O
with	IN	O
normal	JJ	O
renal	JJ	O
function	NN	O
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
divided	VBD	O
into	IN	O
2	CD	DOS
or	CC	O
3	CD	DOS
equal	JJ	UNIT
doses	NNS	UNIT
administered	VBN	O
at	IN	O
equally	RB	O
-	:	O
divided	VBN	O
intervals	NNS	O
,	,	O
i.e	NN	O
,	,	O
7.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
q12h	NN	O
or	CC	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
q8h	NN	O
.	.	O

One	CD	DOS
drop	NN	UNIT
instilled	VBD	O
into	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	PRP	O
)	)	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Table	JJ	O
2	CD	O
:	:	O
3	CD	O
-	:	O
hour	NN	O
Infusion	NNP	O
Weight	NNP	O
-	:	O
Based	VBD	O
Doses	NNS	O
for	IN	O
Patients	NNS	WHO
with	IN	WHO
AMI	NNP	WHO

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Amyvid	NNP	O
is	VBZ	O
370	CD	DOS
MBq	NNP	UNIT
(	(	O
10	CD	DOS
mCi	NN	UNIT
)	)	O
,	,	O
maximum	JJ	O
50	CD	O
μg	JJ	O
mass	NN	O
dose	NN	O
,	,	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
bolus	NN	UNIT
in	IN	O
a	DT	O
total	JJ	O
volume	NN	O
of	IN	O
10	CD	DOS
mL	NN	UNIT
or	CC	O
less	JJR	O
.	.	O

Combination	NNP	O
therapy	NN	O
with	IN	O
NIASPAN	NNP	O
and	CC	O
lovastatin	NN	O
should	MD	O
not	RB	O
exceed	VB	O
doses	NNS	O
of	IN	O
2000	CD	DOS
mg	NN	UNIT
and	CC	O
40	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
,	,	O
respectively	RB	O
.	.	O

For	IN	O
recurrence	NN	O
of	IN	O
severe	JJ	O
neutropenia	NN	O
or	CC	O
severe	JJ	O
sensory	NN	O
neuropathy	NN	O
,	,	O
additional	JJ	O
dose	NN	O
reduction	NN	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
180	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	NN	O
.	.	O

If	IN	O
the	DT	O
migraine	NN	O
returns	NNS	O
or	CC	O
if	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
only	RB	O
partial	JJ	O
response	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
repeated	VBN	O
once	RB	O
after	IN	O
4	CD	O
hours	NNS	O
,	,	O
for	IN	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
in	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
.	.	O

AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
and	CC	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
are	VBP	O
not	RB	O
interchangeable	JJ	O
on	IN	O
a	DT	O
milligram	JJ	O
-	:	O
per	IN	O
-	:	O
milligram	JJ	O
basis	NN	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

Continuous	JJ	O
maintenance	NN	O
therapy	NN	O
with	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
is	VBZ	O
instituted	VBN	O
when	WRB	O
the	DT	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
4000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mcL	NN	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
100000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mcL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

An	DT	O
initial	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
100	CD	DOS
mg	NN	UNIT
of	IN	O
ALDACTONE	NNP	O
administered	VBD	O
in	IN	O
either	DT	O
single	JJ	DOS
or	CC	O
divided	JJ	UNIT
doses	NNS	UNIT
is	VBZ	O
recommended	VBN	O
,	,	O
but	CC	O
may	MD	O
range	VB	O
from	IN	O
25	CD	DOS
to	TO	O
200	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
0.05	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
or	CC	O
less	JJR	O
and	CC	O
is	VBZ	O
adjusted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
blood	NN	O
count	NN	O
.	.	O

If	IN	O
patients	NNS	O
require	VBP	O
co	JJ	O
-	:	O
administration	NN	O
of	IN	O
a	DT	O
moderate	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inhibitor	NN	O
,	,	O
reduce	VB	O
the	DT	O
AFINITOR	NNP	O
dose	NN	O
to	TO	O
2.5	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
bleeding	NN	O
syndromes	NNS	O
due	JJ	O
to	TO	O
elevated	JJ	O
fibrinolytic	JJ	O
activity	NN	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
5	CD	DOS
AMICAR	NNP	UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
1000	CD	DOS
mg	JJ	UNIT
Tablets	NNPS	UNIT
or	CC	O
10	CD	DOS
AMICAR	NNP	UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
500	CD	DOS
mg	JJ	UNIT
Tablets	NNP	UNIT
(	(	O
5	CD	DOS
g	NN	UNIT
)	)	O
or	CC	O
20	CD	DOS
milliliter	NN	UNIT
of	IN	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
Oral	NNP	O
Solution	NNP	O
(	(	O
5	CD	DOS
g	NN	UNIT
)	)	O
be	VB	O
administered	VBN	O
during	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuing	VBG	O
rate	NN	O
of	IN	O
1	CD	DOS
AMICAR	NNP	UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
1000	CD	DOS
mg	JJ	UNIT
Tablet	NNP	UNIT
or	CC	O
2	CD	DOS
AMICAR	NNP	UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
500	CD	DOS
mg	JJ	UNIT
Tablets	NNP	UNIT
(	(	O
1	CD	DOS
g	NN	UNIT
)	)	O
or	CC	O
5	CD	DOS
milliliter	NN	UNIT
of	IN	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
Oral	NNP	O
Solution	NNP	O
(	(	O
1.25	CD	DOS
g	NN	UNIT
)	)	O
per	IN	O
hour	NN	O
.	.	O

The	DT	O
suggested	VBN	O
intravenous	JJ	O
dosage	NN	O
level	NN	O
for	IN	O
Cysteine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
(	(	O
10	CD	DOS
mL	NN	UNIT
)	)	O
for	IN	O
every	DT	O
12.5	CD	DOS
g	NN	UNIT
(	(	O
125	CD	DOS
mL	NN	UNIT
)	)	O
of	IN	O
Aminosyn	NNP	O
-	:	O
PF	VBD	O
10	CD	O
%	NN	O
administered	VBN	O
(	(	O
see	VB	O
package	NN	O
insert	NN	O
for	IN	O
Cysteine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
)	)	O
.	.	O

The	DT	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
dose	VB	O
was	VBD	O
not	RB	O
shown	VBN	O
to	TO	O
be	VB	O
more	RBR	O
efficacious	JJ	O
than	IN	O
the	DT	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
dose	VB	O
.	.	O

To	TO	O
facilitate	VB	O
delivery	NN	O
to	TO	O
the	DT	O
stomach	NN	O
,	,	O
Actonel	NNP	O
should	MD	O
be	VB	O
swallowed	VBN	O
while	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
in	IN	O
an	DT	O
upright	JJ	O
position	NN	O
and	CC	O
with	IN	O
a	DT	O
full	JJ	O
glass	NN	O
of	IN	O
plain	JJ	O
water	NN	O
(	(	O
6	CD	DOS
to	TO	O
8	CD	DOS
oz	NN	UNIT
)	)	O
.	.	O

In	IN	O
depleted	VBN	WHO
and	CC	WHO
severely	RB	WHO
traumatized	JJ	WHO
patients	NNS	WHO
such	JJ	WHO
as	IN	WHO
burned	JJ	WHO
patients	NNS	WHO
or	CC	WHO
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
received	VBN	WHO
major	JJ	WHO
surgery	NN	WHO
with	IN	WHO
complications	NNS	WHO
,	,	O
the	DT	O
requirements	NNS	O
for	IN	O
nutrients	NNS	O
and	CC	O
fluids	NNS	O
may	MD	O
be	VB	O
significantly	RB	O
higher	JJR	O
.	.	O

Onset	NNP	O
of	IN	O
significant	JJ	O
relief	NN	O
of	IN	O
nasal	NN	O
symptoms	NNS	O
was	VBD	O
seen	VBN	O
within	IN	O
two	CD	O
days	NNS	O
after	IN	O
starting	VBG	O
treatment	NN	O
at	IN	O
400	CD	DOS
mcg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Reconstituted	VBN	O
ABRAXANE	NNP	O
in	IN	O
the	DT	O
vial	NN	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
,	,	O
but	CC	O
may	MD	O
be	VB	O
refrigerated	VBN	O
at	IN	O
2°C	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°F	CD	O
to	TO	O
46°F	CD	O
)	)	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
24	CD	O
hours	NNS	O
if	IN	O
necessary	JJ	O
.	.	O

Dose	JJ	O
adjustments	NNS	O
of	IN	O
up	IN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
should	MD	O
occur	VB	O
gradually	RB	O
,	,	O
at	IN	O
intervals	NNS	O
of	IN	O
no	DT	O
less	JJR	O
than	IN	O
1	CD	O
week	NN	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

The	DT	O
dosage	NN	O
to	TO	O
be	VB	O
administered	VBN	O
is	VBZ	O
determined	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
weight	NN	O
(	(	O
1	CD	DOS
mcg	NN	UNIT
corticorelin	NN	O
/	NNP	O
kg	NN	O
)	)	O
.	.	O

Unopened	VBN	O
vials	NNS	O
of	IN	O
lyophilized	VBN	O
material	NN	O
are	VBP	O
to	TO	O
be	VB	O
stored	VBN	O
at	IN	O
temperatures	NNS	O
up	RB	O
to	TO	O
25°	CD	O
C	NNP	O
(	(	O
77°	CD	O
F	NNP	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
pregnancy	NN	O
increases	NNS	O
with	IN	O
each	DT	O
active	JJ	O
(	(	O
pink	NN	O
)	)	O
tablet	NN	O
missed	VBN	O
.	.	O

After	IN	O
reaching	VBG	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
2	CD	DOS
mg	NN	UNIT
,	,	O
further	RB	O
dose	JJ	O
increases	NNS	O
can	MD	O
be	VB	O
made	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
1	CD	DOS
mg	NNS	UNIT
or	CC	O
2	CD	DOS
mg	NNS	UNIT
based	VBN	O
upon	IN	O
the	DT	O
patient	NN	O
's	POS	O
glycemic	JJ	O
response	NN	O
.	.	O

Such	JJ	O
a	DT	O
solution	NN	O
given	VBN	O
at	IN	O
the	DT	O
rate	NN	O
of	IN	O
145	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	JJ	FREQ
day	NN	FREQ
provides	VBZ	O
130	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

As	IN	O
an	DT	O
alternate	NN	O
single	JJ	O
visit	NN	O
dose	NN	O
,	,	O
administer	RB	O
300	CD	DOS
mg	NN	UNIT
stat	NN	O
followed	VBD	O
in	IN	O
one	CD	O
hour	NN	O
by	IN	O
a	DT	O
second	JJ	O
300	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
.	.	O

For	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
100	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosages	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
hypotension	NN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
anesthesia	NN	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mg	NNS	UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
bolus	NN	O
.	.	O

Start	NNP	O
all	DT	WHO
patients	NNS	WHO
with	IN	O
a	DT	O
single	JJ	DOS
100	CD	DOS
mcg	JJ	UNIT
tablet	NN	UNIT
.	.	O

Calculate	VB	O
the	DT	O
exact	JJ	O
total	JJ	O
dosing	NN	O
volume	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	JJ	O
suspension	NN	O
required	VBN	O
for	IN	O
the	DT	O
patient	NN	O
and	CC	O
slowly	RB	O
withdraw	VB	O
the	DT	O
dosing	NN	O
volume	NN	O
of	IN	O
the	DT	O
reconstituted	JJ	O
suspension	NN	O
from	IN	O
the	DT	O
vial	NN	O
(	(	O
s	NN	O
)	)	O
into	IN	O
a	DT	O
syringe	NN	O
:	:	O
Dosing	NN	O
volume	NN	O
(	(	O
mL	NN	O
)	)	O
=Total	NN	O
dose	NN	O
(	(	O
mg	NN	UNIT
)	)	O
/	VBZ	O
5	CD	DOS
(	(	O
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
asthma	NNS	WHO
aged	VBN	WHO
4	CD	WHO
to	TO	WHO
11	CD	WHO
years	NNS	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
controlled	VBN	WHO
on	IN	WHO
an	DT	WHO
inhaled	JJ	WHO
corticosteroid	NN	WHO
,	,	O
the	DT	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
inhalation	NN	UNIT
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
100	CD	O
/	VBD	O
50	CD	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postoperative	JJ	O
inflammation	NN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
undergone	VBN	WHO
cataract	JJ	WHO
extraction	NN	WHO
,	,	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
ACULAR®	NNP	O
ophthalmic	JJ	O
solution	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
beginning	VBG	O
24	CD	O
hours	NNS	O
after	IN	O
cataract	NN	O
surgery	NN	O
and	CC	O
continuing	VBG	O
through	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
class	NN	WHO
C	NNP	WHO
)	)	WHO
or	CC	WHO
requiring	VBG	WHO
moderate	JJ	WHO
CYP3A4	NNP	WHO
/	NNP	WHO
PgP	NNP	WHO
inhibitors	NNS	WHO
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
,	,	O
once	RB	FREQ
daily	JJ	FREQ
[	NNP	O
see	VBP	O
Dose	NNP	O
Modifications	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
]	NNP	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypoproteinemia	NN	O
,	,	O
200	CD	DOS
to	TO	O
300	CD	DOS
mL	NN	UNIT
of	IN	O
25	CD	O
%	NN	O
albumin	NN	O
may	MD	O
be	VB	O
required	VBN	O
to	TO	O
reduce	VB	O
edema	NN	O
and	CC	O
to	TO	O
bring	VB	O
serum	JJ	O
protein	NN	O
values	NNS	O
to	TO	O
normal	JJ	O
.	.	O

To	TO	O
administer	VB	O
1.25	CD	DOS
mg	NN	UNIT
or	CC	O
0.63	CD	DOS
mg	NN	UNIT
of	IN	O
albuterol	NN	O
,	,	O
use	VBP	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
one	CD	DOS
unit	NN	UNIT
-	:	O
dose	JJ	O
vial	JJ	O
(	(	O
3	CD	DOS
mL	NN	UNIT
of	IN	O
1.25	CD	DOS
mg	NNS	UNIT
or	CC	O
0.63	CD	DOS
mg	JJ	UNIT
inhalation	NN	O
solution	NN	O
)	)	O
by	IN	O
nebulization	NN	O
.	.	O

If	IN	O
the	DT	O
dose	NN	O
requires	VBZ	O
more	JJR	O
than	IN	O
one	CD	DOS
vial	NN	UNIT
,	,	O
use	VB	O
a	DT	O
separate	JJ	O
,	,	O
unused	JJ	O
Mix2Vial®	NNP	O
transfer	NN	O
set	NN	O
for	IN	O
each	DT	O
product	NN	O
vial	NN	O
.	.	O

Instruct	IN	O
the	DT	O
patient	NN	O
to	TO	O
keep	VB	O
the	DT	O
wick	NN	O
in	IN	O
for	IN	O
at	IN	PER
least	JJS	PER
24	CD	PER
hours	NNS	PER
and	CC	O
to	TO	O
keep	VB	O
it	PRP	O
moist	JJ	O
by	IN	O
adding	VBG	O
3	CD	DOS
to	TO	O
5	CD	DOS
drops	NNS	UNIT
of	IN	O
Acetic	NNP	O
Acid	NNP	O
Otic	NNP	O
Solution	NNP	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
.	.	O

Patients	NNS	O
must	MD	O
also	RB	O
receive	VB	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
intramuscular	JJ	O
injection	NN	O
of	IN	O
vitamin	JJ	O
B12	NNP	O
during	IN	O
the	DT	O
week	NN	O
preceding	VBG	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
ALIMTA	NNP	O
and	CC	O
every	DT	O
3	CD	O
cycles	NNS	O
thereafter	RB	O
.	.	O

Depending	VBG	O
upon	IN	O
tolerance	NN	O
,	,	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
100	CD	DOS
mg	NNS	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	O
week	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
80	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Oral	JJ	O
:	:	O
One	CD	DOS
tablet	NN	UNIT
one	CD	FREQ
to	TO	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACTIMMUNE	NNP	O
administered	VBD	O
subcutaneously	RB	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
CGD	NNP	WHO
and	CC	WHO
SMO	NNP	WHO
is	VBZ	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
:	:	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
interdigital	JJ	O
tinea	NN	O
pedis	NN	O
,	,	O
ERTACZO	NNP	O
cream	NN	O
,	,	O
2	CD	O
%	NN	O
,	,	O
should	MD	O
be	VB	O
applied	VBN	O
twice	JJ	FREQ
daily	RB	FREQ
for	IN	O
4	CD	PER
weeks	NNS	PER
.	.	O

Patients	NNS	O
receiving	VBG	O
30	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
should	MD	O
receive	VB	O
25	CD	DOS
mg	NN	UNIT
of	IN	O
the	DT	O
solution	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

0	CD	DOS
-	:	O
0.03PPM	CD	DOS

The	DT	O
rate	NN	O
of	IN	O
IV	NNP	O
injection	NN	O
for	IN	O
adults	NNS	WHO
should	MD	O
not	RB	O
exceed	VB	O
50	CD	DOS
mg	JJ	UNIT
/	NNP	O
min	NN	O
to	TO	O
prevent	VB	O
sleep	NN	O
or	CC	O
sudden	JJ	O
respiratory	NN	O
depression	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
for	IN	O
induction	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
0.3	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
,	,	O
injected	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
30	CD	O
to	TO	O
60	CD	O
seconds	NNS	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
underlying	JJ	WHO
cardiac	NNS	WHO
or	CC	WHO
respiratory	JJ	WHO
compromise	NN	WHO
and	CC	WHO
weighing	VBG	WHO
up	RB	WHO
to	TO	WHO
30	CD	WHO
kg	NNS	WHO
,	,	O
physicians	NNS	O
may	MD	O
consider	VB	O
diluting	VBG	O
ALDURAZYME	NNP	O
in	IN	O
a	DT	O
volume	NN	O
of	IN	O
100	CD	DOS
mL	NNS	UNIT
and	CC	O
administering	VBG	O
at	IN	O
a	DT	O
decreased	JJ	O
infusion	NN	O
rate	NN	O
[	NNP	O
see	VBP	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
below	IN	O
,	,	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

Addition	NN	O
of	IN	O
iron	NN	O
is	VBZ	O
more	RBR	O
critical	JJ	O
in	IN	O
the	DT	WHO
infant	NN	WHO
than	IN	O
the	DT	WHO
adult	NN	WHO
because	IN	O
of	IN	O
the	DT	O
increasing	VBG	O
red	JJ	O
cell	NN	O
mass	NN	O
required	VBN	O
for	IN	O
the	DT	O
growing	VBG	O
infant	NN	O
.	.	O

Bottles	NNS	O
of	IN	O
60	CD	O
NDC	NNP	O
64764	CD	O
-	:	O
158	CD	O
-	:	O
60	CD	O
Bottles	NNS	O
of	IN	O
180	CD	O
NDC	NNP	O
64764	CD	O
-	:	O
158	CD	O
-	:	O
18	CD	O

For	IN	O
patients	NNS	WHO
aged	VBN	WHO
12	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
the	DT	O
dosage	NN	O
is	VBZ	O
2	CD	DOS
inhalations	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

0.1	CD	DOS
to	TO	O
0.2	CD	DOS
mL	NNS	UNIT
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
(	(	O
0.045	CD	DOS
to	TO	O
0.09	CD	DOS
mL	NNS	UNIT
per	IN	O
pound	NN	O
of	IN	O
body	NN	O
weight	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
preferable	JJ	O
to	TO	O
initiate	VB	O
dosing	VBG	O
24	CD	O
to	TO	O
28	CD	O
hours	NNS	O
before	IN	O
ascent	NN	O
and	CC	O
to	TO	O
continue	VB	O
for	IN	O
48	CD	PER
hours	NNS	PER
while	IN	O
at	IN	O
high	JJ	O
altitude	NN	O
,	,	O
or	CC	O
longer	RB	O
as	IN	O
necessary	JJ	O
to	TO	O
control	VB	O
symptoms	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	WHO
without	IN	WHO
congestive	JJ	WHO
heart	NN	WHO
failure	NN	WHO
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
or	CC	O
30	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
phosphate	NN	O
added	VBN	O
to	TO	O
a	DT	O
liter	NN	O
of	IN	O
TPN	NNP	O
solution	NN	O
(	(	O
containing	VBG	O
25	CD	O
%	NN	O
dextrose	NN	O
)	)	O
is	VBZ	O
12	CD	DOS
to	TO	O
15	CD	DOS
mM	NNS	UNIT
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
moderately	RB	WHO
impaired	JJ	WHO
hepatic	JJ	WHO
function	NN	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
Class	NNP	WHO
B	NNP	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
16	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
hyperchloremic	JJ	WHO
or	CC	WHO
other	JJ	WHO
metabolic	JJ	WHO
acidoses	NNS	WHO
,	,	O
sodium	NN	O
and	CC	O
potassium	NN	O
may	MD	O
be	VB	O
added	VBN	O
as	IN	O
the	DT	O
acetate	NN	O
salts	NNS	O
to	TO	O
provide	VB	O
bicarbonate	NN	O
precursor	NN	O
.	.	O

The	DT	O
patient	NN	O
may	MD	O
be	VB	O
kept	VBN	O
on	IN	O
his	PRP$	O
schedule	NN	O
until	IN	O
again	RB	O
95	CD	O
percent	NN	O
clear	JJ	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
ADVATE	NN	O
Dosing	VBG	O
for	IN	O
Perioperative	NNP	O
Management	NNP	O
in	IN	O
Adults	NNP	WHO
and	CC	WHO
Children	NNP	WHO

For	IN	O
adults	NNS	WHO
,	,	O
an	DT	O
initial	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NN	UNIT
of	IN	O
ALDACTONE	NNP	O
administered	VBD	O
in	IN	O
either	DT	O
single	JJ	DOS
or	CC	O
divided	JJ	UNIT
doses	NNS	UNIT
is	VBZ	O
recommended	VBN	O
.	.	O

Alosetron	NNP	O
hydrochloride	JJ	O
tablets	NNS	O
should	MD	O
be	VB	O
discontinued	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
not	RB	WHO
had	VBN	WHO
adequate	JJ	WHO
control	NN	WHO
of	IN	O
IBS	NNP	O
symptoms	NNS	O
after	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
1	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
are	VBP	O
at	IN	O
increased	JJ	O
risk	NN	O
of	IN	O
propylene	NN	O
glycol	NN	O
-	:	O
associated	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

In	IN	O
some	DT	O
acute	JJ	O
cases	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
more	JJR	O
satisfactory	JJ	O
to	TO	O
administer	VB	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
500	CD	DOS
mg	NN	UNIT
followed	VBN	O
by	IN	O
125	CD	DOS
or	CC	O
250	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
case	NN	O
.	.	O

ACCOLATE	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatitis	NN	WHO
or	CC	O
in	IN	O
long	JJ	O
-	:	O
term	NN	O
studies	NNS	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
cirrhosis	NN	WHO
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
to	TO	O
2	CD	DOS
g	NNS	UNIT
in	IN	O
two	CD	DOS
to	TO	O
four	CD	DOS
doses	NNS	UNIT
.	.	O

Since	IN	O
such	JJ	O
patients	NNS	O
usually	RB	O
have	VBP	O
approximately	RB	O
normal	JJ	O
blood	NN	O
volume	NN	O
,	,	O
doses	NNS	O
of	IN	O
more	JJR	O
than	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
25	CD	O
%	NN	O
albumin	NN	O
should	MD	O
not	RB	O
be	VB	O
given	VBN	O
faster	JJR	O
than	IN	O
100	CD	DOS
mL	NN	UNIT
in	IN	O
30	CD	O
to	TO	O
45	CD	O
minutes	NNS	O
to	TO	O
avoid	VB	O
circulatory	JJ	O
embarrassment	NN	O
.	.	O

Acute	NNP	O
epididymo	SYM	O
-	:	O
orchitis	NN	O
caused	VBN	O
by	IN	O
C.	NNP	O
trachomatis	NN	O
:	:	O
100	CD	DOS
mg	NN	UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
at	IN	PER
least	JJ	PER
10	CD	PER
days	NNS	PER
.	.	O

To	TO	O
measure	VB	O
ERPF	NNP	O
,	,	O
the	DT	O
concentration	NN	O
of	IN	O
PAH	NNP	O
in	IN	O
the	DT	O
plasma	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
at	IN	O
2	CD	DOS
mg	NNS	UNIT
per	IN	O
100	CD	DOS
mL	NN	UNIT
,	,	O
which	WDT	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
a	DT	O
priming	VBG	O
dose	NN	O
of	IN	O
6	CD	DOS
to	TO	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
and	CC	O
an	DT	O
infusion	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
to	TO	O
24	CD	DOS
mg	NNS	UNIT
/	JJ	O
min	NN	O
.	.	O

The	DT	O
drug	NN	O
is	VBZ	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
infusion	NN	UNIT
over	IN	O
15	CD	O
to	TO	O
20	CD	O
minutes	NNS	O
.	.	O

Acute	NNP	O
epididymo	SYM	O
-	:	O
orchitis	NN	O
caused	VBN	O
by	IN	O
N.	NNP	O
gonorrhoeae	NN	O
:	:	O
100	CD	DOS
mg	NN	UNIT
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
at	IN	PER
least	JJ	PER
10	CD	PER
days	NNS	PER
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
cisplatin	NN	O
is	VBZ	O
75	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
infused	VBD	O
over	IN	O
2	CD	O
hours	NNS	O
beginning	VBG	O
approximately	RB	O
30	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
ALIMTA	NNP	O
administration	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	DOS
applicatorful	NN	UNIT
,	,	O
administered	VBN	O
intravaginally	RB	O
,	,	O
morning	NN	O
and	CC	O
evening	NN	O
.	.	O

Aminosyn	NNP	O
II	NNP	O
8.5	CD	O
%	NN	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
with	IN	O
electrolytes	NNS	O
)	)	O
WITH	NNP	O
ELECTROLYTES	NNP	O
is	VBZ	O
designed	VBN	O
to	TO	O
supply	VB	O
necessary	JJ	O
electrolytes	NNS	O
to	TO	O
patients	NNS	WHO
in	IN	WHO
a	DT	WHO
stable	JJ	WHO
metabolic	JJ	WHO
state	NN	WHO
(	(	O
about	IN	O
three	CD	O
-	:	O
fourths	NNS	O
of	IN	O
all	DT	WHO
patients	NNS	WHO
on	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
)	)	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
adequately	RB	WHO
to	TO	O
the	DT	O
starting	VBG	O
dose	NN	O
after	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
therapy	NN	O
,	,	O
higher	JJR	O
doses	NNS	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

Apply	NNP	O
twice	JJ	FREQ
daily	RB	FREQ
morning	NN	O
and	CC	O
evening	NN	O
(	(	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
)	)	O
,	,	O
for	IN	O
3	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
then	RB	O
withhold	VBD	O
use	NN	O
for	IN	O
4	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

A	DT	O
separate	JJ	O
sterile	JJ	O
syringe	NN	O
and	CC	O
needle	JJ	O
must	MD	O
be	VB	O
used	VBN	O
for	IN	O
each	DT	O
injection	NN	O
to	TO	O
prevent	VB	O
transmission	NN	O
of	IN	O
infectious	JJ	O
agents	NNS	O
from	IN	O
one	CD	O
person	NN	O
to	TO	O
another	DT	O
.	.	O

Patients	NNS	O
should	MD	O
discontinue	VB	O
therapy	NN	O
if	IN	O
Grade	NNP	O
3	CD	O
or	CC	O
4	CD	O
neurotoxicity	NN	O
is	VBZ	O
experienced	VBN	O
.	.	O

(	(	O
2	CD	O
)	)	O
Protective	NNP	O
shielding	NN	O
of	IN	O
lamps	NNS	O
:	:	O
The	DT	O
patient	NN	O
should	MD	O
not	RB	O
be	VB	O
able	JJ	O
to	TO	O
come	VB	O
in	IN	O
contact	NN	O
with	IN	O
the	DT	O
bare	NN	O
lamps	VBZ	O
.	.	O

For	IN	O
smaller	JJR	WHO
patients	NNS	WHO
(	(	WHO
<	JJ	WHO
65	CD	WHO
kg	NN	WHO
)	)	WHO
,	,	O
a	DT	O
dose	NN	O
of	IN	O
1.25	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
administered	VBN	O
over	IN	O
3	CD	O
hours	NNS	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

However	RB	O
,	,	O
older	JJR	WHO
pediatric	JJ	WHO
patients	NNS	WHO
can	MD	O
receive	VB	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
of	IN	O
AKYNZEO	NNP	O
approximately	RB	O
1	CD	O
hour	NN	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
chemotherapy	NN	O
with	IN	O
dexamethasone	NN	O
12	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
chemotherapy	VB	O
on	IN	O
day	NN	O
1	CD	O
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	DOS
g	NNS	UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

Withdraw	JJ	O
0.6	CD	DOS
mL	NN	UNIT
of	IN	O
0.4	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
or	CC	O
Tripedia	NNP	O
vaccine	NN	O
as	IN	O
indicated	JJ	O
.	.	O

If	IN	O
potential	JJ	O
allergy	NN	O
is	VBZ	O
suspected	VBN	O
,	,	O
an	DT	O
intradermal	JJ	O
skin	JJ	O
test	NN	O
may	MD	O
be	VB	O
performed	VBN	O
prior	RB	O
to	TO	O
intravenous	JJ	O
administration	NN	O
,	,	O
i.e	FW	O
,	,	O
0.05	CD	DOS
mL	NN	UNIT
injection	NN	UNIT
intradermally	RB	O
to	TO	O
be	VB	O
evaluated	VBN	O
30	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
following	VBG	O
injection	NN	O
.	.	O

A	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
400	CD	DOS
mcg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
when	WRB	WHO
starting	VBG	WHO
therapy	NN	WHO
with	IN	WHO
AllerNaze	NNP	WHO
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
nasal	IN	O
spray	NN	O
)	)	O
in	IN	O
cases	NNS	O
where	WRB	O
a	DT	O
faster	RBR	O
onset	NN	O
of	IN	O
relief	NN	O
is	VBZ	O
desirable	JJ	O
.	.	O

Apply	NNP	O
and	CC	O
gently	RB	O
massage	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
FINACEA	NNP	O
Gel	NNP	O
into	IN	O
the	DT	O
affected	JJ	O
areas	NNS	O
on	IN	O
the	DT	O
face	NN	O
twice	RB	FREQ
daily	RB	FREQ
(	(	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
.	.	O

Figure	NN	O
1	CD	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
MICRONASE	NNP	O
Tablets	NNP	O
is	VBZ	O
2.5	CD	DOS
to	TO	O
5	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
,	,	O
administered	VBN	O
with	IN	O
breakfast	NN	O
or	CC	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
.	.	O

AVITA®	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
in	IN	O
the	DT	O
evening	NN	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
enough	JJ	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
lightly	RB	O
.	.	O

Alternatively	RB	O
,	,	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
D30	NNP	O
or	CC	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
D50	NNP	O
once	RB	FREQ
daily	JJ	FREQ
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Dosage	NN	O
is	VBZ	O
adjusted	VBN	O
to	TO	O
between	IN	O
1	CD	DOS
and	CC	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
depending	VBG	O
upon	IN	O
the	DT	O
hematological	JJ	O
response	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
8	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

A	DT	O
dose	NN	O
of	IN	O
one	CD	DOS
tablet	NN	UNIT
once	IN	FREQ
daily	JJ	FREQ
is	VBZ	O
recommended	VBN	O
as	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
decreased	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
VPRIV	NNP	O
dosage	NN	O
in	IN	O
naïve	JJ	WHO
adults	NNS	WHO
and	CC	WHO
naïve	JJ	WHO
pediatric	JJ	WHO
patients	NNS	WHO
4	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
60	CD	DOS
Units	NNS	UNIT
/	VBP	O
kg	NN	O
administered	VBN	O
every	DT	O
other	JJ	O
week	NN	O
as	IN	O
a	DT	O
60	CD	DOS
-	:	O
minute	NN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

Syncope	NN	O
in	IN	O
older	JJR	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
related	VBN	O
to	TO	O
an	DT	O
increased	VBN	O
sensitivity	NN	O
and	CC	O
advanced	VBD	O
arteriosclerotic	JJ	O
vascular	JJ	O
disease	NN	O
.	.	O

If	IN	O
such	JJ	O
circumstances	NNS	O
are	VBP	O
suspected	VBN	O
to	TO	O
be	VB	O
present	JJ	O
,	,	O
initiate	JJ	O
dosing	NN	O
at	IN	O
1.25	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

After	IN	O
the	DT	O
first	JJ	O
ABILIFY	NNP	O
MAINTENA	NNP	O
injection	NN	O
,	,	O
administer	RB	O
oral	JJ	O
aripiprazole	NN	O
(	(	O
10	CD	DOS
mg	NN	UNIT
to	TO	O
20	CD	DOS
mg	NNS	UNIT
)	)	O
for	IN	O
14	CD	PER
consecutive	JJ	PER
days	NNS	PER
to	TO	O
achieve	VB	O
therapeutic	JJ	O
aripiprazole	JJ	O
concentrations	NNS	O
during	IN	O
initiation	NN	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
200	CD	DOS
mg	NN	UNIT
and	CC	O
160	CD	DOS
mg	NN	UNIT
dosage	NN	O
adjustments	NNS	O
are	VBP	O
obtained	VBN	O
only	RB	O
by	IN	O
using	VBG	O
the	DT	O
300	CD	DOS
mg	NN	UNIT
or	CC	O
400	CD	DOS
mg	JJ	UNIT
strength	NN	O
vials	NNS	O
.	.	O

PEGANONE	NNP	O
(	(	O
ethotoin	JJ	O
tablets	NNS	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
administered	VBN	O
orally	RB	O
in	IN	O
4	CD	DOS
to	TO	O
6	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
daily	RB	FREQ
.	.	O

100	CD	DOS
mg	NN	UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
at	IN	PER
least	JJ	PER
7	CD	PER
days	NNS	PER
.	.	O

The	DT	O
solution	NN	O
for	IN	O
intravenous	JJ	O
use	NN	O
is	VBZ	O
prepared	VBN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
500	CD	DOS
mg	NN	UNIT
vial	NN	UNIT
to	TO	O
100	CD	DOS
or	CC	O
200	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
diluent	NN	O
such	JJ	O
as	IN	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
or	CC	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
or	CC	O
any	DT	O
other	JJ	O
compatible	JJ	O
solution	NN	O
.	.	O

ALDACTONE	NNP	O
is	VBZ	O
administered	VBN	O
at	IN	O
a	DT	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
400	CD	DOS
mg	NN	UNIT
for	IN	O
three	CD	O
to	TO	O
four	CD	O
weeks	NNS	O
.	.	O

Second	JJ	O
Dose	NNP	O
:	:	O
50	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
250	CD	DOS
mL	NN	UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
4	CD	O
hrs	NNS	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
30	CD	DOS
mg	NN	UNIT
to	TO	O
60	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
used	VBD	O
dose	JJ	O
schedule	NN	O
when	WRB	O
used	VBN	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
is	VBZ	O
60	CD	DOS
to	TO	O
75	CD	DOS
mg	NNS	UNIT
/	JJ	O
m2	NN	O
as	IN	O
a	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
injection	NN	UNIT
administered	VBD	O
at	IN	O
21	CD	O
-	:	O
day	NN	O
intervals	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AFINITOR	NNP	O
Tablets	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
,	,	O
to	TO	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
every	DT	O
day	NN	O
.	.	O

In	IN	O
those	DT	O
patients	NNS	WHO
with	IN	WHO
an	DT	WHO
intact	JJ	WHO
uterus	NN	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
using	VBG	WHO
concomitant	JJ	WHO
progestin	NN	WHO
therapy	NN	WHO
,	,	O
Alora	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
on	IN	O
a	DT	O
cyclic	JJ	O
schedule	NN	O
(	(	O
e.g	NN	O
,	,	O
3	CD	O
weeks	NNS	O
of	IN	O
therapy	NN	O
followed	VBN	O
by	IN	O
1	CD	O
week	NN	O
without	IN	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postmenopausal	NN	O
symptoms	NNS	O
.	.	O

Figure	NN	O
9	CD	O

For	IN	O
some	DT	WHO
patients	NNS	WHO
,	,	O
half	JJ	DOS
tablet	NN	UNIT
(	(	O
18.75	CD	DOS
mg	NN	UNIT
)	)	O
daily	NN	FREQ
may	MD	O
be	VB	O
adequate	JJ	O
,	,	O
while	IN	O
in	IN	O
some	DT	O
cases	NNS	O
it	PRP	O
may	MD	O
be	VB	O
desirable	JJ	O
to	TO	O
give	VB	O
half	NN	DOS
tablets	NNS	UNIT
(	(	O
18.75	CD	DOS
mg	NN	UNIT
)	)	O
two	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
effective	JJ	O
dose	NN	O
is	VBZ	O
1	CD	DOS
-	:	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
but	CC	O
higher	JJR	O
doses	NNS	O
may	MD	O
be	VB	O
required	VBN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
elderly	JJ	WHO
or	CC	WHO
debilitated	JJ	WHO
patients	NNS	WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
treatment	NN	O
regimen	NNS	O
is	VBZ	O
30	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
2	CD	PER
months	NNS	PER
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
require	VBP	WHO
treatment	NN	WHO
with	IN	WHO
moderate	JJ	WHO
CYP3A4	NNP	WHO
/	NNP	O
PgP	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
amprenavir	NN	O
,	,	O
fosamprenavir	NN	O
,	,	O
aprepitant	NN	O
,	,	O
erythromycin	NN	O
,	,	O
fluconazole	NN	O
,	,	O
verapamil	NN	O
,	,	O
diltiazem	NN	O
)	)	O
:	:	O

AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

A	DT	O
basic	JJ	O
solution	NN	O
for	IN	O
pediatric	JJ	O
use	NN	O
should	MD	O
contain	VB	O
25	CD	DOS
grams	NNS	UNIT
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
200	CD	DOS
to	TO	O
250	CD	DOS
grams	NNS	UNIT
of	IN	O
glucose	NN	O
per	IN	O
1000	CD	DOS
mL	NN	UNIT
,	,	O
administered	VBN	O
from	IN	O
bottles	NNS	O
containing	VBG	O
250	CD	DOS
or	CC	O
500	CD	DOS
mL	NN	UNIT
.	.	O

(	(	O
Use	NNP	O
only	RB	O
one	CD	DOS
filter	NN	UNIT
per	IN	O
vial	NN	O
of	IN	O
AmBisome	NNP	O
.	.	O
)	)	O

The	DT	O
solution	NN	O
for	IN	O
intravenous	JJ	O
use	NN	O
is	VBZ	O
prepared	VBN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
500	CD	DOS
mg	NN	UNIT
vial	NN	UNIT
to	TO	O
100	CD	DOS
or	CC	O
200	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
diluent	NN	O
such	JJ	O
as	IN	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
or	CC	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
or	CC	O
any	DT	O
of	IN	O
the	DT	O
compatible	JJ	O
solutions	NNS	O
listed	VBN	O
below	IN	O
.	.	O

AEROSPAN	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
in	IN	O
asthmatic	JJ	WHO
patients	NNS	WHO
aged	VBN	WHO
6	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

ABSTRAL	NNP	O
is	VBZ	O
not	RB	O
equivalent	JJ	O
on	IN	O
a	DT	O
mcg	NN	O
per	IN	O
mcg	JJ	O
basis	NN	O
with	IN	O
all	DT	O
other	JJ	O
fentanyl	NN	O
products	NNS	O
,	,	O
therefore	RB	O
,	,	O
do	VBP	O
not	RB	O
switch	VB	O
patients	NNS	O
on	IN	O
a	DT	O
mcg	NN	O
per	IN	O
mcg	JJ	O
basis	NN	O
from	IN	O
any	DT	O
other	JJ	O
fentanyl	JJ	O
product	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Accutane	NNP	O
(	(	O
isotretinoin	NN	O
)	)	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	O
to	TO	O
20	CD	O
weeks	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	DOS
20	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
three	CD	FREQ
times	NNS	FREQ
daily	JJ	FREQ
before	IN	O
meals	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	DOS
mg	NN	UNIT
)	)	O
for	IN	O
overweight	NN	WHO
adults	NNS	WHO
18	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
1	CD	DOS
60	CD	DOS
-	:	O
mg	NN	UNIT
capsule	NN	UNIT
with	IN	O
each	DT	O
meal	NN	O
containing	VBG	O
fat	NN	O
.	.	O

Estimated	VBN	O
Increment	NNP	O
of	IN	O
Factor	NNP	O
VIII	NNP	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
=	FW	O
[	JJ	O
Total	NNP	O
Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
/	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
]	VBZ	O
x	$	O
2	CD	DOS
(	(	O
IU	NNP	O
/	NNP	O
dL	NN	O
per	IN	O
IU	NNP	O
/	NNP	O
kg	NN	O
)	)	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMJEVITA	NNP	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
rheumatoid	JJ	WHO
arthritis	NN	WHO
(	(	O
RA	NNP	O
)	)	O
,	,	O
psoriatic	JJ	O
arthritis	NN	O
(	(	O
PsA	NNP	O
)	)	O
,	,	O
or	CC	O
ankylosing	VBG	O
spondylitis	NN	O
(	(	O
AS	IN	O
)	)	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
administered	VBN	O
every	DT	O
other	JJ	O
week	NN	O
.	.	O

Dosage	NN	O
is	VBZ	O
usually	RB	O
prescribed	VBN	O
on	IN	O
a	DT	O
g	NN	O
/	NNP	O
kg	VBZ	O
body	NN	O
weight	JJ	O
/	NNP	FREQ
day	NN	FREQ
basis	NN	O
and	CC	O
patient	JJ	O
age	NN	O
as	IN	O
follows	VBZ	O
:	:	O
infants	NNS	WHO
,	,	O
2	CD	DOS
to	TO	O
3	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
ages	VBZ	WHO
1	CD	WHO
to	TO	WHO
3	CD	WHO
years	NNS	WHO
,	,	O
2	CD	DOS
to	TO	O
2.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
ages	VBZ	WHO
4	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
,	,	O
2	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
ages	VBZ	WHO
13	CD	WHO
to	TO	WHO
15	CD	WHO
years	NNS	WHO
,	,	O
1.7	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
ages	VBZ	WHO
16	CD	WHO
and	CC	WHO
above	RB	WHO
,	,	O
1.5	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
hyperchloremic	JJ	WHO
or	CC	WHO
other	JJ	WHO
metabolic	JJ	WHO
acidosis	NN	WHO
,	,	O
sodium	NN	O
and	CC	O
potassium	NN	O
may	MD	O
be	VB	O
added	VBN	O
as	IN	O
the	DT	O
acetate	NN	O
or	CC	O
lactate	NN	O
salts	NNS	O
to	TO	O
provide	VB	O
bicarbonate	NN	O
alternates	NNS	O
.	.	O

A	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
maintenance	NN	O
dosage	NN	O
is	VBZ	O
usually	RB	O
4	CD	DOS
to	TO	O
8	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

Storage	NN	O
:	:	O
Store	NN	O
at	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
BLOCADREN	NNP	O
(	(	O
timolol	NN	O
)	)	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
whether	IN	O
used	VBN	O
alone	RB	O
or	CC	O
added	VBN	O
to	TO	O
diuretic	JJ	O
therapy	NN	O
.	.	O

Image	NN	O
reconstruction	NN	O
should	MD	O
include	VB	O
attenuation	NN	O
correction	NN	O
with	IN	O
resulting	VBG	O
transaxial	JJ	O
pixel	NN	O
sizes	NNS	O
between	IN	O
2	CD	O
and	CC	O
3	CD	O
mm	NN	O
.	.	O

Given	VBN	O
the	DT	O
possibility	NN	O
of	IN	O
extravasation	NN	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
closely	RB	O
monitor	VB	O
the	DT	O
infusion	NN	O
site	NN	O
for	IN	O
possible	JJ	O
infiltration	NN	O
during	IN	O
drug	NN	O
administration	NN	O
.	.	O

Children	NNS	WHO
:	:	O
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
100	CD	WHO
pounds	NNS	WHO
(	(	WHO
45	CD	WHO
kg	NN	WHO
)	)	WHO
:	:	O
1	CD	DOS
mg	NN	UNIT
/	NN	O
lb	NN	O
(	(	O
2.2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
60	CD	PER
days	NNS	PER
.	.	O

Examples	NNS	O
of	IN	O
cartridge	NN	O
combinations	NNS	O
for	IN	O
doses	NNS	O
of	IN	O
up	IN	O
to	TO	O
24	CD	DOS
units	NNS	UNIT
are	VBP	O
shown	VBN	O
in	IN	O
Figure	NNP	O
1	CD	O
.	.	O

If	IN	O
immediate	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
possible	JJ	O
,	,	O
the	DT	O
diluted	JJ	O
solution	NN	O
should	MD	O
be	VB	O
stored	VBN	O
refrigerated	VBN	O
at	IN	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
for	IN	O
up	IN	O
to	TO	O
36	CD	O
hours	NNS	O
.	.	O

Use	NNP	O
of	IN	O
NIASPAN	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
or	CC	O
hepatic	JJ	O
insufficiency	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

A	DT	O
patient	NN	WHO
who	WP	WHO
becomes	VBZ	WHO
hypotensive	VBP	WHO
at	IN	WHO
this	DT	WHO
dose	NN	WHO
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
1.25	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
and	CC	O
after	IN	O
one	CD	O
week	NN	O
at	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
,	,	O
patients	NNS	O
should	MD	O
then	RB	O
be	VB	O
titrated	VBN	O
(	(	O
if	IN	O
tolerated	VBN	O
)	)	O
toward	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
with	IN	O
dosage	NN	O
increases	NNS	O
being	VBG	O
about	IN	O
3	CD	O
weeks	NNS	O
apart	RB	O
.	.	O

Dosage	NN	O
for	IN	O
Adults	NNP	WHO
-	:	O
a	DT	O
single	JJ	DOS
0.075	CD	DOS
mg	NN	UNIT
intravenous	JJ	UNIT
dose	NN	UNIT
administered	VBD	O
over	IN	O
10	CD	O
seconds	NNS	O
immediately	RB	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Acetadote	NNP	O
recommended	VBD	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
15,000	CD	DOS
mg	NNS	UNIT
infused	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
one	CD	O
hour	NN	O
followed	VBN	O
by	IN	O
a	DT	O
first	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
5,000	CD	DOS
mg	NN	UNIT
over	IN	O
4	CD	O
hours	NNS	O
and	CC	O
a	DT	O
second	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
10,000	CD	DOS
mg	NN	UNIT
over	IN	O
16	CD	O
hours	NNS	O
(	(	O
See	VB	O
Table	NNP	O
3	CD	O
)	)	O
.	.	O

Administer	RB	O
ABLAVAR	NNP	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
,	,	O
manually	RB	O
or	CC	O
by	IN	O
power	NN	O
injection	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.12	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
(	(	O
0.03	CD	DOS
mmol	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
up	IN	O
to	TO	O
30	CD	O
seconds	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
25	CD	DOS
-	:	O
30	CD	DOS
mL	NN	UNIT
normal	JJ	O
saline	JJ	O
flush	NN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
1.25	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
10	CD	DOS
mg	JJ	UNIT
once	RB	FREQ
daily	JJ	FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
the	DT	O
evening	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
Hepatic	JJ	WHO
Impairment	NN	WHO
:	:	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
failure	NN	WHO
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

If	IN	O
patients	NNS	O
require	VBP	O
co	JJ	O
-	:	O
administration	NN	O
of	IN	O
a	DT	O
strong	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inducer	NN	O
,	,	O
consider	VB	O
doubling	VBG	O
the	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
AFINITOR	NNP	O
using	VBG	O
increments	NNS	O
of	IN	O
5	CD	DOS
mg	NN	UNIT
or	CC	O
less	JJR	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
20	CD	DOS
-	:	O
60	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
in	IN	O
single	JJ	DOS
doses	NNS	UNIT
taken	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

Doses	NNS	O
of	IN	O
ADVICOR	NNP	O
greater	JJR	O
than	IN	O
2000	CD	DOS
mg	NN	UNIT
/	VBD	O
40	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

AMEVIVE®	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
if	IN	O
the	DT	O
counts	NNS	O
remain	VBP	O
below	IN	O
250	CD	DOS
cells	NNS	UNIT
/	JJ	O
µL	NNP	O
for	IN	O
one	CD	PER
month	NN	PER
[	VBD	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

With	IN	O
one	CD	O
hand	NN	O
,	,	O
grasp	VBP	O
the	DT	O
AFSTYLA	NNP	O
side	NN	O
of	IN	O
the	DT	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
and	CC	O
with	IN	O
the	DT	O
other	JJ	O
hand	NN	O
grasp	VBD	O
the	DT	O
blue	JJ	O
diluent	NN	O
-	:	O
side	NN	O
of	IN	O
the	DT	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
,	,	O
and	CC	O
unscrew	VBD	O
the	DT	O
set	VBN	O
into	IN	O
two	CD	O
pieces	NNS	O
.	.	O

100	CD	DOS
mg	NN	UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Aldara	NNP	O
Cream	NNP	O
is	VBZ	O
packaged	VBN	O
in	IN	O
single	JJ	DOS
-	:	O
use	NN	O
packets	NNS	O
,	,	O
with	IN	O
12	CD	DOS
packets	NNS	UNIT
supplied	VBN	O
per	IN	O
box	NN	O
.	.	O

A	DT	O
single	JJ	DOS
vaccine	NN	UNIT
dose	NN	UNIT
is	VBZ	O
administered	VBN	O
orally	RB	O
as	IN	O
two	CD	DOS
tablets	NNS	UNIT
:	:	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
Adenovirus	NNP	O
Type	NNP	O
4	CD	O
and	CC	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
Adenovirus	NNP	O
Type	NNP	O
7	CD	O
.	.	O

Titration	NN	O
Steps	NNS	O
:	:	O
If	IN	O
adequate	JJ	O
analgesia	NN	O
was	VBD	O
not	RB	O
obtained	VBN	O
with	IN	O
the	DT	O
first	JJ	O
100	CD	DOS
mcg	NN	UNIT
dose	NN	UNIT
,	,	O
continue	VBP	O
dose	JJ	O
escalation	NN	O
in	IN	O
a	DT	O
stepwise	NN	O
manner	NN	O
over	IN	O
consecutive	JJ	O
breakthrough	NN	O
episodes	NNS	O
until	IN	O
adequate	JJ	O
analgesia	NNS	O
with	IN	O
tolerable	JJ	O
side	NN	O
effects	NNS	O
is	VBZ	O
achieved	VBN	O
.	.	O

Following	VBG	O
an	DT	O
anesthetic	JJ	O
induction	NN	O
dose	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
,	,	O
infusion	NN	O
rate	NN	O
requirements	NNS	O
are	VBP	O
reduced	VBN	O
by	IN	O
30	CD	O
-	:	O
50	CD	O
%	NN	O
for	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
maintenance	NN	O
.	.	O

Regimens	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
ACCURETIC	NNP	O
need	MD	O
not	RB	O
take	VB	O
account	NN	O
of	IN	O
renal	JJ	O
function	NN	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
patient	NN	O
's	POS	O
creatinine	JJ	O
clearance	NN	O
is	VBZ	O
>	JJ	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	DOS
m²	NN	UNIT
(	(	O
serum	JJ	O
creatinine	NN	O
roughly	RB	O
≤	$	O
3	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	UNIT
or	CC	O
265	CD	DOS
μmol	JJ	UNIT
/	NNP	O
L	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
CHOLBAM	NNP	O
is	VBZ	O
10	CD	DOS
to	TO	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
administered	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
or	CC	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
,	,	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
and	CC	WHO
in	IN	WHO
adults	NNS	WHO
.	.	O

UVA	NNP	O
exposure	NN	O
may	MD	O
be	VB	O
held	VBN	O
constant	JJ	O
or	CC	O
increased	VBN	O
by	IN	O
up	IN	O
to	TO	O
1.0	CD	DOS
Joule	NNP	UNIT
/	NNP	O
cm²	NN	UNIT
at	IN	O
each	DT	O
treatment	NN	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
.	.	O

0.140	CD	DOS
(	(	O
mg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
min	NN	O
)	)	O
x	FW	O
total	JJ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
/	FW	O
Adenoscan	JJ	O
concentration	NN	O
(	(	O
3mg	CD	DOS
/	NNP	O
mL	NN	O
)	)	O
=	VBZ	O
Infusion	NNP	O
rate	NN	O
(	(	O
mL	JJ	O
/	NNP	O
min	NN	O
)	)	O

Each	DT	O
vial	NN	O
of	IN	O
ALDURAZYME	NNP	O
provides	VBZ	O
2.9	CD	DOS
milligrams	NNS	UNIT
(	(	O
mg	NN	UNIT
)	)	O
of	IN	O
laronidase	NN	O
in	IN	O
5.0	CD	DOS
milliliters	NNS	UNIT
(	(	O
mL	NN	O
)	)	O
of	IN	O
solution	NN	O
and	CC	O
is	VBZ	O
intended	VBN	O
for	IN	O
single	JJ	O
use	NN	O
only	RB	O
.	.	O

Patients	NNS	O
should	MD	O
not	RB	O
begin	VB	O
a	DT	O
new	JJ	O
cycle	NN	O
of	IN	O
treatment	NN	O
unless	IN	O
the	DT	O
ANC	NNP	O
is	VBZ	O
≥	JJ	O
1500	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
,	,	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
>	JJ	O
100,000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
,	,	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
is	VBZ	O
≥	JJ	O
45	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
1,200	CD	DOS
mg	NN	UNIT
(	(	O
twenty	JJ	O
-	:	O
four	CD	DOS
50	CD	DOS
-	:	O
mg	NN	UNIT
capsules	NNS	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

Osserman	NNP	O
and	CC	O
Takatsuki	NNP	O
have	VBP	O
used	VBN	O
an	DT	O
initial	JJ	O
course	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
7	CD	O
to	TO	O
10	CD	O
days	NNS	O
.	.	O

This	DT	O
process	NN	O
should	MD	O
continue	VB	O
until	IN	O
sinus	JJ	O
rhythm	NN	O
is	VBZ	O
established	VBN	O
or	CC	O
a	DT	O
maximum	JJ	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
0.3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
is	VBZ	O
used	VBN	O
.	.	O

Direct	JJ	O
Instillation	NN	O
:	:	O
When	WRB	O
used	VBN	O
by	IN	O
direct	JJ	O
instillation	NN	O
,	,	O
1	CD	DOS
to	TO	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
a	DT	O
10	CD	O
%	NN	O
to	TO	O
20	CD	O
%	NN	O
solution	NN	O
may	MD	O
be	VB	O
given	VBN	O
as	RB	O
often	RB	O
as	IN	O
every	DT	FREQ
hour	NN	FREQ
.	.	O

An	DT	WHO
adult	NN	WHO
patient	NN	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
with	IN	WHO
restricted	JJ	WHO
activity	NN	WHO
who	WP	WHO
is	VBZ	WHO
not	RB	WHO
hypermetabolic	JJ	WHO
,	,	O
requires	VBZ	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
most	RBS	O
commonly	RB	O
used	VBD	O
dose	NN	O
of	IN	O
oral	JJ	O
folic	JJ	O
acid	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
was	VBD	O
400	CD	DOS
mcg	JJ	UNIT
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Consider	VB	O
a	DT	O
starting	NN	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
,	,	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
when	WRB	O
initiating	VBG	O
Adempas	NNP	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
strong	JJ	WHO
cytochrome	NN	WHO
P450	NNP	WHO
(	(	O
CYP	NNP	O
)	)	O
and	CC	O
P	NNP	O
-	:	O
glycoprotein	NN	O
/	JJ	O
breast	NN	O
cancer	NN	O
resistance	NN	O
protein	NN	O
(	(	O
P	NNP	O
-	:	O
gp	NN	O
/	NNP	O
BCRP	NNP	O
)	)	O
inhibitors	NNS	O
such	JJ	O
as	IN	O
azole	JJ	O
antimycotics	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
itraconazole	NN	O
)	)	O
or	CC	O
HIV	NNP	O
protease	NN	O
inhibitors	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
ritonavir	NN	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
for	IN	O
adult	NN	WHO
schizophrenic	JJ	WHO
patients	NNS	WHO
is	VBZ	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
with	IN	O
a	DT	O
gradual	JJ	O
increment	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
800	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
if	IN	O
necessary	JJ	O
.	.	O

No	DT	O
data	NN	O
are	VBP	O
available	JJ	O
on	IN	O
more	JJR	O
than	IN	O
1	CD	O
course	NN	O
of	IN	O
retreatment	NN	O
.	.	O

Adacel	NNP	O
vaccine	NN	O
is	VBZ	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
intramuscular	JJ	O
injection	NN	O
into	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INVEGA®	NNP	O
(	(	O
paliperidone	NN	O
)	)	O
Extended	VBD	O
-	:	O
Release	NNP	O
Tablets	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
schizophrenia	NN	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

If	IN	O
a	DT	O
tent	NN	O
or	CC	O
Croupette	NNP	O
must	MD	O
be	VB	O
used	VBN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
the	DT	O
volume	NN	O
of	IN	O
acetylcysteine	NN	O
(	(	O
using	VBG	O
10	CD	O
or	CC	O
20	CD	O
%	NN	O
)	)	O
that	WDT	O
will	MD	O
maintain	VB	O
a	DT	O
very	RB	O
heavy	JJ	O
mist	NN	O
in	IN	O
the	DT	O
tent	NN	O
or	CC	O
Croupette	NNP	O
for	IN	O
the	DT	O
desired	JJ	O
period	NN	O
.	.	O

IU	NNP	O
/	NNP	O
dL	NN	O
(	(	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
=	FW	O
[	JJ	O
Total	NNP	O
Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
/	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
]	VBZ	O
x	$	O
2	CD	DOS
[	NNP	O
IU	NNP	O
/	NNP	O
dL	NN	O
]	NNP	O
/	NNP	O
[	NNP	O
IU	NNP	O
/	NNP	O
kg	VBD	O
]	NN	O

Rapidly	RB	O
make	VB	O
15	CD	O
jabs	NN	O
of	IN	O
the	DT	O
needle	JJ	O
perpendicular	NN	O
to	TO	O
the	DT	O
skin	NN	O
through	IN	O
the	DT	O
vaccine	NN	O
droplet	NN	O
to	TO	O
puncture	VB	O
the	DT	O
skin	NN	O
,	,	O
within	IN	O
a	DT	O
diameter	NN	O
of	IN	O
about	IN	O
5	CD	O
mm	NNS	O
.	.	O

While	IN	O
Recommended	VBN	O
Dietary	NNP	O
Allowances	NNPS	O
for	IN	O
oral	JJ	O
protein	NNS	O
are	VBP	O
approximately	RB	O
0.8	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
for	IN	O
the	DT	O
healthy	JJ	WHO
adult	NN	WHO
,	,	O
protein	NN	O
and	CC	O
caloric	JJ	O
requirements	NNS	O
in	IN	O
traumatized	JJ	WHO
or	CC	WHO
maInourished	JJ	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
substantially	RB	O
increased	VBN	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
NAFTIN	NNP	O
Cream	NNP	O
once	RB	FREQ
-	:	O
daily	NN	FREQ
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
plus	CC	O
a	DT	O
½	JJ	O
inch	NN	O
margin	NN	O
of	IN	O
healthy	JJ	O
surrounding	VBG	O
skin	NN	O
for	IN	O
2	CD	PER
weeks	NNS	PER
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
AGRYLIN	NNP	O
is	VBZ	O
0.5	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

A	DT	O
-	:	O
Methapred	NNP	O
(	(	O
methylprednisolone	CD	O
sodium	NN	O
succinate	NN	O
)	)	O
may	MD	O
be	VB	O
administered	VBN	O
by	IN	O
intravenous	JJ	O
or	CC	O
intramuscular	JJ	O
injection	NN	O
or	CC	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
,	,	O
the	DT	O
preferred	JJ	O
method	NN	O
for	IN	O
initial	JJ	O
emergency	NN	O
use	NN	O
being	VBG	O
intravenous	JJ	O
injection	NN	O
.	.	O

(	(	O
6	CD	O
)	)	O
Non	NNP	O
-	:	O
skid	NN	O
floor	NN	O
:	:	O
The	DT	O
floor	NN	O
should	MD	O
be	VB	O
of	IN	O
a	DT	O
non	JJ	O
-	:	O
skid	JJ	O
nature	NN	O
.	.	O

There	EX	O
are	VBP	O
inadequate	JJ	O
data	NNS	O
to	TO	O
make	VB	O
dosage	NN	O
recommendations	NNS	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
in	IN	O
patients	NNS	WHO
below	IN	WHO
the	DT	WHO
age	NN	WHO
of	IN	WHO
ten	NN	WHO
(	(	WHO
10	CD	WHO
)	)	WHO
years	NNS	WHO
;	:	O
therefore	RB	O
,	,	O
such	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Clearance	NN	O
measurements	NNS	O
using	VBG	O
single	JJ	O
injection	NN	O
techniques	NNS	O
are	VBP	O
generally	RB	O
inaccurate	JJ	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
measurement	NN	O
of	IN	O
ERPF	NNP	O
.	.	O

Second	JJ	O
Dose	NNP	O
:	:	O
50	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
4	CD	O
hrs	NNS	O

The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
PIPRACIL	NNP	O
(	(	O
piperacillin	JJ	O
sodium	NN	O
)	)	O
for	IN	O
serious	JJ	O
infections	NNS	O
is	VBZ	O
3	CD	DOS
to	TO	O
4	CD	DOS
g	NNS	UNIT
given	VBN	O
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
as	IN	O
a	DT	O
-	:	O
20	CD	O
to	TO	O
30	CD	O
-	:	O
minute	NN	O
infusion	NN	O
.	.	O

Recommended	VBN	O
dose	JJ	O
modifications	NNS	O
for	IN	O
other	JJ	O
adverse	JJ	O
drug	NN	O
reactions	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
adenocarcinoma	NN	WHO
of	IN	O
the	DT	O
pancreas	NNS	O
are	VBP	O
provided	VBN	O
in	IN	O
Table	JJ	O
5	CD	O
.	.	O

Vials	NNS	O
of	IN	O
Accretropin™	NNP	O
(	(	O
somatropin	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
should	MD	O
be	VB	O
stored	VBN	O
in	IN	O
the	DT	O
refrigerator	NN	O
[	VBD	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
]	NN	O
.	.	O

Before	IN	O
administration	NN	O
of	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
,	,	O
administer	RB	O
Potassium	NNP	O
Iodide	NNP	O
Oral	NNP	O
Solution	NNP	O
or	CC	O
Lugol	NNP	O
's	POS	O
Solution	NNP	O
(	(	O
equivalent	JJ	O
to	TO	O
100	CD	DOS
mg	NNS	UNIT
iodide	RB	O
for	IN	O
adults	NNS	WHO
,	,	O
body	NN	O
-	:	O
weight	NN	O
adjusted	VBN	O
for	IN	O
children	NNS	WHO
)	)	O
or	CC	O
potassium	NN	O
perchlorate	NN	O
(	(	O
400	CD	DOS
mg	NN	UNIT
for	IN	O
adults	NNS	WHO
,	,	O
body	NN	O
-	:	O
weight	NN	O
adjusted	VBN	O
for	IN	O
children	NNS	WHO
)	)	O
to	TO	O
block	VB	O
uptake	NN	O
of	IN	O
iodine	NN	O
123	CD	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
thyroid	NN	O
.	.	O

For	IN	O
immunocompromised	JJ	WHO
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
clear	JJ	WHO
parasites	NNS	WHO
or	CC	WHO
who	WP	WHO
experience	VBP	WHO
relapses	NNS	WHO
,	,	O
expert	JJ	O
advice	NN	O
regarding	VBG	O
further	JJ	O
treatment	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
<	VBD	WHO
40	CD	DOS
ml	NN	UNIT
/	NNP	O
min	NN	O
/	NN	O
1.73m2	CD	O
(	(	O
serum	JJ	O
creatinine	NN	O
approximately	RB	O
>	JJ	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
dl	NN	O
)	)	O
doses	VBZ	O
only	RB	O
25	CD	O
%	NN	O
of	IN	O
those	DT	O
normally	NNS	O
used	VBN	O
should	MD	O
be	VB	O
expected	VBN	O
to	TO	O
induce	VB	O
full	JJ	O
therapeutic	JJ	O
levels	NNS	O
of	IN	O
ramiprilat	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
5.25	CD	DOS
to	TO	O
15	CD	DOS
mg.	NN	UNIT
No	NNP	O
additional	JJ	O
benefit	NN	O
was	VBD	O
demonstrated	VBN	O
for	IN	O
15	CD	DOS
mg	NNS	UNIT
compared	VBN	O
to	TO	O
9.75	CD	DOS
mg.	NN	UNIT
A	DT	O
lower	JJR	O
dose	NN	O
of	IN	O
5.25	CD	DOS
mg	NN	UNIT
may	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
clinical	JJ	O
factors	NNS	O
warrant	VBP	O
.	.	O

Withdraw	IN	O
the	DT	O
appropriate	JJ	O
dose	NN	O
of	IN	O
ABELCET®	NNP	O
(	(	O
amphotericin	IN	O
b	NN	O
)	)	O
from	IN	O
the	DT	O
required	JJ	O
number	NN	O
of	IN	O
vials	NNS	O
into	IN	O
one	CD	O
or	CC	O
more	JJR	O
sterile	JJ	O
syringes	NNS	O
using	VBG	O
an	DT	O
18	CD	O
-	:	O
gauge	NN	O
needle	NN	O
.	.	O

AmBisome	NNP	O
must	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
1	CD	DOS
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	RB	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

AMERGE	NNP	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
:	:	O
<	JJ	O
15	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
because	IN	O
of	IN	O
decreased	JJ	O
clearance	NN	O
of	IN	O
the	DT	O
drug	NN	O
[	NNP	O
see	NN	O
CONTRAINDICATIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

One	CD	DOS
or	CC	O
two	CD	DOS
drops	NNS	UNIT
instilled	VBD	O
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	PRP	O
)	)	O
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
may	MD	WHO
not	RB	WHO
tolerate	VB	WHO
the	DT	WHO
hypotensive	JJ	WHO
effect	NN	WHO
of	IN	WHO
Adempas	NNP	WHO
,	,	O
consider	VB	O
a	DT	O
starting	NN	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
taken	VBN	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

For	IN	O
AFREZZA	NNP	O
doses	VBZ	O
exceeding	VBG	O
12	CD	DOS
units	NNS	UNIT
,	,	O
inhalations	NNS	O
from	IN	O
multiple	JJ	O
cartridges	NNS	O
are	VBP	O
necessary	JJ	O
.	.	O

The	DT	O
initial	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
Sandimmune	NNP	O
(	(	O
cyclosporine	NN	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
4	CD	O
to	TO	O
12	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
transplantation	NN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

Limited	JJ	O
information	NN	O
is	VBZ	O
available	JJ	O
regarding	VBG	O
the	DT	O
dosing	NN	O
requirements	NNS	O
of	IN	O
patients	NNS	WHO
that	WDT	WHO
weigh	VBP	WHO
more	JJR	WHO
than	IN	WHO
100	CD	WHO
kg	NN	WHO
.	.	O

If	IN	O
deficiencies	NNS	O
of	IN	O
ASS	NNP	O
or	CC	O
ASL	NNP	O
are	VBP	O
excluded	VBN	O
as	IN	O
diagnostic	JJ	O
possibilities	NNS	O
,	,	O
the	DT	O
intravenous	JJ	O
dose	NN	O
of	IN	O
arginine	JJ	O
HCl	NNP	O
should	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
2	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
Arginine	NNP	O
HCl	NNP	O
Injection	NNP	O
10	CD	O
%	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
2	CD	DOS
inhalations	NNS	UNIT
of	IN	O
ADVAIR	NNP	O
HFA	NNP	O
230	CD	O
/	VBD	O
21	CD	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Doses	NNS	O
greater	JJR	O
than	IN	O
2000	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

b	NN	O
)	)	O
Rotate	NNP	O
sites	NNS	O
of	IN	O
injections	NNS	O
between	IN	O
the	DT	O
two	CD	O
deltoid	NN	O
or	CC	O
gluteal	NN	O
muscles	NNS	O
.	.	O

Inspect	VB	O
the	DT	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
vial	NN	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

For	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
less	JJR	WHO
than	IN	WHO
3	CD	WHO
years	NNS	WHO
old	JJ	WHO
,	,	O
the	DT	O
volume	NN	O
of	IN	O
a	DT	O
single	JJ	O
clysis	NN	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
200	CD	DOS
mL	NN	UNIT
;	:	O
and	CC	O
in	IN	O
premature	JJ	WHO
infants	NNS	WHO
or	CC	O
during	IN	O
the	DT	O
neonatal	JJ	O
period	NN	O
,	,	O
the	DT	O
daily	JJ	FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
25	CD	DOS
mL	JJ	UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
;	:	O
the	DT	O
rate	NN	O
of	IN	O
administration	NN	O
should	MD	O
not	RB	O
be	VB	O
greater	JJR	O
than	IN	O
2	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
.	.	O

To	TO	O
satisfy	VB	O
protein	NN	O
needs	NNS	O
and	CC	O
promote	VB	O
positive	JJ	O
nitrogen	NN	O
balance	NN	O
,	,	O
the	DT	O
daily	JJ	FREQ
dosage	NN	O
level	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
adequate	JJ	WHO
caloric	NNS	WHO
intake	VBP	WHO
is	VBZ	O
approximately	RB	O
1.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	FREQ
dose	NN	O
ranges	VBZ	O
from	IN	O
300	CD	DOS
to	TO	O
600	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
,	,	O
Sulfite	NNP	O
-	:	O
Free	JJ	O
,	,	O
(	(	O
an	DT	O
amino	NN	O
acid	NN	O
injection	NN	O
—	NNP	O
renal	JJ	O
formula	NN	O
)	)	O
equivalent	NN	O
to	TO	O
2.4	CD	DOS
to	TO	O
4.7	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
in	IN	O
15.7	CD	DOS
to	TO	O
31	CD	DOS
grams	NNS	UNIT
of	IN	O
essential	JJ	O
amino	NN	O
acids	NNS	O
.	.	O

Store	NN	O
at	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

Increase	NNP	O
to	TO	O
40	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
based	VBN	O
upon	IN	O
individual	JJ	O
tolerability	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Doses	NNS	O
of	IN	O
AEROSPAN	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
Note	NN	O
:	:	O
In	IN	O
all	DT	WHO
patients	NNS	WHO
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
titrate	VB	O
to	TO	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
once	RB	O
asthma	JJ	O
stability	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

A	DT	O
mixture	NN	O
containing	VBG	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
HBC	$	O
7	CD	O
%	NN	O
with	IN	O
500	CD	DOS
mL	NNS	UNIT
of	IN	O
concentrated	JJ	O
dextrose	NN	O
supplemented	VBN	O
with	IN	O
electrolytes	NNS	O
,	,	O
trace	NN	O
metals	NNS	O
and	CC	O
vitamins	NNS	O
may	MD	O
be	VB	O
administered	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
approximately	RB	O
8	CD	O
hours	NNS	O
.	.	O

Although	IN	O
occasional	JJ	WHO
patients	NNS	WHO
have	VBP	O
responded	VBN	O
to	TO	O
higher	JJR	O
doses	NNS	O
,	,	O
the	DT	O
maximum	NN	O
recommended	VBD	FREQ
daily	JJ	FREQ
dosage	NN	O
is	VBZ	O
3	CD	DOS
g.	NN	UNIT
Once	NNP	O
an	DT	O
effective	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
attained	VBN	O
,	,	O
a	DT	O
smooth	JJ	O
blood	NN	O
pressure	NN	O
response	NN	O
occurs	VBZ	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
in	IN	O
12	CD	O
to	TO	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
regimen	NN	O
is	VBZ	O
a	DT	O
single	JJ	DOS
100	CD	DOS
-	:	O
mg	NN	UNIT
tablet	NN	UNIT
of	IN	O
TROVAN	NNP	O
and	CC	O
a	DT	O
single	JJ	DOS
1	CD	DOS
-	:	O
gram	NN	UNIT
(	(	O
1000	CD	DOS
mg	NN	UNIT
)	)	O
dose	NN	UNIT
of	IN	O
ZITHROMAX	NNP	O
for	IN	O
oral	JJ	O
suspension	NN	O
.	.	O

Third	JJ	O
Dose	NNP	O
:	:	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
14	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
16	CD	DOS
hrs	NNS	UNIT

Prepare	NNP	O
ALDURAZYME	NNP	O
using	VBG	O
low	JJ	O
-	:	O
protein	NN	O
-	:	O
binding	NN	O
containers	NNS	O
and	CC	O
administer	NN	O
with	IN	O
a	DT	O
low	JJ	O
-	:	O
protein	NN	O
-	:	O
binding	NN	O
infusion	NN	O
set	VBN	O
equipped	VBN	O
with	IN	O
an	DT	O
in	IN	O
-	:	O
line	NN	O
,	,	O
low	JJ	O
-	:	O
protein	NN	O
-	:	O
binding	VBG	O
0.2	CD	DOS
micrometer	NN	UNIT
(	(	O
μm	NNP	O
)	)	O
filter	NN	O
.	.	O

ALBENZA	NNP	O
chewable	JJ	O
tablets	NNS	O
are	VBP	O
also	RB	O
available	JJ	O
for	IN	O
children	NNS	WHO
and	CC	WHO
patients	NNS	WHO
who	WP	O
may	MD	O
experience	VB	O
swallowing	VBG	O
difficulties	NNS	O
.	.	O

When	WRB	O
the	DT	O
drug	NN	O
is	VBZ	O
used	VBN	O
chronically	RB	O
at	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
,	,	O
patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
periodically	RB	O
for	IN	O
effects	NNS	O
on	IN	O
the	DT	O
hypothalamic	JJ	O
-	:	O
pituitary	JJ	O
-	:	O
adrenal	NN	O
(	(	O
HPA	NNP	O
)	)	O
axis	NN	O
.	.	O

This	DT	O
12	CD	DOS
mg	NNS	UNIT
dose	NN	UNIT
may	MD	O
be	VB	O
repeated	VBN	O
a	DT	O
second	JJ	O
time	NN	O
if	IN	O
required	VBN	O
.	.	O

A	DT	O
dose	NN	O
of	IN	O
1	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
is	VBZ	O
the	DT	O
lowest	JJS	O
dose	NN	O
that	WDT	O
produces	VBZ	O
maximal	JJ	O
cortisol	NN	O
responses	NNS	O
and	CC	O
significant	JJ	O
(	(	O
though	IN	O
apparently	RB	O
sub	JJ	O
-	:	O
maximal	NN	O
)	)	O
ACTH	NNP	O
responses	NNS	O
.	.	O

If	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
remains	VBZ	O
greater	JJR	O
than	IN	O
95	CD	O
mmHg	NN	O
and	CC	O
the	DT	O
patient	NN	O
has	VBZ	O
no	DT	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
hypotension	NN	O
,	,	O
up	RB	O
-	:	O
titrate	VB	O
the	DT	O
dose	NN	O
by	IN	O
0.5	CD	DOS
mg	NNS	UNIT
taken	VBN	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

A	DT	O
4.25	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
is	VBZ	O
too	RB	O
concentrated	JJ	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
one	CD	WHO
year	NN	WHO
old	JJ	WHO
,	,	O
who	WP	O
generally	RB	O
receive	VBP	O
a	DT	O
2.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
titration	NN	O
should	MD	O
proceed	VB	O
over	IN	O
a	DT	O
7	CD	PER
-	:	O
14	CD	PER
day	NN	PER
period	NN	O
starting	VBG	O
with	IN	O
30	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

For	IN	O
bronchial	JJ	O
asthma	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
administer	RB	O
0.01	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBD	O
or	CC	O
0.3	CD	DOS
mg	NNS	UNIT
/	JJ	O
m2	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
subcutaneously	RB	O
,	,	O
repeated	VBD	O
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
if	IN	O
required	VBN	O
.	.	O

In	IN	O
children	NNS	WHO
from	IN	WHO
3	CD	WHO
to	TO	WHO
5	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
start	VBP	O
with	IN	O
2.5	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
;	:	O
daily	JJ	FREQ
dosage	NN	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
2.5	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

In	IN	O
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
start	VBP	O
with	IN	O
10	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
;	:	O
daily	JJ	FREQ
dosage	NN	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
10	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

Clearance	NN	O
measurements	NNS	O
using	VBG	O
single	JJ	DOS
injection	NN	UNIT
techniques	NNS	O
are	VBP	O
generally	RB	O
inaccurate	JJ	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
measurement	NN	O
of	IN	O
ERPF	NNP	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ADVICOR	NNP	O
should	MD	O
not	RB	O
be	VB	O
increased	VBN	O
by	IN	O
more	JJR	O
than	IN	O
500	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
(	(	O
based	VBN	O
on	IN	O
the	DT	O
NIASPAN	NNP	O
component	NN	O
)	)	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
.	.	O

Note	NN	O
:	:	O
The	DT	O
Adrenalin®	NNP	O
30	CD	DOS
mL	NN	UNIT
multiple	JJ	O
-	:	O
dose	JJ	O
vial	NN	O
is	VBZ	O
not	RB	O
for	IN	O
ophthalmic	JJ	O
use	NN	O
.	.	O

Prescott	NNP	O
LF	NNP	O
,	,	O
J	NNP	O
Pharm	NNP	O
Pharmacol	NNP	O
1971	CD	O
,	,	O
23	CD	O
(	(	O
10	CD	O
)	)	O
:807	SYM	O
-	:	O
808	CD	O
(	(	O
October	NNP	O
)	)	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	NNP	FREQ
day	NN	FREQ
based	VBN	O
on	IN	O
clinical	JJ	O
response	NN	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
infused	JJ	O
dextrose	NN	O
provides	VBZ	O
3.4	CD	O
kcal	JJ	O
;	:	O
each	DT	O
gram	NN	O
of	IN	O
infused	JJ	O
fat	NN	O
provides	VBZ	O
9	CD	O
kcal	NN	O
.	.	O

Total	JJ	O
dosage	NN	O
per	IN	FREQ
day	NN	FREQ
should	MD	O
not	RB	O
exceed	VB	O
12	CD	DOS
inhalations	NNS	UNIT
.	.	O

Use	NNP	O
another	DT	O
rabeprazole	NN	O
formulation	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
1	CD	WHO
year	NN	WHO
to	TO	WHO
less	JJR	WHO
than	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
10	CD	DOS
-	:	O
60	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
in	IN	O
single	JJ	O
doses	NNS	O
.	.	O

If	IN	O
the	DT	O
6.25	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
is	VBZ	O
not	RB	O
effective	JJ	O
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
12.5	CD	DOS
mg	NNS	UNIT
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
recommended	JJ	O
starting	NN	O
dose	NN	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
as	IN	O
monotherapy	NN	O
and	CC	O
10	CD	DOS
mg	NN	UNIT
to	TO	O
15	CD	DOS
mg	NNS	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
as	IN	O
adjunctive	JJ	O
therapy	NN	O
with	IN	O
lithium	NN	O
or	CC	O
valproate	NN	O
.	.	O

Three	CD	O
weeks	NNS	O
constitutes	VBZ	O
an	DT	O
adequate	JJ	O
period	NN	O
of	IN	O
trial	NN	O
providing	NN	O
dosage	NN	O
has	VBZ	O
reached	VBN	O
300	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
(	(	O
or	CC	O
lower	JJR	O
level	NN	O
of	IN	O
tolerance	NN	O
)	)	O
for	IN	O
at	IN	PER
least	JJS	PER
two	CD	PER
weeks	NNS	PER
.	.	O

One	CD	DOS
pink	NN	UNIT
tablet	NN	UNIT
should	MD	O
be	VB	O
taken	VBN	O
daily	RB	FREQ
for	IN	O
21	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
followed	VBN	O
by	IN	O
one	CD	DOS
light	NN	UNIT
-	:	O
green	JJ	UNIT
inert	JJ	UNIT
tablet	NN	UNIT
daily	RB	FREQ
for	IN	O
7	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

Single	NNP	DOS
Dose	NNP	UNIT
-	:	O
Actidose®	NNP	O
-	:	O
Aqua	NN	O

AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
never	RB	WHO
taken	VBN	WHO
aripiprazole	NN	WHO
,	,	O
establish	VB	O
tolerability	NN	O
with	IN	O
oral	JJ	O
aripiprazole	JJ	O
prior	NN	O
to	TO	O
initiating	VBG	O
treatment	NN	O
with	IN	O
ABILIFY	NNP	O
MAINTENA	NNP	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
,	,	O
as	IN	O
needed	VBN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
16	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Dovonex®	NNP	O
(	(	O
calcipotriene	JJ	O
ointment	NN	O
)	)	O
ointment	NN	O
once	RB	FREQ
or	CC	O
twice	JJ	FREQ
daily	JJ	FREQ
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
and	CC	O
completely	RB	O
.	.	O

Acetaminophen	NNP	O
Assays	NNP	O
-	:	O
Interpretation	NN	O
and	CC	O
Methodology	NN	O
:	:	O
The	DT	O
acute	JJ	O
ingestion	NN	O
of	IN	O
acetaminophen	NN	O
in	IN	O
quantities	NNS	O
of	IN	O
150	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
or	CC	O
greater	JJR	O
may	MD	O
result	VB	O
in	IN	O
hepatic	JJ	O
toxicity	NN	O
.	.	O

Instill	NNP	O
1	CD	DOS
drop	NN	UNIT
every	DT	O
5	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
for	IN	O
5	CD	DOS
to	TO	O
7	CD	DOS
doses	NNS	UNIT
.	.	O

No	DT	O
more	JJR	O
than	IN	O
two	CD	DOS
doses	NNS	UNIT
of	IN	O
ABSTRAL	NNP	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
treat	VB	O
an	DT	O
episode	NN	O
of	IN	O
breakthrough	NN	O
pain	NN	O
.	.	O

When	WRB	O
given	VBN	O
as	IN	O
the	DT	O
sole	JJ	O
agent	NN	O
for	IN	O
diuresis	NN	O
,	,	O
ALDACTONE	NNP	O
should	MD	O
be	VB	O
continued	VBN	O
for	IN	O
at	IN	PER
least	JJS	PER
five	CD	PER
days	NNS	PER
at	IN	O
the	DT	O
initial	JJ	O
dosage	NN	O
level	NN	O
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
may	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
the	DT	O
optimal	JJ	O
therapeutic	JJ	O
or	CC	O
maintenance	NN	O
level	NN	O
administered	VBN	O
in	IN	O
either	DT	O
single	JJ	DOS
or	CC	O
divided	JJ	O
daily	JJ	FREQ
doses	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
4	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
two	CD	DOS
inhalations	NNS	UNIT
15	CD	O
to	TO	O
30	CD	O
minutes	NNS	O
before	IN	O
exercise	NN	O
.	.	O

men	NNS	WHO
675	CD	DOS
±	$	O
150	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NNP	O
women	NNS	WHO
595	CD	DOS
±	JJ	O
125	CD	DOS
mL	NN	UNIT
/	CD	O
min	NN	O

Although	IN	O
100	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
daily	JJ	FREQ
may	MD	O
be	VB	O
adequate	JJ	O
for	IN	O
many	JJ	WHO
elderly	JJ	WHO
patients	NNS	WHO
,	,	O
some	DT	O
may	MD	O
require	VB	O
higher	JJR	O
dosage	NN	O
.	.	O

Pentacel	NNP	O
vaccine	NN	O
is	VBZ	O
to	TO	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
4	CD	DOS
dose	JJ	UNIT
series	NN	UNIT
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
15	CD	O
-	:	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	VBZ	O
24	CD	O
HOUR	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
180	CD	O
and	CC	O
pseudoephendrine	VB	O
hcl	NN	O
240	CD	O
)	)	O
Extended	VBN	O
-	:	O
Release	NNP	O
Tablets	NNPS	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
administered	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
with	IN	O
water	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
(	(	O
37.5	CD	DOS
mg	NN	UNIT
)	)	O
daily	RB	FREQ
as	IN	O
prescribed	VBN	O
by	IN	O
the	DT	O
physician	NN	O
,	,	O
administered	VBN	O
before	IN	O
breakfast	NN	O
or	CC	O
1	CD	O
to	TO	O
2	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
for	IN	O
appetite	JJ	O
control	NN	O
.	.	O

The	DT	O
recommended	VBN	O
intravenous	JJ	O
dose	NN	O
of	IN	O
Aminosyn	NNP	O
-	:	O
PF	VBD	O
10	CD	O
%	NN	O
is	VBZ	O
up	RB	O
to	TO	O
2.5	CD	DOS
g	NN	UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
infants	NNS	WHO
up	RB	WHO
to	TO	WHO
10	CD	WHO
kg	NNS	WHO
.	.	O

ERPF	NNP	O
=	VBD	O
8	CD	DOS
x	JJ	O
1.5	CD	DOS
/	JJ	O
0.02	CD	DOS
=	JJ	O
600	CD	DOS
mL	NN	UNIT
/	CD	O
min	NN	O

In	IN	O
many	JJ	WHO
patients	NNS	WHO
,	,	O
provision	NN	O
of	IN	O
adequate	JJ	O
calories	NNS	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
hypertonic	JJ	O
dextrose	NN	O
may	MD	O
require	VB	O
the	DT	O
administration	NN	O
of	IN	O
exogenous	JJ	O
insulin	NN	O
to	TO	O
prevent	VB	O
hyperglycemia	NN	O
and	CC	O
glycosuria	NN	O
.	.	O

Increase	VB	O
the	DT	O
dose	JJ	O
by	IN	O
100	CD	DOS
mcg	NNS	UNIT
multiples	VBZ	O
up	IN	O
to	TO	O
400	CD	DOS
mcg	NNS	UNIT
as	IN	O
needed	VBN	O
.	.	O

ALINIA	NNP	O
tablets	NNS	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
to	TO	O
pediatric	VB	WHO
patients	NNS	WHO
11	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
younger	JJR	WHO
because	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
contains	VBZ	O
a	DT	O
greater	JJR	O
amount	NN	O
of	IN	O
nitazoxanide	NN	O
than	IN	O
the	DT	O
recommended	JJ	O
dosing	NN	O
in	IN	O
this	DT	O
pediatric	JJ	O
age	NN	O
group	NN	O
.	.	O

The	DT	O
benzyl	NN	O
alcohol	NN	O
in	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
may	MD	O
cause	VB	O
serious	JJ	O
adverse	JJ	O
reactions	NNS	O
in	IN	O
premature	NN	WHO
or	CC	WHO
low	JJ	WHO
birth	NN	WHO
-	:	WHO
weight	NN	WHO
infants	NNS	WHO
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Treat	NNP	O
single	JJ	O
lesions	NNS	O
or	CC	O
an	DT	O
entire	JJ	O
field	NN	O
affected	VBN	O
by	IN	O
multiple	JJ	O
lesions	NNS	O
with	IN	O
AMELUZ	NNP	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
red	JJ	O
light	JJ	O
photodynamic	JJ	O
therapy	NN	O
(	(	O
PDT	NNP	O
)	)	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
opioid	JJ	WHO
tolerant	NN	WHO
are	VBP	O
those	DT	O
receiving	VBG	O
,	,	O
for	IN	O
one	CD	PER
week	NN	PER
or	CC	O
longer	JJR	O
,	,	O
at	IN	O
least	JJS	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
morphine	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mcg	NN	UNIT
transdermal	JJ	O
fentanyl	NN	O
per	IN	O
hour	NN	O
,	,	O
30	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxycodone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
8	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydromorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxymorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydrocodone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
or	CC	O
an	DT	O
equianalgesic	JJ	O
dose	NN	O
of	IN	O
another	DT	O
opioid	NN	O
.	.	O

Scabies	NNS	O
rarely	RB	O
infests	VBZ	O
the	DT	O
scalp	NN	O
of	IN	O
adults	NNS	WHO
,	,	O
although	IN	O
the	DT	O
hairline	NN	O
,	,	O
neck	NN	O
,	,	O
temple	NN	O
,	,	O
and	CC	O
forehead	NN	O
may	MD	O
be	VB	O
infested	VBN	O
in	IN	O
infants	NNS	WHO
and	CC	WHO
geriatric	JJ	WHO
patients	NNS	WHO
.	.	O

Use	NNP	O
sufficient	JJ	O
amount	NN	O
of	IN	O
gel	NN	O
to	TO	O
cover	VB	O
the	DT	O
single	JJ	O
lesions	NNS	O
or	CC	O
if	IN	O
multiple	JJ	O
lesions	NNS	O
,	,	O
the	DT	O
entire	JJ	O
area	NN	O
.	.	O

Intramuscular	JJ	O
Administration	NNP	O
for	IN	O
Patients	NNPS	WHO
with	IN	WHO
Normal	NNP	WHO
Renal	NNP	WHO
Function	NN	WHO
:	:	O
The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
,	,	WHO
children	NNS	WHO
and	CC	WHO
older	JJR	WHO
infants	NNS	WHO
(	(	O
see	VB	O
DESCRIPTION	NNP	O
:	:	O
WARNINGS	JJ	O
With	IN	O
normal	JJ	O
renal	JJ	O
function	NN	O
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
divided	VBD	O
into	IN	O
2	CD	DOS
or	CC	O
3	CD	DOS
equal	JJ	UNIT
doses	NNS	UNIT
administered	VBN	O
at	IN	O
equally	RB	O
-	:	O
divided	VBN	O
intervals	NNS	O
i.e	VBP	O
,	,	O
7.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
q12h	NN	O
or	CC	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
q8h	NN	O
.	.	O

During	IN	O
dialysis	NN	O
,	,	O
perindopril	NN	O
is	VBZ	O
removed	VBN	O
with	IN	O
the	DT	O
same	JJ	O
clearance	NN	O
as	IN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
normal	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

The	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dosage	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
infusion	NN	UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
schedule	NN	O
is	VBZ	O
10	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	NN	O
for	IN	O
the	DT	O
first	JJ	O
dose	NN	O
,	,	O
15	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	NN	O
for	IN	O
the	DT	O
second	JJ	O
dose	NN	O
,	,	O
and	CC	O
20	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	NN	O
for	IN	O
the	DT	O
third	JJ	O
dose	NN	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
for	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
but	CC	O
should	MD	O
be	VB	O
governed	VBN	O
more	JJR	O
by	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
and	CC	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
than	IN	O
by	IN	O
age	NN	O
or	CC	O
size	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
for	IN	O
women	NNS	WHO
and	CC	O
either	DT	O
5	CD	DOS
or	CC	O
10	CD	DOS
mg	NN	UNIT
for	IN	O
men	NNS	WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	O
per	IN	O
night	NN	O
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7–8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

Adults	NNS	WHO
:	:	O
100	CD	DOS
mg	NN	UNIT
,	,	O
of	IN	O
doxycycline	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
60	CD	PER
days	NNS	PER
.	.	O

Continuous	JJ	O
Infusion	NN	O
:	:	O
0.5	CD	DOS
to	TO	O
3	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
administered	VBN	O
with	IN	O
nitrous	JJ	O
oxide	JJ	O
/	NN	O
oxygen	NN	O
in	IN	O
patients	NNS	WHO
undergoing	VBG	WHO
general	JJ	WHO
surgery	NN	WHO
.	.	O

Subcutaneously	RB	O
or	CC	O
intramuscularly	RB	O
-	:	O
0.2	CD	DOS
to	TO	O
1	CD	DOS
mL	NN	UNIT
(	(	O
mg	NN	UNIT
)	)	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
of	IN	O
ACCURETIC	NNP	O
,	,	O
the	DT	O
average	JJ	O
change	NN	O
in	IN	O
serum	NN	O
potassium	NN	O
was	VBD	O
near	JJ	O
zero	NN	O
in	IN	O
subjects	NNS	WHO
who	WP	WHO
received	VBD	WHO
HCTZ	NNP	WHO
6.25	CD	DOS
mg	NN	UNIT
in	IN	O
the	DT	O
combination	NN	O
,	,	O
and	CC	O
the	DT	O
average	JJ	O
subject	NN	O
who	WP	O
received	VBD	O
10	CD	DOS
to	TO	O
40	CD	DOS
/	NNS	O
12.5	CD	DOS
to	TO	O
25	CD	DOS
mg	NNS	UNIT
experienced	VBD	O
a	DT	O
milder	NN	O
reduction	NN	O
in	IN	O
serum	NN	O
potassium	NN	O
than	IN	O
that	DT	O
experienced	VBN	O
by	IN	O
the	DT	O
average	JJ	O
subject	JJ	O
receiving	VBG	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
hydrochlorothiazide	JJ	O
monotherapy	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
and	CC	O
pseudoephedrine	VB	O
hcl	NN	O
)	)	O
12	CD	O
HOUR	NNP	O
Extended	NNP	O
-	:	O
Release	NNP	O
Tablets	NNPS	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
administered	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
with	IN	O
water	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
CrCl	NNP	O
51	CD	DOS
–	VBD	O
80	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
AMPYRA	NNP	O
plasma	NN	O
levels	NNS	O
may	MD	O
approach	VB	O
those	DT	O
seen	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
15	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
a	DT	O
dose	NN	O
that	WDT	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
seizures	NNS	O
.	.	O

The	DT	O
average	JJ	O
intramuscular	JJ	O
dose	NN	O
ranges	VBZ	O
from	IN	O
65	CD	DOS
mg	NNS	UNIT
to	TO	O
0.5	CD	DOS
g.	NNS	UNIT
A	DT	O
volume	NN	O
of	IN	O
5	CD	DOS
mL	NN	UNIT
(	(	O
irrespective	JJ	O
of	IN	O
concentration	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
at	IN	O
any	DT	O
one	CD	O
site	NN	O
because	IN	O
of	IN	O
possible	JJ	O
tissue	NN	O
irritation	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
not	RB	O
adhered	VBN	O
to	TO	O
the	DT	O
prescribed	VBN	O
schedule	NN	O
(	(	O
missed	JJ	O
one	CD	DOS
or	CC	O
more	JJR	O
tablets	NNS	O
or	CC	O
started	VBD	O
taking	VBG	O
them	PRP	O
on	IN	O
a	DT	O
day	NN	O
later	RB	O
than	IN	O
she	PRP	O
should	MD	O
have	VB	O
)	)	O
,	,	O
the	DT	O
probability	NN	O
of	IN	O
pregnancy	NN	O
should	MD	O
be	VB	O
considered	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
first	JJ	O
missed	JJ	O
period	NN	O
and	CC	O
appropriate	JJ	O
diagnostic	JJ	O
measures	NNS	O
taken	VBN	O
.	.	O

IPLEX	NNP	O
(	(	O
mecasermin	JJ	O
rinfabate	NN	O
[	NNP	O
rdna	NN	O
origin	NN	O
]	NNP	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
via	IN	O
subcutaneous	JJ	O
injection	NN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
to	TO	O
be	VB	O
increased	VBN	O
into	IN	O
the	DT	O
therapeutic	JJ	O
dose	NN	O
range	NN	O
of	IN	O
1	CD	DOS
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Intraspinal	JJ	O
use	NN	O
(	(	O
Amp	NNP	O
88	CD	O
)	)	O
-	:	O
Usual	JJ	O
dose	NN	O
is	VBZ	O
0.2	CD	DOS
to	TO	O
0.4	CD	DOS
mL	NN	UNIT
(	(	O
0.2	CD	DOS
to	TO	O
0.4	CD	DOS
mg	NN	UNIT
)	)	O
added	VBD	O
to	TO	O
anesthetic	JJ	O
spinal	JJ	O
fluid	NN	O
mixture	NN	O
(	(	O
may	MD	O
prolong	VB	O
anesthetic	JJ	O
action	NN	O
by	IN	O
limiting	VBG	O
absorption	NN	O
)	)	O
.	.	O

Figure	NN	O
1	CD	O
:	:	O
Examples	NNS	O
of	IN	O
Amyvid	NNP	O
negative	JJ	O
scans	NNS	O
(	(	O
top	JJ	O
two	CD	O
rows	NNS	O
)	)	O
and	CC	O
positive	JJ	O
scans	NNS	O
(	(	O
bottom	JJ	O
two	CD	O
rows	NNS	O
)	)	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
to	TO	WHO
AIRDUO	NNP	WHO
RESPICLICK	NNP	WHO
55	CD	DOS
/	VBD	O
14	CD	DOS
mcg	NN	UNIT
after	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
therapy	NN	O
,	,	O
increasing	VBG	O
the	DT	O
dose	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

When	WRB	O
AZILECT	NNP	O
is	VBZ	O
prescribed	VBN	O
as	IN	O
monotherapy	NN	O
or	CC	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	WHO
not	RB	WHO
taking	VBG	WHO
levodopa	NN	WHO
,	,	O
patients	NNS	O
may	MD	O
start	VB	O
AZILECT	NNP	O
at	IN	O
the	DT	O
recommended	JJ	O
dose	NN	O
of	IN	O
1	CD	DOS
mg	NNS	UNIT
administered	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
80	CD	DOS
to	TO	O
120	CD	DOS
g	NN	UNIT
of	IN	O
amino	NN	O
acids	NNS	O
(	(	O
12	CD	DOS
to	TO	O
18	CD	DOS
g	NN	UNIT
of	IN	O
nitrogen	NN	O
)	)	O
as	IN	O
Aminosyn	NNP	O
-	:	O
HF	$	O
8	CD	O
%	NN	O
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BONIVA	NNP	O
Injection	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
is	VBZ	O
3	CD	DOS
mg	NN	UNIT
every	DT	FREQ
3	CD	FREQ
months	NNS	FREQ
administered	VBN	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
15	CD	O
to	TO	O
30	CD	O
seconds	NNS	O
.	.	O

Adults	NNS	WHO
:	:	O
100	CD	DOS
mg	NN	UNIT
of	IN	O
doxycycline	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
60	CD	PER
days	NNS	PER
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
ADZENYS	NNP	O
XR	NNP	O
-	:	O
ODT	$	O
12.5	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

A	DT	O
10	CD	O
-	:	O
minute	NN	O
PET	NNP	O
image	NN	O
should	MD	O
be	VB	O
acquired	VBN	O
starting	VBG	O
30	CD	O
to	TO	O
50	CD	O
minutes	NNS	O
after	IN	O
Amyvid	NNP	O
intravenous	JJ	O
injection	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
taking	VBG	WHO
danazol	NN	WHO
,	,	WHO
diltiazem	NN	WHO
,	,	WHO
or	CC	WHO
verapamil	NNS	WHO
concomitantly	RB	WHO
with	IN	WHO
lovastatin	NN	WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
)	)	O
,	,	O
therapy	NN	O
should	MD	O
begin	VB	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
of	IN	O
lovastatin	NN	O
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Upper	NNP	O
GI	NNP	O
X	NNP	O
-	:	O
rays	NNS	O
are	VBP	O
desirable	JJ	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
an	DT	WHO
ulcer	JJ	WHO
history	NN	WHO
or	CC	WHO
significant	JJ	WHO
dyspepsia	NN	WHO
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Three	CD	O
Bag	NNP	O
Method	NNP	O
Dosage	NNP	O
Guide	NNP	O
by	IN	O
Weight	NNP	O
in	IN	O
Patients	NNP	WHO
21	CD	WHO
kg	NN	WHO
to	TO	WHO
40	CD	WHO
kg	NNS	WHO

After	IN	O
one	CD	O
week	NN	O
at	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
,	,	O
increase	NN	O
dose	NN	O
(	(	O
if	IN	O
tolerated	VBN	O
)	)	O
toward	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
with	IN	O
dosage	NN	O
increases	NNS	O
being	VBG	O
about	IN	O
3	CD	O
weeks	NNS	O
apart	RB	O
.	.	O

Syphilis	NN	O
of	IN	O
more	JJR	O
than	IN	O
one	CD	O
year	NN	O
's	POS	O
duration	NN	O
(	(	O
except	IN	O
neurosyphilis	RB	O
)	)	O
,	,	O
500	CD	DOS
mg	NN	UNIT
q.i.d	NN	O
.	.	O

Administer	NNP	O
HYQVIA	NNP	O
at	IN	O
300	CD	DOS
to	TO	O
600	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
at	IN	O
3	CD	O
to	TO	O
4	CD	O
week	NN	O
intervals	NNS	O
,	,	O
after	IN	O
initial	JJ	O
ramp	NN	O
-	:	O
up	RB	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
:	:	O
For	IN	O
adolescents	NNS	WHO
(	(	WHO
13	CD	WHO
to	TO	WHO
16	CD	WHO
years	NNS	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
1,200	CD	DOS
mg	NN	UNIT
(	(	O
twenty	JJ	O
-	:	O
four	CD	DOS
50	CD	DOS
-	:	O
mg	NN	UNIT
capsules	NNS	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
ACCUPRIL	NNP	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
followed	VBN	O
by	IN	O
titration	NN	O
(	(	O
as	IN	O
described	VBN	O
above	IN	O
)	)	O
to	TO	O
the	DT	O
optimal	JJ	O
response	NN	O
.	.	O

The	DT	O
total	JJ	O
volume	NN	O
administered	VBD	O
should	MD	O
be	VB	O
adjusted	VBN	O
for	IN	O
patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
40	CD	WHO
kg	NNS	WHO
and	CC	O
for	IN	O
those	DT	O
requiring	VBG	O
fluid	JJ	O
restriction	NN	O
(	(	O
see	VB	O
Tables	NNP	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
.	.	O

0.25	CD	DOS
mg	NN	UNIT

Adding	VBG	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
chamber	NN	O
and	CC	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
the	DT	O
dextrose	JJ	O
chamber	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
(	(	O
in	IN	O
mEq	NN	O
/	NNP	O
L	NNP	O
)	)	O
as	IN	O
follows	VBZ	O
:	:	O
54	CD	O
sodium	NN	O
,	,	O
42	CD	O
potassium	NN	O
,	,	O
35	CD	O
chloride	NN	O
,	,	O
5	CD	O
magnesium	NN	O
,	,	O
4.5	CD	O
calcium	NN	O
,	,	O
60.1	CD	O
acetate	NN	O
,	,	O
and	CC	O
15	CD	O
(	(	O
mM	NN	O
)	)	O
phosphate	NN	O
.	.	O

When	WRB	O
used	VBN	O
for	IN	O
the	DT	O
routine	JJ	O
nursing	NN	O
care	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
tracheostomy	NN	WHO
,	,	O
1	CD	DOS
to	TO	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
a	DT	O
10	CD	O
%	NN	O
to	TO	O
20	CD	O
%	NN	O
solution	NN	O
may	MD	O
be	VB	O
given	VBN	O
every	DT	O
1	CD	O
to	TO	O
4	CD	O
hours	NNS	O
by	IN	O
instillation	NN	O
into	IN	O
the	DT	O
tracheostomy	NN	O
.	.	O

Dosage	NN	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
to	TO	O
1000	CD	DOS
mg	NN	UNIT
daily	RB	FREQ
,	,	O
in	IN	O
divided	JJ	O
doses	NNS	O
using	VBG	O
tablets	NNS	O
or	CC	O
sustained	VBN	O
-	:	O
release	NN	O
capsules	NNS	O
as	IN	O
appropriate	NN	O
.	.	O

Average	JJ	O
daily	JJ	FREQ
adult	NN	WHO
fluid	NN	O
requirements	NNS	O
are	VBP	O
between	IN	O
2500	CD	DOS
and	CC	O
3000	CD	DOS
mL	NN	UNIT
and	CC	O
may	MD	O
be	VB	O
much	JJ	O
higher	JJR	O
with	IN	O
losses	NNS	O
from	IN	O
fistula	JJ	O
drainage	NN	O
or	CC	O
severe	JJ	O
burns	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Estimated	VBN	O
Absorbed	NNP	O
Radiation	NNP	O
Dose	NNP	O
from	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O

However	RB	O
,	,	O
for	IN	O
patients	NNS	WHO
converting	VBG	WHO
from	IN	WHO
Actiq	NNP	WHO
,	,	O
see	VBP	O
Table	JJ	O
1	CD	O
:	:	O
Initial	JJ	O
Dosing	NNP	O
Recommendations	NNP	O
for	IN	O
Patients	NNPS	WHO
on	IN	WHO
ACTIQ	NNP	WHO
.	.	O

The	DT	O
recommended	VBN	O
AMJEVITA	NNP	O
dose	JJ	O
regimen	NNS	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
ulcerative	JJ	WHO
colitis	NN	WHO
(	(	O
UC	NNP	O
)	)	O
is	VBZ	O
160	CD	DOS
mg	NN	UNIT
initially	RB	O
on	IN	O
Day	NNP	O
1	CD	O
(	(	O
given	VBN	O
as	IN	O
four	CD	DOS
40	CD	DOS
mg	NN	UNIT
injections	NNS	UNIT
in	IN	O
one	CD	PER
day	NN	PER
or	CC	O
as	IN	O
two	CD	DOS
40	CD	DOS
mg	NNS	UNIT
injections	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
for	IN	O
two	CD	PER
consecutive	JJ	PER
days	NNS	PER
)	)	O
,	,	O
followed	VBN	O
by	IN	O
80	CD	DOS
mg	NNS	UNIT
two	CD	O
weeks	NNS	O
later	RB	O
(	(	O
Day	NNP	O
15	CD	O
)	)	O
.	.	O

Using	VBG	O
a	DT	O
large	JJ	O
bore	NN	O
needle	NN	O
(	(	O
e.g	UH	O
,	,	O
18	CD	O
gauge	NN	O
)	)	O
and	CC	O
a	DT	O
syringe	NN	O
,	,	O
reconstitute	NN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
accompanying	VBG	O
50	CD	DOS
mL	JJ	UNIT
vial	NN	UNIT
of	IN	O
SWFI	NNP	O
to	TO	O
the	DT	O
50	CD	DOS
mg	JJ	UNIT
vial	NN	UNIT
of	IN	O
Activase	NNP	O
,	,	O
directing	VBG	O
the	DT	O
SWFI	NNP	O
stream	NN	O
into	IN	O
the	DT	O
lyophilized	JJ	O
cake	NN	O
.	.	O

Each	DT	O
filter	NN	O
needle	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
filter	VB	O
the	DT	O
contents	NNS	O
of	IN	O
up	IN	O
to	TO	O
four	CD	DOS
100	CD	DOS
mg	NN	UNIT
vials	NNS	UNIT
.	.	O

Immediately	RB	O
after	IN	O
removing	VBG	O
occlusion	NN	O
and	CC	O
any	DT	O
remaining	VBG	O
gel	NN	O
,	,	O
illuminate	VB	O
the	DT	O
treatment	NN	O
area	NN	O
with	IN	O
BF	NNP	O
-	:	O
RhodoLED®	NNP	O
,	,	O
a	DT	O
red	JJ	O
light	NN	O
credit	NN	O
with	IN	O
a	DT	O
narrow	JJ	O
spectrum	NN	O
around	IN	O
635	CD	O
nm	NNS	O
that	IN	O
delivers	VBZ	O
a	DT	O
light	JJ	O
dose	NN	O
of	IN	O
approximately	RB	O
37	CD	DOS
J	NNP	UNIT
/	NNP	O
cm²	NN	UNIT
within	IN	O
10	CD	O
minutes	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
congestive	JJ	WHO
heart	NN	WHO
failure	NN	WHO
(	(	O
NYHA	NNP	O
Class	NNP	O
I	PRP	O
or	CC	O
II	NNP	O
)	)	O
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

1	CD	O

Further	JJ	O
increases	NNS	O
of	IN	O
5	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
week	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
,	,	O
but	CC	O
a	DT	O
maximum	JJ	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
30	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	NN	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

Begin	NNP	O
whole	JJ	O
body	NN	O
planar	JJ	O
scintigraphy	NN	O
imaging	VBG	O
24	CD	O
±	JJ	O
6	CD	O
hours	NNS	O
following	VBG	O
administration	NN	O
of	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
.	.	O

Dosage	NN	O
for	IN	O
Adults	NNP	WHO
-	:	O
a	DT	O
single	JJ	DOS
0.075	CD	DOS
mg	NN	UNIT
intravenous	JJ	O
dose	NN	O
administered	VBD	O
over	IN	O
10	CD	O
seconds	NNS	O
immediately	RB	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
1	CD	DOS
gram	NN	UNIT
administered	VBN	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
every	DT	O
8	CD	O
to	TO	O
12	CD	O
hours	NNS	O
.	.	O

Pediatric	JJ	WHO
patients	NNS	WHO
should	MD	O
administer	VB	O
this	DT	O
product	NN	O
under	IN	O
adult	JJ	O
supervision	NN	O
.	.	O

If	IN	O
,	,	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
,	,	O
blood	NN	O
glucose	NN	O
control	NN	O
is	VBZ	O
not	RB	O
achieved	VBN	O
with	IN	O
increased	JJ	O
AFREZZA	NNP	O
doses	NNS	O
,	,	O
consider	VB	O
use	NN	O
of	IN	O
subcutaneous	JJ	O
mealtime	JJ	O
insulin	NN	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
should	MD	O
occur	VB	O
gradually	RB	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
at	IN	O
intervals	NNS	O
of	IN	O
no	DT	O
less	JJR	O
than	IN	O
1	CD	O
week	NN	O
.	.	O

A	DT	O
previously	RB	WHO
unvaccinated	JJ	WHO
child	NN	WHO
15	CD	WHO
months	NNS	WHO
through	IN	WHO
5	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
should	MD	O
receive	VB	O
one	CD	DOS
dose	NN	UNIT
of	IN	O
ActHIB	NNP	O
vaccine	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Teflaro	NNP	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
administered	VBN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
by	IN	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
over	IN	O
5	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
in	IN	O
patients	NNS	WHO
≥	JJ	WHO
18	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

Evidence	NN	O
is	VBZ	O
available	JJ	O
that	IN	O
in	IN	O
some	DT	O
types	NNS	O
of	IN	O
neoplastic	JJ	O
disease	NN	O
combination	NN	O
chemotherapy	NN	O
is	VBZ	O
superior	JJ	O
to	TO	O
single	JJ	O
agents	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
acceptable	JJ	O
in	IN	O
pediatrics	NNS	O
to	TO	O
start	VB	O
with	IN	O
a	DT	O
nutritional	JJ	O
solution	NN	O
of	IN	O
half	JJ	O
strength	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
about	IN	O
60	CD	DOS
to	TO	O
70	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
gonorrhea	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
by	IN	O
mouth	NN	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
seven	CD	PER
days	NNS	PER
.	.	O

If	IN	O
a	DT	O
flare	NN	O
occurs	VBZ	O
less	JJR	O
than	IN	O
6	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
last	JJ	O
treatment	NN	O
,	,	O
25	CD	O
percent	NN	O
of	IN	O
the	DT	O
maximum	JJ	O
exposure	NN	O
received	VBD	O
during	IN	O
the	DT	O
clearing	NN	O
phase	NN	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
and	CC	O
then	RB	O
proceed	VB	O
with	IN	O
the	DT	O
clearing	NN	O
schedule	NN	O
previously	RB	O
followed	VBD	O
for	IN	O
this	DT	O
patient	NN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
experience	VBP	WHO
severe	JJ	WHO
neutropenia	NN	WHO
(	(	O
neutrophils	VBZ	O
less	JJR	O
than	IN	O
500	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
for	IN	O
a	DT	PER
week	NN	PER
or	CC	O
longer	JJR	O
)	)	O
or	CC	O
severe	JJ	O
sensory	JJ	O
neuropathy	JJ	O
during	IN	O
ABRAXANE	NNP	O
therapy	NN	O
should	MD	O
have	VB	O
dosage	NN	O
reduced	VBN	O
to	TO	O
220	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	NN	O
for	IN	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
ABRAXANE	NNP	O
.	.	O

If	IN	O
potential	JJ	O
allergy	NN	O
is	VBZ	O
suspected	VBN	O
,	,	O
an	DT	O
intradermal	JJ	O
skin	JJ	O
test	NN	O
may	MD	O
be	VB	O
performed	VBN	O
prior	RB	O
to	TO	O
intravenous	JJ	O
administration	NN	O
,	,	O
i.e	FW	O
,	,	O
0.05	CD	DOS
mL	NN	UNIT
injection	NN	O
intradermally	RB	O
to	TO	O
be	VB	O
evaluated	VBN	O
30	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
following	VBG	O
injection	NN	O
.	.	O

Recommended	VBN	O
dosage	NN	O
is	VBZ	O
250	CD	DOS
to	TO	O
375	CD	DOS
mg	NN	UNIT
of	IN	O
acetaZOLAMIDE	NN	O
once	IN	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
one	CD	PER
or	CC	O
two	CD	PER
days	NNS	PER
,	,	O
alternating	VBG	O
with	IN	O
a	DT	O
day	NN	O
of	IN	O
rest	NN	O
.	.	O

In	IN	O
cases	NNS	O
of	IN	O
suspected	JJ	O
massive	JJ	O
overdose	NN	O
,	,	O
or	CC	O
with	IN	O
concomitant	JJ	O
ingestion	NN	O
of	IN	O
other	JJ	O
substances	NNS	O
,	,	O
or	CC	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
preexisting	VBG	WHO
liver	JJ	WHO
disease	NN	WHO
,	,	O
the	DT	O
absorption	NN	O
and	CC	O
/	NN	O
or	CC	O
the	DT	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
acetaminophen	NN	O
may	MD	O
be	VB	O
prolonged	VBN	O
,	,	O
in	IN	O
such	JJ	O
cases	NNS	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
the	DT	O
need	NN	O
for	IN	O
continued	JJ	O
infusion	NN	O
of	IN	O
N	NNP	O
-	:	O
acetylcysteine	NN	O
beyond	IN	O
21	CD	O
hours	NNS	O
.	.	O

The	DT	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
NIASPAN	NNP	O
should	MD	O
not	RB	O
be	VB	O
increased	VBN	O
by	IN	O
more	JJR	O
than	IN	O
500	CD	DOS
mg	NNS	UNIT
in	IN	O
any	DT	O
4	CD	O
-	:	O
week	NN	O
period	NN	O
.	.	O

Usual	JJ	O
regimens	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
ALTACE	NNP	O
may	MD	O
be	VB	O
followed	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
estimated	VBN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
>	VBD	WHO
40	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
.	.	O

The	DT	O
usual	JJ	O
single	JJ	O
dose	NN	O
is	VBZ	O
two	CD	DOS
to	TO	O
three	CD	DOS
inhalations	NNS	UNIT
.	.	O

Give	VB	O
first	JJ	O
dose	NN	O
on	IN	O
awakening	VBG	O
;	:	O
additional	JJ	O
doses	NNS	O
(	(	O
1	CD	DOS
or	CC	O
2	CD	DOS
)	)	O
at	IN	O
intervals	NNS	O
of	IN	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
.	.	O

If	IN	O
CD4+	NNP	O
T	NNP	O
lymphocyte	NN	O
counts	NNS	O
are	VBP	O
below	IN	O
250	CD	DOS
cells	NNS	UNIT
/	JJ	O
µL	NNP	O
,	,	O
AMEVIVE®	NNP	O
dosing	NN	O
should	MD	O
be	VB	O
withheld	VBN	O
and	CC	O
weekly	JJ	O
monitoring	NN	O
instituted	VBN	O
.	.	O

Fluid	NNP	O
intake	NN	O
for	IN	O
the	DT	O
infant	NN	O
receiving	VBG	O
central	JJ	O
venous	JJ	O
TPN	NNP	O
should	MD	O
be	VB	O
approximately	RB	O
125	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	JJ	FREQ
day	NN	FREQ
(	(	O
range	NN	O
:	:	O
100	CD	DOS
to	TO	O
175	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
clinical	JJ	O
condition	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
for	IN	O
patients	NNS	WHO
2	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
or	CC	O
0.63	CD	DOS
mg	NN	UNIT
of	IN	O
AccuNeb	NNP	O
(	(	O
albuterol	JJ	O
sulfate	NN	O
inhalation	NN	O
solution	NN	O
)	)	O
administered	VBD	O
3	CD	FREQ
or	CC	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
as	IN	O
needed	VBN	O
,	,	O
by	IN	O
nebulization	NN	O
.	.	O

In	IN	O
the	DT	O
management	NN	O
of	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
(	(	O
particularly	RB	O
chronic	JJ	O
infections	NNS	O
of	IN	O
the	DT	O
urinary	JJ	O
tract	NN	O
)	)	O
,	,	O
100	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

A	DT	O
0.5	CD	DOS
mL	NN	UNIT
dose	NN	UNIT
of	IN	O
ActHIB	NNP	O
is	VBZ	O
approved	VBN	O
for	IN	O
intramuscular	JJ	O
administration	NN	O
in	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
,	,	O
2	CD	O
months	NNS	O
through	IN	O
5	CD	O
years	NNS	O
of	IN	O
age	NN	O
as	IN	O
a	DT	O
4	CD	DOS
-	:	O
dose	JJ	O
series	NN	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
10	CD	DOS
to	TO	O
40	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

A	DT	O
mixture	NN	O
of	IN	O
Aminosyn	NNP	O
II	NNP	O
and	CC	O
dextrose	RB	O
diluted	VBN	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
and	CC	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
is	VBZ	O
suitable	JJ	O
for	IN	O
administration	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
fat	JJ	O
provides	VBZ	O
9	CD	O
kcal	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
that	WDT	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
24	CD	O
hours	NNS	O
is	VBZ	O
two	CD	DOS
doses	NNS	UNIT
of	IN	O
ALSUMA	NNP	O
separated	VBN	O
by	IN	O
at	IN	O
least	JJS	O
1	CD	O
hour	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
CR	NNP	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
6.25	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
immediately	RB	O
before	IN	O
bedtime	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

A	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NN	UNIT
may	MD	O
be	VB	O
considered	VBN	O
for	IN	O
patients	NNS	WHO
requiring	VBG	WHO
smaller	JJR	WHO
reductions	NNS	WHO
.	.	O

For	IN	O
patients	NNS	WHO
aged	VBN	WHO
12	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
the	DT	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
taken	VBN	O
3	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Normal	JJ	O
Dosage	NNP	O
at	IN	O
Prolonged	NNP	O
Intervals	NNS	O
:	:	O
If	IN	O
the	DT	O
creatinine	JJ	O
clearance	NN	O
rate	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
is	VBZ	O
stable	JJ	O
,	,	O
a	DT	O
dosage	NN	O
interval	NN	O
in	IN	O
hours	NNS	O
for	IN	O
the	DT	O
normal	JJ	O
dose	NN	O
can	MD	O
be	VB	O
calculated	VBN	O
by	IN	O
multiplying	VBG	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
by	IN	O
9	CD	O
,	,	O
e.g	NN	O
,	,	O
if	IN	O
the	DT	O
serum	NN	O
creatinine	NN	O
concentration	NN	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
/	VBD	O
100	CD	DOS
mL	NN	UNIT
,	,	O
the	DT	O
recommended	VBN	O
single	JJ	DOS
dose	NN	UNIT
(	(	O
7.5mg	CD	DOS
/	NNP	O
kg	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
every	DT	FREQ
18	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
starting	NN	O
dosage	NN	O
for	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
is	VBZ	O
based	VBN	O
upon	IN	O
patients	NNS	WHO
'	POS	WHO
asthma	JJ	WHO
severity	NN	WHO
.	.	O

To	TO	O
minimize	VB	O
radiation	NN	O
dose	NN	O
to	TO	O
the	DT	O
bladder	NN	O
,	,	O
prior	RB	O
to	TO	O
and	CC	O
following	VBG	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
administration	NN	O
,	,	O
encourage	VB	O
hydration	NN	O
to	TO	O
permit	VB	O
frequent	JJ	O
voiding	NN	O
.	.	O

The	DT	O
dose	JJ	O
increment	NN	O
should	MD	O
not	RB	O
exceed	VB	O
0.5	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
any	DT	O
one	CD	O
week	NN	O
.	.	O

If	IN	O
there	EX	O
are	VBP	O
adverse	JJ	O
reactions	NNS	O
with	IN	O
the	DT	O
400	CD	DOS
mg	NN	UNIT
dosage	NN	O
,	,	O
consider	VB	O
reducing	VBG	O
the	DT	O
dosage	NN	O
to	TO	O
300	CD	DOS
mg	NN	UNIT
once	RB	FREQ
monthly	RB	FREQ
.	.	O

The	DT	O
daily	JJ	FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	WHO
adult	NN	WHO
patient	NN	WHO
,	,	WHO
not	RB	WHO
hypermetabolic	JJ	WHO
,	,	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
and	CC	WHO
with	IN	WHO
restricted	JJ	WHO
physical	JJ	WHO
activity	NN	WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	DOS
to	TO	O
18	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1.0	CD	DOS
to	TO	O
1.5	CD	DOS
g	NN	UNIT
amino	NN	O
acids	NNS	O
/	VBP	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	DOS
and	CC	O
3000	CD	DOS
mL	NN	UNIT
of	IN	O
fluids	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
total	NN	O
doses	NNS	O
for	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
AMI	NNP	O
)	)	O
is	VBZ	O
based	VBN	O
on	IN	O
patient	JJ	O
weight	NN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
100	CD	DOS
mg	NNS	UNIT
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
selected	VBN	O
administration	NN	O
regimen	NNS	O
(	(	O
accelerated	VBD	O
or	CC	O
3	CD	O
hour	NN	O
,	,	O
described	VBN	O
below	IN	O
)	)	O
.	.	O

However	RB	O
,	,	O
older	JJR	WHO
pediatric	JJ	WHO
patients	NNS	WHO
can	MD	O
tolerate	VB	O
amino	JJ	O
acids	NNS	O
in	IN	O
concentrations	NNS	O
of	IN	O
up	IN	O
to	TO	O
5	CD	O
%	NN	O
.	.	O

After	IN	O
failure	NN	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
for	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
or	CC	O
relapse	NN	O
within	IN	O
6	CD	O
months	NNS	O
of	IN	O
adjuvant	JJ	O
chemotherapy	NN	O
,	,	O
the	DT	O
recommended	JJ	O
regimen	NNS	O
for	IN	O
ABRAXANE	NNP	O
is	VBZ	O
260	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
30	CD	O
minutes	NNS	O
every	DT	FREQ
3	CD	FREQ
weeks	NNS	FREQ
.	.	O

Since	IN	O
the	DT	O
doses	NNS	O
of	IN	O
epinephrine	NN	O
delivered	VBN	O
from	IN	O
Adrenaclick	NNP	O
are	VBP	O
fixed	VBN	O
,	,	O
consider	VB	O
using	VBG	O
other	JJ	O
forms	NNS	O
of	IN	O
injectable	JJ	O
epinephrine	NN	O
if	IN	O
doses	NNS	O
lower	JJR	O
than	IN	O
0.15	CD	DOS
mg	NNS	UNIT
are	VBP	O
deemed	VBN	O
necessary	JJ	O
.	.	O

In	IN	O
patients	NNS	WHO
taking	VBG	WHO
amiodarone	NN	WHO
or	CC	WHO
verapamil	NN	WHO
concomitantly	RB	WHO
with	IN	WHO
ALTOCORTM	NNP	WHO
,	,	O
the	DT	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
40	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Mypoathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NN	O
INTERACTIONS	NNP	O
,	,	O
Other	JJ	O
Drug	NNP	O
Interactions	NNP	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
Bumex	NNP	O
(	(	O
bumetanide	NN	O
)	)	O
is	VBZ	O
0.5	CD	DOS
mg	NN	UNIT
to	TO	O
2	CD	DOS
mg	NNS	UNIT
and	CC	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
is	VBZ	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

See	NNP	O
also	RB	O
Section	NNP	O
titled	VBD	O
Volume	NN	O
Adjustment	NN	O
:	:	O
Patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
40	CD	WHO
kg	NNS	WHO
and	CC	WHO
Requiring	VBG	WHO
Fluid	NNP	WHO
Restriction	NN	WHO

They	PRP	O
may	MD	O
be	VB	O
restarted	VBN	O
at	IN	O
0.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

In	IN	O
the	DT	O
above	JJ	O
solutions	NNS	O
with	IN	O
Amikacin	NNP	O
Sulfate	NNP	O
Injection	NNP	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
,	,	O
solutions	NNS	O
aged	VBD	O
for	IN	O
60	CD	PER
days	NNS	PER
at	IN	O
4°C	CD	O
and	CC	O
then	RB	O
stored	VBD	O
at	IN	O
25°C	CD	O
had	VBD	O
utility	NN	O
times	NNS	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

or	CC	O
250	CD	DOS
mg	JJ	UNIT
q.i.d	NN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
bleeding	NN	O
syndromes	NNS	O
due	JJ	O
to	TO	O
elevated	JJ	O
fibrinolytic	JJ	O
activity	NN	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
5	CD	DOS
AMICAR	NNP	UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
1000	CD	DOS
mg	JJ	UNIT
Tablets	NNPS	UNIT
or	CC	O
10	CD	DOS
AMICAR	NNP	UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
500	CD	DOS
mg	JJ	UNIT
Tablets	NNP	UNIT
(	(	O
5	CD	DOS
g	NN	UNIT
)	)	O
or	CC	O
20	CD	DOS
milliliter	NN	UNIT
of	IN	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
Oral	NNP	O
Solution	NNP	O
(	(	O
5	CD	DOS
g	NN	UNIT
)	)	O
be	VB	O
administered	VBN	O
during	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuing	VBG	O
rate	NN	O
of	IN	O
1	CD	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
1000	CD	DOS
mg	JJ	UNIT
Tablet	NNP	UNIT
or	CC	O
2	CD	DOS
AMICAR	NNP	UNIT
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
500	CD	DOS
mg	JJ	UNIT
Tablets	NNP	UNIT
(	(	O
1	CD	DOS
g	NN	UNIT
)	)	O
or	CC	O
5	CD	DOS
milliliter	NN	UNIT
of	IN	O
AMICAR	NNP	O
(	(	O
aminocaproic	JJ	O
acid	NN	O
)	)	O
Oral	NNP	O
Solution	NNP	O
(	(	O
1.25	CD	DOS
g	NN	UNIT
)	)	O
per	IN	O
hour	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
100	CD	DOS
to	TO	O
200	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
MINTEZOL	NNP	O
(	(	O
thiabendazole	NN	O
)	)	O
is	VBZ	O
3	CD	DOS
grams	NNS	UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
COPD	NNP	WHO
is	VBZ	O
1	CD	DOS
inhalation	NN	UNIT
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
250	CD	O
/	VBD	O
50	CD	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

Figure	NN	O
16	CD	O

If	IN	O
dose	JJ	O
reduction	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
patients	NNS	WHO
receiving	VBG	WHO
the	DT	WHO
lowest	JJS	WHO
available	JJ	WHO
strength	NN	WHO
,	,	O
administer	NN	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
.	.	O

In	IN	O
adults	NNS	WHO
with	IN	WHO
ADHD	NNP	WHO
who	WP	WHO
are	VBP	WHO
either	DT	WHO
starting	VBG	WHO
treatment	NN	WHO
for	IN	WHO
the	DT	WHO
first	JJ	WHO
time	NN	WHO
or	CC	WHO
switching	VBG	WHO
from	IN	WHO
another	DT	WHO
medication	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Administer	NNP	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
dose	NN	UNIT
.	.	O

Changes	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
that	WDT	O
indicate	VBP	O
a	DT	O
response	NN	O
to	TO	O
surgical	JJ	O
stress	NN	O
or	CC	O
lightening	NN	O
of	IN	O
anesthesia	NN	O
may	MD	O
be	VB	O
controlled	VBN	O
by	IN	O
increasing	VBG	O
the	DT	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
4	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
and	CC	O
/	NN	O
or	CC	O
administration	NN	O
of	IN	O
bolus	JJ	O
doses	NNS	O
of	IN	O
7	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

For	IN	O
new	JJ	WHO
or	CC	WHO
worsening	VBG	WHO
Grade	JJ	WHO
2	CD	WHO
or	CC	WHO
3	CD	WHO
neuropathy	JJ	WHO
,	,	O
dosing	VBG	O
should	MD	O
be	VB	O
held	VBN	O
until	IN	O
neuropathy	JJ	O
improves	NNS	O
to	TO	O
Grade	VB	O
1	CD	O
or	CC	O
baseline	NN	O
and	CC	O
then	RB	O
restarted	VBD	O
at	IN	O
1.2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
<	VBP	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
weighing	VBG	WHO
<	$	WHO
70	CD	WHO
kg	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
should	MD	O
be	VB	O
calculated	VBN	O
according	VBG	O
to	TO	O
patient	NN	O
body	NN	O
weight	VBD	O
as	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
[	NN	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
AmBisome	NNP	O
for	IN	O
each	DT	O
indication	NN	O
for	IN	O
adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O

ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	FW	O
hydrochloride	NN	O
)	)	O
is	VBZ	O
supplied	VBN	O
in	IN	O
individually	RB	O
sealed	VBN	O
dosage	NN	O
forms	NNS	O
which	WDT	O
pose	VBP	O
no	DT	O
known	VBN	O
risk	NN	O
to	TO	O
health	NN	O
-	:	O
care	NN	O
providers	NNS	O
having	VBG	O
incidental	JJ	O
contact	NN	O
.	.	O

Titrate	NNP	O
GRALISE	NNP	O
to	TO	O
an	DT	O
1800	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
the	DT	O
evening	NN	O
meal	NN	O
.	.	O

AGRIFLUshould	RB	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
intramuscular	JJ	O
injection	NN	UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
region	NN	O
of	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

Adding	VBG	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
chamber	NN	O
and	CC	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
the	DT	O
dextrose	JJ	O
chamber	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
(	(	O
in	IN	O
mEq	NN	O
/	NNP	O
L	NNP	O
)	)	O
as	IN	O
follows	VBZ	O
:	:	O
53	CD	O
sodium	NN	O
,	,	O
42	CD	O
potassium	NN	O
,	,	O
35	CD	O
chloride	NN	O
,	,	O
5	CD	O
magnesium	NN	O
,	,	O
4.5	CD	O
calcium	NN	O
,	,	O
54.7	CD	O
acetate	NN	O
,	,	O
and	CC	O
15	CD	O
(	(	O
mM	NN	O
)	)	O
phosphate	NN	O
.	.	O

Patients	NNS	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
with	IN	WHO
more	RBR	WHO
severe	JJ	WHO
asthma	NN	WHO
(	(	O
baseline	JJ	O
FEV1	NNP	O
less	JJR	O
than	IN	O
60	CD	O
%	NN	O
predicted	VBN	O
)	)	O
,	,	O
weight	VBD	WHO
>	$	WHO
40	CD	WHO
kg	NN	WHO
,	,	WHO
or	CC	WHO
patients	NNS	WHO
11	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
may	MD	O
achieve	VB	O
a	DT	O
better	JJR	O
initial	JJ	O
response	NN	O
with	IN	O
the	DT	O
1.25	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
.	.	O

The	DT	O
highest	JJS	O
recommended	VBD	O
dose	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
is	VBZ	O
232	CD	DOS
/	JJ	O
14	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
amiodarone	NN	O
is	VBZ	O
about	IN	O
1000	CD	DOS
mg	NN	UNIT
over	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
of	IN	O
therapy	NN	O
,	,	O
delivered	VBN	O
by	IN	O
the	DT	O
following	JJ	O
infusion	NN	O
regimen	NNS	O
:	:	O

Due	JJ	O
to	TO	O
incompletely	RB	O
developed	JJ	O
renal	JJ	O
function	NN	O
affecting	VBG	O
elimination	NN	O
of	IN	O
amoxicillin	NN	O
in	IN	O
this	DT	O
age	NN	O
group	NN	O
,	,	O
the	DT	O
recommended	VBN	O
upper	JJ	O
dose	NN	O
of	IN	O
AMOXIL	NNP	O
is	VBZ	O
30	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
divided	VBD	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Patients	NNS	WHO
already	RB	WHO
receiving	VBG	WHO
a	DT	WHO
stable	JJ	WHO
dose	NN	WHO
of	IN	WHO
lovastatin	NN	WHO
who	WP	WHO
require	VBP	WHO
further	JJ	WHO
TG	NNP	WHO
-	:	O
lowering	NN	O
or	CC	O
HDL	NNP	O
-	:	O
raising	NN	O
(	(	O
e.g	UH	O
,	,	O
to	TO	O
achieve	VB	O
NCEP	NNP	O
non	SYM	O
-	:	O
HDL	NNP	O
-	:	O
C	NNP	O
goals	NNS	O
)	)	O
,	,	O
may	MD	O
receive	VB	O
concomitant	JJ	O
dosage	NN	O
titration	NN	O
with	IN	O
NIASPAN	NNP	O
per	IN	O
NIASPAN	NNP	O
recommended	VBD	O
initial	JJ	O
titration	NN	O
schedule	NN	O
(	(	O
see	VB	O
Table	NNP	O
10	CD	O
,	,	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
section	NN	O
)	)	O
.	.	O

To	TO	O
prepare	VB	O
TriHIBit	NNP	O
vaccine	NN	O
,	,	O
thoroughly	RB	O
agitate	VBP	O
the	DT	O
vial	NN	O
of	IN	O
Sanofi	NNP	O
Pasteur	NNP	O
Inc.	NNP	O
Tripedia	NNP	O
vaccine	NN	O
then	RB	O
withdraw	VBZ	O
0.6	CD	DOS
mL	NN	UNIT
and	CC	O
inject	NN	O
into	IN	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
ActHIB	NNP	O
vaccine	NN	O
.	.	O

In	IN	O
these	DT	WHO
patients	NNS	WHO
,	,	O
serum	JJ	O
amikacin	JJ	O
concentrations	NNS	O
should	MD	O
be	VB	O
measured	VBN	O
to	TO	O
assure	VB	O
accurate	JJ	O
administration	NN	O
of	IN	O
amikacin	NNS	O
and	CC	O
to	TO	O
avoid	VB	O
concentrations	NNS	O
above	IN	O
35	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

One	CD	DOS
drop	NN	UNIT
of	IN	O
Isopto®	NNP	O
Carpine	NNP	O
1	CD	O
%	NN	O
,	,	O
2	CD	O
%	NN	O
or	CC	O
4	CD	O
%	NN	O
should	MD	O
be	VB	O
applied	VBN	O
topically	RB	O
in	IN	O
the	DT	O
eye	NN	O
(	(	O
s	NN	O
)	)	O
up	IN	O
to	TO	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Peak	JJ	O
concentrations	NNS	O
(	(	O
30	CD	O
to	TO	O
90	CD	O
minutes	NNS	O
after	IN	O
injection	NN	O
)	)	O
above	IN	O
35	CD	DOS
µg	NNS	UNIT
per	IN	O
mL	NN	O
and	CC	O
trough	JJ	O
concentrations	NNS	O
(	(	O
just	RB	O
prior	RB	O
to	TO	O
the	DT	O
next	JJ	O
dose	NN	O
)	)	O
above	IN	O
10	CD	DOS
µg	NNS	UNIT
per	IN	O
mL	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

Apply	NNP	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
3	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
then	RB	O
discontinue	NN	O
for	IN	O
4	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
ADLYXIN	NNP	O
is	VBZ	O
10	CD	DOS
mcg	NN	UNIT
subcutaneously	RB	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
14	CD	PER
days	NNS	PER
.	.	O

DUTREBIS	NNP	O
is	VBZ	O
a	DT	O
fixed	JJ	O
-	:	O
dose	JJ	O
combination	NN	O
product	NN	O
containing	VBG	O
150	CD	DOS
mg	NN	UNIT
of	IN	O
lamivudine	NN	O
and	CC	O
300	CD	DOS
mg	NN	UNIT
of	IN	O
raltegravir	NN	O
.	.	O

Flushing	VBG	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
see	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
may	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
frequency	NN	O
or	CC	O
severity	NN	O
by	IN	O
pretreatment	NN	O
with	IN	O
aspirin	NN	O
up	RB	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
325	CD	DOS
mg	NN	UNIT
(	(	O
taken	VBN	O
up	RP	O
to	TO	O
approximately	RB	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
ADVICOR	NNP	O
dose	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
older	JJR	WHO
pediatric	JJ	WHO
patients	NNS	WHO
can	MD	O
receive	VB	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
.	.	O

Iron	NNP	O
supplementation	NN	O
is	VBZ	O
more	RBR	O
critical	JJ	O
in	IN	O
the	DT	WHO
child	NN	WHO
than	IN	O
the	DT	WHO
adult	NN	WHO
because	IN	O
of	IN	O
the	DT	O
increasing	VBG	O
red	JJ	O
cell	NN	O
mass	NN	O
required	VBN	O
by	IN	O
the	DT	O
growing	VBG	O
child	NN	O
.	.	O

Part	NN	O
of	IN	O
the	DT	O
nonprotein	JJ	O
caloric	JJ	O
requirement	NN	O
may	MD	O
be	VB	O
provided	VBN	O
as	IN	O
lipid	JJ	O
emulsion	NN	O
administered	VBD	O
concurrently	RB	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
60	CD	O
%	NN	O
of	IN	O
daily	JJ	FREQ
calories	NNS	O
at	IN	O
a	DT	O
dose	NN	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
g	JJ	UNIT
fat	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

USE	NNP	O
ONLY	NNP	O
THE	NNP	O
ADRENALIN	NNP	O
1	CD	DOS
ML	NNP	UNIT
SINGLE	NNP	O
-	:	O
USE	NN	O
VIAL	NNP	O
FOR	NNP	O
OPHTHALMIC	NNP	O
USE	NNP	O
.	.	O

The	DT	O
maximum	JJ	O
radiant	JJ	O
exposure	NN	O
or	CC	O
irradiance	NN	O
(	(	O
within	IN	O
±15	NNP	O
percent	NN	O
)	)	O
of	IN	O
UVA	NNP	O
(	(	O
320	CD	DOS
–	RB	O
400	CD	DOS
nm	NNS	UNIT
)	)	O
delivered	VBN	O
to	TO	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
using	VBG	O
an	DT	O
appropriate	JJ	O
radiometer	NN	O
calibrated	VBD	O
to	TO	O
be	VB	O
read	VBN	O
in	IN	O
Joules	NNP	UNIT
/	NNP	O
cm²	NN	UNIT
or	CC	O
mW	NN	UNIT
/	JJ	O
cm²	NN	UNIT
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
ACTOS	NNP	O
is	VBZ	O
15	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
when	WRB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
gemfibrozil	NN	O
or	CC	O
other	JJ	O
strong	JJ	O
CYP2C8	NNP	O
inhibitors	NNS	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

If	IN	O
no	DT	O
response	NN	O
is	VBZ	O
seen	VBN	O
at	IN	O
300	CD	DOS
mg	NN	UNIT
,	,	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
,	,	O
depending	VBG	O
upon	IN	O
tolerance	NN	O
,	,	O
up	RB	O
to	TO	O
400	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

Elderly	RB	WHO
or	CC	WHO
debilitated	VBN	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
especially	RB	O
sensitive	JJ	O
to	TO	O
the	DT	O
effects	NNS	O
of	IN	O
zolpidem	NN	O
tartrate	NN	O
.	.	O

The	DT	O
usual	JJ	O
IV	NNP	O
dose	NN	O
is	VBZ	O
16	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
.	.	O

ACIPHEX	NNP	O
Sprinkle	NNP	O
is	VBZ	O
recommended	VBN	O
for	IN	O
up	RB	O
to	TO	O
12	CD	O
weeks	NNS	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
1	CD	WHO
to	TO	WHO
11	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	O
is	VBZ	O
dosed	VBN	O
by	IN	O
body	NN	O
weight	NN	O
:	:	O

In	IN	O
elderly	JJ	WHO
patients	NNS	WHO
(	(	WHO
greater	JJR	WHO
than	IN	WHO
70	CD	WHO
years	NNS	WHO
)	)	WHO
,	,	O
ACEON	NNP	O
should	MD	O
be	VB	O
given	VBN	O
as	IN	O
a	DT	O
2	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
first	JJ	O
week	NN	O
,	,	O
followed	VBN	O
by	IN	O
4	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
second	JJ	O
week	NN	O
and	CC	O
8	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
maintenance	NN	O
dose	NN	O
if	IN	O
tolerated	VBN	O
.	.	O

Figure	NN	O
10	CD	O

Usual	JJ	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
200	CD	DOS
to	TO	O
300	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
suspension	NN	O
for	IN	O
infusion	NN	O
when	WRB	O
prepared	VBN	O
as	IN	O
recommended	VBN	O
in	IN	O
an	DT	O
infusion	NN	O
bag	NN	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
,	,	O
but	CC	O
may	MD	O
be	VB	O
refrigerated	VBN	O
at	IN	O
2°C	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°F	CD	O
to	TO	O
46°F	CD	O
)	)	O
and	CC	O
protected	VBN	O
from	IN	O
bright	JJ	O
light	NN	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Three	CD	O
Bag	NNP	O
Method	NNP	O
Dosage	NNP	O
Guide	NNP	O
by	IN	O
Weight	NNP	O
in	IN	O
Patients	NNP	WHO
41	CD	WHO
kg	NN	WHO
to	TO	WHO
100	CD	WHO
kg	NNS	WHO

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
syphilis	NN	O
in	IN	O
patients	NNS	WHO
allergic	JJ	WHO
to	TO	WHO
penicillin	VB	WHO
,	,	O
the	DT	O
following	JJ	O
dosage	NN	O
of	IN	O
Achromycin	NNP	O
V	NNP	O
(	(	O
Tetracycline	NNP	O
HCl	NNP	O
Capsules	NNP	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
recommended	VBN	O
:	:	O
early	JJ	O
syphilis	NN	O
(	(	O
less	JJR	O
than	IN	O
one	CD	O
year	NN	O
's	POS	O
duration	NN	O
)	)	O
,	,	O
500	CD	DOS
mg	NN	UNIT
q.i.d	NN	O
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
may	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
as	IN	O
50	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Nebulization	NNP	O
-	:	O
Face	NN	O
Mask	NNP	O
,	,	O
Mouthpiece	NNP	O
,	,	O
Tracheostomy	NNP	O
:	:	O
When	WRB	O
nebulized	VBN	O
into	IN	O
a	DT	O
face	NN	O
mask	NN	O
,	,	O
mouthpiece	NN	O
,	,	O
or	CC	O
tracheostomy	NN	O
,	,	O
1	CD	DOS
to	TO	O
10	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
solution	NN	O
or	CC	O
2	CD	DOS
to	TO	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
may	MD	O
be	VB	O
given	VBN	O
every	DT	O
2	CD	O
to	TO	O
6	CD	O
hours	NNS	O
;	:	O
the	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
most	JJS	WHO
patients	NNS	WHO
is	VBZ	O
3	CD	DOS
to	TO	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
solution	NN	O
or	CC	O
6	CD	DOS
to	TO	O
10	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
three	CD	O
to	TO	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Control	NNP	O
and	CC	O
Prevention	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
doses	NNS	O
higher	JJR	O
than	IN	O
800	CD	DOS
mcg	NNS	UNIT
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
in	IN	O
patients	NNS	WHO
.	.	O

May	NNP	O
be	VB	O
administered	VBN	O
by	IN	O
needle	JJ	O
and	CC	O
syringe	NN	O
(	(	O
5	CD	DOS
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
)	)	WHO
or	CC	O
PharmaJet	NNP	O
Stratis	NNP	O
Needle	NNP	O
-	:	O
Free	JJ	O
Injection	NN	O
System	NNP	O
(	(	O
18	CD	O
through	IN	O
64	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
only	RB	WHO
)	)	WHO
.	.	O

In	IN	O
some	DT	WHO
patients	NNS	WHO
,	,	O
the	DT	O
higher	JJR	O
morning	NN	O
blood	NN	O
levels	NNS	O
following	VBG	O
use	NN	O
of	IN	O
the	DT	O
12.5	CD	DOS
mg	NN	UNIT
dose	JJ	O
increase	NN	O
the	DT	O
risk	NN	O
of	IN	O
next	JJ	O
day	NN	O
impairment	NN	O
of	IN	O
driving	NN	O
and	CC	O
other	JJ	O
activities	NNS	O
that	WDT	O
require	VBP	O
full	JJ	O
alertness	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Treatment	NN	O
with	IN	O
Anafranil	NNP	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
25	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
and	CC	O
gradually	RB	O
increased	VBD	O
,	,	O
as	IN	O
tolerated	VBN	O
,	,	O
to	TO	O
approximately	RB	O
100	CD	DOS
mg	NNS	UNIT
during	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
.	.	O

Acetylcysteine	NNP	O
Solution	NNP	O
,	,	O
USP	NNP	O
(	(	O
n	JJ	O
-	:	O
acetyl	NN	O
-	:	O
l	NN	O
-	:	O
cysteine	NN	O
)	)	O
is	VBZ	O
available	JJ	O
in	IN	O
rubber	NN	O
stoppered	JJ	O
glass	NN	O
vials	NNS	O
containing	VBG	O
10	CD	DOS
mL	NN	UNIT
or	CC	O
30	CD	DOS
mL	NN	UNIT
.	.	O

Uncomplicated	VBN	O
urethral	JJ	O
,	,	O
endocervical	JJ	O
,	,	O
or	CC	O
rectal	JJ	O
infection	NN	O
caused	VBN	O
by	IN	O
Chlamydia	NNP	O
trachomatis	NN	O
:	:	O
100	CD	DOS
mg	NN	UNIT
by	IN	O
mouth	NN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

(	(	O
c	NN	O
)	)	O
Slowly	RB	O
inject	VBP	O
the	DT	O
recommended	JJ	O
volume	NN	O
as	IN	O
a	DT	O
single	JJ	DOS
intramuscular	JJ	UNIT
injection	NN	UNIT
into	IN	O
the	DT	O
deltoid	NN	O
or	CC	O
gluteal	JJ	O
muscle	NN	O
.	.	O

If	IN	O
patients	NNS	WHO
develop	VBP	WHO
nonhematologic	JJ	WHO
toxicities	NNS	WHO
(	(	O
excluding	VBG	O
neurotoxicity	NN	O
)	)	O
>	NN	O
Grade	NNP	O
3	CD	O
,	,	O
treatment	NN	O
should	MD	O
be	VB	O
withheld	VBN	O
until	IN	O
resolution	NN	O
to	TO	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
pre	JJ	O
-	:	O
therapy	NN	O
value	NN	O
.	.	O

Administer	NNP	O
only	RB	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
within	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

When	WRB	O
amikacin	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
uncomplicated	JJ	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
250	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
may	MD	O
be	VB	O
used	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
ABILIFY	NNP	O
as	IN	O
adjunctive	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	WHO
already	RB	WHO
taking	VBG	WHO
an	DT	WHO
antidepressant	NN	WHO
is	VBZ	O
2	CD	DOS
to	TO	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

A	DT	O
normal	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
is	VBZ	O
15	CD	O
–	JJ	O
20	CD	O
weeks	NNS	O
.	.	O

The	DT	O
solution	NN	O
is	VBZ	O
administered	VBN	O
to	TO	O
adults	NNS	WHO
over	IN	O
a	DT	O
30	CD	O
to	TO	O
60	CD	O
minute	JJ	O
period	NN	O
.	.	O

Caregivers	NNS	O
of	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
receiving	VBG	WHO
doxorubicin	NN	WHO
should	MD	O
be	VB	O
counseled	VBN	O
to	TO	O
take	VB	O
precautions	NNS	O
(	(	O
such	JJ	O
as	IN	O
wearing	VBG	O
latex	JJ	O
gloves	NNS	O
)	)	O
to	TO	O
prevent	VB	O
contact	NN	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
urine	NN	O
and	CC	O
other	JJ	O
body	NN	O
fluids	NNS	O
for	IN	O
at	IN	PER
least	JJ	PER
5	CD	PER
days	NNS	PER
after	IN	O
each	DT	O
treatment	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
0.25	CD	O
percent	NN	O
Preservative	NNP	O
-	:	O
free	JJ	O
TIMOPTIC	NNP	O
in	IN	O
OCUDOSE	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
administered	VBD	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Alosetron	NNP	O
hydrochloride	JJ	O
tablets	NNS	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
or	CC	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
and	CC	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
]	NNP	O
,	,	O
and	CC	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

The	DT	O
sterile	JJ	O
solution	NN	O
containing	VBG	O
50	CD	DOS
mcg	JJ	UNIT
corticorelin	NN	O
/	NNP	O
mL	NN	O
is	VBZ	O
then	RB	O
ready	JJ	O
for	IN	O
injection	NN	O
by	IN	O
the	DT	O
intravenous	JJ	O
route	NN	O
.	.	O

Fat	NNP	O
emulsion	NN	O
may	MD	O
comprise	VB	O
up	RB	O
to	TO	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
daily	JJ	FREQ
caloric	JJ	O
intake	NN	O
at	IN	O
a	DT	O
dosage	NN	O
level	NN	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
g	JJ	UNIT
fat	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

There	EX	O
are	VBP	O
two	CD	DOS
Activase	NNP	UNIT
dose	NN	UNIT
regimens	NNS	O
(	(	O
accelerated	VBN	O
and	CC	O
3	CD	O
-	:	O
hour	NN	O
)	)	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
AMI	NNP	O
;	:	O
there	EX	O
are	VBP	O
no	DT	O
controlled	JJ	O
studies	NNS	O
to	TO	O
compare	VB	O
clinical	JJ	O
outcomes	NNS	O
with	IN	O
these	DT	O
regimens	NNS	O
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

For	IN	O
patients	NNS	WHO
converting	VBG	WHO
from	IN	WHO
Actiq	NNP	WHO
doses	VBZ	WHO
400	CD	DOS
mcg	NN	UNIT
and	CC	O
below	IN	O
,	,	O
initiate	JJ	O
titration	NN	O
with	IN	O
100	CD	DOS
mcg	JJ	UNIT
Abstral	NNP	O
and	CC	O
proceed	VB	O
using	VBG	O
multiples	NNS	O
of	IN	O
this	DT	O
strength	NN	O
.	.	O

Apply	NNP	O
to	TO	O
affected	VB	O
area	NN	O
3	CD	FREQ
to	TO	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

â€¢	JJ	O
Increase	NNP	O
the	DT	O
dose	NN	O
to	TO	O
the	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
20	CD	DOS
mcg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
starting	VBG	O
on	IN	O
Day	NNP	O
15	CD	O
.	.	O

In	IN	O
studies	NNS	O
comparing	VBG	O
0.1	CD	O
,	,	O
0.5	CD	O
,	,	O
and	CC	O
1.0	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
day,8	VBD	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
after	IN	O
one	CD	O
week	NN	O
if	IN	O
ADHD	NNP	O
symptoms	NNS	O
are	VBP	O
not	RB	O
adequately	RB	O
controlled	VBN	O
.	.	O

Reconstituted	VBN	O
AFSTYLA	NNP	O
may	MD	O
be	VB	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
25°C	CD	O
(	(	O
77°F	CD	O
)	)	O
,	,	O
for	IN	O
up	IN	O
to	TO	O
4	CD	O
hours	NNS	O
.	.	O

Amphadase®	NNP	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
small	JJ	O
volumes	NNS	O
of	IN	O
solution	NN	O
(	(	O
up	IN	O
to	TO	O
200	CD	DOS
mL	NN	UNIT
)	)	O
,	,	O
such	JJ	O
as	IN	O
small	JJ	O
clysis	NN	O
for	IN	O
infants	NNS	WHO
or	CC	O
solutions	NNS	O
of	IN	O
drugs	NNS	O
for	IN	O
subcutaneous	JJ	O
injection	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMERGE	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
or	CC	O
2.5	CD	DOS
mg	NN	UNIT
.	.	O

If	IN	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
use	VB	O
amiloride	JJ	O
HCl	NNP	O
alone	RB	O
(	(	O
see	VB	O
INDICATIONS	NNP	O
)	)	O
,	,	O
the	DT	O
starting	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
one	CD	DOS
5	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
daily	RB	FREQ
.	.	O

300	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
for	IN	O
at	IN	PER
least	JJ	PER
10	CD	PER
days	NNS	PER
.	.	O

Two	CD	DOS
to	TO	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
solution	NN	O
may	MD	O
then	RB	O
be	VB	O
instilled	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
syringe	NN	O
connected	VBN	O
to	TO	O
the	DT	O
catheter	NN	O
.	.	O

A	DT	O
basic	JJ	O
solution	NN	O
for	IN	O
pediatric	JJ	O
use	NN	O
should	MD	O
contain	VB	O
25	CD	DOS
grams	NNS	UNIT
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
200	CD	DOS
to	TO	O
250	CD	DOS
grams	NNS	UNIT
of	IN	O
glucose	NN	O
per	IN	O
1000	CD	DOS
mL	NN	UNIT
,	,	O
administered	VBN	O
from	IN	O
containers	NNS	O
containing	VBG	O
250	CD	DOS
or	CC	O
500	CD	DOS
mL	NN	UNIT
.	.	O

In	IN	O
a	DT	O
large	JJ	O
randomized	VBN	O
study	NN	O
(	(	O
NSABP	NNP	O
B	NNP	O
-	:	O
15	CD	O
)	)	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
early	JJ	WHO
breast	NN	WHO
cancer	NN	WHO
involving	VBG	WHO
axillary	JJ	WHO
lymph	NN	WHO
nodes	NNS	WHO
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
Clinical	NNP	O
Studies	NNPS	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
,	,	O
Adverse	NNP	O
Reactions	NNP	O
in	IN	O
Patients	NNPS	WHO
with	IN	WHO
Early	JJ	WHO
Breast	NNP	WHO
Cancer	NNP	WHO
Receiving	NNP	WHO
Doxorubicin	NNP	WHO
-	:	O
Containing	VBG	O
Adjuvant	NNP	O
Therapy	NNP	O
)	)	O
,	,	O
the	DT	O
combination	NN	O
dosage	NN	O
regimen	NNS	O
of	IN	O
AC	NNP	O
(	(	O
doxorubicin	JJ	O
60	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
and	CC	O
cyclophosphamide	VB	O
600	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
)	)	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
treatment	NN	O
cycle	NN	O
.	.	O

After	IN	O
a	DT	O
period	NN	O
of	IN	O
2	CD	PER
months	NNS	PER
or	CC	O
more	JJR	O
off	IN	O
therapy	NN	O
,	,	O
and	CC	O
if	IN	O
warranted	VBN	O
by	IN	O
persistent	NN	O
or	CC	O
recurring	VBG	O
severe	JJ	O
nodular	JJ	O
acne	NN	O
,	,	O
a	DT	O
second	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
may	MD	O
be	VB	O
initiated	VBN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
are	VBP	O
at	IN	O
increased	JJ	O
risk	NN	O
of	IN	O
propylene	NN	O
glycol	NN	O
-	:	O
associated	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

Figure	NN	O
13	CD	O

However	RB	O
,	,	O
on	IN	O
limited	JJ	O
clinical	JJ	O
experience	NN	O
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
SYPRINE	NNP	O
is	VBZ	O
500	CD	DOS
-	:	O
750	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
and	CC	O
750	CD	DOS
-	:	O
1250	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
for	IN	O
adults	NNS	WHO
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
two	CD	O
,	,	O
three	CD	FREQ
or	CC	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Hospitalized	VBN	WHO
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
been	VBN	WHO
refractory	JJ	WHO
to	TO	WHO
antidepressant	VB	WHO
therapy	NN	WHO
and	CC	WHO
who	WP	WHO
have	VBP	WHO
no	DT	WHO
history	NN	WHO
of	IN	WHO
convulsive	JJ	WHO
seizures	NNS	WHO
may	MD	O
have	VB	O
dosage	NN	O
raised	VBN	O
cautiously	RB	O
up	IN	O
to	TO	O
600	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
opioids	NNS	O
,	,	O
the	DT	O
safety	NN	O
of	IN	O
patients	NNS	WHO
using	VBG	WHO
such	JJ	WHO
products	NNS	WHO
is	VBZ	O
dependent	JJ	O
on	IN	O
health	NN	O
care	NN	O
professionals	NNS	O
prescribing	VBG	O
them	PRP	O
in	IN	O
strict	JJ	O
conformity	NN	O
with	IN	O
their	PRP$	O
approved	JJ	O
labeling	NN	O
with	IN	O
respect	NN	O
to	TO	O
patient	JJ	O
selection	NN	O
,	,	O
dosing	NN	O
,	,	O
and	CC	O
proper	JJ	O
conditions	NNS	O
for	IN	O
use	NN	O
.	.	O

Example	NN	O
:	:	O
UPAH	NNP	O
=	VBZ	O
8	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O

Adult	NN	WHO
patients	NNS	WHO
whose	WP$	WHO
disease	NN	WHO
is	VBZ	WHO
very	RB	WHO
severe	JJ	WHO
with	IN	WHO
scarring	NN	WHO
or	CC	O
is	VBZ	O
primarily	RB	O
manifested	VBN	O
on	IN	O
the	DT	O
trunk	NN	O
may	MD	O
require	VB	O
dose	NN	O
adjustments	NNS	O
up	IN	O
to	TO	O
2.0	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
as	IN	O
tolerated	VBN	O
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	DOS
g	NNS	UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

Third	JJ	O
Dose	NNP	O
:	:	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBN	O
in	IN	O
1000	CD	DOS
mL	NN	UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
16	CD	DOS
hrs	NNS	UNIT

ABELCET®	NNP	O
(	(	O
amphotericin	IN	O
b	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
2.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	JJ	O
h	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
of	IN	O
ALDURAZYME	NNP	O
is	VBZ	O
0.58	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
administered	VBN	O
once	RB	FREQ
weekly	JJ	FREQ
as	IN	O
an	DT	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
.	.	O

Unopened	VBN	O
vials	NNS	O
of	IN	O
ABRAXANE	NNP	O
are	VBP	O
stable	JJ	O
until	IN	O
the	DT	O
date	NN	O
indicated	VBD	O
on	IN	O
the	DT	O
package	NN	O
when	WRB	O
stored	VBD	O
between	IN	O
20°C	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°F	CD	O
to	TO	O
77°F	CD	O
)	)	O
in	IN	O
the	DT	O
original	JJ	O
package	NN	O
.	.	O

Schnurr	NNP	O
,	,	O
E.	NNP	O
;	:	O
Lahme	NNP	O
,	,	O
W.	NNP	O
;	:	O
Kuppers	NNP	O
,	,	O
H.	NNP	O
:	:	O
Measurement	NN	O
of	IN	O
renal	JJ	O
clearance	NN	O
of	IN	O
inulin	NN	O
and	CC	O
PAH	NNP	O
in	IN	O
the	DT	O
steady	JJ	O
state	NN	O
without	IN	O
urine	JJ	O
collection	NN	O
;	:	O
Clinical	NNP	O
Nephrology	NNP	O
,	,	O
13	CD	O
(	(	O
1	CD	O
)	)	O
:	:	O
(	(	O
26	CD	O
-	:	O
29	CD	O
)	)	O
,	,	O
1980	CD	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
30	CD	DOS
micrograms	NN	UNIT
once	RB	FREQ
a	DT	FREQ
week	NN	FREQ
.	.	O

For	IN	O
previously	RB	WHO
unvaccinated	JJ	WHO
children	NNS	WHO
,	,	O
the	DT	O
number	NN	O
of	IN	O
doses	NNS	O
of	IN	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
Vaccine	NNP	O
needed	VBD	O
depends	VBZ	O
on	IN	O
the	DT	O
age	NN	O
at	IN	O
which	WDT	O
the	DT	O
immunization	NN	O
series	NN	O
is	VBZ	O
begun	VBN	O
.	.	O

15	CD	DOS
mg	NN	UNIT
/	VBD	O
850	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
:	:	O
white	JJ	O
to	TO	O
off	VB	O
-	:	O
white	JJ	O
,	,	O
oblong	JJ	O
,	,	O
film	NN	O
-	:	O
coated	VBN	O
tablet	NN	O
with	IN	O
“	JJ	O
4833M	CD	O
”	NN	O
on	IN	O
one	CD	O
side	NN	O
and	CC	O
“	$	O
15	CD	O
/	$	O
850	CD	O
”	NN	O
on	IN	O
the	DT	O
other	JJ	O
,	,	O
available	JJ	O
in	IN	O
:	:	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
dosage	NN	O
increases	NNS	O
above	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
should	MD	O
only	RB	O
be	VB	O
considered	VBN	O
if	IN	O
the	DT	O
expected	JJ	O
benefit	NN	O
exceeds	VBZ	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
myopathy	JJ	O
/	JJ	O
rhabdomyolysis	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
Hepatic	JJ	WHO
Impairment	NN	WHO
:	:	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
or	CC	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

Figure	NN	O
5	CD	O

To	TO	O
prepare	VB	O
ActHIB	NNP	O
vaccine	NN	O
,	,	O
withdraw	JJ	O
0.6	CD	DOS
mL	NN	UNIT
of	IN	O
saline	JJ	O
diluent	NN	O
(	(	O
0.4	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
)	)	O
and	CC	O
inject	VB	O
into	IN	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
ActHIB	NNP	O
vaccine	NN	O
.	.	O

Although	IN	O
there	EX	O
was	VBD	O
a	DT	O
threefold	JJ	O
increase	NN	O
in	IN	O
acetylcysteine	JJ	O
plasma	NN	O
concentrations	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
cirrhosis	NN	WHO
,	,	O
no	DT	O
data	NNS	O
are	VBP	O
available	JJ	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
required	VBN	O
.	.	O

Note	NN	O
:	:	O
this	DT	O
0.3	CD	DOS
mL	NN	UNIT
of	IN	O
diluent	NN	O
is	VBZ	O
not	RB	O
the	DT	O
entire	JJ	O
content	NN	O
of	IN	O
the	DT	O
diluent	JJ	O
vial	NN	O
.	.	O

Loading	VBG	O
Dose	NNP	O
:	:	O
150	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
1	CD	DOS
hr	NNS	UNIT

If	IN	O
a	DT	O
patient	NN	O
is	VBZ	O
to	TO	O
receive	VB	O
more	JJR	O
than	IN	O
one	CD	DOS
vial	NN	UNIT
of	IN	O
ADYNOVATE	NNP	O
,	,	O
the	DT	O
contents	NNS	O
of	IN	O
multiple	JJ	O
vials	NNS	O
may	MD	O
be	VB	O
drawn	VBN	O
into	IN	O
the	DT	O
same	JJ	O
syringe	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
24	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
orally	RB	O
with	IN	O
food	NN	O
and	CC	O
water	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
for	IN	O
children	NNS	WHO
is	VBZ	O
30	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
;	:	O
doses	VBZ	O
greater	JJR	O
than	IN	O
30	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
of	IN	O
ADDERALL	NNP	O
XR	NNP	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
children	NNS	WHO
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
dose	NN	O
for	IN	O
an	DT	WHO
adult	NN	WHO
is	VBZ	O
1	CD	DOS
g	NN	UNIT
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
kcal	JJ	O
.	.	O

For	IN	O
severely	RB	WHO
catabolic	JJ	WHO
,	,	WHO
depleted	JJ	WHO
patients	NNS	WHO
or	CC	WHO
those	DT	WHO
who	WP	WHO
require	VBP	WHO
long	JJ	WHO
-	:	WHO
term	NN	WHO
parenteral	JJ	WHO
nutrition	NN	WHO
,	,	O
central	JJ	O
venous	JJ	O
nutrition	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

When	WRB	O
the	DT	O
dose	NN	O
counter	NN	O
reaches	VBZ	O
20	CD	O
,	,	O
the	DT	O
color	NN	O
of	IN	O
the	DT	O
numbers	NNS	O
will	MD	O
change	VB	O
to	TO	O
red	VB	O
to	TO	O
remind	VB	O
the	DT	O
patient	NN	O
to	TO	O
contact	VB	O
their	PRP$	O
pharmacist	NN	O
for	IN	O
a	DT	O
refill	NN	O
of	IN	O
medication	NN	O
or	CC	O
consult	VB	O
their	PRP$	O
physician	NN	O
for	IN	O
a	DT	O
prescription	NN	O
refill	NN	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
nebulizers	NNS	O
tested	VBN	O
will	MD	O
supply	VB	O
a	DT	O
high	JJ	O
proportion	NN	O
of	IN	O
the	DT	O
drug	NN	O
solution	NN	O
as	IN	O
particles	NNS	O
of	IN	O
less	JJR	O
than	IN	O
10	CD	DOS
microns	NNS	UNIT
in	IN	O
diameter	NN	O
.	.	O

If	IN	O
adequate	JJ	O
analgesia	NN	O
is	VBZ	O
not	RB	O
obtained	VBN	O
with	IN	O
a	DT	O
400	CD	DOS
mcg	NN	UNIT
dose	NN	UNIT
,	,	O
the	DT	O
next	JJ	O
titration	NN	O
step	NN	O
is	VBZ	O
600	CD	DOS
mcg	NN	UNIT
.	.	O

ALDACTONE	NNP	O
is	VBZ	O
administered	VBN	O
at	IN	O
a	DT	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
400	CD	DOS
mg	NNS	UNIT
for	IN	O
four	CD	PER
days	NNS	PER
.	.	O

Adding	VBG	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
multiple	JJ	O
electrolyte	NN	O
additive	NN	O
,	,	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
each	DT	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
solution	NN	O
and	CC	O
4	CD	DOS
to	TO	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
each	DT	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
40	CD	O
to	TO	O
50	CD	O
%	NN	O
dextrose	JJ	O
solution	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
appropriate	VBP	O
for	IN	O
central	JJ	O
vein	JJ	O
administration	NN	O
.	.	O

Titrate	VB	O
the	DT	O
dose	NN	O
to	TO	O
attain	VB	O
trough	JJ	O
concentrations	NNS	O
of	IN	O
5	CD	O
to	TO	O
15	CD	DOS
ng	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Akten™	NNP	O
(	(	O
lidocaine	JJ	O
hydrochloride	NN	O
ophthalmic	JJ	O
gel	NN	O
)	)	O
is	VBZ	O
2	CD	DOS
drops	NNS	UNIT
applied	VBN	O
to	TO	O
the	DT	O
ocular	JJ	O
surface	NN	O
in	IN	O
the	DT	O
area	NN	O
of	IN	O
the	DT	O
planned	JJ	O
procedure	NN	O
.	.	O

Some	DT	WHO
patients	NNS	WHO
may	MD	O
require	VB	O
up	IN	O
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
,	,	O
given	VBN	O
as	IN	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
AMRIX	$	O
30	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
as	IN	O
two	CD	DOS
(	(	O
2	CD	DOS
)	)	O
AMRIX	$	O
15	CD	DOS
mg	NN	UNIT
capsules	NNS	UNIT
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

In	IN	O
adults	NNS	WHO
,	,	O
in	IN	O
one	CD	O
clinical	JJ	O
trial	NN	O
,	,	O
doses	VBZ	O
over	IN	O
600	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACULAR	NNP	O
LS™	NNP	O
(	(	O
ketorolac	FW	O
tromethamine	VB	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
ophthalmic	JJ	O
solution	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
in	IN	O
the	DT	O
operated	JJ	O
eye	NN	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
and	CC	O
burning	NN	O
/	NN	O
stinging	VBG	O
for	IN	O
up	IN	O
to	TO	O
4	CD	O
days	NNS	O
following	VBG	O
corneal	JJ	O
refractive	JJ	O
surgery	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Vizamyl	NNP	O
is	VBZ	O
185	CD	DOS
megabecquerels	NNS	UNIT
(	(	O
MBq	NNP	O
)	)	O
[	VBD	O
5	CD	DOS
millicuries	NNS	UNIT
(	(	O
mCi	NN	O
)	)	O
]	NN	O
in	IN	O
a	DT	O
maximum	JJ	O
dose	JJ	O
volume	NN	O
of	IN	O
10	CD	DOS
mL	NNS	UNIT
,	,	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
bolus	NN	UNIT
within	IN	O
40	CD	O
seconds	NNS	O
.	.	O

Only	RB	O
in	IN	O
rare	JJ	O
cases	NNS	O
will	MD	O
it	PRP	O
be	VB	O
necessary	JJ	O
to	TO	O
exceed	VB	O
a	DT	O
total	NN	O
of	IN	O
40	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
calories	NNS	O
—	JJ	O
1000	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
will	MD	O
provide	VB	O
5.6	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
and	CC	O
850	CD	O
calories	NNS	O
.	.	O

A	DT	O
10	CD	O
%	NN	O
lipid	JJ	O
emulsion	NN	O
contains	VBZ	O
1.1	CD	O
kcal	JJ	O
/	NN	O
mL	NN	O
.	.	O

(	(	O
Initial	JJ	O
dosage	NN	O
of	IN	O
300	CD	DOS
mg	NNS	UNIT
daily	JJ	FREQ
may	MD	O
be	VB	O
given	VBN	O
,	,	O
but	CC	O
notable	JJ	O
sedation	NN	O
may	MD	O
occur	VB	O
in	IN	O
some	DT	WHO
patients	NNS	WHO
during	IN	O
the	DT	O
first	JJ	O
few	JJ	O
days	NNS	O
of	IN	O
therapy	NN	O
at	IN	O
this	DT	O
level	NN	O
.	.	O
)	)	O

Recommended	VBN	O
starting	JJ	O
dosage	NN	O
of	IN	O
amoxapine	NN	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
small	JJ	O
syringes	NNS	O
(	(	O
0.5	CD	DOS
mL	NN	UNIT
or	CC	O
1	CD	DOS
mL	NNS	UNIT
)	)	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
minimize	VB	O
any	DT	O
product	NN	O
loss	NN	O
.	.	O

Do	NNP	O
not	RB	O
combine	VB	O
the	DT	O
2	CD	O
dosage	NN	O
forms	NNS	O
(	(	O
AFINITOR	NNP	O
Tablets	NNP	O
and	CC	O
AFINITOR	NNP	O
DISPERZ	NNP	O
)	)	O
to	TO	O
achieve	VB	O
the	DT	O
desired	JJ	O
total	NN	O
dose	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
weighing	VBG	WHO
≥	JJ	WHO
65	CD	WHO
kg	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBD	O
as	IN	O
60	CD	DOS
mg	NN	UNIT
in	IN	O
the	DT	O
first	JJ	O
hour	NN	O
(	(	O
6	CD	DOS
-	:	O
10	CD	DOS
mg	NN	UNIT
administered	VBN	O
as	IN	O
a	DT	O
bolus	NN	O
)	)	O
,	,	O
20	CD	DOS
mg	NN	UNIT
over	IN	O
the	DT	O
second	JJ	O
hour	NN	O
,	,	O
and	CC	O
20	CD	DOS
mg	NN	UNIT
over	IN	O
the	DT	O
third	JJ	O
hour	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
AllerNaze	NNP	O
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
nasal	IN	O
spray	NN	O
)	)	O
for	IN	O
most	JJS	WHO
patients	NNS	WHO
is	VBZ	O
200	CD	DOS
mcg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
given	VBN	O
as	IN	O
2	CD	DOS
sprays	NNS	UNIT
(	(	O
approximately	RB	O
50	CD	DOS
mcg	NNS	UNIT
/	NNP	O
spray	NN	O
)	)	O
in	IN	O
each	DT	O
nostril	NN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ABRAXANE	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
30	CD	O
minutes	NNS	O
on	IN	O
Days	NNP	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

The	DT	O
dosages	NNS	O
used	VBN	O
in	IN	O
neonates	NNS	WHO
,	,	O
infants	NNS	WHO
,	,	WHO
children	NNS	WHO
and	CC	WHO
adolescents	NNS	WHO
were	VBD	WHO
equivalent	JJ	WHO
to	TO	WHO
those	DT	WHO
administered	VBN	WHO
to	TO	WHO
adults	NNS	WHO
on	IN	O
a	DT	O
weight	JJ	O
basis	NN	O
.	.	O

Therefore	RB	O
,	,	O
appropriate	JJ	O
caution	NN	O
and	CC	O
follow	VB	O
-	:	O
up	RP	O
should	MD	O
be	VB	O
exercised	VBN	O
if	IN	O
alosetron	JJ	O
hydrochloride	NN	O
tablets	NNS	O
are	VBP	O
prescribed	VBN	O
for	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

ALIMTA	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
if	IN	O
a	DT	O
patient	NN	WHO
experiences	VBZ	WHO
any	DT	WHO
hematologic	NN	WHO
or	CC	WHO
nonhematologic	JJ	WHO
Grade	NNP	WHO
3	CD	WHO
or	CC	WHO
4	CD	WHO
toxicity	NN	WHO
after	IN	O
2	CD	DOS
dose	JJ	UNIT
reductions	NNS	UNIT
or	CC	O
immediately	RB	O
if	IN	O
Grade	VBN	O
3	CD	O
or	CC	O
4	CD	O
neurotoxicity	NN	O
is	VBZ	O
observed	VBN	O
.	.	O

4	CD	O

Reduced	VBN	O
Dosage	NN	O
at	IN	O
Fixed	NNP	O
Time	NNP	O
Intervals	NNS	O
:	:	O
When	WRB	O
renal	JJ	O
function	NN	O
is	VBZ	O
impaired	JJ	O
and	CC	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
administer	VB	O
amikacin	NN	O
at	IN	O
a	DT	O
fixed	JJ	O
time	NN	O
interval	NN	O
,	,	O
dosage	NN	O
must	MD	O
be	VB	O
reduced	VBN	O
.	.	O

One	CD	DOS
drop	NN	UNIT
of	IN	O
ACUVAIL®	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
twice	RB	FREQ
daily	RB	FREQ
beginning	VBG	O
1	CD	O
day	NN	O
prior	RB	O
to	TO	O
cataract	VB	O
surgery	NN	O
,	,	O
continued	VBD	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
surgery	NN	O
,	,	O
and	CC	O
through	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

Vials	NNS	O
of	IN	O
AmBisome	NNP	O
containing	VBG	O
50	CD	DOS
mg	NN	UNIT
of	IN	O
amphotericin	NN	O
B	NNP	O
are	VBP	O
prepared	JJ	O
as	IN	O
follows	VBZ	O
:	:	O

UVA	NNP	O
exposure	NN	O
may	MD	O
be	VB	O
held	VBN	O
constant	JJ	O
or	CC	O
increased	VBN	O
by	IN	O
up	IN	O
to	TO	O
1	CD	DOS
Joule	NNP	UNIT
/	NNP	O
cm²	NN	UNIT
at	IN	O
each	DT	O
treatment	NN	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
.	.	O

Doses	NNS	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
either	RB	O
by	IN	O
administering	VBG	O
normal	JJ	O
doses	NNS	O
at	IN	O
prolonged	JJ	O
intervals	NNS	O
or	CC	O
by	IN	O
administering	VBG	O
reduced	JJ	O
doses	NNS	O
at	IN	O
afixed	JJ	O
interval	NN	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
ALDACTAZIDE	NNP	O
is	VBZ	O
100	CD	DOS
mg	JJ	UNIT
each	DT	O
of	IN	O
spironolactone	NN	O
and	CC	O
hydrochlorothiazide	JJ	O
daily	RB	FREQ
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
but	CC	O
may	MD	O
range	VB	O
from	IN	O
25	CD	DOS
mg	NNS	UNIT
to	TO	O
200	CD	DOS
mg	NNS	UNIT
of	IN	O
each	DT	O
component	JJ	O
daily	JJ	FREQ
depending	VBG	O
on	IN	O
the	DT	O
response	NN	O
to	TO	O
the	DT	O
initial	JJ	O
titration	NN	O
.	.	O

When	WRB	O
renal	JJ	O
function	NN	O
is	VBZ	O
impaired	JJ	O
and	CC	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
administer	VB	O
amikacin	NN	O
at	IN	O
a	DT	O
fixed	JJ	O
time	NN	O
interval	NN	O
,	,	O
dosage	NN	O
must	MD	O
be	VB	O
reduced	VBN	O
.	.	O

Insufficient	JJ	O
information	NN	O
is	VBZ	O
available	JJ	O
to	TO	O
warrant	VB	O
use	NN	O
in	IN	O
children	NNS	WHO
under	IN	WHO
age	NN	WHO
6	CD	WHO
.	.	O

Apply	NNP	O
Cloderm	NNP	O
(	(	O
clocortolone	NN	O
pivalate	NN	O
)	)	O
Cream	NNP	O
0.1	CD	O
%	NN	O
sparingly	RB	O
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
.	.	O

Most	JJS	WHO
patients	NNS	WHO
have	VBP	O
required	VBN	O
dosages	NNS	O
of	IN	O
20	CD	DOS
,	,	O
40	CD	DOS
,	,	O
or	CC	O
80	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
in	IN	O
two	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

In	IN	O
hyperammonemic	JJ	WHO
infants	NNS	WHO
with	IN	WHO
suspected	JJ	WHO
,	,	WHO
but	CC	WHO
unconfirmed	JJ	WHO
urea	JJ	WHO
cycle	NN	WHO
disorders	NNS	WHO
,	,	O
intravenous	JJ	O
arginine	NN	O
should	MD	O
be	VB	O
given	VBN	O
(	(	O
6	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
Arginine	NNP	O
HCl	NNP	O
Injection	NNP	O
10	CD	O
%	NN	O
,	,	O
over	IN	O
90	CD	O
minutes	NNS	O
followed	VBN	O
by	IN	O
the	DT	O
same	JJ	O
dose	JJ	O
given	VBN	O
as	IN	O
a	DT	O
maintenance	NN	O
infusion	NN	O
over	IN	O
24	CD	O
hours	NNS	O
)	)	O
.	.	O

ACTOPLUS	NNP	O
MET	NNP	O
is	VBZ	O
available	JJ	O
in	IN	O
15	CD	DOS
mg	NN	UNIT
pioglitazone	NN	O
(	(	O
as	IN	O
the	DT	O
base	NN	O
)	)	O
/	VBZ	O
500	CD	DOS
mg	NN	UNIT
metformin	NN	O
hydrochloride	NN	O
and	CC	O
15	CD	DOS
mg	NN	UNIT
pioglitazone	NN	O
(	(	O
as	IN	O
the	DT	O
base	NN	O
)	)	O
/	VBZ	O
850	CD	DOS
mg	NN	UNIT
metformin	NN	O
hydrochloride	JJ	O
tablets	NNS	O
as	IN	O
follows	VBZ	O
:	:	O

AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
children	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

Ambien	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
and	CC	O
should	MD	O
not	RB	O
be	VB	O
readministered	VBN	O
during	IN	O
the	DT	O
same	JJ	O
night	NN	O
.	.	O

Children	NNP	WHO
less	JJR	WHO
than	IN	WHO
30	CD	WHO
kg	NN	WHO
(	(	WHO
66	CD	WHO
lbs	NN	WHO
)	)	WHO
:	:	O
0.01	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
(	(	O
0.01	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
of	IN	O
undiluted	JJ	O
Adrenalin®	NNP	O
administered	VBD	O
intramuscularly	RB	O
or	CC	O
subcutaneously	RB	O
in	IN	O
the	DT	O
anterolateral	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
thigh	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
0.3	CD	DOS
mg	NN	UNIT
(	(	O
0.3	CD	DOS
mL	NN	UNIT
)	)	O
per	IN	O
injection	NN	O
,	,	O
repeated	VBN	O
every	DT	O
5	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
as	IN	O
necessary	JJ	O
.	.	O

UPAH	NNP	O
=	VBD	O
9.55	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
V	NNP	O
=	VBZ	O
16.68	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
GFR	NNP	O
=	VBZ	O
120	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
PPAH	NNP	O
=	VBZ	O
0.60	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
Then	RB	O
TmPAH	NNP	O
=	NNP	O
9.55	CD	O
x	VBD	O
16.68	CD	DOS
–	NNP	UNIT
(	(	O
120	CD	O
x	RB	O
0.60	CD	O
x	JJ	O
0.83	CD	O
)	)	O
=	VBD	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
min	NN	O
.	.	O

Solutions	NNS	O
containing	VBG	O
3.5	CD	O
to	TO	O
5	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
glucose	NN	O
may	MD	O
be	VB	O
infused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ALOPRIM	NNP	O
(	(	O
allopurinol	JJ	O
sodium	NN	O
)	)	O
for	IN	O
Injection	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
to	TO	O
avoid	VB	O
accumulation	NN	O
of	IN	O
allopurinol	NN	O
and	CC	O
its	PRP$	O
metabolites	NNS	O
:	:	O

Luminescence	NN	O
appears	VBZ	O
in	IN	O
the	DT	O
retina	NN	O
and	CC	O
choroidal	NN	O
vessels	NNS	O
in	IN	O
9	CD	O
to	TO	O
14	CD	O
seconds	NNS	O
and	CC	O
can	MD	O
be	VB	O
observed	VBN	O
by	IN	O
standard	JJ	O
viewing	VBG	O
equipment	NN	O
.	.	O

The	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
in	IN	O
children	NNS	WHO
and	CC	WHO
adults	NNS	WHO
is	VBZ	O
1	CD	DOS
-	:	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	JJ	O
per	IN	FREQ
day	NN	FREQ
.	.	O

7	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
(	(	O
e.	JJ	O
g.	NN	O
,	,	O
100	CD	DOS
-	:	O
125	CD	DOS
mcg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
for	IN	O
a	DT	O
70	CD	WHO
kg	NN	WHO
adult	NN	WHO
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
by	IN	O
IV	NNP	O
infusion	NN	O
over	IN	O
2	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
total	NN	O
(	(	O
diet	JJ	O
and	CC	O
otherwise	RB	O
)	)	O
daily	RB	FREQ
calcium	JJ	O
intake	NN	O
in	IN	O
postmenopausal	JJ	WHO
women	NNS	WHO
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
of	IN	O
elemental	JJ	O
calcium	NN	O
.	.	O

The	DT	O
estimated	VBN	O
absorbed	IN	O
radiation	NN	O
doses	NNS	O
to	TO	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
from	IN	O
intravenous	JJ	O
administration	NN	O
of	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
are	VBP	O
as	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
:	:	O

Estimated	VBN	O
Increment	NNP	O
of	IN	O
factor	NN	O
VIII	NNP	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
=	FW	O
[	JJ	O
Total	NNP	O
Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
/	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
]	VBZ	O
x	$	O
2	CD	DOS
(	(	O
IU	NNP	O
/	NNP	O
dL	NN	O
per	IN	O
IU	NNP	O
/	NNP	O
kg	NN	O
)	)	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ARAVA	NNP	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
target	NN	O
dose	NN	O
of	IN	O
ABILIFY	NNP	O
is	VBZ	O
10	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
of	IN	O
Acetadote	NNP	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
3	CD	DOS
separate	JJ	UNIT
doses	NNS	UNIT
and	CC	O
administered	VBN	O
over	IN	O
a	DT	O
total	NN	O
of	IN	O
21	CD	O
hours	NNS	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
range	NN	O
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
to	TO	O
8	CD	DOS
mg	NNS	UNIT
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
or	CC	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
is	VBZ	O
6.3	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dosage	NN	O
range	NN	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
to	TO	O
20	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
in	IN	O
two	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

For	IN	O
patients	NNS	WHO
between	IN	WHO
4	CD	WHO
and	CC	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
for	IN	WHO
patients	NNS	WHO
13	CD	WHO
to	TO	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
with	IN	WHO
weight	NN	WHO
of	IN	WHO
<	$	WHO
50	CD	WHO
kg	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
twice	RB	FREQ
daily	RB	FREQ
or	CC	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBD	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
to	TO	O
a	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
2,400	CD	DOS
mg	NN	UNIT
)	)	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

If	IN	O
no	DT	O
intolerance	NN	O
is	VBZ	O
observed	VBN	O
,	,	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	O
week	NN	O
to	TO	O
50	CD	DOS
mg	NNS	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Patients	NNS	WHO
whose	WP$	WHO
blood	NN	WHO
pressures	NNS	WHO
are	VBP	WHO
adequately	RB	WHO
controlled	VBN	WHO
with	IN	WHO
25	CD	DOS
mg	NNS	UNIT
of	IN	O
daily	JJ	FREQ
hydrochlorothiazide	NN	O
,	,	O
but	CC	O
who	WP	O
experience	VBP	O
significant	JJ	O
potassium	NN	O
loss	NN	O
with	IN	O
this	DT	O
regimen	NNS	O
,	,	O
may	MD	O
achieve	VB	O
blood	NN	O
pressure	NN	O
control	NN	O
with	IN	O
less	JJR	O
electrolyte	JJ	O
disturbance	NN	O
if	IN	O
they	PRP	O
are	VBP	O
switched	VBN	O
to	TO	O
ACCURETIC	NNP	O
10	CD	O
/	NNP	O
12.5	CD	O
or	CC	O
20	CD	O
/	JJ	O
12.5	CD	O
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
the	DT	O
highest	JJS	O
tolerated	JJ	O
dosage	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
2.5	CD	DOS
mg	NN	UNIT
taken	VBN	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Complete	JJ	O
blood	NN	O
cell	NN	O
counts	NNS	O
,	,	O
including	VBG	O
platelet	NN	O
counts	NNS	O
,	,	O
should	MD	O
be	VB	O
performed	VBN	O
on	IN	O
all	DT	WHO
patients	NNS	WHO
receiving	VBG	WHO
ALIMTA	NNP	WHO
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
:	:	O
total	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
reduction	NN	O
of	IN	O
recommended	JJ	O
individual	JJ	O
doses	NNS	O
and	CC	O
/	NN	O
or	CC	O
by	IN	O
extending	VBG	O
time	NN	O
intervals	NNS	O
between	IN	O
doses	NNS	O
.	.	O

The	DT	O
dosage	NN	O
employed	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
simple	NN	O
(	(	O
open	JJ	O
-	:	O
angle	NN	O
)	)	O
glaucoma	NN	O
ranges	VBZ	O
from	IN	O
250	CD	DOS
mg	NNS	UNIT
to	TO	O
1	CD	DOS
g	NN	UNIT
of	IN	O
acetaZOLAMIDE	JJ	O
per	IN	O
24	CD	O
hours	NNS	O
,	,	O
usually	RB	O
in	IN	O
divided	JJ	O
doses	NNS	O
for	IN	O
amounts	NNS	O
over	IN	O
250	CD	DOS
mg	NNS	UNIT
.	.	O

Usual	JJ	O
starting	VBG	O
dosage	NN	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
suggested	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
patients	NNS	WHO
aged	VBN	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
is	VBZ	O
5	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
;	:	O
daily	RB	FREQ
dose	VB	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
for	IN	O
patients	NNS	WHO
not	RB	WHO
on	IN	WHO
inhaled	JJ	WHO
corticosteroids	NNS	WHO
is	VBZ	O
55	CD	DOS
/	JJ	O
14	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMJEVITA	NNP	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
plaque	JJ	WHO
psoriasis	NN	WHO
(	(	O
Ps	NNP	O
)	)	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
80	CD	DOS
mg	NN	UNIT
,	,	O
followed	VBN	O
by	IN	O
40	CD	DOS
mg	NNS	UNIT
given	VBN	O
every	DT	O
other	JJ	O
week	NN	O
starting	VBG	O
one	CD	O
week	NN	O
after	IN	O
the	DT	O
initial	JJ	O
dose	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
UPTRAVI	NNP	O
is	VBZ	O
200	CD	DOS
micrograms	NNS	UNIT
(	(	O
mcg	NN	O
)	)	O
given	VBN	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

1	CD	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
upward	RB	O
until	IN	O
blood	NN	O
pressure	NN	O
is	VBZ	O
controlled	VBN	O
or	CC	O
to	TO	O
a	DT	O
maximum	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
5	CD	DOS
mg	NN	UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
ABSORICA	NNP	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
for	IN	O
15	CD	O
to	TO	O
20	CD	O
weeks	NNS	O
(	(	O
see	VB	O
Table	NNP	O
1	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	WHO
administered	VBN	WHO
anesthetic	JJ	WHO
(	(	O
induction	NN	O
)	)	O
dosages	NNS	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
that	IN	O
qualified	JJ	O
personnel	NNS	O
and	CC	O
adequate	JJ	O
facilities	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
intraoperative	JJ	O
and	CC	O
postoperative	JJ	O
respiratory	NN	O
depression	NN	O
.	.	O

Typically	RB	O
,	,	O
a	DT	O
hospitalized	JJ	WHO
patient	NN	WHO
may	MD	O
lose	VB	O
12	CD	DOS
to	TO	O
18	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
a	DT	FREQ
day	NN	FREQ
,	,	O
and	CC	O
in	IN	O
severe	JJ	O
trauma	VBP	O
the	DT	O
daily	JJ	FREQ
loss	NN	O
may	MD	O
be	VB	O
20	CD	DOS
to	TO	O
25	CD	DOS
grams	NNS	UNIT
or	CC	O
more	JJR	O
.	.	O

Concomitant	JJ	O
Therapy	NN	O
:	:	O
If	IN	O
AGENERASE	NNP	O
and	CC	O
ritonavir	NN	O
are	VBP	O
used	VBN	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
regimens	NNS	O
are	VBP	O
:	:	O
AGENERASE	$	O
1200	CD	DOS
mg	NN	UNIT
with	IN	O
ritonavir	JJ	O
200	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
AGENERASE	$	O
600	CD	DOS
mg	NN	UNIT
with	IN	O
ritonavir	JJ	O
100	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

A	DT	O
thiazide	NN	O
may	MD	O
be	VB	O
added	VBN	O
at	IN	O
any	DT	O
time	NN	O
during	IN	O
methyldopa	JJ	O
therapy	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
if	IN	O
therapy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
started	VBN	O
with	IN	O
a	DT	O
thiazide	NN	O
or	CC	O
if	IN	O
effective	JJ	O
control	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
can	MD	O
not	RB	O
be	VB	O
maintained	VBN	O
on	IN	O
2	CD	DOS
g	NN	UNIT
of	IN	O
methyldopa	JJ	O
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
VEMLIDY	NNP	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
(	(	O
one	CD	DOS
tablet	NN	UNIT
)	)	O
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ABRAXANE	NNP	O
is	VBZ	O
125	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
30	CD	O
-	:	O
40	CD	O
minutes	NNS	O
on	IN	O
Days	NNP	O
1	CD	O
,	,	O
8	CD	O
and	CC	O
15	CD	O
of	IN	O
each	DT	O
28	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

6	CD	O

Figure	NN	O
6	CD	O
:	:	O
Hold	CD	O
Breath	NN	O

When	WRB	O
undiluted	JJ	O
albumin	NN	O
solution	NN	O
is	VBZ	O
administered	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
normal	JJ	WHO
blood	NN	WHO
volume	NN	WHO
,	,	O
the	DT	O
rate	NN	O
of	IN	O
infusion	NN	O
should	MD	O
be	VB	O
slow	JJ	O
enough	RB	O
(	(	O
1	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
)	)	O
to	TO	O
prevent	VB	O
too	RB	O
rapid	JJ	O
expansion	NN	O
of	IN	O
plasma	NN	O
volume	NN	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
and	CC	WHO
patients	NNS	WHO
with	IN	WHO
cardiovascular	JJ	WHO
disease	NN	WHO
the	DT	O
drug	NN	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
to	TO	O
a	DT	O
final	JJ	O
infusion	NN	O
concentration	NN	O
of	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

This	DT	O
solution	NN	O
is	VBZ	O
indicated	VBN	O
for	IN	O
patients	NNS	WHO
requiring	VBG	WHO
larger	JJR	WHO
amounts	NNS	WHO
of	IN	WHO
nitrogen	NN	WHO
than	IN	O
could	MD	O
otherwise	RB	O
be	VB	O
provided	VBN	O
or	CC	O
where	WRB	O
total	JJ	O
fluid	NN	O
load	NN	O
must	MD	O
be	VB	O
kept	VBN	O
to	TO	O
a	DT	O
minimum	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
failure	NN	WHO
.	.	O

A	DT	O
thin	JJ	O
film	NN	O
of	IN	O
the	DT	O
gel	NN	O
should	MD	O
be	VB	O
applied	VBN	O
,	,	O
avoiding	VBG	O
eyes	NNS	O
,	,	O
lips	NNS	O
,	,	O
and	CC	O
mucous	JJ	O
membranes	NNS	O
.	.	O

ALLZITAL	NNP	O
(	(	O
butalbital	JJ	O
and	CC	O
acetaminophen	NN	O
,	,	O
25	CD	DOS
mg	NN	UNIT
/	VBD	O
325	CD	DOS
mg	NN	UNIT
)	)	O
tablets	NNS	O
:	:	O
Two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Olux	NNP	O
-	:	O
E	NN	O
(	(	O
clobetasol	JJ	O
propionate	NN	O
foam	NN	O
)	)	O
Foam	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
(	(	O
s	PRP	O
)	)	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
morning	NN	O
and	CC	O
evening	NN	O
for	IN	O
up	IN	O
to	TO	O
2	CD	O
consecutive	JJ	O
weeks	NNS	O
.	.	O

Patients	NNS	WHO
previously	RB	WHO
receiving	VBG	WHO
niacin	JJ	WHO
products	NNS	WHO
other	JJ	WHO
than	IN	WHO
NIASPAN	NNP	WHO
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
NIASPAN	NNP	O
with	IN	O
the	DT	O
recommended	VBN	O
NIASPAN	NNP	O
titration	NN	O
schedule	NN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
subsequently	RB	O
be	VB	O
individualized	VBN	O
based	VBN	O
on	IN	O
patient	JJ	O
response	NN	O
.	.	O

To	TO	O
combine	VB	O
two	CD	DOS
or	CC	O
more	JJR	O
vials	NNS	O
of	IN	O
ALPROLIX™	NNP	O
,	,	O
follow	VBP	O
the	DT	O
following	VBG	O
pooling	JJ	O
steps	NNS	O
.	.	O

The	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
4	CD	DOS
inhalations	NNS	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
2	CD	DOS
mg	NN	UNIT
.	.	O

Both	DT	O
methods	NNS	O
are	VBP	O
based	VBN	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
creatinine	JJ	O
clearance	NN	O
or	CC	O
serum	JJ	O
creatinine	NN	O
values	NNS	O
since	IN	O
these	DT	O
have	VBP	O
been	VBN	O
found	VBN	O
to	TO	O
correlate	VB	O
with	IN	O
aminoglycoside	JJ	O
half	NN	O
-	:	O
lives	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
diminished	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
episodes	NNS	O
of	IN	O
bronchospasm	NN	O
or	CC	O
prevention	NN	O
of	IN	O
asthmatic	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
usual	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
4	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
two	CD	DOS
inhalations	NNS	UNIT
repeated	VBD	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
.	.	O

Subsequent	JJ	O
dose	NN	O
increases	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
5	CD	DOS
mg	NN	UNIT
increments	NNS	UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
subsequent	JJ	O
administrations	NNS	O
is	VBZ	O
up	IN	O
to	TO	O
4	CD	DOS
mL	NN	UNIT
of	IN	O
IMLYGIC	NNP	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
108	CD	O
(	(	O
100	CD	O
million	CD	O
)	)	O
PFU	NNP	O
per	IN	O
mL	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Accelerated	VBN	O
Infusion	NNP	O
Weight	NNP	O
-	:	O
Based	VBD	O
Doses	NNS	O
for	IN	O
Patients	NNS	WHO
with	IN	WHO
AMI	NNP	WHO

The	DT	O
solution	NN	O
should	MD	O
be	VB	O
stored	VBN	O
at	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
to	TO	O
77°F	CD	O
)	)	O
and	CC	O
administration	NN	O
should	MD	O
begin	VB	O
within	IN	O
10	CD	O
hours	NNS	O
after	IN	O
reconstitution	NN	O
.	.	O

Actonel	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
.	.	O

Adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
advised	VBN	O
not	RB	O
to	TO	O
take	VB	O
supplemental	JJ	O
vitamin	NN	O
E	NNP	O
since	IN	O
the	DT	O
vitamin	NN	O
E	NNP	O
content	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
exceeds	VBZ	O
the	DT	O
Reference	NNP	O
Daily	NNP	FREQ
Intake	NNP	O
(	(	O
adults	NNS	WHO
30	CD	O
IU	NNP	O
,	,	O
pediatrics	NNS	O
approximately	RB	O
10	CD	DOS
IU	NNP	UNIT
)	)	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
)	)	O
.	.	O

If	IN	O
the	DT	O
diuretic	NN	O
can	MD	O
not	RB	O
be	VB	O
discontinued	VBN	O
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
1.25	CD	DOS
mg	NNS	UNIT
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
avoid	VB	O
excess	JJ	O
hypotension	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Actigall	NNP	O
treatment	NN	O
of	IN	O
radiolucent	JJ	O
gallbladder	NN	O
stones	NNS	O
is	VBZ	O
8	CD	DOS
-	:	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
2	CD	DOS
or	CC	O
3	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

Thereafter	RB	O
,	,	O
the	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
over	IN	O
the	DT	O
next	JJ	O
several	JJ	O
weeks	NNS	O
up	RB	O
to	TO	O
a	DT	O
daily	JJ	FREQ
maximum	NN	FREQ
of	IN	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBD	O
or	CC	O
200	CD	DOS
mg	NN	UNIT
,	,	O
whichever	WP	O
is	VBZ	O
smaller	JJR	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
,	,	O
Pediatric	NNP	O
Use	NNP	O
)	)	O
.	.	O

(	(	O
10	CD	O
)	)	O
Danger	NNP	O
label	NN	O
:	:	O
The	DT	O
unit	NN	O
should	MD	O
have	VB	O
a	DT	O
label	NN	O
prominently	RB	O
displayed	VBD	O
which	WDT	O
reads	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
over	IN	WHO
100	CD	WHO
pounds	NNS	WHO
the	DT	WHO
usual	JJ	WHO
adult	NN	WHO
dose	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

Uncomplicated	VBN	O
gonococcal	JJ	O
infections	NNS	O
in	IN	O
adults	NNS	WHO
(	(	O
except	IN	O
anorectal	JJ	O
infections	NNS	O
in	IN	O
men	NNS	WHO
)	)	WHO
:	:	O
100	CD	DOS
mg	NN	UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Apply	NNP	O
and	CC	O
rub	NN	O
in	IN	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
NORITATE	NNP	O
(	(	O
metronidazole	NN	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
to	TO	O
entire	JJ	O
affected	JJ	O
area	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	DOS
g	NNS	UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
doses	NNS	O
above	IN	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
each	DT	O
maintenance	NN	O
schedule	NN	O
be	VB	O
adhered	VBN	O
to	TO	O
for	IN	O
at	IN	O
least	JJS	O
2	CD	O
treatments	NNS	O
(	(	O
unless	IN	O
erythema	NN	O
or	CC	O
psoriatic	JJ	O
flare	NN	O
occurs	VBZ	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
see	NN	O
(	(	O
2a	CD	O
)	)	O
and	CC	O
(	(	O
2b	CD	O
)	)	O
below	IN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
intravenous	JJ	O
dose	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
140	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
min	NN	O
infused	VBD	O
for	IN	O
six	CD	O
minutes	NNS	O
(	(	O
total	JJ	O
dose	NN	O
of	IN	O
0.84	CD	DOS
mg	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	FREQ
daily	RB	FREQ
dose	NN	O
of	IN	O
methyldopa	NN	O
is	VBZ	O
3	CD	DOS
g	NN	UNIT
.	.	O

Based	VBN	O
on	IN	O
cross	NN	O
-	:	O
study	NN	O
comparisons	NNS	O
,	,	O
the	DT	O
clearance	NN	O
of	IN	O
zafirlukast	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
(	(	WHO
65	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
)	)	WHO
,	,	O
such	JJ	O
that	IN	O
Cmax	NNP	O
and	CC	O
AUC	NNP	O
are	VBP	O
approximately	RB	O
twice	RB	O
those	DT	O
of	IN	O
younger	JJR	WHO
adults	NNS	WHO
.	.	O

The	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
if	IN	O
necessary	JJ	O
.	.	O

However	RB	O
,	,	O
if	IN	O
ALTOCOR™	NNP	O
(	(	O
lovastatin	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
is	VBZ	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
gemfibrozil	NN	O
,	,	O
other	JJ	O
fibrates	NNS	O
,	,	O
or	CC	O
lipid	JJ	O
-	:	O
lowering	NN	O
doses	NNS	O
(	(	O
≥	$	O
1	CD	DOS
g	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
)	)	O
of	IN	O
niacin	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
ALTOCOR™	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	DOS
mg	NNS	UNIT
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

Loading	VBG	O
Dose	NNP	O
:	:	O
150	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
200	CD	DOS
mL	NN	UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
1	CD	DOS
hr	NNS	UNIT

Store	NN	O
unreconstituted	JJ	O
product	NN	O
at	IN	O
20	CD	O
to	TO	O
25°C	CD	O
(	(	O
68	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

Single	NNP	DOS
dose	JJ	UNIT
vial	NN	UNIT
,	,	O
preservative	JJ	O
-	:	O
free	JJ	O
,	,	O
discard	RB	O
unused	JJ	O
portion	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Neulasta	NNP	O
is	VBZ	O
a	DT	O
single	JJ	DOS
subcutaneous	JJ	UNIT
injection	NN	UNIT
of	IN	O
6	CD	DOS
mg	NNS	UNIT
administered	VBN	O
once	RB	O
per	IN	O
chemotherapy	NN	O
cycle	NN	O
.	.	O

Patients	NNS	WHO
at	IN	WHO
increased	VBN	WHO
risk	NN	WHO
for	IN	WHO
hypoglycemia	NN	WHO
(	(	O
e.g	UH	O
,	,	O
the	DT	O
elderly	JJ	WHO
or	CC	WHO
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
)	)	O
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
1	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
[	NNP	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Once	RB	O
a	DT	O
successful	JJ	O
dose	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
(	(	O
i.e	FW	O
,	,	O
an	DT	O
average	JJ	O
episode	NN	O
is	VBZ	O
treated	VBN	O
with	IN	O
a	DT	O
single	JJ	O
unit	NN	O
)	)	O
,	,	O
patients	NNS	O
should	MD	O
limit	VB	O
consumption	NN	O
to	TO	O
four	CD	DOS
or	CC	O
fewer	JJR	DOS
units	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

When	WRB	O
necessary	JJ	O
,	,	O
the	DT	O
next	JJ	O
cycle	NN	O
of	IN	O
treatment	NN	O
cycle	NN	O
was	VBD	O
delayed	VBN	O
until	IN	O
the	DT	O
absolute	JJ	O
neutrophil	NN	O
count	NN	O
(	(	O
ANC	NNP	O
)	)	O
was	VBD	O
≥	JJ	O
1000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm3	NN	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
was	VBD	O
≥	JJ	O
100	CD	DOS
000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm3	NN	O
and	CC	O
nonhematologic	JJ	O
toxicities	NNS	O
had	VBD	O
resolved	VBN	O
.	.	O

The	DT	O
high	JJ	O
solution	NN	O
osmolarity	NN	O
(	(	O
894	CD	DOS
mOsmol	NN	UNIT
/	NNP	O
L	NNP	O
)	)	O
will	MD	O
likely	RB	O
provoke	VB	O
vein	NNS	O
irritation	NN	O
if	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
administered	VBN	O
without	IN	O
fat	JJ	O
emulsion	NN	O
.	.	O

It	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
try	VB	O
to	TO	O
maintain	VB	O
a	DT	O
significant	JJ	O
degree	NN	O
of	IN	O
bone	NN	O
marrow	NN	O
depression	NN	O
so	RB	O
as	IN	O
to	TO	O
keep	VB	O
the	DT	O
leukocyte	NN	O
count	NN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
3,000	CD	DOS
to	TO	O
3,500	CD	DOS
cells	NNS	UNIT
/	JJ	O
mcL	NN	O
.	.	O

When	WRB	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
established	VBN	O
,	,	O
the	DT	O
drug	NN	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
300	CD	DOS
mg	NNS	UNIT
)	)	O
at	IN	O
bedtime	NN	O
.	.	O

Maintenance	NN	O
Dose	NNP	O
Every	NNP	O
12	CD	O
hours	NNS	O
=	RB	O
observed	VBD	O
CC	NNP	O
in	IN	O
mL	NN	O
/	NNP	O
min	NNP	O
/	NNP	O
normal	JJ	O
CC	NNP	O
in	IN	O
mL	NN	O
/	NNP	O
min	NN	O
X	NNP	O
Calculated	NNP	O
loading	VBG	O
dose	NN	O
in	IN	O
mg	NN	UNIT
(	(	O
CC	NNP	O
-	:	O
creatinine	JJ	O
clearance	NN	O
rate	NN	O
)	)	O

The	DT	O
recommended	JJ	O
initial	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
ACEON	NNP	O
for	IN	O
the	DT	WHO
elderly	JJ	WHO
is	VBZ	O
4	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
,	,	O
given	VBN	O
in	IN	O
one	CD	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

Treatment	NN	O
of	IN	O
tinea	NN	O
versicolor	NN	O
:	:	O
Apply	VB	O
to	TO	O
affected	JJ	O
areas	NNS	O
and	CC	O
lather	NN	O
with	IN	O
a	DT	O
small	JJ	O
amount	NN	O
of	IN	O
water	NN	O
.	.	O

While	IN	O
there	EX	O
is	VBZ	O
little	JJ	O
likelihood	NN	O
of	IN	O
ovulation	NN	O
occurring	VBG	O
if	IN	O
only	RB	O
one	CD	DOS
or	CC	O
two	CD	DOS
pink	JJ	UNIT
tablets	NNS	UNIT
are	VBP	O
missed	VBN	O
,	,	O
the	DT	O
possibility	NN	O
of	IN	O
ovulation	NN	O
increases	NNS	O
with	IN	O
each	DT	O
successive	JJ	O
day	NN	O
that	WDT	O
scheduled	VBD	O
pink	JJ	O
tablets	NNS	O
are	VBP	O
missed	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

(	(	O
120	CD	DOS
ml	NN	UNIT
)	)	O
of	IN	O
water	NN	O
or	CC	O
apple	NN	O
juice	NN	O
.	.	O

Butalbital	NNP	O
and	CC	O
Acetaminophen	NNP	O
,	,	O
50	CD	DOS
mg	NN	UNIT
/	VBD	O
325	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
:	:	O
One	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	WHO
Child	NNP	WHO
Pugh	NNP	WHO
score	VBD	WHO
7	CD	WHO
-	:	WHO
9	CD	WHO
)	)	WHO
start	NN	O
AGRYLIN	NNP	O
therapy	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
and	CC	O
monitor	NN	O
frequently	RB	O
for	IN	O
cardiovascular	JJ	O
events	NNS	O
[	JJ	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

One	CD	DOS
to	TO	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
or	CC	O
2	CD	DOS
to	TO	O
4	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
every	DT	O
1	CD	O
to	TO	O
4	CD	O
hours	NNS	O
may	MD	O
then	RB	O
be	VB	O
given	VBN	O
by	IN	O
a	DT	O
syringe	NN	O
attached	VBN	O
to	TO	O
the	DT	O
catheter	NN	O
.	.	O

Ordinarily	RB	O
,	,	O
an	DT	O
intravenous	JJ	O
dose	NN	O
of	IN	O
65	CD	DOS
mg	NNS	UNIT
to	TO	O
0.5	CD	DOS
g	NN	UNIT
may	MD	O
be	VB	O
given	VBN	O
to	TO	O
a	DT	O
child	NN	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

The	DT	O
final	JJ	O
infusion	NN	O
concentration	NN	O
should	MD	O
be	VB	O
1	CD	DOS
mg	JJ	UNIT
/	NNP	O
mL	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
Amturnide	NNP	O
is	VBZ	O
300	CD	DOS
/	JJ	O
10	CD	DOS
/	JJ	O
25	CD	DOS
mg	NN	UNIT
.	.	O

The	DT	O
contents	NNS	O
of	IN	O
the	DT	O
entire	JJ	O
capsule	NN	O
should	MD	O
be	VB	O
taken	VBN	O
,	,	O
and	CC	O
patients	NNS	O
should	MD	O
not	RB	O
take	VB	O
anything	NN	O
less	JJR	O
than	IN	O
one	CD	DOS
capsule	NN	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	WHO
average	NN	WHO
depleted	VBD	WHO
major	JJ	WHO
surgical	JJ	WHO
patient	NN	WHO
with	IN	WHO
complications	NNS	WHO
requires	VBZ	O
between	IN	O
2500	CD	O
and	CC	O
4000	CD	O
kcal	JJ	O
and	CC	O
between	IN	O
12	CD	DOS
and	CC	O
24	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	JJ	O
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
effective	JJ	O
dose	NN	O
resulting	VBG	O
from	IN	O
an	DT	O
administered	VBN	O
activity	NN	O
amount	NN	O
of	IN	O
10	CD	DOS
mCi	NN	UNIT
is	VBZ	O
5.07	CD	DOS
mSv	NN	UNIT
in	IN	O
an	DT	WHO
adult	NN	WHO
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dose	NN	O
is	VBZ	O
1	CD	DOS
gram	NN	UNIT
AMOXIL	NNP	O
,	,	O
500	CD	DOS
mg	NN	UNIT
clarithromycin	NN	O
,	,	O
and	CC	O
30	CD	DOS
mg	NN	UNIT
lansoprazole	NN	UNIT
,	,	O
all	DT	O
given	VBN	O
twice	NNS	FREQ
daily	RB	FREQ
(	(	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
)	)	O
for	IN	O
14	CD	PER
days	NNS	PER
.	.	O

Dosage	NN	O
for	IN	O
Adults	NNP	WHO
-	:	O
one	CD	DOS
0.5	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
administered	VBD	O
approximately	RB	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
chemotherapy	NN	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
breakthrough	NN	O
episodes	NNS	O
of	IN	O
VF	NNP	O
or	CC	O
hemodynamically	RB	O
unstable	JJ	O
VT	NNP	O
,	,	O
150	CD	DOS
mg	NN	UNIT
supplemental	JJ	O
infusions	NNS	O
of	IN	O
amiodarone	NN	O
HCl	NNP	O
injection	NN	O
mixed	VBD	O
in	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
D5W	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
.	.	O

Take	VB	O
a	DT	O
multivitamin	NN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
at	IN	O
bedtime	NN	O
,	,	O
when	WRB	O
using	VBG	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	DOS
mg	NN	UNIT
)	)	O
capsules	NNS	O
.	.	O

Smaller	NNP	O
increments	NNS	O
of	IN	O
intravenous	JJ	O
etomidate	NN	O
may	MD	O
be	VB	O
administered	VBN	O
to	TO	O
adult	VB	WHO
patients	NNS	WHO
during	IN	WHO
short	JJ	WHO
operative	JJ	WHO
procedures	NNS	WHO
to	TO	O
supplement	VB	O
subpotent	JJ	O
anesthetic	JJ	O
agents	NNS	O
,	,	O
such	JJ	O
as	IN	O
nitrous	JJ	O
oxide	NN	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
are	VBP	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
CYP2D6	NNP	WHO
poor	JJ	WHO
metabolizers	NNS	WHO
and	CC	O
in	IN	O
patients	NNS	WHO
taking	VBG	WHO
concomitant	JJ	WHO
CYP3A4	NNP	WHO
inhibitors	NNS	WHO
or	CC	O
CYP2D6	NNP	O
inhibitors	NNS	O
for	IN	O
greater	JJR	O
than	IN	O
14	CD	O
days	NNS	O
(	(	O
see	VB	O
Table	NNP	O
1	CD	O
)	)	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
lesser	JJR	WHO
degrees	NNS	WHO
of	IN	WHO
impairment	NN	WHO
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
2	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
and	CC	O
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
8	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Table	JJ	O
1	CD	O
shows	VBZ	O
the	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACIPHEX	NNP	O
delayed	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
in	IN	O
adults	NNS	WHO
and	CC	WHO
adolescent	JJ	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

Recommended	VBN	O
dose	JJ	O
modifications	NNS	O
for	IN	O
neutropenia	NN	O
and	CC	O
thrombocytopenia	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
adenocarcinoma	NN	WHO
of	IN	O
the	DT	O
pancreas	NNS	O
are	VBP	O
provided	VBN	O
in	IN	O
Table	JJ	O
4	CD	O
.	.	O

ACCOLATE	NN	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
including	VBG	WHO
hepatic	JJ	WHO
cirrhosis	NN	WHO
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

The	DT	O
following	JJ	O
safety	NN	O
features	NNS	O
should	MD	O
be	VB	O
present	JJ	O
:	:	O
(	(	O
1	CD	O
)	)	O
Protection	NN	O
from	IN	O
electrical	JJ	O
hazard	NN	O
:	:	O
All	DT	O
units	NNS	O
should	MD	O
be	VB	O
grounded	VBN	O
and	CC	O
conform	VB	O
to	TO	O
applicable	JJ	O
electrical	JJ	O
codes	NNS	O
.	.	O

Avoid	NNP	O
use	NN	O
of	IN	O
AGRYLIN	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

However	RB	O
,	,	O
older	JJR	WHO
pediatric	JJ	WHO
patients	NNS	WHO
can	MD	O
receive	VB	O
Aminosyn	NNP	O
II	NNP	O
4.25	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
nutritional	JJ	O
management	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
liver	JJ	WHO
disease	NN	WHO
is	VBZ	O
the	DT	O
provision	NN	O
of	IN	O
sufficient	JJ	O
amino	NN	O
acid	NN	O
and	CC	O
caloric	JJ	O
support	NN	O
for	IN	O
protein	NN	O
synthesis	NN	O
without	IN	O
exacerbating	VBG	O
hepatic	JJ	O
encephalopathy	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
the	DT	O
vial	NN	O
more	JJR	O
than	IN	O
one	CD	O
time	NN	O
.	.	O

AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
emits	VBZ	O
radiation	NN	O
and	CC	O
must	MD	O
be	VB	O
handled	VBN	O
with	IN	O
appropriate	JJ	O
safety	NN	O
measures	NNS	O
to	TO	O
minimize	VB	O
radiation	NN	O
exposure	NN	O
to	TO	O
clinical	JJ	O
personnel	NNS	O
and	CC	O
patients	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Perioperative	NNP	O
Management	NNP	O

In	IN	O
contrast	NN	O
,	,	O
aripiprazole	JJ	O
injection	NN	O
(	(	O
9.75	CD	DOS
mg	NN	UNIT
per	IN	O
vial	NN	O
)	)	O
is	VBZ	O
a	DT	O
short	JJ	O
-	:	O
acting	VBG	O
formulation	NN	O
indicated	VBD	O
for	IN	O
agitation	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
schizophrenia	NN	WHO
or	CC	WHO
mania	NN	WHO
.	.	O

If	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
exceeds	VBZ	O
300	CD	DOS
mg	NN	UNIT
,	,	O
it	PRP	O
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

In	IN	O
treatment	NN	O
of	IN	O
secondary	JJ	O
glaucoma	NN	O
and	CC	O
in	IN	O
the	DT	O
preoperative	JJ	O
treatment	NN	O
of	IN	O
some	DT	O
cases	NNS	O
of	IN	O
acute	JJ	O
congestive	NN	O
(	(	O
closed	JJ	O
-	:	O
angle	NN	O
)	)	O
glaucoma	NN	O
,	,	O
the	DT	O
preferred	JJ	O
dosage	NN	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
,	,	O
although	IN	O
some	DT	O
cases	NNS	O
have	VBP	O
responded	VBN	O
to	TO	O
250	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
on	IN	O
short	JJ	O
-	:	O
term	NN	O
therapy	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
intravenous	JJ	O
infusion	NN	O
initially	RB	O
should	MD	O
be	VB	O
2	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
and	CC	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
.	.	O

See	VB	O
Table	JJ	O
1	CD	O
for	IN	O
the	DT	O
recommended	JJ	O
starting	NN	O
dosage	NN	O
.	.	O

The	DT	O
treatment	NN	O
area	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
one	CD	DOS
contiguous	JJ	UNIT
area	NN	UNIT
of	IN	O
approximately	RB	O
25	CD	DOS
cm2	NN	UNIT
(	(	O
e.g	UH	O
,	,	O
5	CD	DOS
cm	NN	UNIT
×	VBD	O
5	CD	DOS
cm	NN	UNIT
)	)	O
on	IN	O
the	DT	O
face	NN	O
(	(	O
e.g	JJ	O
,	,	O
forehead	JJ	O
or	CC	O
one	CD	O
cheek	NN	O
)	)	O
or	CC	O
on	IN	O
the	DT	O
scalp	NN	O
.	.	O

PPAH	NNP	O
=	VBD	O
0.02	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O

If	IN	O
the	DT	O
diuretic	NN	O
can	MD	O
not	RB	O
be	VB	O
discontinued	VBN	O
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
ACCUPRIL	NNP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
careful	JJ	O
medical	JJ	O
supervision	NN	O
for	IN	O
several	JJ	PER
hours	NNS	PER
and	CC	O
until	IN	O
blood	NN	O
pressure	NN	O
has	VBZ	O
stabilized	VBN	O
.	.	O

See	VB	O
instructions	NNS	O
for	IN	O
reconstitution	NN	O
/	NNP	O
injection	NN	O
/	NNP	O
disposal	NN	O
procedures	NNS	O
for	IN	O
1	CD	O
)	)	O
Pre	NNP	O
-	:	O
filled	VBD	O
Dual	JJ	O
Chamber	NNP	O
Syringe	NNP	O
available	JJ	O
in	IN	O
300	CD	DOS
mg	NN	UNIT
or	CC	O
400	CD	DOS
mg	JJ	UNIT
strength	NN	O
syringes	NNS	O
[	VBP	O
see	VB	O
section	NN	O
below	IN	O
]	NNP	O
,	,	O
and	CC	O
2	CD	O
)	)	O
Single	NNP	O
-	:	O
use	NN	O
vials	NNS	O
available	JJ	O
in	IN	O
300	CD	DOS
mg	NN	UNIT
or	CC	O
400	CD	DOS
mg	JJ	UNIT
strength	NN	O
vials	NNS	O
[	VBP	O
see	VB	O
section	NN	O
below	IN	O
]	NN	O
.	.	O

For	IN	O
diuresis	NN	O
in	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
is	VBZ	O
usually	RB	O
250	CD	DOS
to	TO	O
375	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
(	(	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
.	.	O

In	IN	O
these	DT	WHO
patients	NNS	WHO
,	,	O
serum	JJ	O
amikacin	JJ	O
concentrations	NNS	O
should	MD	O
be	VB	O
measured	VBN	O
to	TO	O
assure	VB	O
accurate	JJ	O
administration	NN	O
of	IN	O
amikacin	NNS	O
and	CC	O
to	TO	O
avoid	VB	O
concentrations	NNS	O
above	IN	O
35	CD	DOS
mcg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

The	DT	O
dose	NN	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
and	CC	WHO
in	IN	WHO
pediatric	JJ	WHO
patients	NNS	WHO
above	IN	WHO
the	DT	WHO
age	NN	WHO
of	IN	WHO
ten	NN	WHO
(	(	WHO
10	CD	WHO
)	)	WHO
years	NNS	WHO
will	MD	O
vary	VB	O
between	IN	O
0.2	CD	DOS
and	CC	O
0.6	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
and	CC	O
it	PRP	O
must	MD	O
be	VB	O
individualized	VBN	O
in	IN	O
each	DT	O
case	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
switching	VBG	WHO
to	TO	WHO
AIRDUO	NNP	WHO
RESPICLICK	NNP	WHO
from	IN	O
another	DT	O
inhaled	VBN	O
corticosteroid	NN	O
or	CC	O
combination	NN	O
product	NN	O
,	,	O
select	VBP	O
the	DT	O
low	JJ	O
(	(	O
55	CD	DOS
/	RB	O
14	CD	DOS
mcg	NN	UNIT
)	)	O
,	,	O
medium	NN	O
(	(	O
113	CD	DOS
/	RB	O
14	CD	DOS
mcg	NN	UNIT
)	)	O
or	CC	O
high	JJ	O
(	(	O
232	CD	DOS
/	RB	O
14	CD	DOS
mcg	NN	UNIT
)	)	O
dose	VBP	O
strength	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
based	VBN	O
on	IN	O
the	DT	O
strength	NN	O
of	IN	O
the	DT	O
previous	JJ	O
inhaled	JJ	O
corticosteroid	JJ	O
product	NN	O
or	CC	O
the	DT	O
strength	NN	O
of	IN	O
the	DT	O
inhaled	JJ	O
corticosteroid	NN	O
from	IN	O
a	DT	O
combination	NN	O
product	NN	O
and	CC	O
disease	NN	O
severity	NN	O
.	.	O

Typically	RB	O
,	,	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
HF	$	O
8	CD	O
%	NN	O
appropriately	RB	O
mixed	JJ	O
with	IN	O
500	CD	DOS
mL	NNS	UNIT
of	IN	O
50	CD	O
%	NN	O
dextrose	NN	O
supplemented	VBN	O
with	IN	O
electrolytes	NNS	O
and	CC	O
vitamins	NNS	O
is	VBZ	O
administered	VBN	O
over	IN	O
an	DT	O
8	CD	O
to	TO	O
12	CD	O
hour	NN	O
period	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dosage	NN	O
for	IN	O
active	JJ	O
duodenal	JJ	O
ulcer	NN	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
at	IN	O
bedtime	NN	O
.	.	O

Begin	NNP	O
steady	JJ	O
state	NN	O
imaging	NN	O
after	IN	O
dynamic	JJ	O
imaging	NN	O
has	VBZ	O
been	VBN	O
completed	VBN	O
,	,	O
generally	RB	O
5	CD	O
to	TO	O
7	CD	O
minutes	NNS	O
following	VBG	O
ABLAVAR	NNP	O
administration	NN	O
.	.	O

Figure	NN	O
2	CD	O

ONE	CD	DOS
APPLICATION	NNP	UNIT
IS	NNP	O
GENERALLY	NNP	O
CURATIVE	NNP	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
continued	VBD	O
monitoring	NN	O
of	IN	O
immune	JJ	O
function	NN	O
and	CC	O
clinical	JJ	O
status	NN	O
is	VBZ	O
essential	JJ	O
in	IN	O
any	DT	O
patient	NN	O
with	IN	O
a	DT	O
primary	JJ	O
immunodeficiency	NN	O
disease	NN	O
and	CC	O
should	MD	O
be	VB	O
continued	VBN	O
in	IN	O
patients	NNS	WHO
undergoing	VBG	WHO
treatment	NN	WHO
with	IN	WHO
ADAGEN®	NNP	WHO
(	(	O
pegademase	VB	O
bovine	NN	O
)	)	O
Injection	NN	O
.	.	O

Once	RB	O
an	DT	O
appropriate	JJ	O
dose	NN	O
for	IN	O
pain	NN	O
management	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
,	,	O
instruct	NN	O
patients	NNS	O
to	TO	O
use	VB	O
only	RB	O
one	CD	DOS
ABSTRAL	NNP	UNIT
tablet	NN	UNIT
of	IN	O
the	DT	O
appropriate	JJ	O
strength	NN	O
per	IN	O
dose	NN	O
.	.	O

Higher	JJR	O
doses	NNS	O
such	JJ	O
as	IN	O
500	CD	DOS
mg	NN	UNIT
q.i.d	NN	O
.	.	O

Good	JJ	O
results	NNS	O
,	,	O
however	RB	O
,	,	O
have	VBP	O
been	VBN	O
seen	VBN	O
in	IN	O
patients	NNS	WHO
,	,	WHO
both	DT	WHO
children	NNS	WHO
and	CC	WHO
adults	NNS	WHO
,	,	O
in	IN	O
other	JJ	O
types	NNS	O
of	IN	O
seizures	NNS	O
such	JJ	O
as	IN	O
grand	JJ	O
mal	NN	O
,	,	O
mixed	JJ	O
seizure	NN	O
patterns	NNS	O
,	,	O
myoclonic	JJ	O
jerk	NN	O
patterns	NNS	O
,	,	O
etc	FW	O
.	.	O

Reductions	NNS	O
may	MD	O
be	VB	O
made	VBN	O
after	IN	O
an	DT	O
interval	NN	O
of	IN	O
one	CD	PER
or	CC	O
two	CD	PER
weeks	NNS	PER
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Initial	JJ	O
amino	NN	O
acid	JJ	O
dosage	NN	O
levels	NNS	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
in	IN	O
increments	NNS	O
of	IN	O
0.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
to	TO	O
approximate	VB	O
desired	JJ	O
intake	NN	O
levels	NNS	O
.	.	O

When	WRB	O
amikacin	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
newborns	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
box	NN	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
be	VB	O
administered	VBN	O
initially	RB	O
to	TO	O
be	VB	O
followed	VBN	O
with	IN	O
7.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Available	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
about	IN	O
one	CD	O
third	NN	O
to	TO	O
one	CD	O
half	NN	O
of	IN	O
the	DT	O
patients	NNS	WHO
with	IN	WHO
multiple	JJ	WHO
myeloma	NN	WHO
show	NN	O
a	DT	O
favorable	JJ	O
response	NN	O
to	TO	O
oral	JJ	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
considered	VBN	WHO
unsuitable	JJ	WHO
for	IN	WHO
surgery	NN	WHO
,	,	O
ALDACTONE	NNP	O
may	MD	O
be	VB	O
employed	VBN	O
for	IN	O
long	JJ	O
-	:	O
term	NN	O
maintenance	NN	O
therapy	NN	O
at	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dosage	NN	O
determined	VBD	O
for	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
.	.	O

Total	JJ	O
daily	JJ	FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
12	CD	DOS
tablets	NNS	UNIT
.	.	O

The	DT	O
clearance	NN	O
of	IN	O
zafirlukast	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
stable	JJ	WHO
alcoholic	JJ	WHO
cirrhosis	NN	WHO
such	JJ	O
that	IN	O
the	DT	O
Cmax	NNP	O
and	CC	O
AUC	NNP	O
are	VBP	O
approximately	RB	O
50	CD	O
-	:	O
60	CD	O
%	NN	O
greater	JJR	O
than	IN	O
those	DT	O
of	IN	O
normal	JJ	WHO
adults	NNS	WHO
.	.	O

Instill	NNP	O
1	CD	DOS
or	CC	O
2	CD	DOS
drops	NNS	UNIT
immediately	RB	O
before	IN	O
measurement	NN	O
.	.	O

As	IN	O
individual	JJ	O
monotherapy	NN	O
,	,	O
quinapril	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
of	IN	O
hypertension	NN	O
in	IN	O
once	RB	FREQ
-	:	O
daily	JJ	FREQ
doses	NNS	O
of	IN	O
10	CD	DOS
to	TO	O
80	CD	DOS
mg	NNS	UNIT
and	CC	O
hydrochlorothiazide	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
doses	NNS	O
of	IN	O
12.5	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
.	.	O

In	IN	O
some	DT	WHO
patients	NNS	WHO
,	,	O
the	DT	O
higher	JJR	O
morning	NN	O
blood	NN	O
levels	NNS	O
following	VBG	O
use	NN	O
of	IN	O
the	DT	O
10	CD	DOS
mg	NN	UNIT
dose	JJ	O
increase	NN	O
the	DT	O
risk	NN	O
of	IN	O
next	JJ	O
day	NN	O
impairment	NN	O
of	IN	O
driving	NN	O
and	CC	O
other	JJ	O
activities	NNS	O
that	WDT	O
require	VBP	O
full	JJ	O
alertness	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Occasionally	RB	O
,	,	O
the	DT	O
inactive	JJ	O
ingredients	NNS	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
and	CC	O
pseudoephedrine	VB	O
hcl	NN	O
)	)	O
12	CD	O
HOUR	NNP	O
may	MD	O
be	VB	O
eliminated	VBN	O
in	IN	O
the	DT	O
feces	NNS	O
in	IN	O
a	DT	O
form	NN	O
that	WDT	O
may	MD	O
resemble	VB	O
the	DT	O
original	JJ	O
tablet	NN	O
.	.	O

Begin	NNP	O
titration	NN	O
of	IN	O
all	DT	WHO
patients	NNS	WHO
with	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
ABSTRAL	NNP	O
of	IN	O
100	CD	DOS
mcg	NN	UNIT
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALIMTA	NNP	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
10	CD	O
minutes	NNS	O
on	IN	O
Day	NNP	O
1	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

UPAH	NNP	O
=	VBD	O
9.55	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
V	NNP	O
=	VBZ	O
16.68	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
GFR	NNP	O
=	VBZ	O
120	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
PPAH	NNP	O
=	VBZ	O
0.6	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
Then	RB	O
TmPAH	NNP	O
=	NNP	O
9.55	CD	O
x	VBD	O
16.68	CD	DOS
–	NNP	UNIT
(	(	O
120	CD	O
x	RB	O
0.6	CD	O
x	JJ	O
0.83	CD	O
)	)	O
=	VBD	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
min	NN	O
.	.	O

Before	IN	O
initiating	VBG	O
AFREZZA	NNP	O
,	,	O
perform	VB	O
a	DT	O
medical	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
and	CC	O
spirometry	NN	O
(	(	O
FEV1	NNP	O
)	)	O
in	IN	O
all	DT	WHO
patients	NNS	WHO
to	TO	O
identify	VB	O
potential	JJ	O
lung	NN	O
disease	NN	O
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
and	CC	O
WARNING	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

0.5	CD	DOS
mg	NN	UNIT

If	IN	O
ongoing	JJ	O
ABILIFY	NNP	O
therapy	NN	O
is	VBZ	O
clinically	RB	O
indicated	VBN	O
,	,	O
oral	JJ	O
ABILIFY	NNP	O
in	IN	O
a	DT	O
range	NN	O
of	IN	O
10	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
should	MD	O
replace	VB	O
ABILIFY	NNP	O
injection	NN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
[	NN	O
see	VBP	O
Schizophrenia	NNP	O
and	CC	O
Bipolar	NNP	O
I	PRP	O
Disorder	VBP	O
sections	NNS	O
above	IN	O
]	NN	O
.	.	O

Due	JJ	O
to	TO	O
differences	NNS	O
in	IN	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
and	CC	O
individual	JJ	O
variability	NN	O
,	,	O
even	RB	O
patients	NNS	WHO
switching	VBG	WHO
from	IN	WHO
other	JJ	WHO
fentanyl	NN	WHO
containing	VBG	WHO
products	NNS	WHO
to	TO	WHO
ABSTRAL	NNP	WHO
must	MD	O
start	VB	O
with	IN	O
the	DT	O
100	CD	DOS
mcg	NN	UNIT
dose	NN	UNIT
.	.	O

Alosetron	NNP	O
hydrochloride	JJ	O
tablets	NNS	O
should	MD	O
not	RB	O
be	VB	O
restarted	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
develop	VBP	WHO
ischemic	JJ	WHO
colitis	NN	WHO
.	.	O

The	DT	O
concentrated	JJ	O
solution	NN	O
for	IN	O
infusion	NN	O
must	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
to	TO	O
a	DT	O
final	JJ	O
volume	NN	O
of	IN	O
100	CD	DOS
mL	NNS	UNIT
or	CC	O
250	CD	DOS
mL	NN	UNIT
,	,	O
using	VBG	O
aseptic	JJ	O
techniques	NNS	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
essential	JJ	WHO
hypertension	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

However	RB	O
,	,	O
if	IN	O
a	DT	O
patient	NN	O
is	VBZ	O
unable	JJ	O
to	TO	O
take	VB	O
oral	JJ	O
nourishment	NN	O
for	IN	O
a	DT	O
prolonged	JJ	O
period	NN	O
of	IN	O
time	NN	O
,	,	O
institution	NN	O
of	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
with	IN	O
exogenous	JJ	O
calories	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

Usually	RB	O
30	CD	DOS
grams	NNS	UNIT
is	VBZ	O
sufficient	JJ	O
for	IN	O
an	DT	O
average	JJ	WHO
adult	NN	WHO
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FLECTOR	NNP	O
PATCH	NNP	O
is	VBZ	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
patch	NN	UNIT
to	TO	O
the	DT	O
most	RBS	O
painful	JJ	O
area	NN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Admixtures	NNS	O
of	IN	O
3.5	CD	O
to	TO	O
4.25	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
glucose	NN	O
may	MD	O
be	VB	O
coinfused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
1250	CD	DOS
mg	NN	UNIT
(	(	O
five	CD	DOS
250	CD	DOS
mg	NN	UNIT
tablets	NNS	UNIT
or	CC	O
two	CD	DOS
625	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
or	CC	O
750	CD	DOS
mg	NN	UNIT
(	(	O
three	CD	DOS
250	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
)	)	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

See	JJ	O
Dosage	NNP	O
Guidelines	NNP	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
:	:	O
1	CD	O
)	)	O
by	IN	O
incremental	JJ	O
injection	NN	O
as	IN	O
an	DT	O
analgesic	JJ	O
adjunct	NN	O
to	TO	O
anesthesia	VB	O
with	IN	O
barbiturate	JJ	O
/	NNS	O
nitrous	JJ	O
oxide	IN	O
/	NNP	O
oxygen	NN	O
for	IN	O
short	JJ	O
surgical	JJ	O
procedures	NNS	O
(	(	O
expected	VBN	O
duration	NN	O
of	IN	O
less	JJR	O
than	IN	O
one	CD	O
hour	NN	O
)	)	O
;	:	O
2	CD	O
)	)	O
by	IN	O
continuous	JJ	O
infusion	NN	O
as	IN	O
a	DT	O
maintenance	NN	O
analgesic	JJ	O
with	IN	O
nitrous	JJ	O
oxide	JJ	O
/	NNP	O
oxygen	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
;	:	O
and	CC	O
3	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
in	IN	O
anesthetic	JJ	O
doses	NNS	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
with	IN	O
a	DT	O
minimum	NN	O
expected	VBN	O
duration	NN	O
of	IN	O
45	CD	O
minutes	NNS	O
;	:	O
and	CC	O
4	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
as	IN	O
the	DT	O
analgesic	JJ	O
component	NN	O
for	IN	O
monitored	JJ	O
anesthesia	NN	O
care	NN	O
(	(	O
MAC	NNP	O
)	)	O
.	.	O

For	IN	O
the	DT	O
relief	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
or	CC	O
osteoarthritis	NN	O
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
1200	CD	DOS
mg	FW	UNIT
daily	RB	FREQ
)	)	O
,	,	O
preferably	RB	O
including	VBG	O
a	DT	O
dose	NN	O
on	IN	O
arising	VBG	O
and	CC	O
a	DT	O
dose	NN	O
at	IN	O
bedtime	NN	O
.	.	O

One	CD	DOS
suppository	NN	UNIT
in	IN	O
the	DT	O
rectum	NN	O
morning	NN	O
and	CC	O
night	NN	O
for	IN	O
two	CD	PER
weeks	NNS	PER
,	,	O
in	IN	O
nonspecific	JJ	O
proctitis	NN	O
.	.	O

2	CD	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACTEMRA	NNP	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
given	VBN	O
as	IN	O
a	DT	O
60	CD	DOS
-	:	O
minute	NN	O
single	JJ	O
intravenous	JJ	O
drip	NN	O
infusion	NN	O
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
followed	VBN	O
by	IN	O
an	DT	O
increase	NN	O
to	TO	O
8	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
based	VBN	O
on	IN	O
clinical	JJ	O
response	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
small	JJ	O
syringes	NNS	O
(	(	O
0.5	CD	DOS
mL	NN	UNIT
or	CC	O
1	CD	DOS
mL	NN	UNIT
)	)	O
be	VB	O
used	VBN	O
to	TO	O
minimize	VB	O
any	DT	O
product	NN	O
loss	NN	O
.	.	O

In	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
3	CD	DOS
to	TO	O
4	CD	DOS
drops	NNS	UNIT
may	MD	O
be	VB	O
sufficient	JJ	O
due	JJ	O
to	TO	O
the	DT	O
smaller	JJR	O
capacity	NN	O
of	IN	O
the	DT	O
ear	JJ	O
canal	NN	O
.	.	O

Renal	JJ	O
Insufficiency	NN	O
:	:	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
failure	NN	WHO
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
NEXAVAR	NNP	O
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
(	(	O
2	CD	DOS
x	RB	O
200	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
)	)	O
taken	VBN	O
twice	RB	FREQ
daily	RB	FREQ
without	IN	O
food	NN	O
(	(	O
at	IN	O
least	JJS	O
1	CD	O
hour	NN	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
a	DT	O
meal	NN	O
)	)	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
meclizine	JJ	O
hydrochloride	NN	O
,	,	O
should	MD	O
be	VB	O
taken	VBN	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
travel	VB	O
for	IN	O
protection	NN	O
against	IN	O
motion	NN	O
sickness	NN	O
.	.	O

Figure	NN	O
17	CD	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
(	(	O
more	JJR	O
than	IN	O
one	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
of	IN	O
the	DT	O
prescribed	JJ	O
strength	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
as	IN	O
some	DT	WHO
patients	NNS	WHO
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
adverse	JJ	O
effects	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
salmeterol	NN	O
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
likelihood	NN	O
of	IN	O
hypotension	NN	O
,	,	O
the	DT	O
diuretic	NN	O
should	MD	O
,	,	O
if	IN	O
possible	JJ	O
,	,	O
be	VB	O
discontinued	VBN	O
two	CD	O
to	TO	O
three	CD	O
days	NNS	O
prior	RB	O
to	TO	O
beginning	VBG	O
therapy	NN	O
with	IN	O
ALTACE	NNP	O
.	.	O

5	CD	O

When	WRB	O
amikacin	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
newborns	NNS	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
:	:	O
WARNINGS	VB	O
It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
be	VB	O
administered	VBN	O
initially	RB	O
to	TO	O
be	VB	O
followed	VBN	O
with	IN	O
7.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Nongonococcal	JJ	O
urethritis	NN	O
(	(	O
NGU	NNP	O
)	)	O
caused	VBN	O
by	IN	O
C.	NNP	O
trachomatis	NN	O
and	CC	O
U.	NNP	O
urealyticum	NN	O
:	:	O
100	CD	DOS
mg	NN	UNIT
by	IN	O
mouth	NN	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
immediately	RB	O
before	IN	O
bedtime	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Figure	NN	O
14	CD	O

In	IN	O
adults	NNS	WHO
,	,	O
strongly	RB	O
hypertonic	JJ	O
admixtures	NNS	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	VB	O
may	MD	O
be	VB	O
safely	RB	O
administered	VBN	O
only	RB	O
by	IN	O
continuous	JJ	O
infusion	NN	O
through	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
with	IN	O
the	DT	O
tip	NN	O
located	VBN	O
in	IN	O
the	DT	O
superior	JJ	O
vena	NN	O
cava	NN	O
.	.	O

Typically	RB	O
,	,	O
each	DT	O
liter	NN	O
of	IN	O
central	JJ	O
vein	NNS	O
TPN	NNP	O
solution	NN	O
for	IN	O
adults	NNS	WHO
contains	NNS	O
42.5	CD	DOS
to	TO	O
50	CD	DOS
g	NN	UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
with	IN	O
approximately	RB	O
250	CD	DOS
±	JJ	O
100	CD	DOS
g	NN	UNIT
of	IN	O
dextrose	NN	O
;	:	O
supplementary	JJ	O
nonprotein	NN	O
calories	NNS	O
from	IN	O
intravenous	JJ	O
fat	JJ	O
emulsion	NN	O
may	MD	O
be	VB	O
prescribed	VBN	O
,	,	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
physician	NN	O
.	.	O

two	CD	DOS
tablets	NNS	UNIT
of	IN	O
500	CD	DOS
mg	NNS	UNIT
/	VBD	O
20	CD	DOS
mg	NN	UNIT
and	CC	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
1000	CD	DOS
mg	NN	UNIT
/	VBD	O
40	CD	DOS
mg	NN	UNIT
)	)	O
are	VBP	O
not	RB	O
interchangeable	JJ	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
body	NN	WHO
weight	NN	WHO
of	IN	WHO
20	CD	WHO
kg	NNS	WHO
or	CC	WHO
less	JJR	WHO
should	MD	O
receive	VB	O
a	DT	O
total	JJ	O
volume	NN	O
of	IN	O
100	CD	DOS
mL	NN	UNIT
.	.	O

A	DT	O
dosage	NN	O
of	IN	O
2.4	CD	DOS
to	TO	O
4.7	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	JJ	O
per	IN	FREQ
day	NN	FREQ
(	(	O
from	IN	O
essential	JJ	O
amino	NN	O
acids	NNS	O
)	)	O
with	IN	O
adequate	JJ	O
calories	NNS	O
will	MD	O
maintain	VB	O
nitrogen	JJ	O
equilibrium	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
uremia	JJ	WHO
.	.	O

Each	DT	O
vial	NN	O
of	IN	O
ALDURAZYME	NNP	O
provides	VBZ	O
2.9	CD	DOS
milligrams	NNS	UNIT
(	(	O
mg	NN	UNIT
)	)	O
of	IN	O
laronidase	NN	O
in	IN	O
5	CD	DOS
milliliters	NNS	UNIT
(	(	O
mL	NN	O
)	)	O
of	IN	O
solution	NN	O
and	CC	O
is	VBZ	O
intended	VBN	O
for	IN	O
single	JJ	O
use	NN	O
only	RB	O
.	.	O

Monitor	NNP	O
everolimus	JJ	O
whole	JJ	O
blood	NN	O
trough	NN	O
levels	NNS	O
routinely	RB	O
in	IN	O
all	DT	WHO
patients	NNS	WHO
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
20	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	FW	O
per	IN	O
week	NN	O
.	.	O

When	WRB	O
the	DT	O
patient	NN	O
is	VBZ	O
switching	VBG	O
from	IN	O
a	DT	O
28	CD	O
-	:	O
day	NN	O
regimen	NNS	O
of	IN	O
tablets	NNS	O
,	,	O
she	PRP	O
should	MD	O
start	VB	O
her	PRP$	O
first	JJ	O
pack	NN	O
of	IN	O
ALESSE	NNP	O
(	(	O
levonorgestrel	NN	O
and	CC	O
ethinyl	VB	O
estradiol	NN	O
)	)	O
on	IN	O
the	DT	O
day	NN	O
after	IN	O
her	PRP$	O
last	JJ	O
tablet	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
chronic	JJ	WHO
kidney	NN	WHO
disease	NN	WHO
and	CC	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
less	JJR	O
than	IN	O
60	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
VYTORIN	NNP	O
is	VBZ	O
10	CD	DOS
/	JJ	O
20	CD	DOS
/	JJ	O
18	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
the	DT	O
evening	NN	O
.	.	O

Continuous	JJ	O
maintenance	NN	O
therapy	NN	O
with	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
is	VBZ	O
instituted	VBN	O
when	WRB	O
the	DT	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
4,000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mcL	NN	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
100,000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mcL	NN	O
.	.	O

SYLVANT	NNP	O
11	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
is	VBZ	O
given	VBN	O
over	IN	O
1	CD	O
hour	NN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
administered	VBD	O
every	DT	FREQ
3	CD	FREQ
weeks	NNS	FREQ
until	IN	O
treatment	NN	O
failure	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Savella	NNP	O
is	VBZ	O
100	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
50	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

Within	IN	O
24	CD	O
to	TO	O
48	CD	O
hours	NNS	O
the	DT	O
volume	NN	O
and	CC	O
concentration	NN	O
of	IN	O
the	DT	O
solution	NN	O
can	MD	O
be	VB	O
increased	VBN	O
until	IN	O
the	DT	O
full	JJ	O
strength	NN	O
pediatric	JJ	O
solution	NN	O
(	(	O
amino	JJ	O
acids	NNS	O
and	CC	O
dextrose	NN	O
)	)	O
is	VBZ	O
given	VBN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
125	CD	DOS
to	TO	O
150	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
daily	JJ	FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	WHO
adult	NN	WHO
patient	NN	WHO
,	,	WHO
not	RB	WHO
hypermetabolic	JJ	WHO
,	,	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
and	CC	WHO
with	IN	WHO
restricted	JJ	WHO
physical	JJ	WHO
activity	NN	WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	DOS
to	TO	O
18	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1	CD	DOS
to	TO	O
1.5	CD	DOS
g	NN	UNIT
amino	NN	O
acids	NNS	O
/	VBP	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	DOS
and	CC	O
3000	CD	DOS
mL	NN	UNIT
of	IN	O
fluids	NNS	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
calories	NNS	O
—	JJ	O
1000	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
5	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
will	MD	O
provide	VB	O
7.7	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
and	CC	O
850	CD	O
calories	NNS	O
.	.	O

Adrenalin®	$	O
1	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O
(	(	O
1:1000	CD	O
)	)	O
epinephrine	NN	O
injection	NN	O
,	,	O
1	CD	DOS
mL	JJ	UNIT
solution	NN	UNIT
in	IN	O
a	DT	O
single	JJ	O
-	:	O
use	NN	O
clear	JJ	O
glass	NN	O
vial	NN	O
and	CC	O
30	CD	DOS
mL	JJ	UNIT
solution	NN	UNIT
in	IN	O
a	DT	O
multiple	JJ	O
-	:	O
dose	JJ	O
amber	JJ	O
glass	NN	O
vial	NN	O
.	.	O

Each	DT	O
actuation	NN	O
of	IN	O
PROVENTIL®	NNP	O
HFA	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
delivers	VBZ	O
108	CD	DOS
mcg	NN	UNIT
of	IN	O
albuterol	NN	O
sulfate	NN	O
(	(	O
equivalent	JJ	O
to	TO	O
90	CD	DOS
mcg	NN	UNIT
of	IN	O
albuterol	JJ	O
base	NN	O
)	)	O
from	IN	O
the	DT	O
mouthpiece	NN	O
.	.	O

The	DT	O
maximum	JJ	O
rate	NN	O
at	IN	O
which	WDT	O
dextrose	NN	O
can	MD	O
be	VB	O
infused	VBN	O
without	IN	O
producing	VBG	O
glycosuria	NN	O
is	VBZ	O
0.5	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
hour	NN	O
;	:	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
0.8	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
hour	NN	O
,	,	O
about	RB	O
95	CD	O
%	NN	O
of	IN	O
the	DT	O
infused	JJ	O
dextrose	NN	O
is	VBZ	O
retained	VBN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
prescribed	VBN	O
no	DT	O
more	JJR	O
than	IN	O
36	CD	DOS
packets	NNS	UNIT
for	IN	O
the	DT	O
6	CD	O
-	:	O
week	NN	O
treatment	NN	O
period	NN	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
parenteral	JJ	O
administration	NN	O
of	IN	O
a	DT	O
solution	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	JJ	O
requires	VBZ	O
an	DT	O
accurate	JJ	O
estimate	NN	O
of	IN	O
the	DT	O
total	JJ	O
fluid	NN	O
,	,	O
electrolytes	NNS	O
and	CC	O
acid	SYM	O
-	:	O
base	NN	O
needed	VBN	O
to	TO	O
compensate	VB	O
for	IN	O
the	DT	O
patient	NN	O
's	POS	O
measurable	JJ	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
i.e	FW	O
,	,	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
daily	JJ	FREQ
losses	NNS	O
.	.	O

For	IN	O
the	DT	O
prevention	NN	O
of	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
,	,	O
the	DT	O
minimum	JJ	O
dose	NN	O
of	IN	O
Alora	NNP	O
that	WDT	O
has	VBZ	O
been	VBN	O
studied	VBN	O
and	CC	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
is	VBZ	O
0.025	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
applied	VBD	O
to	TO	O
the	DT	O
skin	NN	O
twice	RB	FREQ
weekly	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
BUPHENYL	NNP	O
Tablets	NNP	O
and	CC	O
Powder	NNP	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
urea	JJ	WHO
cycle	NN	WHO
disorders	NNS	WHO
is	VBZ	O
450	CD	DOS
-	:	O
600	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
patients	NNS	WHO
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
20	CD	WHO
kg	NN	WHO
,	,	O
or	CC	O
9.9	CD	DOS
-	:	O
13	CD	DOS
g	NN	UNIT
/	NNP	O
m²	NN	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
larger	JJR	WHO
patients	NNS	WHO
.	.	O

Rather	RB	O
than	IN	O
an	DT	O
increase	NN	O
in	IN	O
infusion	NN	O
rate	NN	O
,	,	O
7	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
bolus	NN	O
doses	NNS	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
or	CC	O
a	DT	O
potent	JJ	O
inhalation	NN	O
agent	NN	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
response	NN	O
to	TO	O
signs	NNS	O
of	IN	O
lightening	NN	O
of	IN	O
anesthesia	NN	O
within	IN	O
the	DT	O
last	JJ	O
15	CD	O
minutes	NNS	O
of	IN	O
surgery	NN	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
folic	JJ	O
acid	NNS	O
studied	VBD	O
ranged	VBN	O
from	IN	O
350	CD	DOS
to	TO	O
1000	CD	DOS
mcg	NN	UNIT
,	,	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
vitamin	NN	O
B12	NNP	O
was	VBD	O
1000	CD	DOS
mcg	NN	UNIT
.	.	O

It	PRP	O
has	VBZ	O
usually	RB	O
been	VBN	O
found	VBN	O
that	IN	O
a	DT	O
dosage	NN	O
in	IN	O
excess	NN	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
per	IN	O
24	CD	O
hours	NNS	O
does	VBZ	O
not	RB	O
produce	VB	O
an	DT	O
increased	JJ	O
effect	NN	O
.	.	O

As	IN	O
an	DT	O
example	NN	O
of	IN	O
the	DT	O
preparation	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
for	IN	O
infusion	NN	O
,	,	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
added	VBD	O
to	TO	O
230	CD	DOS
mL	NN	UNIT
of	IN	O
diluent	NN	O
provides	VBZ	O
40	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NNP	O
solution	NN	O
of	IN	O
Alfentanil	NNP	O
.	.	O

The	DT	O
effective	JJ	O
dose	NN	O
resulting	VBG	O
from	IN	O
a	DT	O
370	CD	DOS
MBq	NNP	UNIT
(	(	O
10	CD	DOS
mCi	NN	UNIT
)	)	O
dose	NN	O
of	IN	O
Am	NNP	O
yvid	NNP	O
is	VBZ	O
7	CD	DOS
mSv	NN	UNIT
in	IN	O
an	DT	WHO
adult	NN	WHO
,	,	O
(	(	O
19	CD	O
x	RB	O
370	CD	O
=	JJ	O
7030	CD	DOS
μSv	NNP	UNIT
=	VBD	O
7.03	CD	DOS
mSv	NN	UNIT
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
4.5	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
,	,	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Generally	RB	O
,	,	O
the	DT	O
ACTIQ	NNP	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
only	RB	O
when	WRB	O
a	DT	O
single	JJ	DOS
administration	NN	UNIT
of	IN	O
the	DT	O
current	JJ	O
dose	NN	O
fails	NNS	O
to	TO	O
adequately	RB	O
treat	VB	O
the	DT	O
breakthrough	NN	O
pain	NN	O
episode	NN	O
for	IN	O
several	JJ	O
consecutive	JJ	O
episodes	NNS	O
.	.	O

Loading	VBG	O
Dose	NNP	O
:	:	O
150	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
3	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
1	CD	DOS
hr	NNS	UNIT

The	DT	O
dose	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
greater	JJR	WHO
than	IN	WHO
two	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
one	CD	DOS
to	TO	O
two	CD	DOS
drops	NNS	UNIT
in	IN	O
each	DT	O
affected	JJ	O
eye	NN	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
for	IN	O
up	IN	PER
to	TO	PER
3	CD	PER
months	NNS	PER
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
stable	JJ	WHO
coronary	JJ	WHO
artery	NN	WHO
disease	NN	WHO
,	,	O
ACEON	NNP	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
4	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
for	IN	O
2	CD	PER
weeks	NNS	PER
,	,	O
and	CC	O
then	RB	O
increased	VBD	O
as	IN	O
tolerated	VBN	O
,	,	O
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
8	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
starting	JJ	O
dosage	NN	O
of	IN	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
in	IN	O
the	DT	O
first	JJ	O
48	CD	O
hours	NNS	O
.	.	O

Growth	NNP	O
hormone	NN	O
deficiency	NN	O
-	:	O
The	DT	O
recommended	JJ	O
weekly	JJ	FREQ
dose	NN	O
is	VBZ	O
0.18	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	VBD	O
to	TO	O
0.3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
0.9	CD	DOS
IU	NNP	UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
.	.	O

Sufficient	JJ	O
cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
cover	VB	O
the	DT	O
treatment	NN	O
area	NN	O
,	,	O
including	VBG	O
1	CD	O
centimeter	NN	O
of	IN	O
skin	NN	O
surrounding	VBG	O
the	DT	O
tumor	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
10	CD	DOS
-	:	O
80	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
single	JJ	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
;	:	O
the	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
80	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Dosage	NNP	O
reduction	NN	O
of	IN	O
up	IN	O
to	TO	O
50	CD	O
%	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
insufficiency	NN	WHO
(	(	O
BUN	NNP	O
≥	VBZ	O
30	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	O
)	)	O
(	(	O
see	JJ	O
PRECAUTIONS	NNP	O
:	:	O
General	NNP	O
)	)	O
.	.	O

If	IN	O
changes	NNS	O
are	VBP	O
not	RB	O
controlled	VBN	O
after	IN	O
three	CD	DOS
bolus	NN	UNIT
doses	NNS	UNIT
given	VBN	O
over	RP	O
a	DT	O
five	CD	O
minute	NN	O
period	NN	O
,	,	O
a	DT	O
barbiturate	NN	O
,	,	O
vasodilator	NN	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
inhalation	NN	O
agent	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

Most	JJS	O
patients	NNS	O
will	MD	O
experience	VB	O
an	DT	O
adequate	JJ	O
response	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1.5	CD	DOS
to	TO	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

If	IN	O
you	PRP	O
start	VBP	O
to	TO	O
regain	VB	O
weight	NN	O
after	IN	O
you	PRP	O
stop	VBP	O
taking	VBG	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	DOS
mg	NN	UNIT
)	)	O
,	,	O
you	PRP	O
may	MD	O
need	VB	O
to	TO	O
start	VB	O
taking	VBG	O
alli	JJ	O
(	(	O
orlistat	JJ	O
60	CD	DOS
mg	NN	UNIT
)	)	O
again	RB	O
along	IN	O
with	IN	O
your	PRP$	O
diet	JJ	O
and	CC	O
exercise	JJ	O
program	NN	O
.	.	O

Adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
advised	VBN	O
not	RB	O
to	TO	O
take	VB	O
supplemental	JJ	O
vitamin	NN	O
E	NNP	O
since	IN	O
the	DT	O
vitamin	NN	O
E	NNP	O
content	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
exceeds	VBZ	O
the	DT	O
Reference	NNP	O
Daily	NNP	FREQ
Intake	NNP	O
(	(	O
adults	NNS	WHO
30	CD	O
IU	NNP	O
,	,	O
pediatrics	NNS	O
approximately	RB	O
10	CD	DOS
IU	NNP	UNIT
)	)	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
)	)	O
.	.	O

Drug	NNP	O
-	:	O
Induced	VBD	O
Edema	NNP	O
:	:	O
Recommended	JJ	O
dosage	NN	O
is	VBZ	O
250	CD	DOS
to	TO	O
375	CD	DOS
mg	NN	UNIT
of	IN	O
acetazolamide	NN	O
once	IN	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
one	CD	PER
or	CC	O
two	CD	PER
days	NNS	PER
,	,	O
alternating	VBG	O
with	IN	O
a	DT	O
day	NN	O
of	IN	O
rest	NN	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Body	NNP	WHO
Weight	NNP	WHO
≥	VBZ	WHO
50	CD	WHO
kg	NN	WHO
:	:	O
Administer	NNP	O
the	DT	O
adult	NN	WHO
dose	NN	O
.	.	O

As	IN	O
reported	VBN	O
in	IN	O
the	DT	O
literature	NN	O
,	,	O
the	DT	O
dosage	NN	O
and	CC	O
constant	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
intravenous	JJ	O
dextrose	NN	O
must	MD	O
be	VB	O
selected	VBN	O
with	IN	O
caution	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	WHO
particularly	RB	WHO
neonates	NNS	WHO
and	CC	WHO
low	JJ	WHO
birth	NN	WHO
weight	NN	WHO
infants	NNS	WHO
,	,	O
because	IN	O
of	IN	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
hyperglycemia	NN	O
/	NNP	O
hypoglycemia	NN	O
.	.	O

A	DT	O
2.5	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
of	IN	O
albuterol	NN	O
provided	VBN	O
by	IN	O
a	DT	O
higher	JJR	O
concentration	NN	O
product	NN	O
(	(	O
2.5	CD	DOS
mg	NN	UNIT
albuterol	NN	O
per	IN	O
3	CD	DOS
mL	NN	UNIT
)	)	O
may	MD	O
be	VB	O
more	JJR	O
appropriate	JJ	O
for	IN	O
treating	VBG	O
acute	JJ	O
exacerbations	NNS	O
,	,	O
particularly	RB	O
in	IN	O
children	NNS	WHO
6	CD	WHO
years	NNS	WHO
old	JJ	WHO
and	CC	WHO
above	JJ	WHO
.	.	O

An	DT	O
AFINITOR	NNP	O
dose	JJ	O
increase	NN	O
from	IN	O
2.5	CD	DOS
mg	NNS	UNIT
to	TO	O
5	CD	DOS
mg	NN	UNIT
may	MD	O
be	VB	O
considered	VBN	O
based	VBN	O
on	IN	O
patient	JJ	O
tolerance	NN	O
.	.	O

Initial	JJ	O
dosage	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
daily	RB	FREQ
in	IN	O
two	CD	DOS
to	TO	O
four	CD	DOS
doses	NNS	UNIT
.	.	O

Turner	NNP	O
Syndrome	NNP	O
-	:	O
The	DT	O
recommended	JJ	O
weekly	JJ	FREQ
dose	NN	O
is	VBZ	O
0.36	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
patients	NNS	WHO
not	RB	WHO
receiving	VBG	WHO
a	DT	WHO
diuretic	JJ	WHO
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
is	VBZ	O
3.75	CD	DOS
mg	NN	UNIT
,	,	O
incorporated	VBN	O
in	IN	O
a	DT	O
depot	NN	O
formulation	NN	O
.	.	O

Slowly	RB	O
inject	VBP	O
the	DT	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
over	IN	O
a	DT	O
minimum	NN	O
of	IN	O
1	CD	O
minute	NN	O
,	,	O
using	VBG	O
the	DT	O
sterile	JJ	O
syringe	NN	O
to	TO	O
direct	VB	O
the	DT	O
solution	NN	O
flow	NN	O
onto	IN	O
the	DT	O
INSIDE	NNP	O
WALL	NNP	O
OF	IN	O
THE	NNP	O
VIAL	NNP	O
.	.	O

Dosage	NNP	O
adjustment	NN	O
of	IN	O
ACTIQ	NNP	O
may	MD	O
be	VB	O
required	VBN	O
in	IN	O
some	DT	WHO
patients	NNS	WHO
in	IN	O
order	NN	O
to	TO	O
continue	VB	O
to	TO	O
provide	VB	O
adequate	JJ	O
relief	NN	O
of	IN	O
breakthrough	NN	O
pain	NN	O
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
moderate	JJ	O
-	:	O
to	TO	O
-	:	O
severe	JJ	O
vasomotor	NN	O
symptoms	NNS	O
,	,	O
vulvar	NN	O
and	CC	O
vaginal	JJ	O
atrophy	NN	O
associated	VBN	O
with	IN	O
the	DT	O
menopause	NN	O
,	,	O
hypogonadism	NN	O
,	,	O
castration	NN	O
,	,	O
or	CC	O
primary	JJ	O
ovarian	JJ	O
failure	NN	O
,	,	O
treatment	NN	O
is	VBZ	O
usually	RB	O
initiated	VBN	O
with	IN	O
Alora	NNP	O
0.05	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
applied	VBD	O
to	TO	O
the	DT	O
skin	NN	O
twice	RB	FREQ
weekly	RB	FREQ
.	.	O

Each	DT	O
mL	NN	O
of	IN	O
the	DT	O
reconstituted	VBN	O
formulation	NN	O
will	MD	O
contain	VB	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
paclitaxel	NN	O
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
(	(	O
twenty	JJ	O
-	:	O
four	CD	DOS
50	CD	DOS
-	:	O
mg	NN	UNIT
capsules	NNS	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

A	DT	O
second	JJ	O
6	CD	DOS
mg	NNS	UNIT
dose	NN	UNIT
should	MD	O
only	RB	O
be	VB	O
considered	VBN	O
if	IN	O
some	DT	O
response	NN	O
to	TO	O
a	DT	O
first	JJ	O
injection	NN	O
was	VBD	O
observed	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
9.75	CD	DOS
mg	NN	UNIT
.	.	O

For	IN	O
most	JJS	WHO
pediatric	JJ	WHO
patients	NNS	WHO
on	IN	WHO
intravenous	JJ	WHO
nutrition	NN	WHO
,	,	O
2.5	CD	DOS
grams	NNS	UNIT
amino	JJ	O
acids	NNS	O
/	VBP	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
with	IN	O
dextrose	JJ	O
alone	NNS	O
or	CC	O
with	IN	O
I.V	NNP	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
for	IN	O
200	CD	DOS
mg	NNS	UNIT
and	CC	O
160	CD	DOS
mg	NNS	UNIT
are	VBP	O
obtained	VBN	O
only	RB	O
by	IN	O
using	VBG	O
the	DT	O
300	CD	DOS
mg	NN	UNIT
or	CC	O
400	CD	DOS
mg	JJ	UNIT
strength	NN	O
vials	NNS	O
for	IN	O
intramuscular	JJ	O
deltoid	NN	O
or	CC	O
gluteal	JJ	O
injection	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
ACIPHEX	NNP	O
delayed	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
1	CD	WHO
year	NN	WHO
to	TO	WHO
less	JJR	WHO
than	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
because	IN	O
the	DT	O
lowest	JJS	O
available	JJ	O
tablet	NN	O
strength	NN	O
(	(	O
20	CD	DOS
mg	NN	UNIT
)	)	O
exceeds	VBZ	O
the	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

AIRDUO	NNP	O
RESPICLICK	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Kyprolis	NNP	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
in	IN	O
Cycle	NNP	O
1	CD	O
on	IN	O
Days	NNS	O
1	CD	O
and	CC	O
2	CD	O
.	.	O

However	RB	O
,	,	O
some	DT	O
investigators	NNS	O
feel	VBP	O
that	IN	O
daily	JJ	FREQ
doses	NNS	O
in	IN	O
excess	NN	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
do	VBP	O
not	RB	O
produce	VB	O
any	DT	O
better	JJR	O
results	NNS	O
than	IN	O
a	DT	O
1	CD	DOS
g	NN	UNIT
dose	NN	UNIT
.	.	O

In	IN	O
trials	NNS	O
comparing	VBG	O
0.1	CD	O
,	,	O
0.5	CD	O
,	,	O
and	CC	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

Usual	NNP	O
dose	VBD	O
5	CD	DOS
mg	NN	UNIT
to	TO	O
60	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
dose	NN	O
for	IN	O
most	JJS	WHO
patients	NNS	WHO
is	VBZ	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
AMRIX	$	O
15	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
titrated	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
15	CD	DOS
mg	NN	UNIT
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
45	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
based	VBN	O
on	IN	O
glycemic	JJ	O
response	NN	O
as	IN	O
determined	VBN	O
by	IN	O
HbA1c	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ADCIRCA	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
(	(	O
two	CD	DOS
20	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
)	)	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
weighing	VBG	WHO
50	CD	WHO
kg	NN	WHO
or	CC	WHO
more	JJR	WHO
,	,	O
dosing	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
2	CD	PER
days	NNS	PER
,	,	O
and	CC	O
then	RB	O
increased	VBD	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
5	CD	PER
days	NNS	PER
,	,	O
with	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
on	IN	O
day	NN	O
8	CD	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
hypertension	NN	WHO
and	CC	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	DOS
mg	JJ	UNIT
ALTACE	NNP	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
8	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
orally	RB	O
with	IN	O
food	NN	O
and	CC	O
water	NN	O
.	.	O

In	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
≥	VBD	WHO
45	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
required	VBD	O
no	DT	O
dose	JJ	O
adjustments	NNS	O
other	JJ	O
than	IN	O
those	DT	O
recommended	VBN	O
for	IN	O
all	DT	WHO
patients	NNS	WHO
.	.	O

From	IN	O
this	DT	O
initial	JJ	O
dose	NN	O
,	,	O
closely	RB	O
follow	JJ	O
patients	NNS	O
and	CC	O
change	VB	O
the	DT	O
dosage	NN	O
level	NN	O
until	IN	O
the	DT	O
patient	NN	O
reaches	VBZ	O
a	DT	O
dose	NN	O
that	WDT	O
provides	VBZ	O
adequate	JJ	O
analgesia	NNS	O
using	VBG	O
a	DT	O
single	JJ	DOS
ACTIQ	NNP	O
dosage	NN	O
unit	NN	O
per	IN	O
breakthrough	NN	O
cancer	NN	O
pain	NN	O
episode	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
for	IN	O
On	IN	O
-	:	O
demand	NN	O
Treatment	NNP	O
and	CC	O
Control	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O

In	IN	O
some	DT	WHO
patients	NNS	WHO
it	PRP	O
may	MD	O
be	VB	O
possible	JJ	O
to	TO	O
maintain	VB	O
adequate	JJ	O
remission	NN	O
of	IN	O
lesions	NNS	O
with	IN	O
alternate	JJ	O
day	NN	O
or	CC	O
intermittent	JJ	O
therapy	NN	O
.	.	O

Adding	VBG	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
chamber	NN	O
and	CC	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
the	DT	O
dextrose	JJ	O
chamber	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
(	(	O
in	IN	O
mEq	NN	O
/	NNP	O
L	NNP	O
)	)	O
as	IN	O
follows	VBZ	O
:	:	O
57.2	CD	O
sodium	NN	O
,	,	O
42	CD	O
potassium	NN	O
,	,	O
35	CD	O
chloride	NN	O
,	,	O
5	CD	O
magnesium	NN	O
,	,	O
4.5	CD	O
calcium	NN	O
,	,	O
65.4	CD	O
acetate	NN	O
,	,	O
and	CC	O
15	CD	O
(	(	O
mM	NN	O
)	)	O
phosphate	NN	O
.	.	O

Withdraw	VB	O
a	DT	O
0.5	CD	DOS
mL	NN	UNIT
dose	NN	UNIT
of	IN	O
the	DT	O
reconstituted	JJ	O
vaccine	NN	O
and	CC	O
inject	JJ	O
intramuscularly	RB	O
.	.	O

Dosage	NN	O
adjustment	NN	O
is	VBZ	O
not	RB	O
required	VBN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

When	WRB	O
an	DT	O
area	NN	O
of	IN	O
8	CD	O
x	JJ	O
18	CD	O
cm	NN	O
is	VBZ	O
illuminated	VBN	O
,	,	O
the	DT	O
effective	JJ	O
treatment	NN	O
area	NN	O
is	VBZ	O
6	CD	O
x16	JJ	O
cm	NN	O
.	.	O

In	IN	O
studies	NNS	O
comparing	VBG	O
0.1	CD	O
,	,	O
0.5	CD	O
,	,	O
and	CC	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
day,8	VBD	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

6	CD	O
-	:	O
16	CD	O
Yrs	NN	O

The	DT	O
risk	NN	O
of	IN	O
administering	VBG	O
methylene	NN	O
blue	NN	O
by	IN	O
non	JJ	O
-	:	O
intravenous	JJ	O
routes	NNS	O
(	(	O
such	JJ	O
as	IN	O
oral	JJ	O
tablets	NNS	O
or	CC	O
by	IN	O
local	JJ	O
injection	NN	O
)	)	O
or	CC	O
in	IN	O
intravenous	JJ	O
doses	NNS	O
much	RB	O
lower	JJR	O
than	IN	O
1	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
with	IN	O
Anafranil	NNP	O
is	VBZ	O
unclear	JJ	O
.	.	O

Flushing	VBG	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
see	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
may	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
frequency	NN	O
or	CC	O
severity	NN	O
by	IN	O
pretreatment	NN	O
with	IN	O
aspirin	NN	O
up	RB	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
325	CD	DOS
mg	NN	UNIT
(	(	O
taken	VBN	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
NIASPAN	NNP	O
dose	NN	O
)	)	O
.	.	O

Patients	NNS	O
s	PRP	O
hould	MD	O
be	VB	O
pres	NNS	O
cribed	VBN	O
no	RB	O
more	JJR	O
than	IN	O
36	CD	DOS
packets	NNS	UNIT
for	IN	O
the	DT	O
16	CD	O
-	:	O
week	NN	O
treatment	NN	O
period	NN	O
.	.	O


Changes	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
that	WDT	O
indicate	VBP	O
a	DT	O
response	NN	O
to	TO	O
surgical	JJ	O
stress	NN	O
or	CC	O
lightening	NN	O
of	IN	O
anesthesia	NN	O
may	MD	O
be	VB	O
controlled	VBN	O
by	IN	O
increasing	VBG	O
the	DT	O
alfentanil	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
4	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
and	CC	O
/	NN	O
or	CC	O
administration	NN	O
of	IN	O
bolus	JJ	O
doses	NNS	O
of	IN	O
7	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
between	IN	WHO
4	CD	WHO
and	CC	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
for	IN	WHO
patients	NNS	WHO
13	CD	WHO
to	TO	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
with	IN	WHO
weight	NN	WHO
of	IN	WHO
<	$	WHO
50	CD	WHO
kg	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
twice	RB	FREQ
daily	RB	FREQ
or	CC	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBD	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
to	TO	O
a	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
2400	CD	DOS
mg	NN	UNIT
)	)	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

INJECTION	NN	O
:	:	O
Adults	NNP	WHO
-	:	O
One	CD	DOS
2	CD	DOS
mL	NN	UNIT
vial	NN	UNIT
(	(	O
60	CD	DOS
mg	NN	UNIT
)	)	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
;	:	O
may	MD	O
be	VB	O
repeated	VBN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Therefore	RB	O
,	,	O
ALIMTA	NNP	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
to	TO	O
patients	NNS	WHO
whose	WP$	WHO
creatinine	JJ	WHO
clearance	NN	WHO
is	VBZ	WHO
<	JJ	WHO
45	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
using	VBG	O
the	DT	O
standard	NN	O
Cockcroft	NNP	O
and	CC	O
Gault	NNP	O
formula	NN	O
(	(	O
below	IN	O
)	)	O
or	CC	O
GFR	NNP	O
measured	VBN	O
by	IN	O
Tc99m	NNP	O
-	:	O
DPTA	NNP	O
serum	JJ	O
clearance	NN	O
method	NN	O
:	:	O

Admixtures	NNS	O
of	IN	O
3.5	CD	O
to	TO	O
4.25	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
may	MD	O
be	VB	O
infused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

7	CD	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
to	TO	O
two	CD	DOS
drops	NNS	UNIT
in	IN	O
each	DT	O
affected	JJ	O
eye	NN	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
unable	JJ	WHO
to	TO	WHO
swallow	VB	WHO
whole	JJ	WHO
tablets	NNS	WHO
,	,	O
Adempas	NNP	O
may	MD	O
be	VB	O
crushed	VBN	O
and	CC	O
mixed	JJ	O
with	IN	O
water	NN	O
or	CC	O
soft	JJ	O
foods	NNS	O
(	(	O
such	JJ	O
as	IN	O
applesauce	NN	O
)	)	O
immediately	RB	O
before	IN	O
administration	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

V	NNP	O
=	VBD	O
1.5	CD	DOS
mL	NN	UNIT
/	CD	O
min	NN	O

In	IN	O
the	DT	O
above	JJ	O
solutions	NNS	O
with	IN	O
amikacin	JJ	O
sulfate	JJ	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
,	,	O
solutions	NNS	O
aged	VBD	O
for	IN	O
60	CD	PER
days	NNS	PER
at	IN	O
4°C	CD	O
and	CC	O
then	RB	O
stored	VBD	O
at	IN	O
25°C	CD	O
had	VBD	O
utility	NN	O
times	NNS	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

If	IN	O
erythema	JJ	O
occurs	NNS	O
,	,	O
follow	JJ	O
instructions	NNS	O
outlined	VBN	O
above	IN	O
in	IN	O
the	DT	O
procedures	NNS	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
skin	JJ	WHO
types	NNS	WHO
I	PRP	WHO
,	,	O
II	NNP	O
and	CC	O
III	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
drops	NNS	UNIT
in	IN	O
each	DT	O
eye	NN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
oral	JJ	O
solution	NN	O
can	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
tablets	NNS	O
on	IN	O
a	DT	O
mg	JJ	O
-	:	O
per	IN	O
-	:	O
mg	NN	O
basis	NN	O
up	RB	O
to	TO	O
the	DT	O
25	CD	DOS
mg	NN	UNIT
dose	JJ	O
level	NN	O
.	.	O

Amiloride	NNP	O
HCl	NNP	O
,	,	O
one	CD	DOS
5	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
daily	RB	FREQ
,	,	O
should	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
usual	JJ	O
antihypertensive	NN	O
or	CC	O
diuretic	JJ	O
dosage	NN	O
of	IN	O
a	DT	O
kaliuretic	JJ	O
diuretic	NN	O
.	.	O

Growth	NNP	O
hormone	NN	O
deficiency	NN	O
-	:	O
The	DT	O
recommended	JJ	O
weekly	JJ	FREQ
dose	NN	O
is	VBZ	O
0.18	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	VBD	O
to	TO	O
0.3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
0.90	CD	DOS
IU	NNP	UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
.	.	O

Adjust	NNP	O
dose	NN	O
at	IN	O
2	CD	O
week	NN	O
intervals	NNS	O
as	IN	O
needed	VBN	O
to	TO	O
achieve	VB	O
and	CC	O
maintain	VB	O
trough	JJ	O
concentrations	NNS	O
of	IN	O
5	CD	O
to	TO	O
15	CD	DOS
ng	NNS	UNIT
/	JJ	O
mL	JJ	O
[	NNP	O
see	VBP	O
Therapeutic	JJ	O
Drug	NNP	O
Monitoring	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
and	CC	O
Dose	NNP	O
Modifications	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
]	NNP	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
AMPYRA	NNP	O
is	VBZ	O
one	CD	DOS
10	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
,	,	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

Two	CD	DOS
to	TO	O
six	CD	DOS
inhalations	NNS	UNIT
of	IN	O
the	DT	O
vapors	NNS	O
from	IN	O
the	DT	O
capsule	NN	O
are	VBP	O
usually	RB	O
sufficient	JJ	O
to	TO	O
promptly	RB	O
produce	VB	O
therapeutic	JJ	O
effects	NNS	O
.	.	O

Aripiprazole	NNP	O
was	VBD	O
studied	VBN	O
in	IN	O
adolescent	JJ	WHO
patients	NNS	WHO
13	CD	WHO
to	TO	WHO
17	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
with	IN	WHO
schizophrenia	NN	WHO
at	IN	O
daily	JJ	FREQ
doses	NNS	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
and	CC	O
30	CD	DOS
mg	NN	UNIT
.	.	O

Apply	VB	O
one	CD	DOS
-	:	O
two	CD	DOS
drops	NNS	UNIT
of	IN	O
VEXOL®	NNP	O
1	CD	O
%	NN	O
Ophthalmic	NNP	O
Suspension	NNP	O
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
beginning	VBG	O
24	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
and	CC	O
continuing	VBG	O
throughout	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

The	DT	O
recommended	JJ	O
target	NN	O
dose	NN	O
of	IN	O
ABILIFY	NNP	O
is	VBZ	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
as	IN	O
monotherapy	NN	O
or	CC	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
with	IN	O
lithium	NN	O
or	CC	O
valproate	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
COMBIVENT®	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
is	VBZ	O
two	CD	DOS
inhalations	NNS	UNIT
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
initial	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
with	IN	O
leuprolide	JJ	O
acetate	NN	O
for	IN	O
depot	NN	O
suspension	NN	O
3.75	CD	DOS
mg	NN	UNIT
in	IN	O
combination	NN	O
with	IN	O
norethindrone	JJ	O
acetate	NN	O
5	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
is	VBZ	O
not	RB	O
to	TO	O
exceed	VB	O
six	CD	PER
months	NNS	PER
.	.	O

Children	NNP	WHO
weighing	VBG	WHO
100	CD	WHO
pounds	NNS	WHO
or	CC	WHO
more	JJR	WHO
should	MD	O
receive	VB	O
the	DT	O
adult	NN	WHO
dose	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
doxycycline	NN	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
(	(	O
administered	VBN	O
100	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
or	CC	O
50	CD	DOS
mg	NN	UNIT
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
100	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
;	:	O
or	CC	O
500	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Patients	NNS	WHO
well	RB	WHO
controlled	VBN	WHO
on	IN	O
0.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
or	CC	O
twice	VB	FREQ
a	DT	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
maintained	VBN	O
on	IN	O
this	DT	O
regimen	NNS	O
.	.	O

Store	NN	O
solution	NN	O
at	IN	O
20	CD	O
to	TO	O
25°C	CD	O
(	(	O
68	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

Experience	NN	O
with	IN	O
ACEON	NNP	O
is	VBZ	O
limited	VBN	O
in	IN	O
the	DT	O
elderly	JJ	O
at	IN	O
doses	NNS	O
exceeding	VBG	O
8	CD	DOS
mg	NN	UNIT
.	.	O

For	IN	O
intramuscular	JJ	O
(	(	O
IM	NNP	O
)	)	O
injection	NN	O
only	RB	O
,	,	O
by	IN	O
needle	JJ	O
and	CC	O
syringe	NN	O
(	(	O
5	CD	DOS
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
)	)	WHO
or	CC	O
by	IN	O
PharmaJet®	NNP	O
Stratis®	NNP	O
Needle	NNP	O
-	:	O
Free	JJ	O
Injection	NN	O
System	NNP	O
(	(	O
18	CD	O
through	IN	O
64	CD	O
years	NNS	O
of	IN	O
age	NN	O
)	)	O
.	.	O

(	(	O
2	CD	O
)	)	O

It	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
measure	VB	O
both	DT	O
peak	NN	O
and	CC	O
trough	JJ	O
serum	NN	O
concentrations	NNS	O
intermittently	RB	O
during	IN	O
therapy	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
Dose	NNP	O
Preparation	NNP	O
for	IN	O
Pediatric	NNP	O
Patients*	NNP	O

In	IN	O
patients	NNS	WHO
receiving	VBG	WHO
ritonavir	NN	WHO
for	IN	O
at	IN	O
least	JJS	O
one	CD	O
week	NN	O
,	,	O
start	VBP	O
ADCIRCA	NNP	O
at	IN	O
20	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

For	IN	O
adults	NNS	WHO
,	,	O
4	CD	DOS
drops	NNS	UNIT
of	IN	O
the	DT	O
suspension	NN	O
should	MD	O
be	VB	O
instilled	VBN	O
into	IN	O
the	DT	O
affected	JJ	O
ear	JJ	O
3	CD	FREQ
or	CC	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

A	DT	O
3.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
is	VBZ	O
too	RB	O
concentrated	JJ	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
less	RBR	WHO
than	IN	WHO
1	CD	WHO
year	NN	WHO
old	JJ	WHO
,	,	O
who	WP	O
generally	RB	O
require	VBP	O
a	DT	O
2.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
.	.	O

The	DT	O
amount	NN	O
usually	RB	O
administered	VBN	O
is	VBZ	O
500	CD	DOS
to	TO	O
1000	CD	DOS
mL	NN	UNIT
.	.	O

The	DT	O
recommended	JJ	O
target	NN	O
dose	NN	O
of	IN	O
aripiprazole	NN	O
is	VBZ	O
10	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

After	IN	O
at	IN	O
least	JJS	O
one	CD	O
week	NN	O
following	VBG	O
the	DT	O
initiation	NN	O
of	IN	O
ritonavir	NN	O
,	,	O
resume	VB	O
ADCIRCA	NNP	O
at	IN	O
20	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
for	IN	O
women	NNS	WHO
and	CC	O
either	DT	O
5	CD	DOS
or	CC	O
10	CD	DOS
mg	NN	UNIT
for	IN	O
men	NNS	WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	O
per	IN	O
night	NN	O
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7	CD	O
–	JJ	O
8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

The	DT	O
first	JJ	O
24	CD	O
-	:	O
hour	NN	O
dose	NN	O
may	MD	O
be	VB	O
individualized	VBN	O
for	IN	O
each	DT	O
patient	NN	O
;	:	O
however	RB	O
,	,	O
in	IN	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
,	,	O
mean	JJ	O
daily	JJ	FREQ
doses	NNS	O
above	IN	O
2100	CD	DOS
mg	NN	UNIT
were	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
hypotension	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
or	CC	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
Grade	NNP	WHO
A	NNP	WHO
or	CC	WHO
B	NNP	WHO
)	)	WHO
,	,	O
the	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2.5	CD	DOS
mg	NNS	UNIT
over	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
and	CC	O
a	DT	O
1	CD	DOS
-	:	O
mg	NN	O
starting	VBG	O
dose	NN	O
is	VBZ	O
recommended	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
to	TO	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
currently	RB	O
available	JJ	O
pharmacokinetic	JJ	O
data	NNS	O
do	VBP	O
not	RB	O
justify	VB	O
an	DT	O
absolute	JJ	O
recommendation	NN	O
on	IN	O
dosage	NN	O
reduction	NN	O
to	TO	O
those	DT	O
patients	NNS	O
,	,	O
but	CC	O
it	PRP	O
may	MD	O
be	VB	O
prudent	JJ	O
to	TO	O
use	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
initially	RB	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
ACTIQ	NNP	O
to	TO	O
treat	VB	O
episodes	NNS	O
of	IN	O
breakthrough	NN	O
cancer	NN	O
pain	NN	O
is	VBZ	O
always	RB	O
200	CD	DOS
mcg	NN	UNIT
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
ALESSE	NNP	O
(	(	O
levonorgestrel	NN	O
and	CC	O
ethinyl	VB	O
estradiol	NN	O
)	)	O
-	:	O
28	CD	O
is	VBZ	O
one	CD	DOS
pink	NN	UNIT
tablet	NN	UNIT
daily	RB	FREQ
for	IN	O
21	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
followed	VBN	O
by	IN	O
one	CD	DOS
lightgreen	NN	UNIT
inert	JJ	UNIT
tablet	NN	UNIT
daily	RB	FREQ
for	IN	O
7	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
according	VBG	O
to	TO	O
the	DT	O
prescribed	JJ	O
schedule	NN	O
.	.	O

The	DT	O
total	JJ	O
volume	NN	O
administered	VBD	O
should	MD	O
be	VB	O
adjusted	VBN	O
for	IN	O
patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
40	CD	WHO
kg	NNS	WHO
and	CC	O
for	IN	O
those	DT	O
requiring	VBG	O
fluid	JJ	O
restriction	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
already	RB	WHO
stable	JJ	WHO
on	IN	O
another	DT	O
oral	JJ	O
antipsychotic	NN	O
(	(	O
and	CC	O
known	VBN	O
to	TO	O
tolerate	VB	O
aripiprazole	NN	O
)	)	O
,	,	O
after	IN	O
the	DT	O
first	JJ	O
ABILIFY	NNP	O
MAINTENA	NNP	O
injection	NN	O
,	,	O
continue	VBP	O
treatment	NN	O
with	IN	O
the	DT	O
antipsychotic	JJ	O
for	IN	O
14	CD	PER
consecutive	JJ	PER
days	NNS	PER
to	TO	O
maintain	VB	O
therapeutic	JJ	O
antipsychotic	JJ	O
concentrations	NNS	O
during	IN	O
initiation	NN	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
in	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
achieve	VB	WHO
optimal	JJ	WHO
control	NN	WHO
of	IN	WHO
tics	NNS	WHO
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
total	JJ	O
bilirubin	NN	O
greater	JJR	O
than	IN	O
ULN	NNP	O
and	CC	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
1.5	CD	O
x	NNS	O
ULN	NNP	O
and	CC	O
aspartate	JJ	O
aminotransferase	NN	O
[	NNP	O
AST	NNP	O
]	NNP	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
10	CD	O
x	NNP	O
ULN	NNP	O
)	)	O
,	,	O
no	DT	O
dose	JJ	O
adjustments	NNS	O
are	VBP	O
required	VBN	O
,	,	O
regardless	RB	O
of	IN	O
indication	NN	O
.	.	O

It	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
try	VB	O
to	TO	O
maintain	VB	O
a	DT	O
significant	JJ	O
degree	NN	O
of	IN	O
bone	NN	O
marrow	NN	O
depression	NN	O
so	RB	O
as	IN	O
to	TO	O
keep	VB	O
the	DT	O
leukocyte	NN	O
count	NN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
3000	CD	DOS
to	TO	O
3500	CD	DOS
cells	NNS	UNIT
/	JJ	O
mcL	NN	O
.	.	O

If	IN	O
more	JJR	O
than	IN	O
one	CD	O
topical	JJ	O
ophthalmic	JJ	O
product	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
,	,	O
the	DT	O
different	JJ	O
products	NNS	O
should	MD	O
be	VB	O
instilled	VBN	O
at	IN	O
least	JJS	O
5	CD	O
minutes	NNS	O
apart	RB	O
.	.	O

Actonel	NNP	O
with	IN	O
Calcium	NNP	O
(	(	O
risedronate	VB	O
sodium	NN	O
with	IN	O
calcium	NN	O
carbonate	NN	O
)	)	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Altoprev	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Postmarketing	VBG	O
experience	NN	O
suggests	VBZ	O
that	IN	O
elderly	JJ	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
at	IN	O
greater	JJR	O
risk	NN	O
for	IN	O
complications	NNS	O
of	IN	O
constipation	NN	O
;	:	O
therefore	RB	O
,	,	O
appropriate	JJ	O
caution	NN	O
and	CC	O
follow	VB	O
-	:	O
up	RP	O
should	MD	O
be	VB	O
exercised	VBN	O
if	IN	O
alosetron	JJ	O
hydrochloride	NN	O
tablets	NNS	O
are	VBP	O
prescribed	VBN	O
for	IN	O
these	DT	WHO
patients	NNS	WHO
[	VBP	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

(	(	O
120	CD	DOS
mL	NN	UNIT
)	)	O
of	IN	O
water	NN	O
or	CC	O
apple	NN	O
juice	NN	O
.	.	O

A	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Zonalon	NNP	O
(	(	O
doxepin	NN	O
)	)	O
Cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
four	CD	FREQ
times	NNS	FREQ
each	DT	FREQ
day	NN	FREQ
with	IN	O
at	IN	O
least	JJS	O
a	DT	O
3	CD	O
to	TO	O
4	CD	O
hour	NN	O
interval	NN	O
between	IN	O
applications	NNS	O
.	.	O

If	IN	O
the	DT	O
5	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
is	VBZ	O
not	RB	O
effective	JJ	O
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	DOS
mg	NNS	UNIT
.	.	O

No	DT	O
additional	JJ	O
benefit	NN	O
was	VBD	O
demonstrated	VBN	O
at	IN	O
doses	NNS	O
greater	JJR	O
than	IN	O
10	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
and	CC	O
adverse	JJ	O
reactions	NNS	O
and	CC	O
discontinuations	NNS	O
because	IN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
more	RBR	O
frequent	JJ	O
at	IN	O
higher	JJR	O
doses	NNS	O
[	VBP	O
see	VB	O
FDA	NNP	O
-	:	O
Approved	VBD	O
PATIENT	NNP	O
INFORMATION	NNP	O
for	IN	O
complete	JJ	O
“	NNP	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
”	NNP	O
]	NNP	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
titration	NN	O
should	MD	O
proceed	VB	O
over	IN	O
a	DT	O
7	CD	PER
to	TO	O
14	CD	PER
day	NN	PER
period	NN	O
starting	VBG	O
with	IN	O
30	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
tolerate	VB	WHO
25	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
may	MD	O
have	VB	O
their	PRP$	O
dosage	NN	O
reduced	VBN	O
to	TO	O
25	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
DUEXIS	NNP	O
(	(	O
ibuprofen	NN	O
and	CC	O
famotidine	NN	O
)	)	O
800	CD	DOS
mg	NN	UNIT
/	VBD	O
26.6	CD	DOS
mg	NN	UNIT
is	VBZ	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
administered	VBN	O
orally	RB	O
three	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Dosage	NN	O
and	CC	O
Duration	NNP	O
of	IN	O
ACIPHEX	NNP	O
Delayed	NNP	O
-	:	O
Release	NNP	O
Tablets	NNPS	O
in	IN	O
Adults	NNP	WHO
and	CC	WHO
Adolescents	NNP	WHO
12	CD	WHO
Years	NNS	WHO
of	IN	WHO
Age	NNP	WHO
and	CC	WHO
Older	JJR	WHO

Patients	NNS	WHO
whose	WP$	WHO
blood	NN	WHO
pressures	NNS	WHO
are	VBP	WHO
not	RB	WHO
adequately	RB	WHO
controlled	VBN	WHO
with	IN	WHO
quinapril	JJ	WHO
monotherapy	NN	WHO
may	MD	O
instead	RB	O
be	VB	O
given	VBN	O
ACCURETIC	NNP	O
10	CD	O
/	NNP	O
12.5	CD	O
or	CC	O
20	CD	O
/	JJ	O
12.5	CD	O
.	.	O

The	DT	O
daily	JJ	FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	WHO
adult	NN	WHO
patient	NN	WHO
,	,	WHO
not	RB	WHO
hypermetabolic	JJ	WHO
,	,	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
and	CC	WHO
with	IN	WHO
restricted	JJ	WHO
physical	JJ	WHO
activity	NN	WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	DOS
to	TO	O
18	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
and	CC	O
between	IN	O
2500	CD	DOS
and	CC	O
3000	CD	DOS
mL	NN	UNIT
of	IN	O
fluids	NNS	O
.	.	O

If	IN	O
at	IN	O
any	DT	O
time	NN	O
,	,	O
the	DT	O
patient	NN	O
has	VBZ	O
symptoms	NNS	O
of	IN	O
hypotension	NN	O
,	,	O
decrease	VB	O
the	DT	O
dosage	NN	O
by	IN	O
0.5	CD	DOS
mg	NNS	UNIT
taken	VBN	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Therapy	NN	O
with	IN	O
NIASPAN	NNP	O
must	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
500mg	CD	O
at	IN	O
bedtime	NN	O
in	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
side	NN	O
effects	NNS	O
which	WDT	O
may	MD	O
occur	VB	O
during	IN	O
early	JJ	O
therapy	NN	O
.	.	O

Energy	NNP	O
requirements	NNS	O
for	IN	O
children	NNS	WHO
between	IN	WHO
1	CD	WHO
and	CC	WHO
7	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
are	VBP	O
approximately	RB	O
75	CD	O
to	TO	O
90	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
for	IN	O
children	NNS	WHO
7	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
60	CD	O
to	TO	O
75	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
and	CC	O
for	IN	O
ages	NNS	WHO
12	CD	WHO
to	TO	WHO
18	CD	WHO
years	NNS	WHO
,	,	O
30	CD	O
to	TO	O
60	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
brucellosis	NN	O
,	,	O
500	CD	DOS
mg	NN	UNIT
Achromycin	NNP	O
V	NNP	O
(	(	O
Tetracycline	NNP	O
HCl	NNP	O
Capsules	NNP	O
,	,	O
USP	NNP	O
)	)	O
q.i.d	NN	O
.	.	O

The	DT	O
dose	JJ	O
counter	NN	O
window	NN	O
displays	VBZ	O
the	DT	O
number	NN	O
of	IN	O
actuations	NNS	O
(	(	O
inhalations	NNS	O
)	)	O
left	VBD	O
in	IN	O
the	DT	O
inhaler	NN	O
in	IN	O
units	NNS	O
of	IN	O
two	CD	O
(	(	O
e.g	NN	O
,	,	O
60	CD	O
,	,	O
58	CD	O
,	,	O
56	CD	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
irritability	NN	WHO
associated	VBN	WHO
with	IN	WHO
autistic	JJ	WHO
disorder	NN	WHO
is	VBZ	O
5	CD	DOS
to	TO	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Peak	JJ	O
concentrations	NNS	O
(	(	O
30	CD	O
to	TO	O
90	CD	O
minutes	NNS	O
after	IN	O
injection	NN	O
)	)	O
above	IN	O
35	CD	DOS
micrograms	NNS	UNIT
per	IN	O
mL	NN	O
and	CC	O
trough	JJ	O
concentrations	NNS	O
(	(	O
just	RB	O
prior	RB	O
to	TO	O
the	DT	O
next	JJ	O
dose	NN	O
)	)	O
above	IN	O
10	CD	DOS
micrograms	NNS	UNIT
per	IN	O
mL	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

Amiodarone	NNP	O
HCl	NNP	O
injection	NN	O
concentrations	NNS	O
greater	JJR	O
than	IN	O
3	CD	DOS
mg	JJ	UNIT
/	NNP	O
mL	NN	O
in	IN	O
D5W	NNP	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
a	DT	O
high	JJ	O
incidence	NN	O
of	IN	O
peripheral	JJ	O
vein	NN	O
phlebitis	NN	O
;	:	O
however	RB	O
,	,	O
concentrations	NNS	O
of	IN	O
2.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
or	CC	O
less	JJR	O
appear	JJ	O
to	TO	O
be	VB	O
less	JJR	O
irritating	NN	O
.	.	O

d.	NN	O
For	IN	O
patients	NNS	WHO
converting	VBG	WHO
from	IN	WHO
Actiq	NNP	WHO
doses	NNS	WHO
of	IN	O
1200	CD	DOS
and	CC	O
1600	CD	DOS
mcg	NN	UNIT
,	,	O
initiate	JJ	O
titration	NN	O
with	IN	O
200	CD	DOS
mcg	NNS	UNIT
and	CC	O
400	CD	DOS
mcg	JJ	UNIT
Abstral	NNP	O
,	,	O
respectively	RB	O
and	CC	O
proceed	VB	O
using	VBG	O
multiples	NNS	O
of	IN	O
this	DT	O
strength	NN	O
.	.	O

After	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
,	,	O
the	DT	O
maintenance	NN	O
infusion	NN	O
rate	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
min	NN	O
(	(	O
720	CD	DOS
mg	NN	UNIT
/	VBD	O
24	CD	O
hours	NNS	O
)	)	O
should	MD	O
be	VB	O
continued	VBN	O
utilizing	VBG	O
a	DT	O
concentration	NN	O
of	IN	O
1	CD	DOS
to	TO	O
6	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
(	(	O
amiodarone	JJ	O
HCl	NNP	O
injection	NN	O
concentrations	NNS	O
greater	JJR	O
than	IN	O
2	CD	DOS
mg	JJ	UNIT
/	NNP	O
mL	NN	O
should	MD	O
be	VB	O
administered	VBN	O
via	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
)	)	O
.	.	O

A	DT	O
5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
is	VBZ	O
too	RB	O
concentrated	JJ	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
one	CD	WHO
year	NN	WHO
old	JJ	WHO
,	,	O
who	WP	O
generally	RB	O
receive	VBP	O
a	DT	O
2	CD	O
to	TO	O
2.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
.	.	O

Exogenous	JJ	O
Obesity	NN	O
:	:	O
One	CD	DOS
capsule	NN	UNIT
at	IN	O
approximately	RB	O
2	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
for	IN	O
appetite	JJ	O
control	NN	O
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
Sumavel	NNP	O
DosePro	NNP	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
or	CC	O
cluster	NN	O
headache	NN	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
given	VBN	O
subcutaneously	RB	O
.	.	O

At	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
the	DT	O
ACTH	NNP	O
and	CC	O
cortisol	JJ	O
responses	NNS	O
to	TO	O
ACTHREL®	NNP	O
are	VBP	O
prolonged	VBN	O
and	CC	O
remain	VBP	O
elevated	VBN	O
for	IN	O
up	RB	O
to	TO	O
2	CD	O
hours	NNS	O
.	.	O

Instruct	NN	O
patients	NNS	O
not	RB	O
to	TO	O
use	VB	O
more	JJR	O
than	IN	O
4	CD	DOS
tablets	NNS	UNIT
at	IN	O
one	CD	O
time	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
and	CC	O
maintenance	NN	O
dose	NN	O
of	IN	O
ABILIFY	NNP	O
MAINTENA	NNP	O
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
monthly	RB	FREQ
(	(	O
no	DT	O
sooner	NN	O
than	IN	O
26	CD	O
days	NNS	O
after	IN	O
the	DT	O
previous	JJ	O
injection	NN	O
)	)	O
.	.	O

After	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
hyperaldosteronism	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
by	IN	O
more	RBR	O
definitive	JJ	O
testing	NN	O
procedures	NNS	O
,	,	O
ALDACTONE	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
in	IN	O
doses	NNS	O
of	IN	O
100	CD	DOS
to	TO	O
400	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
in	IN	O
preparation	NN	O
for	IN	O
surgery	NN	O
.	.	O

Lower	JJR	O
concentrations	NNS	O
(	(	O
0.2	CD	DOS
to	TO	O
0.5	CD	DOS
mg	NNS	UNIT
/	NNP	O
mL	NN	O
)	)	O
may	MD	O
be	VB	O
appropriate	JJ	O
for	IN	O
infants	NNS	WHO
and	CC	WHO
small	JJ	WHO
children	NNS	WHO
to	TO	O
provide	VB	O
sufficient	JJ	O
volume	NN	O
for	IN	O
infusion	NN	O
.	.	O

The	DT	O
maximum	JJ	O
dosage	NN	O
is	VBZ	O
65	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBD	O
or	CC	O
3	CD	DOS
g	JJ	UNIT
daily	RB	FREQ
,	,	O
whichever	WP	O
is	VBZ	O
less	JJR	O
.	.	O

The	DT	O
recommended	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
for	IN	O
patients	NNS	WHO
previously	RB	WHO
untreated	VBN	WHO
with	IN	WHO
interferon	NN	WHO
is	VBZ	O
24	CD	O
to	TO	O
48	CD	O
weeks	NNS	O
.	.	O

Revised	VBN	O
:	:	O
Jul	NN	O
2014	CD	O

AFREZZA	NNP	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
chronic	JJ	WHO
lung	NN	WHO
disease	NN	WHO
because	IN	O
of	IN	O
the	DT	O
risk	NN	O
of	IN	O
acute	JJ	O
bronchospasm	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

The	DT	O
recommended	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
1000	CD	DOS
mg	NN	UNIT
(	(	O
two	CD	DOS
500	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
)	)	O
to	TO	O
2000	CD	DOS
mg	NN	UNIT
(	(	O
two	CD	DOS
1000	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
or	CC	O
four	CD	DOS
500	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
bedtime	NN	O
.	.	O

(	(	O
5	CD	O
)	)	O
Door	NNP	O
and	CC	O
latches	NNS	O
:	:	O
Patients	NNS	O
should	MD	O
be	VB	O
able	JJ	O
to	TO	O
open	VB	O
the	DT	O
door	NN	O
from	IN	O
the	DT	O
inside	NN	O
with	IN	O
only	JJ	O
slight	JJ	O
pressure	NN	O
to	TO	O
the	DT	O
door	NN	O
.	.	O

Activella	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
to	TO	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
for	IN	O
use	NN	O
in	IN	O
combination	NN	O
with	IN	O
ritonavir	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

Doses	NNS	O
greater	JJR	O
than	IN	O
12	CD	DOS
mg	NNS	UNIT
are	VBP	O
not	RB	O
recommended	VBN	O
for	IN	O
adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

Infants	NNS	WHO
should	MD	O
receive	VB	O
a	DT	O
1	CD	O
to	TO	O
2	CD	O
hour	NN	O
infusion	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
heart	NN	WHO
failure	NN	WHO
and	CC	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
ACCUPRIL	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
in	IN	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
creatinine	JJ	WHO
clearance	NN	WHO
above	IN	WHO
30	CD	DOS
mL	NNS	UNIT
/	JJ	O
min	NN	O
and	CC	O
2.5	CD	DOS
mg	NNS	UNIT
in	IN	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
creatinine	JJ	WHO
clearance	NN	WHO
of	IN	WHO
10	CD	DOS
to	TO	O
30	CD	DOS
mL	NNS	UNIT
/	JJ	O
min	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Incremental	JJ	O
Rates	NNS	O
for	IN	O
100	CD	DOS
mL	NNS	UNIT
ALDURAZYME®	NNP	O
Infusion	NNP	O
(	(	O
For	IN	O
use	NN	O
with	IN	O
Patients	NNS	WHO
Weighing	VBG	WHO
20	CD	WHO
kg	NN	WHO
or	CC	WHO
Less	NNP	WHO
)	)	WHO

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
parenteral	JJ	O
administration	NN	O
of	IN	O
a	DT	O
solution	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	JJ	O
requires	VBZ	O
an	DT	O
accurate	JJ	O
estimate	NN	O
of	IN	O
the	DT	O
total	JJ	O
fluid	NN	O
,	,	O
electrolyte	NN	O
and	CC	O
acid	JJ	O
-	:	O
base	NN	O
needs	VBZ	O
to	TO	O
compensate	VB	O
for	IN	O
the	DT	O
patient	NN	O
's	POS	O
measurable	JJ	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
i.e	FW	O
,	,	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
daily	JJ	FREQ
losses	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
of	IN	O
AKYNZEO	NNP	O
administered	VBD	O
approximately	RB	O
1	CD	O
hour	NN	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
chemotherapy	NN	O
with	IN	O
dexamethasone	NN	O
12	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
chemotherapy	VB	O
on	IN	O
day	NN	O
1	CD	O
and	CC	O
8	CD	DOS
mg	NNS	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
on	IN	O
days	NNS	O
2	CD	O
to	TO	O
4	CD	O
[	NNS	O
see	VBP	O
Clinical	JJ	O
Studies	NNS	O
,	,	O
Table	JJ	O
5	CD	O
]	NN	O
.	.	O

While	IN	O
there	EX	O
are	VBP	O
no	DT	O
systematic	JJ	O
studies	NNS	O
that	WDT	O
answer	VBP	O
the	DT	O
question	NN	O
of	IN	O
how	WRB	O
long	JJ	O
to	TO	O
continue	VB	O
Anafranil	NNP	O
,	,	O
OCD	NNP	O
is	VBZ	O
a	DT	O
chronic	JJ	O
condition	NN	O
and	CC	O
it	PRP	O
is	VBZ	O
reasonable	JJ	O
to	TO	O
consider	VB	O
continuation	NN	O
for	IN	O
a	DT	O
responding	JJ	WHO
patient	NN	WHO
.	.	O

Average	JJ	O
dosage	NN	O
is	VBZ	O
20	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

Caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
administering	VBG	O
ALIMTA	NNP	O
concurrently	RB	O
with	IN	O
NSAIDs	NNP	O
to	TO	O
patients	NNS	WHO
whose	WP$	WHO
creatinine	JJ	WHO
clearance	NN	WHO
is	VBZ	WHO
<	JJ	WHO
80	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
dosage	NN	O
employed	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
simple	NN	O
(	(	O
open	JJ	O
-	:	O
angle	NN	O
)	)	O
glaucoma	NN	O
ranges	VBZ	O
from	IN	O
250	CD	DOS
mg	NNS	UNIT
to	TO	O
1	CD	DOS
g	NN	UNIT
of	IN	O
acetazolamide	JJ	O
per	IN	O
24	CD	O
hours	NNS	O
,	,	O
usually	RB	O
in	IN	O
divided	JJ	O
doses	NNS	O
for	IN	O
amounts	NNS	O
over	IN	O
250	CD	DOS
mg	NNS	UNIT
.	.	O

For	IN	O
convenience	NN	O
,	,	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
adequately	RB	WHO
treated	VBN	WHO
with	IN	O
20	CD	DOS
mg	NNS	UNIT
of	IN	O
quinapril	NN	O
and	CC	O
25	CD	DOS
mg	NN	UNIT
of	IN	O
hydrochlorothiazide	NN	O
and	CC	O
experience	NN	O
no	DT	O
significant	JJ	O
electrolyte	NN	O
disturbances	NNS	O
may	MD	O
instead	RB	O
wish	VB	O
to	TO	O
receive	VB	O
ACCURETIC	NNP	O
20	CD	O
/	NN	O
25	CD	O
.	.	O

Do	NNP	O
not	RB	O
exceed	VB	O
not	RB	O
exceed	VB	O
6	CD	DOS
tablets	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

For	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
larger	JJR	WHO
than	IN	WHO
10	CD	WHO
kg	NN	WHO
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
should	MD	O
be	VB	O
up	RB	O
to	TO	O
25	CD	DOS
g	NN	UNIT
amino	NN	O
acids	NNS	O
/	VBP	FREQ
day	NN	FREQ
for	IN	O
the	DT	O
first	JJ	O
10	CD	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
plus	CC	O
1	CD	DOS
to	TO	O
1.25	CD	DOS
g	NN	UNIT
amino	NN	O
acid	NN	O
for	IN	O
each	DT	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
over	IN	O
10	CD	O
kg	NNS	O
.	.	O

In	IN	O
the	DT	O
above	JJ	O
solutions	NNS	O
with	IN	O
amikacin	JJ	O
sulfate	JJ	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
5.0	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
,	,	O
solutions	NNS	O
aged	VBD	O
for	IN	O
60	CD	PER
days	NNS	PER
at	IN	O
4°C	CD	O
and	CC	O
then	RB	O
stored	VBD	O
at	IN	O
25°C	CD	O
had	VBD	O
utility	NN	O
times	NNS	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

Patients	NNS	WHO
previously	RB	WHO
receiving	VBG	WHO
other	JJ	WHO
niacin	JJ	WHO
products	NNS	WHO
should	MD	O
be	VB	O
started	VBN	O
with	IN	O
the	DT	O
recommended	VBN	O
NIASPAN	NNP	O
titration	NN	O
schedule	NN	O
(	(	O
see	VB	O
Table	NNP	O
11	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
subsequently	RB	O
be	VB	O
individualized	VBN	O
based	VBN	O
on	IN	O
patient	JJ	O
response	NN	O
.	.	O

The	DT	O
daily	JJ	FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	WHO
adult	NN	WHO
patient	NN	WHO
,	,	WHO
not	RB	WHO
hypermetabolic	JJ	WHO
,	,	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
and	CC	WHO
with	IN	WHO
restricted	JJ	WHO
physical	JJ	WHO
activity	NN	WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	DOS
to	TO	O
18	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1.0	CD	DOS
to	TO	O
1.5	CD	DOS
g	NN	UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	DOS
and	CC	O
3000	CD	DOS
mL	NN	UNIT
of	IN	O
fluids	NNS	O
.	.	O

For	IN	O
doses	NNS	O
above	IN	O
24	CD	DOS
units	NNS	UNIT
,	,	O
combinations	NNS	O
of	IN	O
different	JJ	O
multiple	JJ	O
cartridges	NNS	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O

Oxygen	NN	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
but	CC	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
usual	JJ	O
precautions	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
respiratory	NN	WHO
disease	NN	WHO
and	CC	O
CO2	NNP	O
retention	NN	O
.	.	O

Dilute	NNP	O
1	CD	DOS
mL	NN	UNIT
of	IN	O
Adrenalin®	NNP	O
1	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O
(	(	O
1:1000	CD	O
)	)	O
in	IN	O
100	CD	DOS
to	TO	O
1000	CD	DOS
mL	NN	UNIT
of	IN	O
an	DT	O
ophthalmic	JJ	O
irrigation	NN	O
fluid	NN	O
to	TO	O
create	VB	O
an	DT	O
epinephrine	JJ	O
concentration	NN	O
of	IN	O
1:100,000	CD	O
to	TO	O
1:1,000,000	CD	O
(	(	O
10	CD	DOS
mcg	NN	UNIT
/	NN	O
mL	NN	O
to	TO	O
1	CD	DOS
mcg	NNS	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Instruct	IN	O
the	DT	O
patient	NN	O
to	TO	O
remove	VB	O
the	DT	O
mouthpiece	NN	O
from	IN	O
the	DT	O
mouth	NN	O
and	CC	O
hold	VB	O
the	DT	O
breath	NN	O
for	IN	O
as	RB	O
long	RB	O
as	IN	O
possible	JJ	O
,	,	O
up	RB	O
to	TO	O
10	CD	O
seconds	NNS	O
(	(	O
see	VB	O
Figure	NNP	O
6	CD	O
)	)	O
.	.	O

Each	DT	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
contains	VBZ	O
:	:	O

Figures	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
provide	NN	O
examples	NNS	O
of	IN	O
negative	JJ	O
and	CC	O
positive	JJ	O
scans	NNS	O
.	.	O

AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
dosing	NN	O
is	VBZ	O
based	VBN	O
upon	IN	O
the	DT	O
radioactivity	NN	O
determined	VBD	O
using	VBG	O
a	DT	O
suitable	JJ	O
calibration	NN	O
system	NN	O
immediately	RB	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
prescribed	VBN	O
an	DT	O
initial	JJ	O
titration	NN	O
supply	NN	O
of	IN	O
six	CD	O
200	CD	DOS
mcg	NNS	UNIT
ACTIQ	NNP	O
units	NNS	O
,	,	O
thus	RB	O
limiting	VBG	O
the	DT	O
number	NN	O
of	IN	O
units	NNS	O
in	IN	O
the	DT	O
home	NN	O
during	IN	O
titration	NN	O
.	.	O

In	IN	O
such	JJ	O
cases	NNS	O
,	,	O
4000	CD	O
calories	NNS	O
and	CC	O
25	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
or	CC	O
more	JJR	O
may	MD	O
be	VB	O
required	VBN	O
daily	RB	FREQ
to	TO	O
achieve	VB	O
nitrogen	NN	O
balance	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AGGRENOX	NNP	O
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
given	VBN	O
orally	RB	O
twice	JJ	FREQ
daily	RB	FREQ
,	,	O
one	CD	DOS
in	IN	O
the	DT	O
morning	NN	O
and	CC	O
one	CD	DOS
in	IN	O
the	DT	O
evening	NN	O
.	.	O

During	IN	O
titration	NN	O
,	,	O
patients	NNS	O
can	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
use	VB	O
multiples	NNS	O
of	IN	O
100	CD	DOS
mcg	JJ	UNIT
tablets	NNS	UNIT
and	CC	O
/	NNP	O
or	CC	O
200	CD	DOS
mcg	JJ	UNIT
tablets	NNS	UNIT
for	IN	O
any	DT	O
single	JJ	O
dose	NN	O
.	.	O

Application	NNP	O
area	NN	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	DOS
cm²	NNS	UNIT
and	CC	O
no	DT	O
more	JJR	O
than	IN	O
2	CD	DOS
grams	NNS	UNIT
of	IN	O
AMELUZ	NNP	O
(	(	O
one	CD	DOS
tube	NN	UNIT
)	)	O
should	MD	O
be	VB	O
used	VBN	O
at	IN	O
one	CD	O
time	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Acetadote	NNP	O
recommended	VBD	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
15000	CD	DOS
mg	NNS	UNIT
infused	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
one	CD	O
hour	NN	O
followed	VBN	O
by	IN	O
a	DT	O
first	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
5000	CD	DOS
mg	NN	UNIT
over	IN	O
4	CD	O
hours	NNS	O
and	CC	O
a	DT	O
second	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
10000	CD	DOS
mg	NN	UNIT
over	IN	O
16	CD	O
hours	NNS	O
(	(	O
See	VB	O
Table	NNP	O
3	CD	O
)	)	O
.	.	O

For	IN	O
Grade	NNP	O
3	CD	O
sensory	NN	O
neuropathy	JJ	O
hold	NN	O
treatment	NN	O
until	IN	O
resolution	NN	O
to	TO	O
Grade	VB	O
1	CD	O
or	CC	O
2	CD	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
dose	JJ	O
reduction	NN	O
for	IN	O
all	DT	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
ABRAXANE	NNP	O
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
,	,	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

Typically	RB	O
,	,	O
the	DT	O
8.5	CD	O
%	NN	O
solution	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
equal	JJ	O
volume	NN	O
with	IN	O
50	CD	O
%	NN	O
or	CC	O
70	CD	O
%	NN	O
dextrose	NN	O
to	TO	O
provide	VB	O
an	DT	O
admixture	NN	O
containing	VBG	O
4.25	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
and	CC	O
25	CD	O
%	NN	O
or	CC	O
35	CD	O
%	NN	O
dextrose	JJ	O
respectively	RB	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TECENTRIQ	NNP	O
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	FREQ
3	CD	FREQ
weeks	NNS	FREQ
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

for	IN	O
three	CD	PER
weeks	NNS	PER
should	MD	O
be	VB	O
accompanied	VBN	O
by	IN	O
streptomycin	NN	O
,	,	O
1	CD	DOS
gram	NN	UNIT
intramuscularly	JJ	O
twice	RB	FREQ
daily	RB	FREQ
the	DT	O
first	JJ	O
week	NN	O
and	CC	O
once	RB	FREQ
daily	JJ	FREQ
the	DT	O
second	JJ	O
week	NN	O
.	.	O

After	IN	O
dilution	NN	O
in	IN	O
an	DT	O
ophthalmic	JJ	O
irrigating	NN	O
fluid	NN	O
,	,	O
Adrenalin®	NNP	O
may	MD	O
also	RB	O
be	VB	O
injected	VBN	O
intracamerally	RB	O
as	IN	O
a	DT	O
bolus	NN	O
dose	NN	O
of	IN	O
0.1	CD	DOS
mL	NN	UNIT
at	IN	O
a	DT	O
dilution	NN	O
of	IN	O
1:100,000	CD	O
to	TO	O
1:400,000	CD	O
(	(	O
10	CD	DOS
mcg	NN	UNIT
/	NN	O
mL	NN	O
to	TO	O
2.5	CD	DOS
mcg	NNS	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
fluid	JJ	WHO
restrictions	NNS	WHO
may	MD	O
only	RB	O
tolerate	VB	O
1	CD	O
to	TO	O
2	CD	O
liters	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACULAR®	NNP	O
ophthalmic	JJ	O
solution	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
for	IN	O
relief	NN	O
of	IN	O
ocular	JJ	O
itching	VBG	O
due	JJ	O
to	TO	O
seasonal	JJ	O
allergic	JJ	O
conjunctivitis	NN	O
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
overdosing	VBG	O
during	IN	O
titration	NN	O
,	,	O
patients	NNS	O
should	MD	O
have	VB	O
only	RB	O
one	CD	DOS
strength	NN	UNIT
of	IN	O
ACTIQ	NNP	O
available	JJ	O
at	IN	O
any	DT	O
one	CD	O
time	NN	O
.	.	O

Diagnostic	JJ	O
Bronchograms	NNS	O
:	:	O
For	IN	O
diagnostic	JJ	O
bronchial	JJ	O
studies	NNS	O
,	,	O
2	CD	DOS
or	CC	O
3	CD	DOS
administrations	NNS	UNIT
of	IN	O
1	CD	DOS
to	TO	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
solution	NN	O
or	CC	O
2	CD	DOS
to	TO	O
4	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
should	MD	O
be	VB	O
given	VBN	O
by	IN	O
nebulization	NN	O
or	CC	O
by	IN	O
instillation	NN	O
intratracheally	RB	O
,	,	O
prior	RB	O
to	TO	O
the	DT	O
procedure	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
50	CD	WHO
kg	NNS	WHO
,	,	O
dosing	VBG	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
with	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
after	IN	O
2	CD	O
days	NNS	O
.	.	O

If	IN	O
the	DT	O
dose	NN	O
requires	VBZ	O
more	JJR	O
than	IN	O
one	CD	DOS
vial	NN	UNIT
of	IN	O
ADYNOVATE	NNP	O
,	,	O
reconstitute	VB	O
each	DT	O
vial	NN	O
using	VBG	O
the	DT	O
above	JJ	O
steps	NNS	O
.	.	O

The	DT	O
bottom	JJ	O
two	CD	O
arrows	NNS	O
indicate	VBP	O
areas	NNS	O
of	IN	O
decreased	JJ	O
gray	JJ	O
-	:	O
white	JJ	O
contrast	NN	O
with	IN	O
increased	JJ	O
cortical	JJ	O
radioactivity	NN	O
that	WDT	O
is	VBZ	O
comparable	JJ	O
to	TO	O
the	DT	O
radioactivity	NN	O
in	IN	O
the	DT	O
adjacent	JJ	O
white	JJ	O
matter	NN	O
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
Xiidra	NNP	O
twice	RB	FREQ
daily	RB	FREQ
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
into	IN	O
each	DT	O
eye	NN	O
using	VBG	O
a	DT	O
single	JJ	DOS
-	:	O
use	NN	O
container	NN	O
.	.	O

Administration	NN	O
of	IN	O
Permax	NNP	O
(	(	O
pergolide	JJ	O
mesylate	NN	O
)	)	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
a	DT	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
0.05	CD	DOS
mg	NN	UNIT
for	IN	O
the	DT	O
first	JJ	O
2	CD	O
days	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Amnesteem	NNP	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	O
to	TO	O
20	CD	O
weeks	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
20	CD	DOS
-	:	O
60	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
in	IN	O
single	JJ	O
doses	NNS	O
taken	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
post	NN	WHO
-	:	WHO
infarction	NN	WHO
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
shown	VBN	WHO
signs	NNS	WHO
of	IN	WHO
congestive	JJ	WHO
failure	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
2.5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
5	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
)	)	O
.	.	O

ALOXI	NNP	O
is	VBZ	O
supplied	VBN	O
ready	JJ	O
for	IN	O
intravenous	JJ	O
administration	NN	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
0.05	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
(	(	O
50	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Parkinson	NNP	O
's	POS	O
Disease	NN	O
:	:	O
Oral	JJ	O
:	:	O
The	DT	O
usual	JJ	O
beginning	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
three	CD	FREQ
or	CC	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Treatment	NN	O
of	IN	O
patients	NNS	WHO
in	IN	WHO
the	DT	WHO
heavier	JJR	WHO
weight	JJ	WHO
classes	NNS	WHO
should	MD	O
not	RB	O
exceed	VB	O
1.5	CD	DOS
gram	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Severe	JJ	O
Infections	NNS	O
:	:	O
4	CD	DOS
tablets	NNS	UNIT
(	(	O
2	CD	DOS
g	NN	UNIT
)	)	O
initially	RB	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	DOS
tablets	NNS	UNIT
(	(	O
1	CD	DOS
g	NN	UNIT
)	)	O
three	CD	FREQ
times	NNS	FREQ
daily	JJ	FREQ
thereafter	RB	O
.	.	O

If	IN	O
after	IN	O
4	CD	O
weeks	NNS	O
the	DT	O
dosage	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
but	CC	O
does	VBZ	O
not	RB	O
adequately	RB	O
control	VB	O
IBS	NNP	O
symptoms	NNS	O
,	,	O
then	RB	O
the	DT	O
dosage	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
up	RB	O
to	TO	O
1	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
ACCUPRIL	NNP	O
in	IN	O
patients	NNS	WHO
not	RB	WHO
on	IN	WHO
diuretics	NNS	WHO
is	VBZ	O
10	CD	DOS
or	CC	O
20	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

ACEON	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
<	VBD	WHO
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
severely	RB	WHO
impaired	JJ	WHO
hepatic	JJ	WHO
function	NN	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
Class	NNP	WHO
C	NNP	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
8	CD	DOS
mcg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
maximum	JJ	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
400	CD	DOS
mcg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
dosage	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
with	IN	O
the	DT	O
dose	NN	O
titrated	VBD	O
upward	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
8	CD	DOS
tablets	NNS	UNIT
(	(	O
16	CD	DOS
mg	NN	UNIT
)	)	O
per	IN	O
24	CD	O
hours	NNS	O
.	.	O

and	CC	O
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
2.5	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
.	.	O

Titration	NN	O
to	TO	O
doses	NNS	O
above	IN	O
90	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
Ancobon	NNP	O
is	VBZ	O
50	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
administered	VBD	O
in	IN	O
divided	JJ	O
doses	NNS	O
at	IN	O
6	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
.	.	O

Third	JJ	O
Dose	NNP	O
:	:	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
16	CD	DOS
hrs	NNS	UNIT

Alosetron	NNP	O
hydrochloride	NN	O
tablets	NNS	O
is	VBZ	O
extensively	RB	O
metabolized	VBN	O
by	IN	O
the	DT	O
liver	NN	O
,	,	O
and	CC	O
increased	VBD	O
exposure	NN	O
to	TO	O
alosetron	VB	O
hydrochloride	JJ	O
tablets	NNS	O
is	VBZ	O
likely	JJ	O
to	TO	O
occur	VB	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

g	NN	O
)	)	O
Place	NN	O
and	CC	O
hold	VB	O
the	DT	O
vial	NN	O
of	IN	O
the	DT	O
reconstituted	JJ	O
ABILIFY	NNP	O
MAINTENA	NNP	O
suspension	NN	O
on	IN	O
a	DT	O
hard	JJ	O
surface	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
worse	JJ	WHO
impairment	NN	WHO
,	,	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
ramipril	NN	O
is	VBZ	O
expected	VBN	O
to	TO	O
produce	VB	O
full	JJ	O
therapeutic	JJ	O
levels	NNS	O
of	IN	O
ramiprilat	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
ABRAXANE	NNP	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
metastatic	JJ	WHO
adenocarcinoma	NN	WHO
of	IN	WHO
the	DT	WHO
pancreas	NNS	WHO
who	WP	WHO
have	VBP	WHO
moderate	VBN	WHO
to	TO	WHO
severe	VB	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

No	DT	O
specific	JJ	O
studies	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
use	NN	O
of	IN	O
or	CC	O
necessity	NN	O
of	IN	O
dosing	VBG	O
adjustments	NNS	O
in	IN	O
patients	NNS	WHO
weighing	VBG	WHO
over	IN	WHO
100	CD	WHO
kg	NNS	WHO
.	.	O

The	DT	O
usual	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
is	VBZ	O
7	CD	O
to	TO	O
10	CD	O
days	NNS	O
.	.	O

To	TO	O
achieve	VB	O
the	DT	O
required	JJ	O
total	NN	O
mealtime	NN	O
dose	NN	O
,	,	O
patients	NNS	O
should	MD	O
use	VB	O
a	DT	O
combination	NN	O
of	IN	O
4	CD	O
unit	NN	O
,	,	O
8	CD	O
unit	NN	O
and	CC	O
12	CD	O
unit	NN	O
cartridges	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
ADCETRIS	NNP	O
Dosage	NNP	O

Pediatrics	NNS	O
:	:	O
The	DT	O
recommended	JJ	O
starting	NN	O
dose	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
(	(	WHO
10	CD	WHO
to	TO	WHO
17	CD	WHO
years	NNS	WHO
)	)	WHO
as	IN	O
monotherapy	NN	O
is	VBZ	O
2	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
with	IN	O
titration	NN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
after	IN	O
2	CD	O
days	NNS	O
,	,	O
and	CC	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
after	IN	O
2	CD	O
additional	JJ	O
days	NNS	O
.	.	O

8	CD	O

To	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
constipation	NN	O
,	,	O
alosetron	NN	O
hydrochloride	NN	O
tablets	NNS	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

For	IN	O
adults	NNS	WHO
(	(	WHO
≥	JJ	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	DOS
mCi	NN	UNIT
(	(	O
370	CD	DOS
MBq	NNP	UNIT
)	)	O
.	.	O

Reconstituted	VBN	O
solutions	NNS	O
retain	VBP	O
their	PRP$	O
physical	JJ	O
and	CC	O
chemical	JJ	O
properties	NNS	O
for	IN	O
3	CD	PER
days	NNS	PER
under	IN	O
refrigeration	NN	O
at	IN	O
2°	CD	O
-	:	O
8°	CD	O
C	NNP	O
(	(	O
36°	CD	O
-	:	O
46°	CD	O
F	NNP	O
)	)	O
,	,	O
or	CC	O
12	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
15°	CD	O
-	:	O
30°	CD	O
C	NNP	O
(	(	O
59°	CD	O
-	:	O
86°	CD	O
F	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMEVIVE®	NNP	O
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
intramuscularly	RB	O
once	RB	FREQ
weekly	JJ	FREQ
for	IN	O
12	CD	PER
weeks	NNS	PER
.	.	O

ALLEGRA	NNP	O
-	:	O
D	VBZ	O
24	CD	O
HOUR	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
180	CD	O
and	CC	O
pseudoephendrine	VB	O
hcl	NN	O
240	CD	O
)	)	O
tablets	NNS	UNIT
should	MD	O
generally	RB	O
be	VB	O
avoided	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
insufficiency	NN	WHO
.	.	O

ARMONAIR	NNP	O
RESPICLICK	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
.	.	O

Average	JJ	O
daily	JJ	FREQ
adult	NN	WHO
fluid	NN	O
requirements	NNS	O
are	VBP	O
between	IN	O
2500	CD	DOS
and	CC	O
3000	CD	DOS
mL	NN	UNIT
and	CC	O
may	MD	O
be	VB	O
much	JJ	O
higher	JJR	O
with	IN	O
losses	NNS	O
from	IN	O
fistula	JJ	O
drainage	NN	O
or	CC	O
in	IN	O
severe	JJ	O
burns	NNS	O
.	.	O

Amoxapine	NNP	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
300	CD	DOS
mg	NNS	UNIT
,	,	O
preferably	RB	O
at	IN	O
bedtime	NN	O
.	.	O

Multiple	JJ	O
Myeloma	NNP	O
:	:	O
The	DT	O
usual	JJ	O
oral	JJ	O
dose	NN	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
(	(	O
3	CD	DOS
tablets	NNS	UNIT
)	)	O
daily	RB	FREQ
.	.	O

Once	RB	O
opened	VBN	O
,	,	O
Accretropin™	NNP	O
(	(	O
somatropin	JJ	O
injection	NN	O
)	)	O
may	MD	O
be	VB	O
stored	VBN	O
up	IN	O
to	TO	O
14	CD	O
days	NNS	O
when	WRB	O
refrigerated	VBN	O
[	RB	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
]	NN	O
.	.	O

If	IN	O
agitation	NN	O
warranting	VBG	O
a	DT	O
second	JJ	O
dose	JJ	O
persists	NNS	O
following	VBG	O
the	DT	O
initial	JJ	O
dose	NN	O
,	,	O
cumulative	JJ	O
doses	VBZ	O
up	RP	O
to	TO	O
a	DT	O
total	NN	O
of	IN	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
given	VBN	O
.	.	O

Usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
one	CD	DOS
to	TO	O
two	CD	DOS
tablets	NNS	UNIT
daily	RB	FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Initial	JJ	O
dose	NN	O
:	:	O
6	CD	DOS
mg	NN	UNIT
given	VBN	O
as	IN	O
a	DT	O
rapid	JJ	O
intravenous	JJ	O
bolus	NN	O
(	(	O
administered	VBN	O
over	IN	O
a	DT	O
1	CD	O
-	:	O
2	CD	O
second	JJ	O
period	NN	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
CR	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
12.5	CD	DOS
mg	JJ	UNIT
once	RB	FREQ
daily	JJ	FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
.	.	O

For	IN	O
intramuscular	JJ	O
administration	NN	O
,	,	O
use	VB	O
a	DT	O
needle	JJ	O
long	JJ	O
enough	RB	O
(	(	O
at	IN	O
least	JJS	O
½	JJ	O
inch	NN	O
to	TO	O
5	CD	O
/	NNS	O
8	CD	O
inch	NN	O
)	)	O
to	TO	O
ensure	VB	O
the	DT	O
injection	NN	O
is	VBZ	O
administered	VBN	O
into	IN	O
the	DT	O
muscle	NN	O
.	.	O

AFREZZA	NNP	O
is	VBZ	O
administered	VBN	O
using	VBG	O
a	DT	O
single	JJ	DOS
inhalation	NN	UNIT
per	IN	O
cartridge	NN	O
.	.	O

Hydrochlorothiazide	NNP	O
can	MD	O
be	VB	O
given	VBN	O
at	IN	O
doses	NNS	O
of	IN	O
12.5	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
when	WRB	O
used	VBN	O
alone	RB	O
.	.	O

There	EX	O
is	VBZ	O
insufficient	JJ	O
data	NNS	O
for	IN	O
dosage	NN	O
recommendation	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
creatinine	JJ	WHO
clearance	NN	WHO
less	JJR	WHO
than	IN	O
10	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
(	(	O
see	VB	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
,	,	O
Heart	NNP	O
Failure	NNP	O
,	,	O
WARNINGS	NNP	O
,	,	O
and	CC	O
PRECAUTIONS	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
CYSTARAN	NNP	O
in	IN	O
each	DT	O
eye	NN	O
,	,	O
every	DT	O
waking	VBG	O
hour	NN	O
.	.	O

Stability	NN	O
in	IN	O
IV	NNP	O
Fluids	NNP	O
:	:	O
Amikacin	NNP	O
sulfate	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
in	IN	O
the	DT	O
following	JJ	O
solutions	NNS	O
:	:	O

Aminosyn	NNP	O
II	NNP	O
in	IN	O
the	DT	O
2000	CD	DOS
mL	NN	UNIT
flexible	JJ	O
Pharmacy	NNP	O
Bulk	NNP	O
Package	NNP	O
is	VBZ	O
designed	VBN	O
for	IN	O
use	NN	O
with	IN	O
manual	JJ	O
,	,	O
gravity	NN	O
flow	NN	O
operations	NNS	O
and	CC	O
automated	VBN	O
gravimetric	JJ	O
compounding	NN	O
devices	NNS	O
for	IN	O
preparing	VBG	O
intravenous	JJ	O
nutritional	JJ	O
admixtures	NNS	O
.	.	O

Repeat	JJ	O
administration	NN	O
:	:	O
If	IN	O
conversion	NN	O
of	IN	O
PSVT	NNP	O
does	VBZ	O
not	RB	O
occur	VB	O
within	IN	O
1	CD	O
-	:	O
2	CD	O
minutes	NNS	O
,	,	O
additional	JJ	O
bolus	NN	O
injections	NNS	O
of	IN	O
adenosine	NN	O
can	MD	O
be	VB	O
administered	VBN	O
at	IN	O
incrementally	RB	O
higher	JJR	O
doses	NNS	O
,	,	O
increasing	VBG	O
the	DT	O
amount	NN	O
given	VBN	O
by	IN	O
0.05	CD	DOS
to	TO	O
0.1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

(	(	O
See	VB	O
Table	JJ	O
1	CD	O
for	IN	O
weight	NN	O
-	:	O
adjusted	VBN	O
dose	JJ	O
volumes	NNS	O
)	)	O
.	.	O

The	DT	WHO
normal	JJ	WHO
adult	NN	WHO
(	(	WHO
70	CD	WHO
kg	NN	WHO
)	)	WHO
dose	NN	O
is	VBZ	O
0.259	CD	DOS
-	:	O
0.925	CD	DOS
GBq	NNP	UNIT
(	(	O
7	CD	DOS
-	:	O
25	CD	DOS
mCi	NN	UNIT
)	)	O
as	IN	O
Tc99m	NNP	O
labeled	VBD	O
leukocytes	NNS	O
by	IN	O
intravenous	JJ	O
injection	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
adequately	RB	WHO
to	TO	O
the	DT	O
starting	NN	O
dosage	NN	O
after	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
therapy	NN	O
,	,	O
replacing	VBG	O
the	DT	O
current	JJ	O
strength	NN	O
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
with	IN	O
a	DT	O
higher	JJR	O
strength	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
improvement	NN	O
in	IN	O
asthma	NN	O
control	NN	O
.	.	O

Attempts	NNS	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
maintain	VB	O
a	DT	O
caloric	JJ	O
intake	NN	O
of	IN	O
greater	JJR	O
than	IN	O
80	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

If	IN	O
the	DT	O
creatinine	JJ	O
clearance	NN	O
rate	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
is	VBZ	O
stable	JJ	O
,	,	O
a	DT	O
dosage	NN	O
interval	NN	O
in	IN	O
hours	NNS	O
for	IN	O
the	DT	O
normal	JJ	O
dose	NN	O
can	MD	O
be	VB	O
calculated	VBN	O
by	IN	O
multiplying	VBG	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
by	IN	O
9	CD	O
,	,	O
e.g	NN	O
,	,	O
if	IN	O
the	DT	O
serum	NN	O
creatinine	NN	O
concentration	NN	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
/	VBD	O
100	CD	DOS
mL	NN	UNIT
,	,	O
the	DT	O
recommended	VBN	O
single	JJ	DOS
dose	NN	UNIT
(	(	O
7.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
every	DT	FREQ
18	CD	FREQ
hours	NNS	FREQ
.	.	O

Patients	NNS	O
should	MD	O
not	RB	O
begin	VB	O
a	DT	O
new	JJ	O
cycle	NN	O
of	IN	O
treatment	NN	O
unless	IN	O
the	DT	O
ANC	NNP	O
is	VBZ	O
≥	JJ	O
1500	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
,	,	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
>	JJ	O
100000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
,	,	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
is	VBZ	O
≥	JJ	O
45	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommendations	NNS	O
for	IN	O
Starting	VBG	O
Dose	NNP	O
in	IN	O
Patients	NNP	WHO
with	IN	WHO
Hepatic	NNP	WHO
Impairment	NNP	WHO

200	CD	DOS
mL	NN	UNIT
per	IN	O
liter	NN	O
gives	VBZ	O
a	DT	O
solution	NN	O
which	WDT	O
is	VBZ	O
approximately	RB	O
isotonic	JJ	O
and	CC	O
iso	JJ	O
-	:	O
osmotic	JJ	O
with	IN	O
citrated	JJ	O
plasma	NN	O
.	.	O

When	WRB	O
the	DT	O
white	JJ	O
blood	NN	O
cell	NN	O
and	CC	O
platelet	NN	O
counts	NNS	O
are	VBP	O
rising	VBG	O
,	,	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
2	CD	DOS
mg	NNS	UNIT
daily	JJ	FREQ
may	MD	O
be	VB	O
instituted	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
QBRELIS	NNP	O
,	,	O
when	WRB	O
used	VBN	O
with	IN	O
diuretics	NNS	O
and	CC	O
(	(	O
usually	RB	O
)	)	O
digitalis	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
for	IN	O
systolic	JJ	O
heart	NN	O
failure	NN	O
,	,	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Consult	NN	O
with	IN	O
pharmacist	NN	O
.	.	O

The	DT	O
recommended	VBN	O
AMJEVITA	NNP	O
dose	JJ	O
regimen	NNS	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
Crohn	NNP	WHO
's	POS	WHO
disease	NN	WHO
(	(	O
CD	NN	O
)	)	O
is	VBZ	O
160	CD	DOS
mg	NN	UNIT
initially	RB	O
on	IN	O
Day	NNP	O
1	CD	O
(	(	O
given	VBN	O
as	IN	O
four	CD	DOS
40	CD	DOS
mg	NN	UNIT
injections	NNS	UNIT
in	IN	O
one	CD	PER
day	NN	PER
or	CC	O
as	IN	O
two	CD	DOS
40	CD	DOS
mg	NNS	UNIT
injections	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
for	IN	O
two	CD	PER
consecutive	JJ	PER
days	NNS	PER
)	)	O
,	,	O
followed	VBN	O
by	IN	O
80	CD	DOS
mg	NNS	UNIT
two	CD	O
weeks	NNS	O
later	RB	O
(	(	O
Day	NNP	O
15	CD	O
)	)	O
.	.	O

First	RB	O
,	,	O
initiate	JJ	O
therapy	NN	O
by	IN	O
administering	VBG	O
a	DT	O
normal	JJ	O
dose	NN	O
,	,	O
7.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
,	,	O
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
.	.	O

The	DT	O
lotion	NN	O
may	MD	O
be	VB	O
applied	VBN	O
topically	RB	O
to	TO	O
the	DT	O
specified	VBN	O
lesions	NNS	O
,	,	O
particularly	RB	O
to	TO	O
those	DT	O
in	IN	O
hairy	JJ	O
areas	NNS	O
,	,	O
two	CD	O
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
lotion	NN	O
should	MD	O
be	VB	O
rubbed	VBN	O
into	IN	O
the	DT	O
affected	JJ	O
area	NN	O
completely	RB	O
,	,	O
and	CC	O
the	DT	O
area	NN	O
should	MD	O
be	VB	O
protected	VBN	O
from	IN	O
washing	VBG	O
,	,	O
clothing	NN	O
,	,	O
rubbing	VBG	O
,	,	O
etc.until	VB	O
the	DT	O
lotion	NN	O
is	VBZ	O
dried	VBN	O
.	.	O

Apply	NNP	O
gel	VBD	O
approximately	RB	O
1	CD	DOS
mm	NNS	UNIT
thick	JJ	O
and	CC	O
include	VBP	O
approximately	RB	O
5	CD	DOS
mm	NN	UNIT
of	IN	O
the	DT	O
surrounding	VBG	O
skin	NN	O
.	.	O

Caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
in	IN	O
administering	VBG	O
fat	JJ	O
emulsions	NNS	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
liver	NN	WHO
damage	NN	WHO
.	.	O

For	IN	O
bolus	RB	O
intravenous	JJ	O
administration	NN	O
,	,	O
prepare	VB	O
a	DT	O
solution	NN	O
containing	VBG	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
of	IN	O
AKOVAZ	NNP	O
(	(	O
ephedrine	JJ	O
sulfate	NN	O
injection	NN	O
)	)	O
:	:	O

The	DT	O
system	NN	O
should	MD	O
be	VB	O
pressed	VBN	O
firmly	RB	O
in	IN	O
place	NN	O
with	IN	O
the	DT	O
palm	NN	O
of	IN	O
the	DT	O
hand	NN	O
for	IN	O
about	IN	O
10	CD	O
seconds	NNS	O
,	,	O
making	VBG	O
sure	JJ	O
there	EX	O
is	VBZ	O
good	JJ	O
contact	NN	O
,	,	O
especially	RB	O
around	IN	O
the	DT	O
edges	NNS	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
require	VBP	WHO
treatment	NN	WHO
with	IN	WHO
a	DT	WHO
strong	JJ	WHO
CYP3A4	NNP	WHO
/	NNP	O
PgP	NNP	O
inducer	NN	O
:	:	O

Approximately	RB	O
60	CD	O
to	TO	O
180	CD	O
mEq	NN	O
of	IN	O
potassium	NN	O
,	,	O
10	CD	O
to	TO	O
30	CD	O
mEq	NN	O
of	IN	O
magnesium	NN	O
,	,	O
and	CC	O
10	CD	DOS
to	TO	O
40	CD	DOS
mM	NN	UNIT
of	IN	O
phosphate	JJ	O
/	NNP	FREQ
day	NN	FREQ
appear	VBP	O
necessary	JJ	O
to	TO	O
achieve	VB	O
optimum	JJ	O
metabolic	JJ	O
response	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Three	CD	O
Bag	NNP	O
Method	NNP	O
Dosage	NNP	O
Guide	NNP	O
by	IN	O
Weight	NNP	O
in	IN	O
Patients	NNP	WHO
5	CD	WHO
kg	NN	WHO
to	TO	WHO
20	CD	WHO
kg	NNS	WHO

Withdraw	VB	O
a	DT	O
0.5	CD	DOS
Ml	NNP	UNIT
dose	NN	UNIT
of	IN	O
the	DT	O
combined	JJ	O
vaccines	NNS	O
and	CC	O
inject	JJ	O
intramuscularly	RB	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IRESSA	NNP	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

During	IN	O
withdrawal	NN	O
,	,	O
some	DT	O
patients	NNS	O
may	MD	O
experience	VB	O
symptoms	NNS	O
of	IN	O
systemic	JJ	O
corticosteroid	NN	O
withdrawal	NN	O
;	:	O
e.g	NN	O
.	.	O

In	IN	O
difficult	JJ	O
and	CC	O
complicated	JJ	O
infections	NNS	O
where	WRB	O
treatment	NN	O
beyond	IN	O
10	CD	O
days	NNS	O
is	VBZ	O
considered	VBN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
amikacin	NN	O
should	MD	O
be	VB	O
reevaluated	VBN	O
.	.	O

These	DT	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
treated	VBN	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
,	,	O
as	IN	O
a	DT	O
Type	NN	O
I	PRP	O
patient	VBP	O
.	.	O

Four	CD	DOS
cycles	NNS	UNIT
of	IN	O
treatment	NN	O
were	VBD	O
administered	VBN	O
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
methyldopa	NN	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
to	TO	O
2	CD	O
g.	NN	O
To	TO	O
minimize	VB	O
the	DT	O
sedation	NN	O
associated	VBN	O
with	IN	O
methyldopa	NN	O
,	,	O
start	JJ	O
dosage	NN	O
increases	NNS	O
in	IN	O
the	DT	O
evening	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
adolescents	NNS	WHO
with	IN	WHO
ADHD	NNP	WHO
who	WP	WHO
are	VBP	WHO
13	CD	WHO
-	:	WHO
17	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
are	VBP	WHO
either	DT	WHO
starting	VBG	WHO
treatment	NN	WHO
for	IN	WHO
the	DT	WHO
first	JJ	WHO
time	NN	WHO
or	CC	WHO
switching	VBG	WHO
from	IN	WHO
another	DT	WHO
medication	NN	WHO
is	VBZ	O
10	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

If	IN	O
persistent	JJ	O
hypokalemia	NN	O
is	VBZ	O
documented	VBN	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
15	CD	DOS
mg	NNS	UNIT
,	,	O
then	RB	O
20	CD	DOS
mg	NNS	UNIT
,	,	O
with	IN	O
careful	JJ	O
monitoring	NN	O
of	IN	O
electrolytes	NNS	O
.	.	O

More	JJR	O
than	IN	O
two	CD	DOS
5	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
usually	RB	O
are	VBP	O
not	RB	O
needed	VBN	O
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
little	JJ	O
controlled	JJ	O
experience	NN	O
with	IN	O
such	JJ	O
doses	NNS	O
.	.	O

Nonproteincalories	NNS	O
should	MD	O
be	VB	O
supplied	VBN	O
principally	RB	O
as	IN	O
glucose	NN	O
(	(	O
8	CD	DOS
–	RB	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	NNP	O
min	NN	O
)	)	O
with	IN	O
an	DT	O
intravenous	JJ	O
fat	JJ	O
emulsion	NN	O
added	VBD	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
Abstral	NNP	O
is	VBZ	O
always	RB	O
100	CD	DOS
mcg	NN	UNIT
with	IN	O
the	DT	O
only	JJ	O
exception	NN	O
being	VBG	O
patients	NNS	WHO
already	RB	WHO
using	VBG	WHO
Actiq	NNP	WHO
.	.	O

Topical	JJ	O
corticosteroids	NNS	O
are	VBP	O
generally	RB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
as	IN	O
a	DT	O
thin	JJ	O
film	NN	O
from	IN	O
two	CD	FREQ
to	TO	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

Avoid	NNP	O
AMBIEN	NNP	O
use	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
as	IN	O
it	PRP	O
may	MD	O
contribute	VB	O
to	TO	O
encephalopathy	VB	O
[	NNP	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
schedule	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
weighing	VBG	WHO
100	CD	WHO
pounds	NNS	WHO
or	CC	WHO
less	JJR	WHO
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
lb	NN	O
of	IN	O
body	NN	O
weight	NN	O
divided	VBN	O
into	IN	O
two	CD	DOS
doses	NNS	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
lb	NN	O
of	IN	O
body	NN	O
weight	JJ	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
or	CC	O
divided	VBN	O
into	IN	O
two	CD	DOS
doses	NNS	UNIT
,	,	O
on	IN	O
subsequent	JJ	O
days	NNS	O
.	.	O

ABILIFY	NNP	O
has	VBZ	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
and	CC	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
a	DT	O
dose	JJ	O
range	NN	O
of	IN	O
10	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
,	,	O
when	WRB	O
administered	VBN	O
as	IN	O
the	DT	O
tablet	NN	O
formulation	NN	O
;	:	O
however	RB	O
,	,	O
doses	VBZ	O
higher	JJR	O
than	IN	O
10	CD	DOS
or	CC	O
15	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
were	VBD	O
not	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
10	CD	DOS
or	CC	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

PROVERA	NNP	O
tablets	NNS	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
dosages	NNS	O
of	IN	O
5	CD	DOS
or	CC	O
10	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
for	IN	O
5	CD	O
to	TO	O
10	CD	O
days	NNS	O
.	.	O

Note	NN	O
:	:	O
The	DT	O
dosage	NN	O
recommendations	NNS	O
for	IN	O
glaucoma	NN	O
and	CC	O
epilepsy	NN	O
differ	NN	O
considerably	RB	O
from	IN	O
those	DT	O
for	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
since	IN	O
the	DT	O
first	JJ	O
two	CD	O
conditions	NNS	O
are	VBP	O
not	RB	O
dependent	JJ	O
upon	IN	O
carbonic	JJ	O
anhydrase	NN	O
inhibition	NN	O
in	IN	O
the	DT	O
kidney	NN	O
which	WDT	O
requires	VBZ	O
intermittent	JJ	O
dosage	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
to	TO	O
recover	VB	O
from	IN	O
the	DT	O
inhibitory	JJ	O
effect	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
.	.	O

If	IN	O
desired	VBN	O
,	,	O
only	RB	O
one	CD	O
-	:	O
half	NN	O
of	IN	O
an	DT	O
estimated	VBN	O
daily	JJ	FREQ
amino	NN	O
acid	JJ	O
requirement	NN	O
of	IN	O
1.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	NNS	O
can	MD	O
be	VB	O
given	VBN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
.	.	O

3	LS	O
-	:	O
6	CD	O
Yrs	NN	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
above	IN	WHO
eight	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
:	:	O
The	DT	O
recommended	JJ	O
dosage	NN	O
schedule	NN	O
for	IN	O
children	NNS	WHO
weighing	VBG	WHO
45	CD	WHO
kg	NN	WHO
or	CC	WHO
less	JJR	WHO
is	VBZ	O
4.4	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
divided	VBN	O
into	IN	O
two	CD	DOS
doses	NNS	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
2.2	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
or	CC	O
divided	VBN	O
into	IN	O
two	CD	DOS
doses	NNS	UNIT
on	IN	O
subsequent	JJ	O
days	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
QUILLIVANT	NNP	O
XR	NNP	O
for	IN	O
patients	NNS	WHO
6	CD	WHO
years	NNS	WHO
and	CC	WHO
above	NN	WHO
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

Epithelial	JJ	O
Ovarian	JJ	O
Cancer	NN	O
:	:	O
One	CD	O
commonly	RB	O
employed	JJ	O
regimen	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ovarian	JJ	O
carcinoma	NN	O
has	VBZ	O
been	VBN	O
to	TO	O
administer	VB	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
daily	NN	FREQ
for	IN	O
5	CD	PER
days	NNS	PER
as	IN	O
a	DT	O
single	JJ	O
course	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
6.25	CD	DOS
mg	NN	UNIT
for	IN	O
women	NNS	WHO
and	CC	O
either	DT	O
6.25	CD	DOS
or	CC	O
12.5	CD	DOS
mg	NN	UNIT
for	IN	O
men	NNS	WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	O
per	IN	O
night	NN	O
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7	CD	O
-	:	O
8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ROZEREM	NNP	O
(	(	O
ramelteon	NN	O
)	)	O
is	VBZ	O
8	CD	DOS
mg	NN	UNIT
taken	VBN	O
within	IN	O
30	CD	O
minutes	NNS	O
of	IN	O
going	VBG	O
to	TO	O
bed	VB	O
.	.	O

Clinical	JJ	O
studies	NNS	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
infusion	NN	O
have	VBP	O
been	VBN	O
conducted	VBN	O
with	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
diluted	VBD	O
to	TO	O
a	DT	O
concentration	NN	O
range	NN	O
of	IN	O
25	CD	DOS
mcg	NNS	UNIT
/	JJ	O
mL	NN	O
to	TO	O
80	CD	DOS
mcg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
DuoNeb	NNP	O
(	(	O
ipratropium	JJ	O
bromide	NN	O
and	CC	O
albuterol	VB	O
sulfate	NN	O
)	)	O
is	VBZ	O
one	CD	DOS
3	CD	DOS
mL	NN	UNIT
vial	NN	UNIT
administered	VBD	O
4	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
via	IN	O
nebulization	NN	O
with	IN	O
up	IN	O
to	TO	O
2	CD	DOS
additional	JJ	O
3	CD	DOS
mL	NN	UNIT
doses	NNS	UNIT
allowed	VBN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
if	IN	O
needed	VBN	O
.	.	O

The	DT	O
diluted	VBN	O
ready	JJ	O
-	:	O
for	IN	O
-	:	O
use	NN	O
admixture	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
up	IN	O
to	TO	O
48	CD	O
hours	NNS	O
at	IN	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
and	CC	O
an	DT	O
additional	JJ	O
6	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O

No	DT	O
data	NN	O
are	VBP	O
available	JJ	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
or	CC	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
is	VBZ	O
required	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
intravenous	JJ	O
dose	NN	O
of	IN	O
Aminosyn	NNP	O
-	:	O
PF	VBD	O
7	CD	O
%	NN	O
,	,	O
Sulfite	NNP	O
-	:	O
Free	JJ	O
,	,	O
(	(	O
an	DT	O
amino	NN	O
acid	NN	O
injection	NN	O
—	NNP	O
pediatric	JJ	O
formula	NN	O
)	)	O
is	VBZ	O
up	IN	O
to	TO	O
2.5	CD	DOS
g	NN	UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
infants	NNS	WHO
up	RB	WHO
to	TO	WHO
10	CD	WHO
kg	NNS	WHO
.	.	O

Adults	NNS	WHO
and	CC	WHO
Children	NNP	WHO
30	CD	WHO
kg	NN	WHO
(	(	WHO
66	CD	WHO
lbs	NN	WHO
)	)	WHO
or	CC	WHO
more	JJR	WHO
:	:	O
0.3	CD	DOS
to	TO	O
0.5	CD	DOS
mg	NN	UNIT
(	(	O
0.3	CD	DOS
mL	NN	UNIT
to	TO	O
0.5	CD	DOS
mL	NN	UNIT
)	)	O
of	IN	O
undiluted	JJ	O
Adrenalin®	NNP	O
administered	VBD	O
intramuscularly	RB	O
or	CC	O
subcutaneously	RB	O
in	IN	O
the	DT	O
anterolateral	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
thigh	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
(	(	O
0.5	CD	DOS
mL	NN	UNIT
)	)	O
per	IN	O
injection	NN	O
,	,	O
repeated	VBN	O
every	DT	O
5	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
as	IN	O
necessary	JJ	O
.	.	O

If	IN	O
slower	JJR	O
administration	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
200	CD	DOS
mL	NN	UNIT
of	IN	O
25	CD	O
%	NN	O
albumin	NN	O
may	MD	O
be	VB	O
mixed	JJ	O
with	IN	O
300	CD	DOS
mL	NNS	UNIT
of	IN	O
10	CD	O
%	NN	O
dextrose	JJ	O
solution	NN	O
and	CC	O
administered	VBN	O
by	IN	O
continuous	JJ	O
drip	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
this	DT	O
dextrose	JJ	O
solution	NN	O
an	DT	O
hour	NN	O
.	.	O

The	DT	O
contents	NNS	O
of	IN	O
each	DT	O
30	CD	DOS
mL	NNS	UNIT
vial	JJ	UNIT
should	MD	O
be	VB	O
dissolved	VBN	O
with	IN	O
25	CD	DOS
mL	NNS	UNIT
of	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
.	.	O

A	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
dose	NN	UNIT
of	IN	O
ACTHREL®	NNP	O
at	IN	O
1	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
testing	NN	O
of	IN	O
pituitary	JJ	O
corticotrophin	NN	O
function	NN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
ABRAXANE	NNP	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
total	JJ	WHO
bilirubin	NN	WHO
greater	JJR	WHO
than	IN	WHO
5	CD	WHO
x	JJ	WHO
ULN	NNP	WHO
or	CC	O
AST	NNP	O
greater	JJR	O
than	IN	O
10	CD	O
x	JJ	O
ULN	NNP	O
regardless	NN	O
of	IN	O
indication	NN	O
as	IN	O
these	DT	O
patients	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

Dosages	NNS	O
above	IN	O
8	CD	DOS
mg	NN	UNIT
should	MD	O
be	VB	O
administered	VBN	O
with	IN	O
careful	JJ	O
blood	NN	O
pressure	NN	O
monitoring	NN	O
and	CC	O
dose	JJ	O
titration	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Concentrations	NNS	O
from	IN	O
40	CD	DOS
to	TO	O
60	CD	DOS
mg	NNS	UNIT
per	IN	O
100	CD	DOS
mL	NNS	UNIT
are	VBP	O
usually	RB	O
necessary	JJ	O
.	.	O

Hoogstraten	NNP	O
et	CC	O
al	NNS	O
have	VBP	O
started	VBN	O
treatment	NN	O
with	IN	O
0.15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
dexamethasone	NN	O
4	CD	DOS
mg	NN	UNIT
was	VBD	O
given	VBN	O
by	IN	O
mouth	JJ	O
twice	JJ	FREQ
daily	JJ	FREQ
the	DT	O
day	NN	O
before	IN	O
,	,	O
the	DT	O
day	NN	O
of	IN	O
,	,	O
and	CC	O
the	DT	O
day	NN	O
after	IN	O
ALIMTA	NNP	O
administration	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
dosage	NN	O
of	IN	O
oral	JJ	O
KYTRIL	NNP	O
(	(	O
granisetron	NNP	O
hydrochloride	NN	O
)	)	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
1	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

3	CD	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
insufficiency	NN	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
dosage	NN	O
increases	NNS	O
above	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
should	MD	O
be	VB	O
carefully	RB	O
considered	VBN	O
and	CC	O
,	,	O
if	IN	O
deemed	VBN	O
necessary	JJ	O
,	,	O
implemented	VBN	O
cautiously	RB	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
and	CC	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
)	)	O
.	.	O

In	IN	O
patients	NNS	WHO
taking	VBG	WHO
amiodarone	NN	WHO
concomitantly	RB	WHO
with	IN	WHO
lovastatin	NN	WHO
,	,	O
the	DT	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
40	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NN	O
INTERACTIONS	NNP	O
,	,	O
Other	JJ	O
drug	NN	O
interactions	NNS	O
)	)	O
.	.	O

For	IN	O
maintenance	NN	O
therapy	NN	O
at	IN	O
dosages	NNS	O
of	IN	O
300	CD	DOS
mg	NN	UNIT
or	CC	O
less	JJR	O
,	,	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
at	IN	O
bedtime	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Rather	RB	O
than	IN	O
an	DT	O
increase	NN	O
in	IN	O
infusion	NN	O
rate	NN	O
,	,	O
7	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
bolus	NN	O
doses	NNS	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
or	CC	O
a	DT	O
potent	JJ	O
inhalation	NN	O
agent	NN	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
response	NN	O
to	TO	O
signs	NNS	O
of	IN	O
lightening	NN	O
of	IN	O
anesthesia	NN	O
within	IN	O
the	DT	O
last	JJ	O
15	CD	O
minutes	NNS	O
of	IN	O
surgery	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
of	IN	O
this	DT	O
preparation	NN	O
varies	VBZ	O
from	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mL	NNS	UNIT
at	IN	O
intervals	NNS	O
of	IN	O
1	CD	O
to	TO	O
3	CD	O
days	NNS	O
.	.	O

In	IN	O
some	DT	WHO
patients	NNS	WHO
treated	VBD	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
the	DT	O
antihypertensive	JJ	O
effect	NN	O
may	MD	O
diminish	VB	O
toward	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
dosing	NN	O
interval	NN	O
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
study	NN	O
with	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
,	,	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
score	NN	WHO
ranging	VBG	WHO
from	IN	WHO
5	CD	WHO
to	TO	WHO
8	CD	WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
of	IN	O
513	CD	DOS
mg	NN	UNIT
(	(	O
34	CD	DOS
mL	NN	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
and	CC	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
score	NN	WHO
ranging	VBG	WHO
from	IN	WHO
9	CD	WHO
to	TO	WHO
12	CD	WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
of	IN	O
342	CD	DOS
mg	NN	UNIT
(	(	O
23	CD	DOS
mL	NN	UNIT
)	)	O
twice	RB	FREQ
daily	JJ	FREQ
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
:	:	O
Hepatic	JJ	O
Insufficiency	NNP	O
)	)	O
.	.	O

Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
infused	VBD	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
45	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
will	MD	O
meet	VB	O
the	DT	O
fluid	NN	O
and	CC	O
amino	NN	O
acid	NN	O
requirements	NNS	O
of	IN	O
the	DT	WHO
stable	JJ	WHO
adult	NN	WHO
patient	NN	WHO
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Targretin®	NNP	O
(	(	O
bexarotene	NN	O
)	)	O
capsules	VBZ	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
acute	JJ	O
agitation	NN	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
administered	VBN	O
by	IN	O
oral	JJ	O
inhalation	NN	O
,	,	O
using	VBG	O
a	DT	O
single	JJ	DOS
-	:	O
use	NN	O
inhaler	NN	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
,	,	WHO
other	JJ	WHO
than	IN	WHO
premature	JJ	WHO
infants	NNS	WHO
and	CC	WHO
neonates	NNS	WHO
:	:	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
/	VBD	O
24	CD	O
hr	NN	O
or	CC	O
150	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	NN	O
/	VBD	O
24	CD	O
hr	NN	O
.	.	O

A	DT	O
dose	NN	O
of	IN	O
1500	CD	DOS
international	JJ	UNIT
units	NNS	UNIT
of	IN	O
RIXUBIS	NNP	O
,	,	O
administered	VBD	O
to	TO	O
a	DT	O
20	CD	WHO
kg	NN	WHO
patient	NN	WHO
should	MD	O
be	VB	O
expect	VB	O
to	TO	O
result	VB	O
in	IN	O
a	DT	O
peak	NN	O
post	NN	O
-	:	O
infusion	NN	O
factor	NN	O
IX	NNP	O
increase	NN	O
of	IN	O
1500	CD	DOS
international	JJ	UNIT
units	NNS	UNIT
x	VBP	O
{	(	O
[	JJ	O
0.7	CD	DOS
IU	NNP	UNIT
/	NNP	O
dL	NN	O
]	NNP	O
/	NNP	O
[	NNP	O
IU	NNP	O
/	NNP	O
kg	NN	O
}	)	O
/	NNP	O
[	$	O
20	CD	O
kg	NN	O
]	NNP	O
=	VBZ	O
53.6	CD	DOS
international	JJ	UNIT
units	NNS	UNIT
/	VBP	O
dL	NN	O
(	(	O
53.6	CD	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
.	.	O

ERPF	NNP	O
=	VBD	O
8.0	CD	O
x	JJ	O
1.5	CD	O
/	JJ	O
0.02	CD	O
=	JJ	O
600	CD	DOS
mL	NN	UNIT
/	CD	O
min	NN	O

Approximately	RB	O
60	CD	O
to	TO	O
180	CD	O
mEq	NN	O
of	IN	O
potassium	NN	O
,	,	O
10	CD	O
to	TO	O
30	CD	O
mEq	NN	O
of	IN	O
magnesium	NN	O
,	,	O
and	CC	O
10	CD	DOS
to	TO	O
40	CD	DOS
mMol	NN	UNIT
of	IN	O
phosphorus	JJ	O
per	IN	FREQ
day	NN	FREQ
appear	VBP	O
necessary	JJ	O
to	TO	O
achieve	VB	O
optimum	JJ	O
metabolic	JJ	O
response	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
tablet	NN	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	JJ	O
starting	VBG	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
rufinamide	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
Lennox	NNP	WHO
-	:	WHO
Gastaut	NNP	WHO
Syndrome	NNP	WHO
is	VBZ	O
approximately	RB	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
administered	VBN	O
in	IN	O
two	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

Following	VBG	O
an	DT	O
anesthetic	JJ	O
induction	NN	O
dose	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
,	,	O
infusion	NN	O
rate	NN	O
requirements	NNS	O
are	VBP	O
reduced	VBN	O
by	IN	O
30	CD	O
to	TO	O
50	CD	O
%	NN	O
for	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
maintenance	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
ADVATE	NN	O
Dosing	VBG	O
for	IN	O
Treatment	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O
in	IN	O
Adults	NNP	WHO
and	CC	WHO
Children	NNP	WHO

A	DT	O
single	JJ	DOS
dose	NN	UNIT
is	VBZ	O
0.5	CD	DOS
mL	NN	UNIT
.	.	O

Doses	NNS	O
of	IN	O
400	CD	DOS
mg	NNS	UNIT
to	TO	O
1000	CD	DOS
mg	NN	UNIT
of	IN	O
DEPO	NNP	O
-	:	O
PROVERA	NNP	O
Sterile	NNP	O
Aqueous	NNP	O
Suspension	NNP	O
per	IN	O
week	NN	O
are	VBP	O
recommended	VBN	O
initially	RB	O
.	.	O

Regimens	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
ACCURETIC	NNP	O
need	MD	O
not	RB	O
take	VB	O
account	NN	O
of	IN	O
renal	JJ	O
function	NN	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
patient	NN	O
's	POS	O
creatinine	JJ	O
clearance	NN	O
is	VBZ	O
>	JJ	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	DOS
m²	NN	UNIT
(	(	O
serum	JJ	O
creatinine	NN	O
roughly	RB	O
≤	$	O
3	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	O
or	CC	O
265	CD	DOS
μmol	JJ	UNIT
/	NNP	O
L	NNP	O
)	)	O
.	.	O

Total	JJ	O
parenteral	JJ	O
nutrition	NN	O
(	(	O
TPN	NNP	O
)	)	O
may	MD	O
be	VB	O
started	VBN	O
with	IN	O
10	CD	O
%	NN	O
dextrose	NN	O
added	VBD	O
to	TO	O
the	DT	O
calculated	JJ	O
daily	JJ	FREQ
requirement	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
(	(	O
1.5	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
for	IN	O
a	DT	O
metabolically	RB	WHO
stable	JJ	WHO
patient	NN	WHO
)	)	WHO
.	.	O

The	DT	O
suggested	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
is	VBZ	O
8	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
the	DT	O
dose	NN	O
is	VBZ	O
calculated	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
35	CD	DOS
mg	NNS	UNIT
for	IN	O
each	DT	O
ten	CD	O
pounds	NNS	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

A	DT	O
patient	NN	WHO
who	WP	WHO
becomes	VBZ	WHO
hypotensive	VBP	WHO
at	IN	WHO
this	DT	WHO
dose	NN	WHO
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
1.25	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Flares	NNS	O
During	IN	O
Maintenance	NN	O
:	:	O
If	IN	O
the	DT	O
patient	NN	O
flares	VBZ	O
during	IN	O
maintenance	NN	O
treatment	NN	O
(	(	O
i.e	FW	O
,	,	O
develops	VBZ	O
psoriasis	NN	O
on	IN	O
more	JJR	O
than	IN	O
5	CD	O
percent	NN	O
of	IN	O
the	DT	O
originally	RB	O
involved	VBN	O
areas	NNS	O
of	IN	O
the	DT	O
body	NN	O
)	)	O
his	PRP$	O
maintenance	NN	O
treatment	NN	O
schedule	NN	O
may	MD	O
be	VB	O
changed	VBN	O
to	TO	O
the	DT	O
preceding	VBG	O
maintenance	NN	O
or	CC	O
clearing	NN	O
schedule	NN	O
.	.	O

Doses	NNS	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
either	RB	O
by	IN	O
administering	VBG	O
normal	JJ	O
doses	NNS	O
at	IN	O
prolonged	JJ	O
intervals	NNS	O
or	CC	O
by	IN	O
administering	VBG	O
reduced	JJ	O
doses	NNS	O
at	IN	O
a	DT	O
fixed	JJ	O
interval	NN	O
.	.	O

These	DT	O
patients	NNS	O
should	MD	O
continue	VB	O
treatment	NN	O
until	IN	O
a	DT	O
maximum	NN	O
of	IN	O
16	CD	DOS
cycles	NNS	UNIT
,	,	O
disease	NN	O
progression	NN	O
,	,	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

Doses	NNS	O
above	IN	O
1	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NNS	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Increases	NNS	O
above	IN	O
300	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
should	MD	O
be	VB	O
made	VBN	O
only	RB	O
if	IN	O
300	CD	DOS
mg	JJ	UNIT
daily	NN	FREQ
has	VBZ	O
been	VBN	O
ineffective	JJ	O
during	IN	O
a	DT	O
trial	NN	O
period	NN	O
of	IN	O
at	IN	PER
least	JJS	PER
two	CD	PER
weeks	NNS	PER
.	.	O

150	CD	DOS
U	NNP	UNIT
will	MD	O
facilitate	VB	O
absorption	NN	O
of	IN	O
1000	CD	DOS
mL	NN	UNIT
or	CC	O
more	JJR	O
of	IN	O
solution	NN	O
.	.	O

Patients	NNS	WHO
not	RB	WHO
currently	RB	WHO
on	IN	WHO
NIASPAN	NNP	WHO
must	MD	O
start	VB	O
ADVICOR	NNP	O
at	IN	O
the	DT	O
lowest	JJS	O
initial	JJ	O
ADVICOR	NNP	O
dose	NN	O
,	,	O
a	DT	O
single	JJ	DOS
500	CD	DOS
mg	NN	UNIT
/	VBD	O
20	CD	DOS
mg	NNS	UNIT
tablet	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
at	IN	O
bedtime	NN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
RA	NNP	O
,	,	O
some	DT	WHO
patients	NNS	WHO
not	RB	WHO
taking	VBG	WHO
concomitant	JJ	WHO
MTX	NNP	WHO
may	MD	O
derive	VB	O
additional	JJ	O
benefit	NN	O
from	IN	O
increasing	VBG	O
the	DT	O
dosing	NN	O
frequency	NN	O
of	IN	O
AMJEVITA	NNP	O
to	TO	O
40	CD	DOS
mg	NNS	UNIT
every	DT	O
week	NN	O
.	.	O

In	IN	O
some	DT	O
acute	JJ	O
cases	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
more	JJR	O
satisfactory	JJ	O
to	TO	O
administer	VB	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
500	CD	DOS
mg	NN	UNIT
followed	VBN	O
by	IN	O
125	CD	DOS
mg	NNS	UNIT
or	CC	O
250	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
case	NN	O
.	.	O

In	IN	O
cases	NNS	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
acne	NN	O
which	WDT	O
,	,	O
in	IN	O
the	DT	O
judgement	NN	O
of	IN	O
the	DT	O
clinician	JJ	O
,	,	O
require	VB	O
long	JJ	O
-	:	O
term	NN	O
treatment	NN	O
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
gram	JJ	UNIT
daily	RB	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
3	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Ambien	NNP	O
CR	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
and	CC	O
should	MD	O
not	RB	O
be	VB	O
readministered	VBN	O
during	IN	O
the	DT	O
same	JJ	O
night	NN	O
.	.	O

Some	DT	WHO
patients	NNS	WHO
may	MD	O
obtain	VB	O
relief	NN	O
of	IN	O
symptoms	NNS	O
sooner	VBP	O
when	WRB	O
started	VBN	O
on	IN	O
a	DT	O
400	CD	DOS
mcg	NN	UNIT
per	IN	FREQ
day	NN	FREQ
dose	NN	O
of	IN	O
AllerNaze	NNP	O
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
nasal	IN	O
spray	NN	O
)	)	O
than	IN	O
with	IN	O
200	CD	DOS
mcg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

ACAM2000	NNP	O
is	VBZ	O
reconstituted	VBN	O
by	IN	O
addition	NN	O
of	IN	O
0.3	CD	DOS
mL	NN	UNIT
of	IN	O
diluent	NN	O
to	TO	O
the	DT	O
vial	JJ	O
containing	NN	O
lyophilized	VBN	O
vaccine	NN	O
.	.	O

Table	JJ	O
1	CD	O
summarizes	JJ	O
recommendations	NNS	O
for	IN	O
dose	JJ	O
reduction	NN	O
,	,	O
interruption	NN	O
or	CC	O
discontinuation	NN	O
of	IN	O
AFINITOR	NNP	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
.	.	O

Although	IN	O
some	DT	WHO
patients	NNS	WHO
respond	VBP	O
to	TO	O
a	DT	O
low	JJ	O
dose	NN	O
,	,	O
the	DT	O
optimum	JJ	O
range	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
from	IN	O
375	CD	DOS
to	TO	O
1000	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

Administer	RB	O
Flublok	NNP	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
-	:	O
mL	NN	UNIT
dose	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
hyperchloremic	JJ	WHO
or	CC	WHO
other	JJ	WHO
metabolic	JJ	WHO
acidoses	NNS	WHO
,	,	O
sodium	NN	O
and	CC	O
potassium	NN	O
may	MD	O
be	VB	O
added	VBN	O
as	IN	O
the	DT	O
acetate	NN	O
or	CC	O
lactate	NN	O
salts	NNS	O
to	TO	O
provide	VB	O
bicarbonate	NN	O
precursors	NNS	O
.	.	O

After	IN	O
asthma	JJ	O
stability	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
titrate	VB	O
to	TO	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dosage	NN	O
to	TO	O
reduce	VB	O
the	DT	O
possibility	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
,	,	O
with	IN	O
subsequent	JJ	O
increases	NNS	O
to	TO	O
10	CD	DOS
or	CC	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
if	IN	O
needed	VBN	O
.	.	O

This	DT	O
form	NN	O
of	IN	O
administration	NN	O
requires	VBZ	O
very	RB	O
large	JJ	O
volumes	NNS	O
of	IN	O
the	DT	O
solution	NN	O
,	,	O
occasionally	RB	O
as	RB	O
much	JJ	O
as	IN	O
300	CD	DOS
mL	NN	UNIT
during	IN	O
a	DT	O
single	JJ	O
treatment	NN	O
period	NN	O
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
up	RB	O
to	TO	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
achieve	VB	WHO
optimal	JJ	WHO
control	NN	WHO
of	IN	WHO
tics	NNS	WHO
.	.	O

Controlled	VBN	O
clinical	JJ	O
trials	NNS	O
have	VBP	O
failed	VBN	O
to	TO	O
show	VB	O
a	DT	O
clear	JJ	O
benefit	NN	O
with	IN	O
the	DT	O
administration	NN	O
of	IN	O
a	DT	O
second	JJ	O
6	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
in	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
failed	VBN	WHO
to	TO	WHO
respond	VB	WHO
to	TO	WHO
a	DT	WHO
first	JJ	WHO
dose	NN	WHO
.	.	O

The	DT	O
patient	NN	O
should	MD	O
place	VB	O
the	DT	O
ACTIQ	NNP	O
unit	NN	O
in	IN	O
his	PRP$	O
or	CC	O
her	PRP$	O
mouth	NN	O
between	IN	O
the	DT	O
cheek	NN	O
and	CC	O
lower	JJR	O
gum	NN	O
,	,	O
occasionally	RB	O
moving	VBG	O
the	DT	O
drug	NN	O
matrix	NN	O
from	IN	O
one	CD	O
side	NN	O
to	TO	O
the	DT	O
other	JJ	O
using	VBG	O
the	DT	O
handle	NN	O
.	.	O

Dose	NNP	O
level	NN	O
reductions	NNS	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
adenocarcinoma	NN	WHO
of	IN	O
the	DT	O
pancreas	NNS	O
,	,	O
as	IN	O
referenced	VBN	O
in	IN	O
Tables	NNP	O
4	CD	O
and	CC	O
5	CD	O
,	,	O
are	VBP	O
provided	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
.	.	O

Initial	JJ	O
infusion	NN	O
rates	NNS	O
should	MD	O
be	VB	O
slow	JJ	O
,	,	O
and	CC	O
gradually	RB	O
increased	VBD	O
to	TO	O
the	DT	O
recommended	VBN	O
60	CD	DOS
to	TO	O
125	CD	DOS
mL	NNS	UNIT
/	JJ	O
hour	NN	O
.	.	O

Discontinue	NNP	O
if	IN	O
patients	NNS	O
are	VBP	O
unable	JJ	O
to	TO	O
tolerate	VB	O
the	DT	O
300	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
dose	VB	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
severely	RB	WHO
impaired	JJ	WHO
hepatic	JJ	WHO
function	NN	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
Class	NNP	WHO
C	NNP	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
8	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

For	IN	O
patients	NNS	WHO
already	RB	WHO
receiving	VBG	WHO
a	DT	WHO
stable	JJ	WHO
dose	NN	WHO
of	IN	WHO
NIASPAN	NNP	WHO
who	WP	WHO
require	VBP	WHO
further	JJ	WHO
LDL	NNP	WHO
-	:	O
lowering	NN	O
(	(	O
e.g	UH	O
,	,	O
to	TO	O
achieve	VB	O
NCEP	NNP	O
LDL	NNP	O
-	:	O
C	NNP	O
goals	NNS	O
;	:	O
Table	NNP	O
8	CD	O
)	)	O
,	,	O
the	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
of	IN	O
lovastatin	NN	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
needle	NN	O
will	MD	O
pick	VB	O
up	RP	O
a	DT	O
droplet	NN	O
of	IN	O
vaccine	NN	O
(	(	O
0.0025	CD	DOS
mL	NN	UNIT
)	)	O
within	IN	O
the	DT	O
fork	NN	O
of	IN	O
the	DT	O
bifurcation	NN	O
.	.	O

The	DT	O
daily	JJ	FREQ
requirements	NNS	O
of	IN	O
the	DT	WHO
stable	JJ	WHO
,	,	O
nonhypermetabolic	JJ	WHO
adult	NN	WHO
patient	NN	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
with	IN	WHO
restricted	JJ	WHO
physical	JJ	WHO
activity	NN	WHO
are	VBP	O
approximately	RB	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
1	CD	DOS
to	TO	O
1.5	CD	DOS
g	NN	UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	NN	O
,	,	O
and	CC	O
2500	CD	DOS
to	TO	O
3000	CD	DOS
mL	NN	UNIT
of	IN	O
fluids	NNS	O
.	.	O

ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
2.5	CD	DOS
mg	NNS	UNIT
,	,	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
1	CD	PER
week	NN	PER
,	,	O
5	CD	DOS
mg	NN	UNIT
,	,	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
the	DT	O
next	JJ	O
3	CD	O
weeks	NNS	O
,	,	O
and	CC	O
then	RB	O
increased	VBD	O
as	IN	O
tolerated	VBN	O
,	,	O
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
,	,	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
univasc®	JJ	O
in	IN	O
patients	NNS	WHO
not	RB	WHO
receiving	VBG	WHO
diuretics	NNS	WHO
is	VBZ	O
7.5	CD	DOS
mg	NN	UNIT
,	,	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
meals	NNS	O
,	,	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

If	IN	O
in	IN	O
any	DT	O
cycle	NN	O
the	DT	O
patient	NN	O
starts	VBZ	O
tablets	NNS	O
later	RB	O
than	IN	O
the	DT	O
proper	JJ	O
day	NN	O
,	,	O
she	PRP	O
should	MD	O
protect	VB	O
herself	PRP	O
against	IN	O
pregnancy	NN	O
by	IN	O
using	VBG	O
a	DT	O
nonhormonal	JJ	O
back	NN	O
-	:	O
up	IN	O
method	NN	O
of	IN	O
birth	NN	O
control	NN	O
until	IN	O
she	PRP	O
has	VBZ	O
taken	VBN	O
a	DT	O
pink	JJ	UNIT
tablet	NN	UNIT
daily	RB	FREQ
for	IN	O
7	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

Children	NNS	WHO
:	:	O
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
45	CD	WHO
kg	NNS	WHO
,	,	O
2.2	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
60	CD	PER
days	NNS	PER
.	.	O

More	JJR	O
than	IN	O
two	CD	DOS
sequential	JJ	UNIT
doses	NNS	UNIT
of	IN	O
epinephrine	NN	O
should	MD	O
only	RB	O
be	VB	O
administered	VBN	O
under	IN	O
direct	JJ	O
medical	JJ	O
supervision	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACCOLATE	NNP	O
in	IN	O
children	NNS	WHO
5	CD	WHO
through	IN	WHO
11	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
10	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
usual	JJ	O
daily	JJ	FREQ
dose	NN	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
administered	VBN	O
once	RB	FREQ
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
or	CC	O
300	CD	DOS
mg	NNS	UNIT
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
at	IN	O
8	CD	O
to	TO	O
12	CD	O
hour	NN	O
intervals	NNS	O
.	.	O

The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
ALSUMA	NNP	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
injected	VBD	O
subcutaneously	RB	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
VESIcare	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Plasma	NNP	O
levels	NNS	O
of	IN	O
ADA	NNP	O
more	JJR	O
than	IN	O
twice	RB	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
35	CD	O
μmol	JJ	O
/	NNP	O
hr	NN	O
/	NNP	O
mL	NN	O
have	VBP	O
occurred	VBN	O
on	IN	O
occasion	NN	O
in	IN	O
several	JJ	O
patients	NNS	O
,	,	O
and	CC	O
have	VBP	O
been	VBN	O
maintained	VBN	O
for	IN	O
several	JJ	PER
weeks	NNS	PER
in	IN	O
one	CD	WHO
patient	NN	WHO
who	WP	WHO
received	VBD	WHO
twice	RB	FREQ
weekly	JJ	FREQ
injections	NNS	O
(	(	O
20	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	FW	O
per	IN	O
dose	NN	O
)	)	O
of	IN	O
ADAGEN®	NNP	O
(	(	O
pegademase	VB	O
bovine	NN	O
)	)	O
Injection	NN	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
and	CC	O
may	MD	O
be	VB	O
divided	VBN	O
into	IN	O
either	DT	O
2	CD	DOS
or	CC	O
3	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
at	IN	O
equally	RB	O
-	:	O
divided	VBN	O
intervals	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ENTOCORT	NNP	O
EC	NNP	O
is	VBZ	O
:	:	O
9	CD	DOS
mg	NNS	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
up	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
.	.	O

c.	NN	O
For	IN	O
patients	NNS	WHO
converting	VBG	WHO
from	IN	WHO
Actiq	NNP	WHO
doses	NNS	WHO
of	IN	O
600	CD	DOS
and	CC	O
800	CD	DOS
mcg	NN	UNIT
,	,	O
initiate	JJ	O
titration	NN	O
with	IN	O
200	CD	DOS
mcg	NNS	UNIT
and	CC	O
200	CD	DOS
mcg	JJ	UNIT
Abstral	NNP	O
,	,	O
respectively	RB	O
and	CC	O
proceed	VB	O
using	VBG	O
multiples	NNS	O
of	IN	O
this	DT	O
strength	NN	O
.	.	O

Careful	JJ	O
increases	VBZ	O
up	IN	O
to	TO	O
300	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
are	VBP	O
indicated	VBN	O
in	IN	O
such	JJ	O
cases	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SAPHRIS	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
given	VBN	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Inject	JJ	O
ADYNOVATE	NNP	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
5	CD	O
minutes	NNS	O
(	(	O
maximum	JJ	O
infusion	NN	O
rate	NN	O
10	CD	DOS
mL	NN	UNIT
per	IN	O
min	NN	O
)	)	O
.	.	O

AIRDUO	NNP	O
RESPICLICK	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
one	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

Alosetron	NNP	O
hydrochloride	JJ	O
tablets	NNS	O
should	MD	O
be	VB	O
discontinued	VBN	O
immediately	RB	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
develop	VBP	WHO
constipation	NN	WHO
or	CC	O
signs	NNS	O
of	IN	O
ischemic	JJ	O
colitis	NN	O
.	.	O

A	DT	O
small	JJ	O
quantity	NN	O
of	IN	O
the	DT	O
cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
2	CD	FREQ
to	TO	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
as	IN	O
required	VBN	O
.	.	O

Additional	JJ	O
separate	JJ	O
doses	NNS	O
of	IN	O
methyldopa	NN	O
or	CC	O
replacement	NN	O
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
with	IN	O
single	JJ	O
entity	NN	O
agents	NNS	O
is	VBZ	O
necessary	JJ	O
until	IN	O
the	DT	O
new	JJ	O
effective	JJ	O
dose	NN	O
ratio	NN	O
is	VBZ	O
re	JJ	O
-	:	O
established	VBN	O
by	IN	O
titration	NN	O
.	.	O

When	WRB	O
acetazolamide	NN	O
is	VBZ	O
given	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
anticonvulsants	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
250	CD	DOS
mg	JJ	UNIT
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
existing	VBG	O
medications	NNS	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
elderly	JJ	WHO
or	CC	WHO
debilitated	JJ	WHO
patients	NNS	WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
doses	NNS	O
for	IN	O
women	NNS	WHO
and	CC	WHO
men	NNS	WHO
are	VBP	O
different	JJ	O
because	IN	O
zolpidem	JJ	O
clearance	NN	O
is	VBZ	O
lower	RBR	O
in	IN	O
women	NNS	WHO
.	.	O

Adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
:	:	O
Thoroughly	RB	O
massage	NN	O
Acticin	NNP	O
(	(	O
permethrin	NN	O
)	)	O
Cream	NNP	O
into	IN	O
the	DT	O
skin	NN	O
from	IN	O
the	DT	O
head	NN	O
to	TO	O
the	DT	O
soles	NNS	O
of	IN	O
the	DT	O
feet	NNS	O
.	.	O

For	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
up	IN	O
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
lb	NN	O
of	IN	O
body	NN	O
weight	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
of	IN	O
quinapril	NN	O
/	NNP	O
hydrochlorothiazide	NN	O
combination	NN	O
therapy	NN	O
using	VBG	O
quinapril	JJ	O
doses	NNS	O
of	IN	O
2.5	CD	DOS
to	TO	O
40	CD	DOS
mg	NNS	UNIT
and	CC	O
hydrochlorothiazide	JJ	O
doses	NNS	O
of	IN	O
6.25	CD	DOS
to	TO	O
25	CD	DOS
mg	NN	UNIT
,	,	O
the	DT	O
antihypertensive	JJ	O
effects	NNS	O
increased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
of	IN	O
either	DT	O
component	NN	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
calories	NNS	O
—	JJ	O
1000	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
4.25	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
will	MD	O
provide	VB	O
6.5	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
and	CC	O
850	CD	O
calories	NNS	O
.	.	O

When	WRB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
chemotherapy	NN	O
drugs	NNS	O
,	,	O
the	DT	O
most	RBS	O
commonly	RB	O
used	JJ	O
dosage	NN	O
of	IN	O
doxorubicin	NN	O
is	VBZ	O
40	CD	DOS
to	TO	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	O
m2	RB	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
injection	NN	UNIT
every	DT	O
21	CD	O
to	TO	O
28	CD	O
days	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Tourette	NNP	O
's	POS	O
Disorder	NNP	O
is	VBZ	O
5	CD	DOS
to	TO	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Usual	JJ	O
daily	RB	FREQ
dose	VBP	O
,	,	O
1	CD	DOS
gram	NN	UNIT
as	IN	O
500	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
.	.	O

Although	IN	O
the	DT	O
dosage	NN	O
will	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
titration	NN	O
of	IN	O
the	DT	O
individual	JJ	O
ingredients	NNS	O
,	,	O
many	JJ	WHO
patients	NNS	WHO
will	MD	O
be	VB	O
found	VBN	O
to	TO	O
have	VB	O
an	DT	O
optimal	JJ	O
response	NN	O
to	TO	O
50	CD	DOS
mg	NNS	UNIT
to	TO	O
100	CD	DOS
mg	NNS	UNIT
each	DT	O
of	IN	O
spironolactone	NN	O
and	CC	O
hydrochlorothiazide	JJ	O
daily	JJ	FREQ
,	,	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
(	(	O
more	JJR	O
than	IN	O
1	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
of	IN	O
the	DT	O
prescribed	JJ	O
strength	NN	O
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
as	IN	O
some	DT	WHO
patients	NNS	WHO
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
adverse	JJ	O
effects	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
salmeterol	NN	O
.	.	O

The	DT	O
daily	JJ	FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	WHO
adult	NN	WHO
patient	NN	WHO
,	,	WHO
not	RB	WHO
hypermetabolic	JJ	WHO
,	,	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
and	CC	WHO
with	IN	WHO
restricted	JJ	WHO
physical	JJ	WHO
activity	NN	WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	DOS
to	TO	O
18	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1	CD	DOS
to	TO	O
1.5	CD	DOS
g	NN	UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	DOS
and	CC	O
3000	CD	DOS
mL	NN	UNIT
of	IN	O
fluids	NNS	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Body	NNP	WHO
Weight	NNP	WHO
<	VBZ	WHO
50	CD	WHO
kg	NN	WHO
:	:	O

The	DT	O
wick	NN	O
may	MD	O
be	VB	O
removed	VBN	O
after	IN	O
24	CD	O
hours	NNS	O
but	CC	O
the	DT	O
patient	NN	O
should	MD	O
continue	VB	O
to	TO	O
instill	VB	O
5	CD	DOS
drops	NNS	UNIT
of	IN	O
Acetic	NNP	O
Acid	NNP	O
Otic	NNP	O
Solution	NNP	O
3	CD	FREQ
or	CC	O
4	CD	FREQ
times	NNS	FREQ
daily	JJ	FREQ
thereafter	RB	O
,	,	O
for	IN	O
as	RB	O
long	RB	O
as	IN	O
indicated	VBN	O
.	.	O

A	DT	O
previously	RB	WHO
unvaccinated	JJ	WHO
child	NN	WHO
12	CD	WHO
to	TO	WHO
14	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
should	MD	O
receive	VB	O
one	CD	DOS
dose	NN	UNIT
of	IN	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
Vaccine	NNP	O
followed	VBN	O
by	IN	O
a	DT	O
booster	NN	O
dose	NN	O
at	IN	O
15	CD	O
to	TO	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
(	(	O
doses	VBZ	O
to	TO	O
be	VB	O
separated	VBN	O
by	IN	O
an	DT	O
interval	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
)	)	O
.	.	O

Activase	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
as	IN	O
reconstituted	VBN	O
at	IN	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
or	CC	O
further	RB	O
diluted	VBN	O
immediately	RB	O
before	IN	O
administration	NN	O
in	IN	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
to	TO	O
yield	VB	O
a	DT	O
concentration	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
,	,	O
using	VBG	O
either	CC	O
polyvinyl	JJ	O
chloride	NN	O
bags	NNS	O
or	CC	O
glass	NN	O
vials	NNS	O
.	.	O

An	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
250	CD	DOS
international	JJ	UNIT
unit	NN	UNIT
/	NNP	O
kg	NNP	O
(	(	O
50	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
injection	NN	UNIT
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ITP	NNP	O
.	.	O

lipid	JJ	O
calories	NNS	O
of	IN	O
100	CD	O
to	TO	O
130	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

Dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
10	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
or	CC	O
2.5	CD	DOS
mg	NNS	UNIT
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

There	EX	O
are	VBP	O
insufficient	JJ	O
data	NNS	O
to	TO	O
support	VB	O
this	DT	O
use	NN	O
of	IN	O
etomidate	NN	O
for	IN	O
longer	JJR	WHO
adult	NN	WHO
procedures	NNS	WHO
or	CC	O
for	IN	O
any	DT	O
procedures	NNS	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
;	:	O
therefore	RB	O
,	,	O
such	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
discontinued	VBN	O
from	IN	O
those	DT	O
medications	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
either	DT	O
ABILIFY	NNP	O
15	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
or	CC	O
placebo	NN	O
,	,	O
and	CC	O
observed	VBD	O
for	IN	O
relapse	NN	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

In	IN	O
some	DT	WHO
patients	NNS	WHO
,	,	O
one	CD	DOS
inhalation	NN	UNIT
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
may	MD	O
be	VB	O
sufficient	JJ	O
.	.	O

AGRIFLUshould	RB	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
intramuscular	JJ	UNIT
injection	NN	UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
region	NN	O
of	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

Recommended	VBN	O
starting	NN	O
doses	NNS	O
,	,	O
based	VBN	O
on	IN	O
clinical	JJ	O
and	CC	O
pharmacokinetic	JJ	O
data	NNS	O
from	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O

When	WRB	O
in	IN	O
the	DT	O
judgment	NN	O
of	IN	O
the	DT	O
clinician	NN	O
a	DT	O
lower	JJR	O
initial	JJ	O
dose	NN	O
is	VBZ	O
appropriate	JJ	O
,	,	O
patients	NNS	O
may	MD	O
begin	VB	O
treatment	NN	O
with	IN	O
5	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

Since	IN	O
improvement	NN	O
in	IN	O
immune	JJ	O
function	NN	O
follows	VBZ	O
correction	NN	O
of	IN	O
metabolic	JJ	O
abnormalities	NNS	O
,	,	O
maintenance	NN	O
dosage	NN	O
in	IN	O
individual	JJ	O
patients	NNS	O
should	MD	O
be	VB	O
aimed	VBN	O
at	IN	O
achieving	VBG	O
the	DT	O
following	JJ	O
biochemical	JJ	O
goals	NNS	O
:	:	O
1	CD	O
)	)	O
maintain	NN	O
plasma	JJ	O
ADA	NNP	O
activity	NN	O
(	(	O
trough	JJ	O
levels	NNS	O
before	IN	O
maintenance	NN	O
injection	NN	O
)	)	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
15	CD	O
-	:	O
35	CD	O
μmol	JJ	O
/	NNP	O
hr	NN	O
/	NNP	O
mL	NN	O
(	(	O
assayed	VBN	O
at	IN	O
37°C	CD	O
)	)	O
;	:	O
and	CC	O
2	CD	O
)	)	O
decline	NN	O
in	IN	O
erythrocyte	JJ	O
dATP	NN	O
to	TO	O
≤	VB	O
0.005	CD	O
-	:	O
0.015	CD	DOS
μmol	JJ	UNIT
/	NNP	O
mL	NN	O
packed	VBD	O
erythrocytes	NNS	O
,	,	O
or	CC	O
≤	VB	O
1	CD	O
%	NN	O
of	IN	O
the	DT	O
total	JJ	O
erythrocyte	JJ	O
adenine	NN	O
nucleotide	NN	O
(	(	O
ATP	NNP	O
+	NNP	O
dATP	NN	O
)	)	O
content	NN	O
,	,	O
with	IN	O
a	DT	O
normal	JJ	O
ATP	NNP	O
level	NN	O
,	,	O
as	IN	O
measured	VBN	O
in	IN	O
a	DT	O
pre	NN	O
-	:	O
injection	NN	O
sample	NN	O
.	.	O

See	NNP	O
also	RB	O
Section	NNP	O
on	IN	O
Volume	NN	O
Adjustment	NN	O
:	:	O
Patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
40	CD	WHO
kg	NNS	WHO
and	CC	O
Requiring	VBG	O
Fluid	NNP	O
Restriction	NNP	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
total	JJ	O
daily	JJ	FREQ
doses	NNS	O
greater	JJR	O
than	IN	O
30	CD	DOS
mg	NN	UNIT
or	CC	O
injections	NNS	O
given	VBN	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	FREQ
2	CD	FREQ
hours	NNS	FREQ
have	VBP	O
not	RB	O
been	VBN	O
adequately	RB	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
CAPOTEN	NNP	O
(	(	O
captopril	JJ	O
tablets	NNS	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
.	.	O

Hydrochlorothiazide	NNP	O
doses	VBZ	O
greater	JJR	O
than	IN	O
50	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
at	IN	O
2	CD	O
-	:	O
week	NN	O
intervals	NNS	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
doses	NNS	O
and	CC	O
at	IN	O
4	CD	O
-	:	O
week	NN	O
intervals	NNS	O
thereafter	RB	O
.	.	O

For	IN	O
use	NN	O
with	IN	O
local	JJ	O
anesthetic—Epinephrine	NN	O
1:100,000	CD	O
(	(	O
0.01	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
to	TO	O
1:20,000	CD	DOS
(	(	O
0.05	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
is	VBZ	O
the	DT	O
usual	JJ	O
concentration	NN	O
employed	VBN	O
with	IN	O
local	JJ	O
anesthetics	NNS	O
.	.	O

As	IN	O
Acetadote	NNP	O
is	VBZ	O
hyperosmolar	JJ	O
(	(	O
2600	CD	DOS
mOsmol	NN	UNIT
/	NNP	O
L	NNP	O
)	)	O
,	,	O
caution	NN	O
is	VBZ	O
advised	VBN	O
when	WRB	O
the	DT	O
diluent	NN	O
volume	NN	O
is	VBZ	O
decreased	VBN	O
as	IN	O
the	DT	O
hyperosmolarity	NN	O
of	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
increased	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
ALPHAGAN®	NNP	O
P	NNP	O
(	(	O
brimonidine	JJ	O
tartrate	NN	O
)	)	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	NN	O
)	)	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
approximately	RB	O
8	CD	O
hours	NNS	O
apart	RB	O
.	.	O

The	DT	O
starting	VBG	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
the	DT	O
tablet	NN	O
formulation	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
was	VBD	O
2	CD	DOS
mg	NN	UNIT
,	,	O
which	WDT	O
was	VBD	O
titrated	VBN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
after	IN	O
2	CD	O
days	NNS	O
and	CC	O
to	TO	O
the	DT	O
target	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
after	IN	O
2	CD	O
additional	JJ	O
days	NNS	O
.	.	O

Schedule	NN	O
Of	IN	O
Exposures	NNS	O
:	:	O
When	WRB	O
patients	NNS	O
have	VBP	O
achieved	VBN	O
95	CD	O
percent	NN	O
clearing	NN	O
,	,	O
or	CC	O
Grade	VBD	O
4	CD	O
response	NN	O
(	(	O
Table	JJ	O
2	CD	O
)	)	O
,	,	O
they	PRP	O
may	MD	O
be	VB	O
placed	VBN	O
on	IN	O
the	DT	O
following	JJ	O
maintenance	NN	O
schedules	NNS	O
(	(	O
M1	NNP	O
–	NNP	O
M4	NNP	O
)	)	O
,	,	O
in	IN	O
sequence	NN	O
.	.	O

Administer	NNP	O
additional	JJ	O
boluses	NNS	O
as	IN	O
needed	VBN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
a	DT	O
total	JJ	O
dosage	NN	O
of	IN	O
50	CD	DOS
mg	NN	UNIT
.	.	O

ACAM2000	NN	O
should	MD	O
only	RB	O
be	VB	O
reconstituted	VBN	O
with	IN	O
0.3	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
diluent	NN	O
provided	VBD	O
.	.	O

In	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
daily	JJ	FREQ
doses	NNS	O
of	IN	O
200	CD	DOS
mg	NN	UNIT
of	IN	O
prednisolone	NN	O
for	IN	O
a	DT	PER
week	NN	PER
followed	VBN	O
by	IN	O
80	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
for	IN	O
1	CD	PER
month	NN	PER
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
(	(	O
4	CD	DOS
mg	NN	UNIT
of	IN	O
methylprednisolone	NN	O
is	VBZ	O
equivalent	JJ	O
to	TO	O
5	CD	DOS
mg	NN	UNIT
of	IN	O
prednisolone	NN	O
)	)	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
doses	NNS	O
higher	JJR	O
than	IN	O
800	CD	DOS
mcg	NNS	UNIT
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
in	IN	O
patients	NNS	O
.	.	O

For	IN	O
immunocompetent	JJ	WHO
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
achieve	VB	WHO
parasitic	JJ	WHO
clearance	NN	WHO
with	IN	O
the	DT	O
recommended	VBN	O
dose	NN	O
,	,	O
a	DT	O
repeat	NN	O
course	NN	O
of	IN	O
therapy	NN	O
may	MD	O
be	VB	O
useful	JJ	O
.	.	O

The	DT	O
series	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
primary	JJ	O
immunization	NN	O
course	NN	O
of	IN	O
3	CD	DOS
doses	NNS	UNIT
administered	VBN	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
6	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
followed	VBN	O
by	IN	O
one	CD	DOS
booster	NN	UNIT
dose	NN	UNIT
,	,	O
administered	VBN	O
at	IN	O
15	CD	O
-	:	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Increase	NN	O
in	IN	O
increments	NNS	O
of	IN	O
3.1	CD	DOS
mg	NNS	UNIT
or	CC	O
6.3	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
.	.	O

If	IN	O
such	JJ	O
circumstances	NNS	O
are	VBP	O
suspected	VBN	O
to	TO	O
be	VB	O
present	JJ	O
,	,	O
the	DT	O
initial	JJ	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
1.25	CD	DOS
mg	JJ	UNIT
once	RB	FREQ
daily	JJ	FREQ
.	.	O

5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.2	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.45	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
Normosol®	NNP	O
M	NNP	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
(	(	O
or	CC	O
Plasma	NNP	O
-	:	O
Lyte	NN	O
56	CD	O
Injection	NNP	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
in	IN	O
Water	NNP	O
)	)	O
Normosol®	NNP	O
R	NNP	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
(	(	O
or	CC	O
Plasma	NNP	O
-	:	O
Lyte	NN	O
148	CD	O
Injection	NNP	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
in	IN	O
Water	NNP	O
)	)	O

As	IN	O
with	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
is	VBZ	O
25	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
and	CC	O
should	MD	O
be	VB	O
gradually	RB	O
increased	VBN	O
(	(	O
also	RB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
with	IN	O
meals	NNS	O
to	TO	O
reduce	VB	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
,	,	O
as	IN	O
tolerated	VBN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
daily	JJ	FREQ
maximum	NN	FREQ
of	IN	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBD	O
or	CC	O
100	CD	DOS
mg	NN	UNIT
,	,	O
whichever	WP	O
is	VBZ	O
smaller	JJR	O
.	.	O

Two	CD	O
weeks	NNS	O
later	RB	O
(	(	O
Day	NNP	O
29	CD	O
)	)	O
begin	VB	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
40	CD	DOS
mg	NNS	UNIT
every	DT	O
other	JJ	O
week	NN	O
.	.	O

The	DT	O
optimal	JJ	O
interval	NN	O
before	IN	O
retreatment	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
defined	VBN	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
not	RB	WHO
completed	VBN	WHO
skeletal	JJ	WHO
growth	NN	WHO
.	.	O

NIASPAN	NNP	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
significant	JJ	WHO
or	CC	WHO
unexplained	JJ	WHO
hepatic	JJ	WHO
dysfunction	NN	WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
by	IN	O
all	DT	O
routes	NNS	O
of	IN	O
administration	NN	O
should	MD	O
not	RB	O
exceed	VB	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Instill	NNP	O
1	CD	DOS
or	CC	O
2	CD	DOS
drops	NNS	UNIT
prior	RB	O
to	TO	O
operating	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosages	NNS	O
for	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
for	IN	O
patients	NNS	WHO
aged	VBN	WHO
12	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
are	VBP	WHO
based	VBN	WHO
upon	IN	WHO
patients	NNS	WHO
'	POS	WHO
asthma	JJ	WHO
severity	NN	WHO
.	.	O

Aldara	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
2	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
for	IN	O
a	DT	O
full	JJ	O
16	CD	O
weeks	NNS	O
to	TO	O
a	DT	O
defined	VBN	O
treatment	NN	O
area	NN	O
on	IN	O
the	DT	O
face	NN	O
or	CC	O
scalp	NN	O
(	(	O
but	CC	O
not	RB	O
both	DT	O
concurrently	RB	O
)	)	O
.	.	O

NIASPAN	NNP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
insufficiency	NN	WHO
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dosage	NN	O
range	NN	O
is	VBZ	O
2.5	CD	DOS
to	TO	O
20	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
in	IN	O
two	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Incremental	JJ	O
Rates	NNS	O
for	IN	O
250	CD	DOS
mL	NNS	UNIT
ALDURAZYME®	NNP	O
Infusion	NNP	O
(	(	O
For	IN	O
use	NN	O
with	IN	O
Patients	NNS	WHO
Weighing	VBG	WHO
Greater	NNP	WHO
than	IN	WHO
20	CD	WHO
kg	NNS	WHO
)	)	WHO

Patients	NNS	WHO
with	IN	WHO
erythrodermic	JJ	WHO
psoriasis	NN	WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
special	JJ	O
attention	NN	O
because	IN	O
pre	JJ	O
-	:	O
existing	VBG	O
erythema	NN	O
may	MD	O
obscure	VB	O
observations	NNS	O
of	IN	O
possible	JJ	O
treatment	NN	O
-	:	O
related	JJ	O
phototoxic	NN	O
erythema	NN	O
.	.	O

Two	CD	O
weeks	NNS	O
later	RB	O
(	(	O
Day	NNP	O
29	CD	O
)	)	O
continue	NN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
40	CD	DOS
mg	NNS	UNIT
every	DT	O
other	JJ	O
week	NN	O
.	.	O

The	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

THE	DT	O
100	CD	DOS
mg	NN	UNIT
VIALS	NNP	UNIT
DO	NNP	O
NOT	NNP	O
CONTAIN	NNP	O
VACUUM	NNP	O
.	.	O

15	CD	DOS
mg	NN	UNIT
/	VBD	O
500	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
:	:	O
white	JJ	O
to	TO	O
off	VB	O
-	:	O
white	JJ	O
,	,	O
oblong	JJ	O
,	,	O
film	NN	O
-	:	O
coated	VBN	O
tablet	NN	O
with	IN	O
“	JJ	O
4833M	CD	O
”	NN	O
on	IN	O
one	CD	O
side	NN	O
and	CC	O
“	$	O
15	CD	O
/	$	O
500	CD	O
”	NN	O
on	IN	O
the	DT	O
other	JJ	O
,	,	O
available	JJ	O
in	IN	O
:	:	O

In	IN	O
other	JJ	O
indications	NNS	O
initial	JJ	O
dosage	NN	O
will	MD	O
vary	VB	O
from	IN	O
10	CD	DOS
to	TO	O
40	CD	DOS
mg	NN	UNIT
of	IN	O
methylprednisolone	NN	O
depending	VBG	O
on	IN	O
the	DT	O
clinical	JJ	O
problem	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Available	JJ	O
evidence	NN	O
suggests	VBZ	O
about	IN	O
one	CD	O
third	NN	O
to	TO	O
one	CD	O
half	NN	O
of	IN	O
the	DT	O
patients	NNS	WHO
with	IN	WHO
multiple	JJ	WHO
myeloma	NN	WHO
show	NN	O
a	DT	O
favorable	JJ	O
response	NN	O
to	TO	O
the	DT	O
drug	NN	O
.	.	O

One	CD	O
regimen	NN	O
has	VBZ	O
been	VBN	O
to	TO	O
administer	VB	O
courses	NNS	O
of	IN	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
at	IN	O
0.25	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
4	CD	PER
consecutive	JJ	PER
days	NNS	PER
(	(	O
or	CC	O
,	,	O
0.20	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
5	CD	PER
consecutive	JJ	PER
days	NNS	PER
)	)	O
for	IN	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBP	O
/	JJ	O
course	NN	O
.	.	O

Usage	NN	O
in	IN	O
Children	NNP	WHO
:	:	O
Clinical	JJ	O
data	NNS	O
to	TO	O
support	VB	O
the	DT	O
use	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
in	IN	O
patients	NNS	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
are	VBP	WHO
not	RB	WHO
presently	RB	WHO
available	JJ	WHO
.	.	O

Consider	VB	O
G	NNP	O
-	:	O
CSF	NNP	O
prophylaxis	NN	O
for	IN	O
subsequent	JJ	O
cycles	NNS	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
experience	VBP	WHO
Grade	NNP	WHO
3	CD	WHO
or	CC	WHO
4	CD	WHO
neutropenia	NN	WHO
in	IN	O
the	DT	O
previous	JJ	O
cycle	NN	O
.	.	O

Activella	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
to	TO	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
vasomotor	NN	O
symptoms	NNS	O
due	JJ	O
to	TO	O
menopause	VB	O
.	.	O

g	NN	O
)	)	O
If	IN	O
the	DT	O
injection	NN	O
is	VBZ	O
not	RB	O
performed	VBN	O
immediately	RB	O
after	IN	O
reconstitution	NN	O
keep	VB	O
the	DT	O
vial	NN	O
at	IN	O
room	NN	O
temperature	NN	O
and	CC	O
shake	VB	O
the	DT	O
vial	JJ	O
vigorously	RB	O
for	IN	O
at	IN	O
least	JJS	O
60	CD	O
seconds	NNS	O
to	TO	O
re	VB	O
-	:	O
suspend	NN	O
prior	RB	O
to	TO	O
injection	NN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
clinical	JJ	O
data	NNS	O
with	IN	O
this	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
strong	JJ	WHO
CYP3A4	NNP	WHO
/	NNP	O
PgP	NNP	O
inducers	NNS	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
intolerable	JJ	O
headaches	NNS	O
during	IN	O
initial	JJ	O
treatment	NN	O
,	,	O
switch	VB	O
to	TO	O
one	CD	DOS
capsule	NN	UNIT
at	IN	O
bedtime	NN	O
and	CC	O
low	JJ	O
-	:	O
dose	NN	O
aspirin	NN	O
in	IN	O
the	DT	O
morning	NN	O
.	.	O

Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
=	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
x	NN	O
Desired	NNP	O
Factor	NNP	O
VIII	NNP	O
rise	NN	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
x	VBZ	O
0.5	CD	DOS
(	(	O
IU	NNP	O
/	NNP	O
kg	FW	O
per	IN	O
IU	NNP	O
/	NNP	O
dL	NN	O
)	)	O

Ophthalmologic	NNP	O
use	NN	O
(	(	O
for	IN	O
producing	VBG	O
conjunctival	JJ	O
decongestion	NN	O
,	,	O
to	TO	O
control	VB	O
hemorrhage	NN	O
,	,	O
produce	VBP	O
mydriasis	NN	O
and	CC	O
reduce	VB	O
intraocular	JJ	O
pressure	NN	O
)	)	O
—Use	VBZ	O
a	DT	O
concentration	NN	O
of	IN	O
1:10,000	CD	O
(	(	O
0.1	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
to	TO	O
1:1,000	CD	DOS
(	(	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Hypertension	NN	O
:	:	O
For	IN	O
patients	NNS	WHO
with	IN	WHO
hypertension	NN	WHO
and	CC	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

A	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
ALTABAX	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
(	(	O
up	IN	O
to	TO	O
100	CD	DOS
cm²	NN	UNIT
in	IN	O
total	JJ	O
area	NN	O
in	IN	O
adults	NNS	WHO
or	CC	O
2	CD	O
%	NN	O
total	JJ	O
body	NN	O
surface	NN	O
area	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
aged	VBD	WHO
9	CD	WHO
months	NNS	WHO
or	CC	WHO
older	JJR	WHO
)	)	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
5	CD	PER
days	NNS	PER
.	.	O

ADVAIR	NNP	O
HFA	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
2	CD	DOS
inhalations	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
body	NN	WHO
weight	NN	WHO
greater	JJR	WHO
than	IN	WHO
20	CD	WHO
kg	NNS	WHO
should	MD	O
receive	VB	O
a	DT	O
total	JJ	O
volume	NN	O
of	IN	O
250	CD	DOS
mL	NN	UNIT
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Altoprev	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
40	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
phosphorus	NN	O
added	VBN	O
to	TO	O
a	DT	O
liter	NN	O
of	IN	O
TPN	NNP	O
solution	NN	O
(	(	O
containing	VBG	O
25	CD	O
%	NN	O
dextrose	NN	O
)	)	O
is	VBZ	O
12	CD	DOS
mM	NN	UNIT
.	.	O

Activella	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
to	TO	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
symptoms	NNS	O
of	IN	O
vulvar	NN	O
and	CC	O
vaginal	JJ	O
atrophy	NN	O
due	JJ	O
to	TO	O
menopause	VB	O
.	.	O

Single	NNP	DOS
Dose	NNP	UNIT
-	:	O
Actidose®	NN	O
with	IN	O
Sorbitol	NNP	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
recurrent	JJ	WHO
Grade	NNP	WHO
4	CD	WHO
neutropenia	NN	WHO
despite	IN	O
the	DT	O
use	NN	O
of	IN	O
G	NNP	O
-	:	O
CSF	NNP	O
prophylaxis	NN	O
,	,	O
consider	VB	O
discontinuation	NN	O
or	CC	O
dose	JJ	O
reduction	NN	O
of	IN	O
ADCETRIS	NNP	O
to	TO	O
1.2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
overall	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
or	CC	O
withdrawals	NNS	O
because	IN	O
of	IN	O
adverse	JJ	O
events	NNS	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
.	.	O

Usual	JJ	O
pediatric	JJ	O
dose	NN	O
:	:	O
Initial	JJ	O
dose	NN	O
of	IN	O
4	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
then	RB	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
the	DT	O
usual	JJ	O
adult	NN	WHO
dose	JJ	WHO
Usual	NNP	WHO
adult	NN	WHO
dose	NN	WHO
:	:	O
Initial	JJ	O
dose	NN	O
of	IN	O
200	CD	DOS
mg	NNS	UNIT
,	,	O
then	RB	O
100	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
400	CD	DOS
mg	NNS	UNIT
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
patient	NN	O
begins	VBZ	O
her	PRP$	O
next	JJ	O
and	CC	O
all	DT	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
tablets	NNS	O
on	IN	O
the	DT	O
day	NN	O
after	IN	O
taking	VBG	O
her	PRP$	O
last	JJ	O
light	JJ	O
-	:	O
green	JJ	O
tablet	NN	O
.	.	O

Dosage	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
is	VBZ	O
usually	RB	O
prescribed	VBN	O
on	IN	O
a	DT	O
g	NN	O
/	NNP	O
kg	VBZ	O
body	NN	O
weight	JJ	O
/	NNP	FREQ
day	NN	FREQ
basis	NN	O
,	,	O
with	IN	O
adjustments	NNS	O
for	IN	O
patient	JJ	O
age	NN	O
as	IN	O
follows	VBZ	O
:	:	O
ages	NNS	WHO
1	CD	WHO
to	TO	WHO
3	CD	WHO
years	NNS	WHO
,	,	O
2	CD	DOS
to	TO	O
2.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
ages	VBZ	WHO
4	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
,	,	O
2	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
ages	VBZ	WHO
13	CD	WHO
to	TO	WHO
15	CD	WHO
years	NNS	WHO
,	,	O
1.7	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
ages	VBZ	WHO
16	CD	WHO
and	CC	WHO
above	RB	WHO
,	,	O
1.5	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Subsequent	JJ	O
dose	NN	O
increases	NNS	O
,	,	O
if	IN	O
needed	VBN	O
,	,	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
increments	NNS	O
.	.	O

Methotrexate	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
or	CC	O
intramuscularly	RB	O
in	IN	O
doses	NNS	O
of	IN	O
15	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
for	IN	O
a	DT	O
five	CD	PER
-	:	PER
day	NN	PER
course	NN	O
.	.	O

Telephone	CD	O
1	CD	O
-	:	O
866­792	CD	O
-	:	O
5172	CD	O
.	.	O

The	DT	O
published	VBN	O
medical	JJ	O
literature	NN	O
does	VBZ	O
not	RB	O
indicate	VB	O
that	IN	O
the	DT	O
dose	NN	O
of	IN	O
acetylcysteine	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
should	MD	O
be	VB	O
reduced	VBN	O
.	.	O

ABILIFY	NNP	O
MAINTENA	NNP	O
comes	VBZ	O
in	IN	O
two	CD	O
types	NNS	O
of	IN	O
kits	NNS	O
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
HYZAAR	NNP	O
is	VBZ	O
50	CD	DOS
/	JJ	O
12.5	CD	DOS
(	(	O
losartan	JJ	O
50	CD	DOS
mg	NN	UNIT
/	NNP	O
hydrochlorothiazide	RB	O
12.5	CD	DOS
mg	NN	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Syphilis	NN	O
of	IN	O
more	JJR	O
than	IN	O
one	CD	O
year	NN	O
's	POS	O
duration	NN	O
:	:	O
Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
allergic	JJ	WHO
to	TO	WHO
penicillin	VB	WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
doxycycline	JJ	O
100	CD	DOS
mg	NN	UNIT
by	IN	O
mouth	NN	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
4	CD	PER
weeks	NNS	PER
.	.	O

For	IN	O
children	NNS	WHO
over	IN	WHO
8	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
up	IN	O
to	TO	O
the	DT	O
adult	NN	WHO
dose	NN	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
are	VBP	O
not	RB	O
recommended	VBN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
concomitant	JJ	WHO
use	NN	WHO
of	IN	O
CYP3A4	NNP	O
inhibitors	NNS	O
,	,	O
CYP2D6	NNP	O
inhibitors	NNS	O
or	CC	O
CYP3A4	NNP	O
inducers	NNS	O
for	IN	O
less	JJR	O
than	IN	O
14	CD	O
days	NNS	O
.	.	O

Concomitant	JJ	O
Therapy	NN	O
:	:	O
If	IN	O
AGENERASE	NNP	O
and	CC	O
ritonavir	NN	O
are	VBP	O
used	VBN	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
regimens	NNS	O
are	VBP	O
:	:	O
AGENERASE	$	O
1,200	CD	DOS
mg	NN	UNIT
with	IN	O
ritonavir	JJ	O
200	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
AGENERASE	$	O
600	CD	DOS
mg	NN	UNIT
with	IN	O
ritonavir	JJ	O
100	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

One	CD	O
regimen	NN	O
has	VBZ	O
been	VBN	O
to	TO	O
administer	VB	O
courses	NNS	O
of	IN	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
at	IN	O
0.25	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
4	CD	PER
consecutive	JJ	PER
days	NNS	PER
(	(	O
or	CC	O
,	,	O
0.2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
5	CD	PER
consecutive	JJ	PER
days	NNS	PER
)	)	O
for	IN	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBP	O
/	JJ	O
course	NN	O
.	.	O

Since	IN	O
methyldopa	NN	O
is	VBZ	O
largely	RB	O
excreted	VBN	O
by	IN	O
the	DT	O
kidney	NN	O
,	,	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
may	MD	O
respond	VB	O
to	TO	O
smaller	JJR	O
doses	NNS	O
.	.	O

In	IN	O
children	NNS	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
start	VBP	O
with	IN	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
or	CC	O
twice	JJ	FREQ
daily	RB	FREQ
;	:	O
daily	JJ	FREQ
dosage	NN	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
adequately	RB	WHO
to	TO	O
the	DT	O
starting	VBG	O
dose	NN	O
after	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
therapy	NN	O
,	,	O
replacing	VBG	O
the	DT	O
current	JJ	O
strength	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
with	IN	O
a	DT	O
higher	JJR	O
strength	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
improvement	NN	O
in	IN	O
asthma	NN	O
control	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	WHO
requiring	VBG	WHO
a	DT	WHO
concomitant	NN	WHO
strong	JJ	WHO
CYP3A4	NNP	WHO
inducer	NN	WHO
is	VBZ	O
9	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
,	,	O
once	RB	FREQ
daily	JJ	FREQ
[	NNP	O
see	VBP	O
Dose	NNP	O
Modifications	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
]	NNP	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
given	VBN	O
with	IN	O
the	DT	O
evening	NN	O
meal	NN	O
.	.	O

If	IN	O
the	DT	O
400	CD	DOS
mcg	NN	UNIT
dose	NN	UNIT
is	VBZ	O
used	VBN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
given	VBN	O
either	CC	O
as	IN	O
a	DT	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
dosage	NN	O
(	(	O
4	CD	DOS
sprays	NNS	UNIT
in	IN	O
each	DT	O
nostril	NN	O
)	)	O
or	CC	O
divided	VBN	O
into	IN	O
two	CD	DOS
daily	JJ	FREQ
doses	NNS	UNIT
of	IN	O
two	CD	DOS
sprays	NNS	UNIT
/	VBP	O
nostril	JJ	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

One	CD	O
study	NN	O
by	IN	O
Alexanian	NNP	O
et	NN	O
al	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
prednisone	NN	O
significantly	RB	O
improves	VBZ	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
multiple	JJ	WHO
myeloma	NNS	WHO
who	WP	WHO
achieve	VBP	WHO
palliation	NN	WHO
.	.	O

For	IN	O
prevention	NN	O
of	IN	O
bleeding	VBG	O
episodes	NNS	O
,	,	O
doses	NNS	O
between	IN	O
20	CD	DOS
to	TO	O
40	CD	DOS
International	NNP	UNIT
Units	NNS	UNIT
of	IN	O
Factor	NNP	O
VIII	NNP	O
per	IN	O
kg	NN	O
body	NN	O
weight	JJ	FREQ
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
(	(	O
3	CD	FREQ
to	TO	O
4	CD	FREQ
times	NNS	FREQ
weekly	RB	FREQ
)	)	O
may	MD	O
be	VB	O
utilized	VBN	O
.	.	O

A	DT	O
fluid	JJ	O
intake	NN	O
sufficient	NN	O
to	TO	O
yield	VB	O
a	DT	O
daily	JJ	FREQ
urinary	JJ	O
output	NN	O
of	IN	O
at	IN	O
least	JJS	O
two	CD	O
liters	NNS	O
in	IN	O
adults	NNS	WHO
and	CC	O
the	DT	O
maintenance	NN	O
of	IN	O
a	DT	O
neutral	JJ	O
or	CC	O
,	,	O
preferably	RB	O
,	,	O
slightly	RB	O
alkaline	JJ	O
urine	NN	O
are	VBP	O
desirable	JJ	O
.	.	O

Bottles	NNS	O
of	IN	O
60	CD	O
NDC	NNP	O
64764	CD	O
-	:	O
155	CD	O
-	:	O
60	CD	O
Bottles	NNS	O
of	IN	O
180	CD	O
NDC	NNP	O
64764	CD	O
-	:	O
155	CD	O
-	:	O
18	CD	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
dosage	NN	O
interruption	NN	O
or	CC	O
treatment	NN	O
withdrawal	NN	O
,	,	O
the	DT	O
rebound	NN	O
in	IN	O
platelet	NN	O
count	NN	O
is	VBZ	O
variable	JJ	O
,	,	O
but	CC	O
platelet	NN	O
counts	NNS	O
typically	RB	O
will	MD	O
start	VB	O
to	TO	O
rise	VB	O
within	IN	O
4	CD	O
days	NNS	O
and	CC	O
return	NN	O
to	TO	O
baseline	NN	O
levels	NNS	O
in	IN	O
one	CD	O
to	TO	O
two	CD	O
weeks	NNS	O
,	,	O
possibly	RB	O
rebounding	VBG	O
above	IN	O
baseline	NN	O
values	NNS	O
.	.	O

Refer	NN	O
to	TO	O
Table	VB	O
1	CD	O
for	IN	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
ADZENYS	NNP	O
XR	NNP	O
-	:	O
ODT	NN	O
and	CC	O
ADDERALL	NNP	O
XR	NNP	O
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
ALDACTONE	NNP	O
25	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
if	IN	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
potassium	NN	O
is	VBZ	O
≤	JJ	O
5.0	CD	O
mEq	NN	O
/	NNP	O
L	NNP	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
is	VBZ	O
≤	JJ	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
dextrose	NN	O
in	IN	O
the	DT	O
final	JJ	O
admixture	NN	O
is	VBZ	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
,	,	O
and	CC	O
simultaneous	JJ	O
administration	NN	O
of	IN	O
lipid	JJ	O
emulsion	NN	O
is	VBZ	O
recommended	VBN	O
both	RB	O
as	IN	O
a	DT	O
calorie	NN	O
source	NN	O
and	CC	O
to	TO	O
attenuate	VB	O
the	DT	O
potentially	RB	O
irritating	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
hypertonic	JJ	O
nutritional	JJ	O
admixture	NN	O
.	.	O

Using	VBG	O
aseptic	JJ	O
technique	NN	O
and	CC	O
a	DT	O
sterile	JJ	O
1	CD	DOS
mL	NN	UNIT
syringe	NN	O
fitted	VBN	O
with	IN	O
a	DT	O
25	CD	O
gauge	NN	O
x	NN	O
5	CD	O
/	JJ	O
8	CD	O
”	NN	O
needle	NN	O
(	(	O
provided	VBN	O
)	)	O
,	,	O
draw	VBZ	O
up	RP	O
0.3	CD	DOS
mL	NNS	UNIT
of	IN	O
diluent	NN	O
and	CC	O
transfer	VB	O
the	DT	O
entire	JJ	O
content	NN	O
of	IN	O
the	DT	O
syringe	NN	O
to	TO	O
the	DT	O
vaccine	NN	O
vial	NN	O
.	.	O

A	DT	O
semipermeable	JJ	O
dressing	NN	O
is	VBZ	O
one	CD	O
that	WDT	O
allows	VBZ	O
for	IN	O
the	DT	O
passage	NN	O
of	IN	O
air	NN	O
but	CC	O
does	VBZ	O
not	RB	O
allow	VB	O
for	IN	O
the	DT	O
passage	NN	O
of	IN	O
fluids	NNS	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
15	CD	O
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
or	CC	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
25	CD	O
two	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Dosage	NN	O
adjustments	NNS	O
of	IN	O
up	IN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
should	MD	O
occur	VB	O
gradually	RB	O
,	,	O
at	IN	O
intervals	NNS	O
of	IN	O
no	DT	O
less	JJR	O
than	IN	O
1	CD	O
week	NN	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
:	:	O
For	IN	O
adolescents	NNS	WHO
(	(	WHO
13	CD	WHO
to	TO	WHO
16	CD	WHO
years	NNS	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
(	(	O
twenty	JJ	O
-	:	O
four	CD	DOS
50	CD	DOS
-	:	O
mg	NN	UNIT
capsules	NNS	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

Each	DT	O
Adrenaclick	NNP	O
contains	VBZ	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
epinephrine	NN	O
for	IN	O
single	JJ	O
use	NN	O
injection	NN	O
.	.	O

No	DT	O
more	JJR	O
than	IN	O
one	CD	DOS
packet	NN	UNIT
of	IN	O
Aldara	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
contiguous	JJ	O
treatment	NN	O
area	NN	O
at	IN	O
each	DT	O
application	NN	O
.	.	O

Therefore	RB	O
,	,	O
for	IN	O
infusions	NNS	O
longer	JJR	O
than	IN	O
1	CD	O
hour	NN	O
,	,	O
amiodarone	NN	O
HCl	NNP	O
injection	NN	O
concentrations	NNS	O
should	MD	O
not	RB	O
exceed	VB	O
2	CD	DOS
mg	JJ	UNIT
/	NNP	O
mL	NN	O
unless	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
is	VBZ	O
used	VBN	O
(	(	O
See	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
Postmarketing	NNP	O
Reports	NNP	O
)	)	O
.	.	O

Dose	NNP	O
(	(	O
International	NNP	O
Unit	NNP	O
)	)	O
=	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
x	NN	O
Desired	NNP	O
Factor	NNP	O
VIII	NNP	O
Rise	NNP	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
x	VBZ	O
0.5	CD	DOS
(	(	O
IU	NNP	O
/	NNP	O
kg	FW	O
per	IN	O
IU	NNP	O
/	NNP	O
dL	NN	O
)	)	O

In	IN	O
circumstances	NNS	O
of	IN	O
rapid	JJ	O
ascent	NN	O
,	,	O
such	JJ	O
as	IN	O
in	IN	O
rescue	NN	O
or	CC	O
military	JJ	O
operations	NNS	O
,	,	O
the	DT	O
higher	JJR	O
dose	JJ	O
level	NN	O
of	IN	O
1000	CD	DOS
mg	NN	UNIT
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Tyzeka	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
,	,	O
taken	VBN	O
orally	RB	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

If	IN	O
adequate	JJ	O
analgesia	NN	O
is	VBZ	O
not	RB	O
obtained	VBN	O
with	IN	O
a	DT	O
600	CD	DOS
mcg	NN	UNIT
dose	NN	UNIT
,	,	O
the	DT	O
next	JJ	O
titration	NN	O
step	NN	O
is	VBZ	O
800	CD	DOS
mcg	NN	UNIT
.	.	O

There	EX	O
are	VBP	O
two	CD	DOS
aripiprazole	JJ	UNIT
formulations	NNS	UNIT
for	IN	O
intramuscular	JJ	O
use	NN	O
with	IN	O
different	JJ	O
dosages	NNS	O
,	,	O
dosing	VBG	O
frequencies	NNS	O
,	,	O
and	CC	O
indications	NNS	O
.	.	O

Preparation	NN	O
and	CC	O
Storage	NN	O
of	IN	O
Parenteral	JJ	O
Solution	NN	O
:	:	O
Each	DT	O
500	CD	DOS
mg	NN	UNIT
vial	JJ	UNIT
containing	VBG	O
sterile	JJ	O
acetazolamide	JJ	O
sodium	NN	O
should	MD	O
be	VB	O
reconstituted	VBN	O
with	IN	O
at	IN	O
least	JJS	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

If	IN	O
more	JJR	O
than	IN	O
four	CD	DOS
episodes	NNS	UNIT
of	IN	O
breakthrough	NN	O
pain	NN	O
are	VBP	O
experienced	VBN	O
per	IN	O
day	NN	O
,	,	O
re	VB	O
-	:	O
evaluate	VB	O
the	DT	O
dose	NN	O
of	IN	O
the	DT	O
long	JJ	O
-	:	O
acting	VBG	O
opioid	NN	O
used	VBN	O
for	IN	O
persistent	JJ	O
underlying	JJ	O
cancer	NN	O
pain	NN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
tolerate	VBP	WHO
25	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
may	MD	O
have	VB	O
their	PRP$	O
dosage	NN	O
increased	VBD	O
to	TO	O
50	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
as	IN	O
clinically	RB	O
indicated	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
reconstituted	JJ	O
E	NNP	O
-	:	O
Z	NNP	O
-	:	O
HD	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
between	IN	O
65	CD	DOS
and	CC	O
135	CD	DOS
mL	NN	UNIT
given	VBN	O
orally	RB	O
(	(	O
155	CD	DOS
to	TO	O
321	CD	DOS
grams	NNS	UNIT
of	IN	O
barium	NN	O
sulfate	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Pediatric	NNP	WHO
<	NN	WHO
Patients	NNS	WHO
:	:	O
For	IN	O
children	NNS	WHO
and	CC	WHO
adolescents	NNS	WHO
6	CD	WHO
-	:	WHO
15	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
two	CD	DOS
inhalations	NNS	UNIT
may	MD	O
be	VB	O
administered	VBN	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
1	CD	DOS
mg.	NN	UNIT
Higher	JJR	O
doses	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

Adult	NN	WHO
patients	NNS	WHO
whose	WP$	WHO
disease	NN	WHO
is	VBZ	WHO
very	RB	WHO
severe	JJ	WHO
with	IN	WHO
scarring	NN	WHO
or	CC	O
is	VBZ	O
primarily	RB	O
manifested	VBN	O
on	IN	O
the	DT	O
trunk	NN	O
may	MD	O
require	VB	O
dose	NN	O
adjustments	NNS	O
up	IN	O
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
as	IN	O
tolerated	VBN	O
.	.	O

Usual	JJ	O
daily	RB	FREQ
dose	VBP	O
,	,	O
10	CD	DOS
to	TO	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
lb	NN	O
(	(	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
divided	VBN	O
in	IN	O
four	CD	DOS
equal	JJ	UNIT
doses	NNS	UNIT
.	.	O

Repeat	JJ	O
administration	NN	O
:	:	O
If	IN	O
the	DT	O
first	JJ	O
dose	NN	O
does	VBZ	O
not	RB	O
result	VB	O
in	IN	O
elimination	NN	O
of	IN	O
the	DT	O
supraventricular	JJ	O
tachycardia	NN	O
within	IN	O
1	CD	O
-	:	O
2	CD	O
minutes	NNS	O
,	,	O
12	CD	DOS
mg	NN	UNIT
should	MD	O
be	VB	O
given	VBN	O
as	IN	O
a	DT	O
rapid	JJ	O
intravenous	JJ	O
bolus	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
RAPIVAB	NNP	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
18	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
older	JJR	WHO
with	IN	WHO
acute	NN	WHO
uncomplicated	JJ	WHO
influenza	NN	WHO
is	VBZ	O
a	DT	O
single	JJ	DOS
600	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
,	,	O
administered	VBN	O
via	IN	O
intravenous	JJ	O
infusion	NN	O
for	IN	O
15	CD	O
to	TO	O
30	CD	O
minutes	NNS	O
.	.	O

XTAMPZA	NN	O
ER	NNP	O
is	VBZ	O
administered	VBN	O
,	,	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
,	,	O
and	CC	O
must	MD	O
be	VB	O
taken	VBN	O
with	IN	O
food	NN	O
.	.	O

ADIPEX	NNP	O
-	:	O
P®	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
≤	VBP	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

When	WRB	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
is	VBZ	O
given	VBN	O
with	IN	O
antihypertensives	NNS	O
other	JJ	O
than	IN	O
thiazides	NNS	O
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
methyldopa	NN	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
500	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
these	DT	O
other	JJ	O
agents	NNS	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
adjusted	VBN	O
to	TO	O
effect	NN	O
a	DT	O
smooth	JJ	O
transition	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
18.8	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
for	IN	O
patients	NNS	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
,	,	O
and	CC	O
12.5	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
for	IN	O
patients	NNS	WHO
13	CD	WHO
to	TO	WHO
17	CD	WHO
years	NNS	WHO
[	RB	O
see	VBP	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
Clinical	NNP	O
Studies	NNP	O
]	NNP	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
doses	NNS	O
of	IN	O
40	CD	DOS
–	JJ	O
80	CD	DOS
mg	NN	UNIT
and	CC	O
divided	VBD	O
doses	NNS	O
give	VB	O
a	DT	O
somewhat	RB	O
greater	JJR	O
effect	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
dosing	NN	O
interval	NN	O
.	.	O

ADVAIR	NNP	O
DISKUS	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
AGRYLIN	NNP	O
is	VBZ	O
0.5	CD	DOS
mg	NN	UNIT
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
or	CC	O
1	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
proven	NN	O
dapsone	NN	O
-	:	O
resistant	JJ	O
leprosy	NN	O
,	,	O
Lamprene	NNP	O
(	(	O
clofazimine	NN	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
100	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
in	IN	O
combination	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
antileprosy	JJ	O
drugs	NNS	O
for	IN	O
3	CD	O
years	NNS	O
,	,	O
followed	VBN	O
by	IN	O
monotherapy	NN	O
with	IN	O
100	CD	DOS
mg	NNS	UNIT
of	IN	O
Lamprene	NNP	O
(	(	O
clofazimine	NN	O
)	)	O
daily	RB	FREQ
.	.	O

The	DT	O
dosage	NN	O
should	MD	O
be	VB	O
kept	VBN	O
small	JJ	O
,	,	O
using	VBG	O
0.5	CD	DOS
to	TO	O
2	CD	DOS
mL	NN	UNIT
(	(	O
preferably	RB	O
1	CD	DOS
mL	NNS	UNIT
maximum	JJ	O
)	)	O
for	IN	O
each	DT	O
injection	NN	O
,	,	O
and	CC	O
the	DT	O
maximum	JJ	O
single	JJ	O
treatment	NN	O
should	MD	O
not	RB	O
exceed	VB	O
10	CD	DOS
mL	NNS	UNIT
.	.	O

Therefore	RB	O
,	,	O
if	IN	O
the	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
ACCUPRIL	NNP	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
,	,	O
patients	NNS	O
should	MD	O
then	RB	O
be	VB	O
titrated	VBN	O
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
until	IN	O
an	DT	O
effective	JJ	O
dose	NN	O
,	,	O
usually	RB	O
20	CD	DOS
to	TO	O
40	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
given	VBN	O
in	IN	O
two	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
,	,	O
is	VBZ	O
reached	VBN	O
or	CC	O
undesirable	JJ	O
hypotension	NN	O
,	,	O
orthostatis	NN	O
,	,	O
or	CC	O
azotemia	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
prohibit	NN	O
reaching	VBG	O
this	DT	O
dose	NN	O
.	.	O

Alupent	NNP	O
(	(	O
metaproterenol	JJ	O
sulfate	NN	O
USP	NNP	O
)	)	O
Inhalation	NNP	O
Aerosol	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
children	NNS	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

The	DT	O
lower	JJR	O
dosage	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
inadequate	JJ	WHO
marrow	NN	WHO
reserves	NNS	WHO
due	JJ	WHO
to	TO	WHO
old	JJ	WHO
age	NN	WHO
,	,	O
or	CC	O
prior	RB	O
therapy	NN	O
,	,	O
or	CC	O
neoplastic	JJ	O
marrow	NN	O
infiltration	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
adequately	RB	WHO
to	TO	O
the	DT	O
starting	VBG	O
dose	NN	O
after	IN	O
3	CD	O
-	:	O
4	CD	O
weeks	NNS	O
of	IN	O
therapy	NN	O
,	,	O
higher	JJR	O
doses	NNS	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

Second	JJ	O
Dose	NNP	O
:	:	O
50	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
7	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
4	CD	O
hrs	NNS	O

ACTHREL®	NNP	O
is	VBZ	O
to	TO	O
be	VB	O
reconstituted	VBN	O
aseptically	RB	O
with	IN	O
2	CD	DOS
mL	NNS	UNIT
of	IN	O
Sodium	NNP	O
Chloride	NNP	O
injection	NN	O
,	,	O
USP	NNP	O
(	(	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
)	)	O
,	,	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
use	NN	O
by	IN	O
injecting	VBG	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
saline	JJ	O
diluent	NN	O
into	IN	O
the	DT	O
lyophilized	JJ	O
drug	NN	O
product	NN	O
cake	NN	O
.	.	O

Dividing	VBG	O
the	DT	O
dose	NN	O
(	(	O
40	CD	DOS
mg	NN	UNIT
)	)	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
day	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Accutane	NNP	O
(	(	O
isotretinoin	NN	O
)	)	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
1.0	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
with	IN	O
food	NN	O
for	IN	O
15	CD	O
to	TO	O
20	CD	O
weeks	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Actigall	NNP	O
for	IN	O
gallstone	NN	O
prevention	NN	O
in	IN	O
patients	NNS	WHO
undergoing	VBG	WHO
rapid	JJ	WHO
weight	JJ	WHO
loss	NN	WHO
is	VBZ	O
600	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
300	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
and	CC	O
target	NN	O
dose	NN	O
for	IN	O
ABILIFY	NNP	O
is	VBZ	O
10	CD	DOS
or	CC	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
administered	VBD	O
on	IN	O
a	DT	O
once	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
schedule	NN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
intravenous	JJ	O
doses	NNS	O
for	IN	O
adults	NNS	WHO
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
heart	NN	WHO
failure	NN	WHO
and	CC	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	DOS
mg	JJ	UNIT
ALTACE	NNP	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

For	IN	O
cardiac	JJ	O
resuscitation	NN	O
-	:	O
A	DT	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mL	NN	UNIT
(	(	O
0.5	CD	DOS
mg	NN	UNIT
)	)	O
diluted	VBD	O
to	TO	O
10	CD	DOS
mL	NN	UNIT
with	IN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
can	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
or	CC	O
intracardially	RB	O
to	TO	O
restore	VB	O
myocardial	JJ	O
contrac	NN	O
-	:	O
tility	NN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
1.25	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
and	CC	O
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
2.5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
depending	VBG	O
on	IN	O
clinical	JJ	O
response	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	DOS
g	NNS	UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
4.25	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

1	CD	DOS
mg	NN	UNIT

For	IN	O
conjunctivitis	NN	O
and	CC	O
other	JJ	O
superficial	JJ	O
ocular	JJ	O
infections	NNS	O
:	:	O
Instill	NNP	O
one	CD	DOS
or	CC	O
two	CD	DOS
drops	NNS	UNIT
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
every	DT	O
two	CD	O
to	TO	O
three	CD	O
hours	NNS	O
initially	RB	O
.	.	O

Methyldopa	NNP	O
is	VBZ	O
largely	RB	O
excreted	VBN	O
by	IN	O
the	DT	O
kidney	NN	O
and	CC	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
may	MD	O
respond	VB	O
to	TO	O
smaller	JJR	O
doses	NNS	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
post	NN	WHO
-	:	WHO
myocardial	JJ	WHO
infarction	NN	WHO
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
shown	VBN	WHO
signs	NNS	WHO
of	IN	WHO
congestive	JJ	WHO
heart	NN	WHO
failure	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ALTACE	NNP	O
is	VBZ	O
2.5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
5	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
)	)	O
.	.	O

Instill	NNP	O
1	CD	DOS
or	CC	O
2	CD	DOS
drops	NNS	UNIT
2	CD	O
or	CC	O
3	CD	O
minutes	NNS	O
before	IN	O
removal	NN	O
of	IN	O
stitches	NNS	O
.	.	O

Thus	RB	O
,	,	O
patients	NNS	WHO
should	MD	O
take	VB	O
a	DT	O
maximum	NN	O
of	IN	O
two	CD	DOS
doses	NNS	UNIT
of	IN	O
ACTIQ	NNP	O
for	IN	O
any	DT	O
breakthrough	NN	O
pain	NN	O
episode	NN	O
.	.	O

The	DT	O
suggested	JJ	O
amino	NN	O
acid	JJ	O
dosage	NN	O
level	NN	O
for	IN	O
children	NNS	WHO
between	IN	WHO
4	CD	WHO
and	CC	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
2	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
for	IN	O
13	CD	WHO
to	TO	WHO
15	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
1.7	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
and	CC	O
for	IN	O
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
above	IN	WHO
,	,	O
1.5	CD	DOS
g	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
Striant	NNP	O
is	VBZ	O
the	DT	O
application	NN	O
of	IN	O
one	CD	DOS
buccal	JJ	UNIT
system	NN	UNIT
(	(	O
30	CD	DOS
mg	NN	UNIT
)	)	O
to	TO	O
the	DT	O
gum	JJ	O
region	NN	O
twice	RB	FREQ
daily	RB	FREQ
;	:	O
morning	NN	O
and	CC	O
evening	NN	O
(	(	O
about	IN	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
.	.	O

Effective	JJ	O
dosage	NN	O
of	IN	O
amoxapine	NN	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
may	MD	O
vary	VB	O
from	IN	O
one	CD	O
patient	NN	O
to	TO	O
another	DT	O
.	.	O

When	WRB	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
given	VBN	O
with	IN	O
antihypertensives	NNS	O
other	JJ	O
than	IN	O
thiazides	NNS	O
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
500	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
;	:	O
when	WRB	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
added	VBN	O
to	TO	O
a	DT	O
thiazide	NN	O
,	,	O
the	DT	O
dosage	NN	O
of	IN	O
thiazide	NN	O
need	MD	O
not	RB	O
be	VB	O
changed	VBN	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
is	VBZ	O
20	CD	DOS
,	,	O
40	CD	DOS
,	,	O
or	CC	O
60	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

Syphilis	NNP	WHO
–	VBD	WHO
early	JJ	WHO
:	:	O
Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
allergic	JJ	WHO
to	TO	WHO
penicillin	VB	WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
doxycycline	JJ	O
100	CD	DOS
mg	NN	UNIT
by	IN	O
mouth	NN	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
2	CD	PER
weeks	NNS	PER
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
0.9	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
90	CD	DOS
mg	JJ	UNIT
total	NN	UNIT
dose	NN	UNIT
)	)	O
,	,	O
with	IN	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
total	JJ	O
dose	NN	O
administered	VBD	O
as	IN	O
an	DT	O
initial	JJ	O
intravenous	JJ	O
bolus	NN	O
over	IN	O
1	CD	O
minute	NN	O
and	CC	O
the	DT	O
remainder	NN	O
infused	VBD	O
over	IN	O
60	CD	O
minutes	NNS	O
.	.	O

Solutions	NNS	O
containing	VBG	O
3.5	CD	O
to	TO	O
5	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
glucose	NN	O
may	MD	O
be	VB	O
coinfused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Generally	RB	O
,	,	O
these	DT	O
decrements	NNS	O
should	MD	O
not	RB	O
exceed	VB	O
2.5	CD	DOS
mg	NNS	UNIT
of	IN	O
prednisone	NN	O
or	CC	O
its	PRP$	O
equivalent	NN	O
.	.	O

The	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
Oxtellar	NNP	O
XR®	NNP	O
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
to	TO	O
2400	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Initial	JJ	O
infusion	NN	O
rates	NNS	O
should	MD	O
be	VB	O
slow	JJ	O
,	,	O
generally	RB	O
20	CD	DOS
to	TO	O
30	CD	DOS
mL	NNS	UNIT
/	JJ	O
hour	NN	O
for	IN	O
the	DT	O
first	JJ	O
6	CD	O
to	TO	O
8	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
CLARINEX	NNP	O
-	:	O
D	VBZ	O
24	CD	O
HOUR	NNP	O
Extended	NNP	O
Release	NNP	O
Tablets	NNP	O
is	VBZ	O
1	CD	DOS
tablet	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
,	,	O
administered	VBN	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
meal	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
more	RBR	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
loop	NN	O
diuretics	NNS	O
are	VBP	O
preferred	VBN	O
to	TO	O
thiazides	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
PERFOROMIST	NNP	O
(	(	O
formoterol	VB	O
fumarate	NN	O
)	)	O
Inhalation	NNP	O
Solution	NNP	O
is	VBZ	O
one	CD	DOS
20	CD	DOS
mcg	NN	UNIT
unit	NN	O
-	:	O
dose	JJ	O
vial	JJ	O
administered	VBN	O
twice	RB	FREQ
daily	JJ	FREQ
(	(	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
by	IN	O
nebulization	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
a	DT	O
single	JJ	DOS
capsule	NN	UNIT
should	MD	O
not	RB	O
be	VB	O
divided	VBN	O
.	.	O

Initiate	NNP	O
dosing	NN	O
at	IN	O
2.5	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
for	IN	O
1	CD	PER
week	NN	PER
,	,	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
for	IN	O
the	DT	O
next	JJ	O
3	CD	O
weeks	NNS	O
,	,	O
and	CC	O
then	RB	O
increase	VB	O
as	IN	O
tolerated	JJ	O
,	,	O
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
2	CD	DOS
to	TO	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Dosing	VBG	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Patients	NNS	WHO
with	IN	WHO
skin	JJ	WHO
types	NNS	WHO
IV	NNP	WHO
,	,	O
V	NNP	O
and	CC	O
VI	NNP	O
may	MD	O
be	VB	O
treated	VBN	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
.	.	O

Although	IN	O
nitrogen	NN	O
requirements	NNS	O
may	MD	O
be	VB	O
higher	JJR	O
in	IN	O
severely	RB	WHO
hypercatabolic	JJ	WHO
or	CC	WHO
depleted	JJ	WHO
patients	NNS	WHO
,	,	O
provision	NN	O
of	IN	O
additional	JJ	O
nitrogen	NN	O
may	MD	O
not	RB	O
be	VB	O
possible	JJ	O
due	JJ	O
to	TO	O
fluid	VB	O
intake	VB	O
limits	NNS	O
,	,	O
nitrogen	NN	O
,	,	O
or	CC	O
glucose	JJ	O
intolerance	NN	O
.	.	O

COVERA	NNP	O
-	:	O
HS	NN	O
should	MD	O
be	VB	O
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Silenor	NNP	O
(	(	O
doxepin	JJ	O
tablets	NNS	O
)	)	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

A	DT	O
previously	RB	O
unvaccinated	JJ	O
infant	NN	O
,	,	O
7	CD	O
to	TO	O
11	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
should	MD	O
receive	VB	O
as	IN	O
primary	JJ	O
immunizations	NNS	O
,	,	O
two	CD	DOS
doses	NNS	UNIT
of	IN	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
Vaccine	NNP	O
at	IN	O
8	CD	O
-	:	O
week	NN	O
intervals	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
booster	NN	O
dose	NN	O
at	IN	O
15	CD	O
to	TO	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Uncomplicated	VBN	O
urethral	JJ	O
,	,	O
endocervical	JJ	O
or	CC	O
rectal	JJ	O
infections	NNS	O
in	IN	O
adults	NNS	WHO
caused	VBN	O
by	IN	O
Chlamydiatrachomatis	NN	O
:	:	O
500	CD	DOS
mg	NN	UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
at	IN	PER
least	JJS	PER
seven	CD	PER
days	NNS	PER
.	.	O

Initial	JJ	O
dose	NN	O
:	:	O
Give	VB	O
0.05	CD	DOS
to	TO	O
0.1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
as	IN	O
a	DT	O
rapid	JJ	O
IV	NNP	O
bolus	NN	O
given	VBN	O
either	CC	O
centrally	RB	O
or	CC	O
peripherally	RB	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
and	CC	O
may	MD	O
be	VB	O
divided	VBN	O
into	IN	O
either	DT	O
2	CD	DOS
or	CC	O
3	CD	DOS
equally	RB	UNIT
-	:	UNIT
divided	VBN	UNIT
doses	NNS	UNIT
at	IN	O
equally	RB	O
-	:	O
divided	VBN	O
intervals	NNS	O
.	.	O

0.14	CD	DOS
(	(	O
mg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
min	NN	O
)	)	O
x	FW	O
total	JJ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
/	FW	O
Adenoscan	JJ	O
concentration	NN	O
(	(	O
3mg	CD	DOS
/	NNP	O
mL	NN	O
)	)	O
=	VBZ	O
Infusion	NNP	O
rate	NN	O
(	(	O
mL	JJ	O
/	NNP	O
min	NN	O
)	)	O

Nonprotein	NNP	O
calories	NNS	O
should	MD	O
constitute	VB	O
approximately	RB	O
100	CD	O
to	TO	O
130	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

An	DT	O
example	NN	O
of	IN	O
a	DT	O
5	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
application	NN	O
schedule	NN	O
is	VBZ	O
to	TO	O
apply	VB	O
Aldara	NNP	O
Cream	NNP	O
,	,	O
once	RB	FREQ
per	IN	FREQ
day	NN	FREQ
,	,	O
Monday	NNP	O
through	IN	O
Friday	NNP	O
.	.	O

Atralin	NNP	O
Gel	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
before	IN	O
bedtime	NN	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
a	DT	O
thin	JJ	O
layer	NN	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
.	.	O

UVA	NNP	O
exposure	NN	O
may	MD	O
be	VB	O
held	VBN	O
constant	JJ	O
or	CC	O
increased	VBN	O
by	IN	O
up	IN	O
to	TO	O
1.5	CD	DOS
Joules	NNS	UNIT
/	JJ	O
cm²	NN	UNIT
at	IN	O
each	DT	O
treatment	NN	O
unless	IN	O
erythema	NN	O
occurs	NNS	O
.	.	O

This	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
if	IN	O
necessary	JJ	O
.	.	O

Therefore	RB	O
,	,	O
ACCURETIC	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

In	IN	O
children	NNS	WHO
with	IN	WHO
ADHD	NNP	WHO
who	WP	WHO
are	VBP	WHO
6	CD	WHO
-	:	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
are	VBP	WHO
either	DT	WHO
starting	VBG	WHO
treatment	NN	WHO
for	IN	WHO
the	DT	WHO
first	JJ	WHO
time	NN	WHO
or	CC	WHO
switching	VBG	WHO
from	IN	WHO
another	DT	WHO
medication	NN	WHO
,	,	O
start	VBP	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
;	:	O
daily	JJ	FREQ
dosage	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
or	CC	O
10	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
.	.	O

Calculate	VB	O
the	DT	O
amount	NN	O
of	IN	O
reconstituted	VBN	O
(	(	O
4	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
AmBisome	NNP	O
to	TO	O
be	VB	O
further	RB	O
diluted	VBN	O
.	.	O

0	CD	DOS

Adjust	NNP	O
dose	NN	O
at	IN	O
2	CD	O
week	NN	O
intervals	NNS	O
as	IN	O
needed	VBN	O
to	TO	O
achieve	VB	O
and	CC	O
maintain	VB	O
trough	JJ	O
concentrations	NNS	O
of	IN	O
5	CD	DOS
to	TO	O
15	CD	DOS
ng	NNS	UNIT
/	JJ	O
mL	JJ	O
[	NNP	O
see	VBP	O
Therapeutic	JJ	O
Drug	NNP	O
Monitoring	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
and	CC	O
Dose	NNP	O
Modifications	NNP	O
in	IN	O
SEGA	NNP	O
with	IN	O
TSC	NNP	O
]	NNP	O
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
doxycycline	NN	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
(	(	O
administered	VBN	O
100	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
100	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMBIEN	NNP	O
CR	NNP	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
6.25	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
immediately	RB	O
before	IN	O
bedtime	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
FAMVIR	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
recurrent	NN	O
herpes	NNS	O
labialis	NN	O
is	VBZ	O
1500	CD	DOS
mg	NN	UNIT
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

Geriatric	JJ	WHO
patients	NNS	WHO
may	MD	O
require	VB	O
reduced	JJ	O
doses	NNS	O
of	IN	O
etomidate	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
taking	VBG	WHO
cyclosporin	JJ	WHO
concomitantly	RB	WHO
with	IN	WHO
ALTOCOR™	NNP	WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
)	)	O
,	,	O
therapy	NN	O
should	MD	O
begin	VB	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
of	IN	O
ALTOCOR™	NNP	O
(	(	O
lovastatin	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Aminosyn	RB	O
7	CD	O
%	NN	O
,	,	O
8.5	CD	O
%	NN	O
or	CC	O
10	CD	O
%	NN	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
sterile	JJ	O
water	NN	O
for	IN	O
injection	NN	O
or	CC	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
to	TO	O
achieve	VB	O
a	DT	O
final	JJ	O
amino	NN	O
acid	JJ	O
concentration	NN	O
of	IN	O
3.5	CD	O
,	,	O
4.25	CD	O
or	CC	O
5	CD	O
%	NN	O
for	IN	O
peripheral	JJ	O
administration	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dose	NN	O
is	VBZ	O
1	CD	DOS
gram	NN	UNIT
AMOXIL	NNP	O
and	CC	O
30	CD	DOS
mg	NN	UNIT
lansoprazole	NN	UNIT
,	,	O
each	DT	O
given	VBN	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
)	)	O
for	IN	O
14	CD	PER
days	NNS	PER
.	.	O

Amikacin	NNP	O
sulfate	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
in	IN	O
the	DT	O
following	JJ	O
solutions	NNS	O
:	:	O

For	IN	O
adults	NNS	WHO
(	(	WHO
≥	JJ	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	DOS
mCi	NN	UNIT
(	(	O
370	CD	DOS
MBq	NNP	UNIT
)	)	O
[	VBD	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

For	IN	O
Control	NNP	O
of	IN	O
Hypertension	NNP	O
:	:	O
The	DT	WHO
adult	NN	WHO
initial	JJ	O
dose	NN	O
of	IN	O
MICROZIDE	NNP	O
(	(	O
hydrochlorothiazide	JJ	O
capsule	NN	O
)	)	O
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
whether	IN	O
given	VBN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antihypertensives	NNS	O
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	FREQ
maintenance	NN	O
dose	NN	O
of	IN	O
PURINETHOL	NNP	O
is	VBZ	O
1.5	CD	DOS
to	TO	O
2.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	JJ	FREQ
day	NN	FREQ
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

As	IN	O
an	DT	O
example	NN	O
of	IN	O
the	DT	O
preparation	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfentanil	NN	O
)	)	O
for	IN	O
infusion	NN	O
,	,	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
added	VBD	O
to	TO	O
230	CD	DOS
mL	NN	UNIT
of	IN	O
diluent	NN	O
provides	VBZ	O
40	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NNP	O
solution	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
.	.	O

5	CD	DOS
mg	NN	UNIT
/	VBD	O
400	CD	DOS
mg	NN	UNIT
:	:	O
The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
recommended	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
2	CD	DOS
inhalations	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
morning	NN	O
and	CC	O
evening	NN	O
,	,	O
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
1	CD	DOS
mg	NN	UNIT
.	.	O

Clinical	JJ	O
studies	NNS	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
infusion	NN	O
have	VBP	O
been	VBN	O
conducted	VBN	O
with	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
diluted	VBD	O
to	TO	O
a	DT	O
concentration	NN	O
range	NN	O
of	IN	O
25	CD	DOS
mcg	NNS	UNIT
/	JJ	O
mL	NN	O
to	TO	O
80	CD	DOS
mcg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O
